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ABSTRACT OF THESIS
Experiments were carried out using techniques of biochemical
pharmacology to investigate the influence of Y-aminobutyric acid
(GABA) on the pituitary gland. The properties and effects of GABA
receptors in the gland, and the properties of GABA-releasing nerve
terminals in the median eminence (ME) and neurointermediate lobe of
the pituitary (NI) were studied.
The presence of GABA/\, GABAg and benzodiazepine binding
sites in the pituitary was demonstrated by radioligand binding
studies. GABA/\ sites were detectable in both pars distalis (PD)
and NI, predominantly in PD, but in much lower concentration than in
the CNS. GABAg sites were also detectable in PD, but not in NI.
Both central and peripheral type benzodiazepine sites were present,
but in contrast to GABA/\ sites, both types were more concentrated
in NI. The central type sites were found to be linked to GABA
receptors and to be predominantly of the BZ^ subtype.
The effects of GABA and related compounds on prolactin secretion
in vitro were examined in detail using a superfusion system.
GABA/\ receptor agonists were found to have a biphasic effect on
prolactin secretion, with a transient stimulation following by
sustained inhibition. Evidence was provided, using both agonists
and antagonists, that the two components of the response were
mediated by different types or states of GABA/\ receptor complex.
Benzodiazepines and a barbiturate were found to potentiate the
stimulatory component of this response, but did not affect the
inhibitory part. GABAg receptor effects were also observed on
prolactin secretion, and their possible mediation by an effect on
K+ conductance was investigated.
GABA receptor-mediated effects were also found on the secretion
of growth hormone, luteinizing hormone and adrenocorticotrophic
hormone but not thyroid stimulating hormone. The GABA-containing
dipeptide homocarnosine mimicked some but not all of these effects
of GABA. This appeared to be attributable to homocarnosine itself
as PD was found to contain undetectable homocarnosinase activity.
The properties of GABAergic terminals in ME and NI were studied
using crude synaptosomal preparations. [^HjGABA was accumulated
by both regions with high affinity, showing the characteristics of
neuronal uptake and was released by depolarising stimuli in a
Ca2+-dependent manner. Release from both regions appeared to be
controlled by GABA/\ autoreceptors, and in addition GABAb
autoreceptors were demonstrated in ME. Release from NI was
inhibited by 1C opioid receptor agonists, and experiments to
investigate the mechanism of this effect indicated the involvement
of chloride channels. A variety of other neurotransmitters and
hormones had no effect on release from either area.
A GABAf\ receptor agonist was found to inhibit release of
dopamine (a major prolactin inhibitory factor) from ME but not NI.
This may be the means by which GABA agonists cause the stimulation
of prolactin secretion reported in vivo.
Brattleboro rats were found to have much lower glutamic acid
decarboxylase activity in NI than Long-Evans rats, but there was no
alteration in the number of GABA/\ binding sites. This deficit was
found to be confined to pars nervosa, and was interpreted as a
lesion of the GABA innervation of that region.
These results provide new evidence indicating a diverse
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1.1 GABA as a neurotransmitter
The neutral amino acid y-aminobutyric acid, (GABA) was
discovered to be present in brain in 1950; thereby identifying a
previously unknown ninhydrin-positive substance present in much
higher concentrations in brain than in peripheral tissues of several
species (Awapara, Landura, Fuest and Seale, 1950; Roberts and
Frankel, 1950; Udenfriend, 1950). The first suggestion that GABA
might have an inhibitory function in the nervous system came from
studies by Hayashi (1956) who found that topically applied GABA
caused a marked depression of frog brain electical activity. Florey
(1954) had previously described an extract of mammalian brain called
Factor I, which had an inhibitory action on crayfish stretch
receptor, and the inhibitory activity was subsequently identified as
GABA (Bazemore, Elliot and Florey, 1957). McLennan (1959), however,
found considerable inhibitory activity of a Factor I extract that
was devoid of GABA.
The advent of microiontophoretic techniques permitted the study
of the effect of GABA on individual neurones. GABA was found to
inhibit all classes of spinal interneurones in the cat (Curtis,
Phillis and Watkins, 1959) although those authors concluded at the
time that GABA was unlikely to be the major inhibitory neuro¬
transmitter in the spinal cord because its action was not
antagonised by strychnine. Conversely, on the basis of a study of
the effects of GABA on cortical neurones, Krnjevic and Phillis
(1963) concluded that such properties were "eminently suitable" for
a role for GABA as an inhibitory neurotransmitter.
Subsequent studies on the cerebral cortex provided evidence that
GABA was indeed a major inhibitory neurotransmitter. GABA
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hyperpolarised pyramidal and Purkinje cells by an increase in
membrane conductance to chloride ions, in a manner similar to that
produced by the inhibitory neurotransmitter released from synapses
activated by electrical stimulation of the surface of the cerebral
cortex (Krnjevic and Schwartz, 1966; Dreifuss, Kelly and Krnjevic,
1969). The discovery that the convulsant alkaloid bicuculline is an
antagonist of the depressant effects of GABA (Curtis, Duggan, Felix
and Johnston, 1970; 1971a) (although its specificity and potency
have been criticised (Straughan, Neal, Simmonds, Collins and Hill,
1971)) provided a more precise means for studying the pharmacology
of inhibitory pathways, and using this approach, Curtis and Felix
(1971) concluded that GABA appeared to be the principal inhibitory
neurotransmitter of the cerebellum and cerebral cortex.
1.2 Uptake and release of GABA
Slices of cerebral cortex but not peripheral tissues were
originally shown to be able to greatly concentrate GABA by Elliot
and van Gelder (1958), suggesting that uptake rather than metabolism
is the mechanism of termination of the effect of GABA. There have
since been carried out a very large number of studies on the uptake
and release of GABA.
GABA is accumulated by neuronal tissue through an active
high-affinity mechanism, which is dependent upon sodium (Iversen and
Neal, 1968; Martin and Smith, 1972; Bennet, Logan and Snyder,
1972). An uptake carrier is also present in glial cells (Henn and
Hamberger, 1971; Bowery and Brown, 1972; Schon and Kelly, 1974) with
a similarly high affinity but a different pharmacological
specificity: neuronal uptake can be preferentially inhibited by
2,4-diaminobutyric acid, and glial uptake by 0-alanine (Iversen and
KeUj , 1975") .
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Release of GABA from cat cerebral cortex has been detected in
vivo (Jasper, Khan and Elliott, 1965) and could be altered by
lesions or stimulation of the midbrain (Jasper and Koyama, 1969).
Release could also be increased by electrical stimulation, in a
2+
Ca -dependent manner (Iversen, Mitchell and Srinivasan, 1971).
Similar properties have been observed in vitro but the degree of
2"^* 2"^"
Ca -dependency and the nature of Ca -dependent release has
+
been the subject of some uncertainty. K -induced release is
2+
generally not totally abolished in Ca -free medium (Mulder and
Snyder, 1974) and electrically-induced release has been reported to
be abolished by some (Srinivasan, Neal and Mitchell, 1969) but not
others (Potashner, 1978a). The release of GABA by K+ in a
2+
Ca -independent manner is greater for exogenous than endogenous
GABA (Haycock, Levy, Denner and Cotman, 1978) and may be a result of
membrane transport rather than stimulus-secretion coupling as it is
Na+-dependent (Haycock et al, 1978; Szerb, 1979).
Glial cells can also release GABA in response to K+ (Minchin
2+
and Iversen, 1974), and this shows less Ca -dependence than
neuronal release (Sellstrom and Hamberger, 1977; Neal and Bowery,
1979). These points are discussed further in Chapter 8.
1.3 Metabolism of GABA
GABA is formed in the CNS of vertebrates from L-glutamic acid.
This was first demonstrated by Roberts and Frankel (1950), and the
enzyme responsible, glutamic acid decarboxylase (GAD) has since been
purified (Wu, Matsuda and Roberts, 1973). Early studies suggested
that GAD was confined to neurones (Salganicoff and de Robertis,
1965; Neal and Iversen, 1969), and this has been confirmed by
immunohistochemical studies using antibodies against purified GAD
-4-
(McLaughlin, Wood, Saito, Barber, Vaughan, Roberts and Wu, 1974).
Non-neuronal GAD has also been demonstrated (Haber, Kuriyama and
Roberts, 1970) but this is a different enzyme which does not appear
to cross-react with antibodies to authentic neuronal GAD (Wu, Chude,
Wein, Roberts, Saito and Wong, 1978).
Although glutamate is the direct precursor of GABA, slices of
rat brain form more GABA when loaded with glutamine than with
glutamate (Benjamin and Quastel, 1972). This result led to the
suggestion of a neuronal/g1ial cycle, whereby there is a flow of
GABA and glutamate from nerve endings to astrocytes, and of
glutamine from astrocytes to nerve endings (Hertz, 1979). Such a
model depends upon high-affinity uptake of glutamine into neurones.
This was demonstrated by Balcar and Johnston (1975), but others
could only demonstrate low-affinity uptake (Baldessarini and Yorke,
1974).
GABA is degraded by undergoing a transamination reaction with
a-ketoglutarate to produce succinic semialdehyde (Roberts and
Bregoff, 1953) which can enter the tricarboxylic acid cycle. GABA
transaminase has been localized immunohistochemically in the
cerebellum (Barber and Saito, 1976), and was found to be present in
neuronal cell bodies and dendrites and glial processes but not nerve
terminals. This supported the results of subcellular distribution
studies (Salganicoff and De Robertis, 1965). Therefore as a general
principle, it seems possible that GABA released from a nerve
terminal and reaccumulated by a terminal will be re-released, not
metabolised, while if it is taken up by glial cells it will be
metabolised. This anatomical arrangement would explain why drugs
which inhibit GABA-transaminase greatly increase the amount of GABA
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in brain without greatly affecting the actions of endogenous or
exogenous GABA (Gottesfeld, Kelly and Renaud, 1972), again
suggesting that the synaptic action of GABA is not predominantly
terminated by metabolism. More recent immunohistochemical studies
have localised GABA-transaminase in cerebellum in both neurones and
glia (Chan-Palay, Wu and Palay, 1979) but using a histochemical
approached applied to striatal efferent pathways, Vincent, Kimura
and McGeer (1981) demonstrated that the enzyme was mainly present in
GABAergic neurones, with little in glia.
GABA and its two associated enzymes are also involved in
intermediary metabolism, in the "GABA shunt" whereby glutamine and
glutamate can enter the tricarboxylic acid cycle (Roberts, 1956).
1.4 Anatomical considerations
The distribution of GABAergic markers in presumed strategic
sites for neuroendocrine control will be discussed in this section.
Four methods have been used tothe presence of GABAergic
neurones:
I) The measurement of endogenous GABA.
II) The measurement of GAD activity.
Ill) Autoradiography following uptake of [^H]GABA.
IV) Immunohistochemical visualisation of GAD.
A fifth method, autoradiography of GABA binding sites, has not
been applied to the pituitary or the hypothalamus, although membrane
binding studies have been carried out. They have revealed the
presence of GABA binding sites in both the hypothalamus (Williams
and Risley, 1979) and pituitary (Grandison and Guidotti, 1979).
The measurement of endogenous GABA is complicated by rapid
postmortem increases, which appear to be directly related to GAD
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activity in the region (Tappaz, Brownstein and Kopin, 1977).
Furthermore, both this method and the assay of GAD activity (even
allowing for the validity of the assay method) are limited by the
dissection, and the average values obtained for the dissected sample
can be misleading. In a study of GAD activity and GABA content of
hypothalamic nuclei, Tappaz et al (1977) found that the median
eminence (ME) had the lowest content of both markers, and concluded
that "GABAergic neurones might not be involved in neuroendocrine
regulation at the median eminence level". Subsequently,
immunohistochemical studies showed that GAD was mainly confined to
the external layer of ME (Tappaz, Wassef, Oertel, Pant and Pujol,
1981). GABA was relatively evenly distributed compared to GAD,
possibly reflecting the redistribution of released GABA into
surrounding glial cells.
Nevertheless, the microchemical assay of GAD activity has
provided evidence for a tuberoinfundibular GABA pathway.
Deafferentation of the hypothalamus, or lesions separating medial
from lateral hypothalamus did not affect GAD activity in ME, but
partly reduced GAD activity in the arcuate and ventromedial nuclei
(Tappaz and Brownstein, 1977). Administration of monosodium
glutamate to neonate rats, a treatment which selectively lesions the
arcuate nucleus, reduced GAD activity in ME (Walaas and Fonnum,
1978).
3
Infusion of [ H]GABA into the third ventricle predominantly
labelled neuropil adjacent to the site of infusion, but labelled and
unlabelled cells could be differentiated (Makara, Rappay and Stark,
1975). Presynaptic terminals which had accumulated tritium could
also be seen on electron microscopic examination, but the
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accumulation by glial cells and the different pattern of labelling
at different distances from the ventricle demonstrates the limited
potential of this technique. Intracardiac injection of [ H]GABA
was successfully used to selectively label neuronal sites in the
external but not the internal layer of ME (Tappaz, Aguera, Bel in and
Pujol, 1980), providing the first anatomical evidence pointing
strongly towards GABAergic neuroendocrine control of the anterior
pituitary.
These techniques were also used to investigate GABAergic markers
in the pituitary*. GABA is synthesized in the pituitary (Anderson,
Larsson and Pocchiari, 1961; Minchin and Beart, 1975) and endogenous
GABA is found throughout the gland (Labella, Vivian and Queen, 1968;
Beart, Schon and Kelly, 1974). The posterior pituitary was able to
accumulate [ H]GABA into glial cells and contained low but
detectable GAD activity (Beart et al, 1979). The pars distalis (PD)
was found to be devoid of GAD activity but contained higher GABA-
transaminase activity than the posterior pituitary or the
hypothalamus (Racagni, Apud, Locatelli, Cocchi, Nistico, diGiorgio
and Muller, 1979). The precise neuroanatomical basis for this
pattern of GABAergic markers being present in pituitary was unclear
for some years.
* FOOTNOTE
The terminology used in this Thesis is as follows: the pituitary
gland is divided into three lobes: pars distalis (PD), pars
intermedia (PI) and pars nervosa (PN). The latter two, which are
anatomically more closely related, are often considered together as
the neurointermediate lobe (NI). The terms 'posterior pituitary'
and 'neurohypophysis' will only be used in discussion of results
where the original authors have used those terms.
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The development of antisera to GAD however, allowed
clarification of these results. GAD is generally considered to be a
reliable marker for GABAergic neurones, and immunohistochemical
studies have been carried out at both light- and
electron-microscopic level. Studies of GAD-immunoreactivity
(GAD-IR) in the hypothalamus and pituitary have been carried out by
Vincent, Hokfelt and Wu (1982), Oertel, Mugnaini, Tappaz, Wise,
Dahl, Schmechel and Kopin (1982) and Tappaz et al (1983).
PD was found to be devoid of GAD-IR, but there was a rich
distribution of fibres in pars intermedia (PI) and scattered
varicosities in PN. Terminals were described in apposition to
glial cells and unlabelled axons and formed synapse-like contacts
with secretory cells in PI, and apposed to terminals, pituicytes and
fenestrated portal capillaries in PN. GAD activity was reduced by
>95% after stalk sectioning, and no GAD-IR was observable,
suggesting a central origin of this innervation. Clusters of
magnocel1ular GAD-IR cell bodies were described in the posterior
hypothalamus, and it was suggested that these might be the origin of
the innervation of NI, but subsequent studies demonstrated a
projection of these cells to the cortex, amygdala and striatum
(Vincent, Hokfelt, Skirboll and Wu, 1983).
In ME, labelling was predominantly observed over the external
layer, following outlines of capillary loops. Terminals were found
in close contact with tanocytes and intermingled with bundles of
unlabelled axons and neurosecretory endings, in some cases between
the basement membrane and endothelial cells of the capillaries, but
as in PN, no morphological synapses were found.
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Some of the GABAergic projection to ME may arise from cell
bodies in the arcuate nucleus, as discussed above, and GAD-IR cell
bodies were observed there. Other candidate nuclei, eg the
periventricular nucleus, may also project to ME (Wiegiand and Price,
1980) but there is no evidence to implicate GABA in this
projection. GAD-IR terminals were found throughout the
hypothalamus, and several areas of cell bodies were found but the
weakness of the immune reaction, even after colchicine treatment,
precluded definitive description. Groups of cell bodies were found
adjacent to the magnocellular supraoptic and paraventricular nuclei,
which may project with the peptidergic neurones to PN as well as
locally. Overall, no obvious pattern of innervation was clear from
these studies, although much is likely to be intrinsic to the
hypothalamus (Tappaz and Brownstein, 1977).
Furthermore, these studies did not reveal any differential
distribution of GAD-IR terminals in the external layer of ME, but a
recent study has suggested that GAD-IR terminals are mainly observed
in the lateral palisade zone, where there was a partial overlap with
tyrosine hydroxylase-immunoreactive terminals (Everitt, Hokfelt, Wu
and Goldstein, 1984). A conserable proportion of GAD-IR cell bodies
in the arcuate nucleus also stained for tyrosine hydroxylase,
suggesting coexistence of GABA and dopamine (DA) in tubero-
infundibular neurones (Everitt et al, 1984).
Although GABA itself can now be detected immunohistochemically,
(Storm-Mathison, Leknes, Bore Vaaland, Edminson, Haug and Ottersen,
1983) this approach has not yet been applied to the hypothalamus or
pituitary.
Further to this important but essentially circumstantial
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evidence pointing to a functional role for GABA in the
hypothalamo-hypophysial system, a range of more direct physiological
studies have been carried out. Evidence is available for GABA
having regulatory effects on the secretion of a variety of pituitary
hormones with examples from each zone of the gland.
1.5 Effects of GABA on secretion of Pars Distalis hormones
GABA may exert its various influences on PD hormone secretion
either by a direct action on the endocrine cell or indirectly by
acting on neurones which either themselves release transmitters into
hypophysial portal blood or from synapses with other neurones that
do. Theoretically, any number of intermediate neurones may be
involved, and in vivo experiments measuring plasma hormone
concentration provide no information on this, even when
pharmacological or surgical attempts are made to elucidate the
involvement of other systems. Thus although the results of Makara
and Stark (1974) demonstrate a hypothalamic site of action of GABA
in the control of adrenocorticotrophic hormone (ACTH) secretion, no
information is obtained about the possibility of a direct effect on
the pituitary, or whether the hypothalamic action is a direct effect
on corticotrophin releasing hormone (CRH) secretion or not.
Similarly, Vijayan and McCann (1979) attempted to use pimozide to
distinguish DAmiediated from DA-independent effects of GABA on PD
hormone secretion, though the confused state of the literature about
the involvement of DA in, for example, the control of luteinizing
hormone (LH) secretion (Weiner and Ganong, 1978) makes the
interpretation of such multiple-variable experiments hazardous.
There is considerable evidence that GABA can affect the
secretion of the PD hormones LH, ACTH, growth hormone (GH) and
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thyroid stimulating hormone (TSH) by actions within the hypothalamus
(Elias, Valenta, Szekeres and Grossmann, 1982; Racagni, Apud,
Cocchi, Locatelli and Muller, 1982). Both stimulatory and
inhibitory effects on each hormone have been reported, and in some
cases in vitro experiments have provided evidence as to the
mechanism of action: for example GABA inhibits the release of CRH
(Burden, Hillhouse and Jones, 1974) and somatostatin (Gamse,
Vaccaro, Gamse, DiPace, Fox and Leeman, 1980) which might account
for the inhibitory effect of GABA on ACTH secretion (Makara and
Stark, 1974) and the stimulatory effect on GH secretion (Vijayan and
McCann, 1978b). Evidence for direct effects of GABA on cells of PD
has been less forthcoming. In 1977, Schally, Redding, Arimura,
Dupont and Linthicum isolated from hypothalamus a substance,
distinct from catecholamines, which had inhibitory effects on
prolactin secretion both in vivo and in vitro. This substance was
identified as GABA. Subsequent studies have since confirmed the
inhibitory effect of GABAergic agonists on prolactin secretion in
vitro (eg Enjalbert, Ruberg, Arancibia, Fiore, Priam and Kordon,
1979a) but there have been no previous reports of effects on other
PD hormones in vitro.
Although PD contains no GAD, it contains considerable amounts of
GABA and GABA-transaminase (Racagni et al, 1979) and the
concentration of GABA falls if the pituitary is ectopically
transplanted. Inhibition of GABA-transaminase by central
administration of ethanolamine-O-sulphate (EOS) increased PD GABA
concentration and reduced plasma prolactin concentration, while
peripheral administration of EOS did neither (Racagni et al, 1979),
suggesting an 'over-flow' of GABA from the CNS to the pituitary.
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The efficacy of EOS in apparently augmenting GABAergic function in
this case contrasts with the generally slight effects of inhibition
of GABA-transaminase on GABAergic function in the CNS (Gottesfeld et
al, 1972). This may reflect the relative unimportance of metabolism
of GABA in the CNS in the termination of its synaptic action, as
discussed in Section 1.3 above and suggests that metabolism may be a
more important, possibly limiting factor in the control of
hypothalamo-hypophysial GABAergic function. Alternatively it could
be argued from the results of Racagni et al (1979) that GABA-
transaminase normally 'protects' PD from the effects of GABA. GABA
has been detected in hypophysial portal blood, but in both
dioestrous female and male rats the concentrations in peripheral and
portal blood were not significantly different (Mulchahey and Neill,
1982; Mitchell, Grieve, Dow and Fink, 1983). The concentration of
GABA in hypophysial portal but not peripheral blood was greatly
increased by electrical stimulation of ME (Mitchell et al, 1983) or
by EOS (Gudelsky, Apud, Masotto, Locatelli, Cocchi, Racagni and
Muller, 1983). Intracerebroventricular (i.e.v.) injection of
prolactin has also been reported to increase GABA secretion into
hypophysial portal blood (Apud, Gudelsky, Masotto, Locatelli,
Cocchi, Racagni and Muller, 1984a), providing evidence consistent
with a negative feedback pathway.
In addition to GABA itself, higher concentrations of the
GABA-containing dipeptide homocarnosine were found in hypophysial
portal blood, than in peripheral blood, and its concentration was
unaffected by electrical stimulation of ME (Mitchell et al, 1983).
Schally et al (1977) had previously shown that homocarnosine could
inhibit prolactin secretion in vitro and further experiments on this
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substance have been carried out in this Thesis (Chapters 5, 7 and
12).
Evidence relevant to the control of prolactin secretion by GABA
is discussed further in Chapter 5, and of other PD hormones in
Chapter 7.
1.6 Effects of GABA on the Secretion of Neurointermediate lobe
hormones
Again, effects of GABA on NI can be divided into direct and
indirect, the latter particularly encompassing effects on the
paraventricular and supraoptic nuclei, the origins of the
peptidergic projections to PN.
GABA has been reported to inhibit the firing of cells in the
supraoptic nucleus (Nicoll and Barker, 1971; Bioulac, Gaffori,
Harris and Vincent, 1978), and to reduce the amplitude of the
.antidromic compound action potential in the neurohypophysial stalk
(Zingg, Baertschi and Dreifuss, 1979) GABA has also been shown to
depolarise these fibres (Loeffler, Desaulleus, Demeneix and Feltz,
1982). i.c.v. GABA and drugs that increase GABAergic transmission
inhibited vasopressin secretion in vivo (Knepel, Nutto and Hertting,
1980) but GABA enhanced stimulated vasopressin secretion in vitro
(Knepel, Nutto, Loeffler and Feltz, 1984). GABA has also been
reported to have no effect on vasopressin secretion in vitro
(Iversen, Iversen and Bloom, 1980). There is a brief report that
GABA inhibited oxytoxin secretion in vitro (Dyball and Shaw, 1979)
but this has not been confirmed.
The original demonstration that GABA inhibits a melanocyte
stimulating hormone (aMSH) secretion in vitro (Hadley, Davis and
Morgan, 1977) has recently been considerably refined. Taraskevich
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and Douglas (1982) demonstrated that GABA depolarised PI cells in
culture, causing a flurry of action potentials with subsequent
quiescence. This effect showed the typical pharmacology of a
GABA^ receptor: bicuculline- sensitive, apparently mediated by
opening chloride channels and potentiated by diazepam. Subsequent
studies on the effects of GABA on ctMSH secretion showed a biphasic
effect (Tomiko, Taraskevich and Douglas, 1983), the stimulatory
component of which has been shown to be GABA^-receptor mediated,
and the inhibitory component GABAg-receptor mediated (Demeneix,
Desaulles, Feltz and Loeffler, 1984; Taraskevich and Douglas, 1985).
Recent in vitro electrophysiological experiments on a mediobasal
hypothalamus/NI preparation suggest that the dopaminergic
innervation of PI is tonically active and causes substantial
inhibition of the gland (Davis, Haas and Lichtensteiger, 1985).
These results support conclusions from in vivo experiments (Passo,
Thornborough and Ferris, 1981). Bicuculline had no effect on
stimulus-induced inhibition of PI cell electrical activity, which
was blocked by sulpiride, but no experiments on the effect of
bicuculline on stimulus-induced PI cell action potentials were
reported (Davis et al, 1985). The question as to whether GABA
mediates this neuronal stimulatory input to PI, which would be
compatible with the results of Taraskevich and Douglas (1982), is
therefore unresolved. This type of preparation may provide
considerable information as to the cellular function of the
postsynaptic GABA^ and GABAg receptors on melanotrophes.
The GABAergic innervation of NI may also contribute to the
control of hormone secretion from PD. GAD-IR terminals were
observed adjacent to fenestrated capillaries in PN (Oertel et al,
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1982) and intrapituitary blood flow from PN to PD has been reported
(Bergland and Page, 1979; Page, 1983). Removal of PN has been
demonstrated to increase the concentration of prolactin in
peripheral plasma (Oliver, Mical and Porter, 1977; Peters, Hoefer
and Ben-Jonathan, 1981) and also to affect the secretion of LH
(Fagin and Neill, 1982; Ben-Jonathan and Peters, 1982).
Although a variety of actions of GABA can be observed, these
must be considered in the context of other influences. The control
of prolactin secretion provides a useful example to consider.
1.7 The control of prolactin secretion
Prolactin secretion has long been recognised to be under the
predominantly inhibitory control of the hypothalamus. This is
illustrated by the increases in prolactin secretion following lesion
of the pituitary stalk (Jacobsohn and Westman, 1945) or ectopic
transplants in hypophysectomized rats (Everett, 1954). Following
the demonstration of DA-containing nerve terminals in ME (Hokfelt
1967), DA was shown to inhibit prolactin secretion in vitro (Birge,
Jacobs, Hammer and Daughaday, 1970). DA has been detected in
hypophysial portal blood in sufficient quantity to inhibit prolactin
secretion (Ben-Jonathan, Oliver, Weiner, Mical and Porter, 1977;
Gibbs and Neill, 1978) and DA receptors have been demonstrated on
lactotrophes (Goldsmith, Cronin and Weiner, 1979).
While there is general agreement about the importance of DA as a
prolactin-inhibitory factor (PIF), there is considerably less
evidence for the physiological involvement of other PIFs or
prolactin-releasing factors (PRFs). As discussed above, GABA has
been proposed to be a PIF, and is considered in detail in Chapter
5. The thyrotropin releasing hormone (TRH) metabolite
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histidylprol ine-diketopiperazine has been demonstrated to inhibit
prolactin secretion in vitro (Enjalbert, Ruberg, Arancibia, Priam,
Bauer and Kordon, 1979b) as have catecholoestrogens (Linton, White,
de Tineo and Jeffcoate, 1981) and somatostatin (Vale, Rivier,
Brazeau and Guilleman, 1974) (although somatostatin has also been
shown to stimulate prolactin secretion in vitro (Mitchell and Ogier,
1985). A peptidergic PIF has recently been described (Nikolics,
Mason, Szonyi, Ramachandran and Seeburg, 1985).
The abrupt increase in prolactin secretion caused by the
initiation of suckling has led to suggestions that withdrawal of
tonic inhibition may not completely account for this. As DA is not
the sole PIF, this cannot be very readily examined, but the
involvement of stimulatory factors has been increasingly examined.
A very large number of substances have been reported to have PRF
activity (Leong, Frawley and Neill, 1983) including TRH (Tashjian,
Barowsky and Jensen, 1971), opiates (Enjalbert, Ruberg, Arancibia,
Priam and Kordon, 1979c) and vasoactive intestinal peptide (VIP)
(Ruberg, Rotsztein, Arancibia, Besson and Enjalbert, 1978). VIP is
found in brain and in hypophysial portal blood (Said and Porter,
1979) and antiserum to VIP has recently been shown to have
pronounced effects on the stimulation of prolactin secretion by both
suckling and ether (Abe, Engler, Molitch, Bollinger-Gruber and
Reichlin, 1985). There is also evidence that oxytocin is a PRF: it
is found in a projection to ME (Silverman, 1976) and in hypophysial
portal blood (Horn, Robinson and Fink, 1985), and stimulates
prolactin secretion in vitro (Lumpkin, Samson and McCann, 1983).
The control of prolactin secretion may therefore have more in common
with other PD hormones than has previously been recognised, in terms
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of peptidergic stimulation (and inhibition) of secretion.
The apparent complexity of control at the level of the pituitary
suggests that particular PIFs and PRFs may act only under certain
conditions. This may be regulated by 'prolactin responsiveness
factors' (Leong et al, 1983), which may or may not have direct
effects on prolactin secretion. An interaction between DA and TRH
has been demonstrated in vivo and in vitro, the presence or absence
of DA reducing or increasing respectively the responsiveness to TRH
in a more than additive manner (Fagin and Neill, 1981; Plotksy and
Neill, 1982). These results are however complicated by a 'rebound'
effect of withdrawal of DA seen in vitro, such that secretion is
transiently stimulated above basal rates (Matsushita, Kato,
Shimatsu, Katakami, Yanaihara and Imura, 1983).
Steroids may also modulate lactotrophe responsiveness:
preincubation of PD cells in culture with oestradiol has been
reported to prevent the inhibitory effect of DA but to enhance the
stimulatory effect of TRH (Raymond, Beaulieu, Labrie and Boissier,
1978). Corresponding electrophysiological observations have also
been made (Dufy, Vincent, Fleury, Du Pasquier, Gourdji and
Tixier-Vidal, 1978; 1979). Such an interaction may participate in
the proestrus prolactin surge.
A third method of control of lactotrophe responsiveness may be
by a paracrine interaction with other cells, both with other
lactotrophes (which may contribute to the pulsatile nature of
prolactin secretion (Shin and Chi, 1979; Shin and Reifel, 1981) and
other cell types, for example gonadotrophes. Luteinizing hormone
releasing hormone (LHRH) was reported to have no effect on prolactin
secretion from partially purified lactotrophes, but stimulated
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prolactin secretion after addition of gonadotropics (Denef and
Andries, 1983). Recent in vivo experiments have provided support
for this interaction (Debeljuk, Torres-Aleman and Schally, 1985).
The low concentration of GABA in hypophysial portal blood under
basal conditions (Mitchell et al, 1983) suggests that it is not of
major importance in the maintenance of tonic inhibitory control of
prolactin secretion. The secretion of GABA from ME could be greatly
increased by electrical stimulation (Mitchell et al, 1983) or by
i.c.v. prolactin injection (Apud et al, 1984a) suggesting that GABA
may provide a reserve of inhibitory control in feedback regulation.
A further possibility is that GABA may modulate lactotrophe
responsiveness to PRFs e.g. TRH and VIP, and experiments
investigating this are described in Chapter 5.
Most studies investigating prolactin secretion in vivo or
in vitro rely on radioimmunoassay measurements, but there is
considerable evidence that prolactin is not a homogeneous
substance. Suh and Frantz (1974) demonstrated two forms of
prolactin in human plasma by gel filtration, with identical
immunological properties. Variations in bioassay to
radioimmunoassay potencies have been described for different forms
of prolactin separated by gel electrophoresis (Asawaroengchai,
Russell and Nicholl, 1978) and one of three bands separated by Sinha
and Baxter (1979) had very high bioassay activity but no immunologic
cross-reactivity with the major band. The presence of a cleaved
form of rat prolactin has been demonstrated (Mittra, 1980a) which
was present in different ratios to prolactin in different
physiological states, eg pregnancy, and had potent mitogenic
activity in mammary epithelial cells, a property not shared with
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prolactin standards (Mittra, 1980b). The suggestion in these
studies that different forms are differentially controlled and have
different functions is supported by the demonstration that TRH and
serotonin stimulated the secretion of different forms in vivo
(Lawson, Gala, Chin and Haisenleder, 1980). Transformation of
prolactin from one form to another may underly observations of
depletion of pituitary prolactin during suckling (Grosvenor, Mena
and Whitworth, 1980).
1.8 Aims of this Thesis
The primary aim of this Thesis was to provide further evidence
for neuroendocrine actions and function of GABA, in both PD and NI.
Three broad areas of approach were to be used:
I) Radioligand binding studies to investigate the
GABA/benzodiazepine receptor complex in the pituitary.
II) In vitro superfusion of PD tissue to determine the effects
of GABA on pituitary hormone secretion.
Ill) Investigation of the properties of the nerve terminals of
the GABAergic innervation of ME and NI, and their
interactions with other neuroendocrine transmitter systems,
particularly with the dopaminergic innervation of both
areas.
These various models were also to be used for the investigation
of the principles and mechanisms of GABAergic transmission in
general, particularly postsynaptic GABA receptor pharmacology of





Animals used for the majority of experiments were male Wistar
rats supplied by the University of Edinburgh Centre for Laboratory
Animals. For the experiments in Chapter 12 homozygous Brattleboro
rats were bred in the Department of Pharmacology, and Long Evans
rats were purchased from Charles River, U.K. Ltd (Margate, Kent).
The animals were maintained under controlled lighting (lights on
05.00-19.OOh) and temperature (22°C) and had free access to tap
water and Diet 41B (Oxoid, Basingstoke, Hants).
2.2. Dissection of tissues
For all dissections, rats were stunned, decapitated and their
brains removed. The pituitary gland was then removed from the base
of the skull and NI was then separated from the PD with fine
forceps. For dissection of PI and PN, NI was put on a chilled glass
plate under a binocular microscope. PI lobules of cells were
visible, and could be carefully removed from PN using a pair of
insect pincers. ME was dissected under a binocular microscope on a
chilled glass plate according to Cuello, Horn, Mackay and Iversen
(1973). The cut pituitary stalk was held with fine forceps and the
borders of ME (defined by the presence of capillary loops) cut to a
depth of 0.2-0.3mm with iridectomy scissors. The cerebellum was
dissected from the pons, and after a coronal section at the caudal
limit of the olfactory tubercles, the frontal cortex was dissected
from the anterior block of brain. The hippocampus was dissected from
the posterior block after making a midline sagittal section. When
required, kidneys were also rapidly removed and were dissected free
of the surrounding connective tissue before use.
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2.3 Radioimmunoassays.
Numerous reviews on the techniques and principles of radio¬
immunoassay (RIA) have been published (Midgley, Niswender and Rebar,
1969; Kirkham and Hunter, 1971; Yalow and Berson, 1971; Yalow,
1980), and therefore only the methods used in this Thesis to measure
hormones in in vitro perfusates of rat pituitary glands will be
described here. Individual details of the methods of preparation
and purification of radio-labelled hormones and the buffers used are
given in the appendices.
The underlying principle of RIA is the competition between a
fixed amount of radiolabelled antigen and the unknown amount of
unlabelled antigen for binding sites on a limited number of primary
antibody molecules. Binding of radiolabeled antigen is inversely
dependent on the concentration of unlabelled antigen in the sample
which can then be determined by reference to a set of standards of
known concentration.
11
Hormones were labelled with I (Na I, lOOmCi/ml,
Amersham International) using modifications of the chloramine-T
method (Greenwood, Hunter and Glover, 1963). In all assays, free
hormone was separated from antibody-bound by the double antibody
technique (Utiger, Parker and Daughaday, 1962). Bound hormone was
retained for counting using a Berthold Mag310 Gamma counter (Scotlab
Instrument Sales, Bellshill, Scotland).
Assay results were calculated by the inbuilt machine programme
of the counter, by linear regression of the standard curves with
logit B/Bo on the ordinate and log concentration on the abscissa.
B/Bo represents the ratio of bound (standard or sample) to total
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bound, and logit B/Bo = In (B/Bo/(1-B/Bo)). Upper and lower limits
of detection of assays were taken as the concentrations which caused
90% and 10% displacement respectively of labelled antigen from the
primary antibody. The reproducibility and reliability of the assays
were monitored by the inclusion of two known quality control pools
in each assay, enabling calculation of intra- and inter-assay
coefficients of variation (Rodbard, 1971). Additional quality
control data was obtained by recording total counts, and blanks (no
primary antibody) and total bound (no unlabelled antigen) as
percentages of total counts, and the calculated equivalent
concentrations of hormone corresponding to 20%, 50% and 80% B/Bo.
Standards in triplicate and samples in duplicate were aliquoted
into disposable plastic tubes (LP3, Luckham Ltd) using automatic
pipettes (Pipetman or Microman, Gilson) and reagents were dispersed
using a Compupet automatic pipetting system (General Diagnostics).
2.3.1. Radioimmunoassay of prolactin
Pituitary superfusate concentrations of prolactin were measured
using double antibody RIA kits supplied by the National Institute of
Arthritis, Diabetes, Digestive and Kidney Diseases (NIADDK,
Baltimore, USA), as described by Pickering (1978). The assay is
outlined in Appendix I. Standards (range 0.5-64ng/ml) were prepared
from rat-PRL-RP-1 and rat-PRL-I-5 was used for iodination. The
primary antiserum was rabbit anti-rat-PRL-S5, at a final dilution of
1:20,000. After incubation the antiserum-bound hormone was
separated by precipitation with goat anti-rabbit gamma globulin
(ARGG) (Scottish Antibody Production Unit (SAPU), Law Hospital,
Carluke, Lanarkshire) at a final dilution of 1:100.
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A representative standard curve and quality control data are
shown in Figures 2.1 and 2.2 respectively. The inter- and
intra-assay coefficients of variation were 5.3% and 1.4%
respectively, and the lower limit of detection was 12-16 ng/ml for
20yl samples of superfusate.
2.3.2. Radioimmunoassay for growth hormone.
Pituitary superfusate concentrations of GH were measured by
double-antibody RIA using materials provided by NIADDK. The assay
is outlined in Appendix I. Standards (range 0.5-32ng/ml) were
prepared from rat-GH-RP-1 and rat-GH-I-4 was used for iodination.
The primary antiserum was monkey anti-rat-GH-S4 used at a final
dilution of 1:36,000. After incubation bound hormone was separated
from free using anti-human gamma globulin (SAPU) at a final dilution
of 1:150.
A representative standard curve is shown in Figure 2.3. The
inter- and intra-assay coefficients of variation were 12% and 9%
respectively. 40ul aliquots of a 1:20 dilution of superfusate were
assayed and the lower limit of detection was 100-120 ng/ml.
2.3.3. Radioimmunoassay for luteinizing hormone
Pituitary superfusate concentrations of LH were measured using
the ovine-ovine RIA developed by Niswender, Midgley, Monroe and
Reichert (1968). The protocol is outlined in Appendix I.
Standards (range 0.25-16ng/ml) were prepared from ovine LH
(NIH-LH-S18) and ovine LH (LER-1056-C2) provided by
Dr L. E. Reichert Jr, (NIADDK) was used for iodination. The primary
antiserum (GDN-15) was provided by Dr. G.D. Niswender and was used
1
at a final dilution of 1:240,000. After incubation of I-LH
with antiserum and standards/samples, bound was separated from free
hormone using ARGG (SAPU) at a final dilution of 1:100.
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A representative standard curve is shown in Figure 2.4 and
quantity control data in Figure 2.5. The inter- and intra-assay
coefficients of variation were 1% and 9% respectively. 100ul
aliquots of supefusate were assayed in duplicate, and the lower
limit of detection of the assay was 0.35 - 0.45 ng/ml.
2.3.4. Radioimmunoassay for ACTH
ACTH was measured in pituitary superfusate using double antibody
RIA. The protocol used in this Thesis is given in Appendix II.
Standards (range 3-200pg/ml) were prepared from synthetic human ACTH
(1-39) provided by NIADDK, which was also used for iodination. The
primary antiserum used was IgG-ACTH-1 (IgG Corporation, Nashville,
USA) at a final dilution of 1:30,000. Bound was separated from free
hormone using ARGG (SAPU) at a final dilution of 1:20.
A representative standard curve is shown in Figure 2.7. Only
three ACTH assays were performed, and quality control data conformed
to values previously established.
2.3.5. Radioimmunoassay for thyroid stimulating hormone
TSH was measured in pituitary superfusate by double antibody RIA
using materials supplied by NIADDK. An outline of the protocol is
given in Appendix I. Standards (range 0.3-50 ng/ml) were prepared
from rat-TSH-RP-2 and rat-TSH-I-6 was used for iodination. The
primary antiserum was anti-rat-TSH-S-2 at a final dilution of
1:10,000 and after incubation bound hormone was separated from free
using ARGG (SAPU) at a final dilution of 1:100.
All results in this Thesis derive from one assay, the standard
curve for which is shown in Figure 2.6. The intraassay coefficient




All protein assays in this Thesis were carried out according to
the method of Geiger and Bessman (1972). Aliquots of homogenate or
bovine serum albumin standards (range 4-20yg) were made up to 200ul
with distilled water in LP3 tubes and 500vil alkaline copper reagent
was added. After 20 min 1ml of diluted Folin-Ciocalteau reagent was
added, and absorbance of the solution was measured at 725nm using a
Gil son model 250 spectrophotometer. Details of the method are given
in Appendix III. Values for samples were read off from the standard
curve, which showed linear absorbance against protein concentration
over the range used.
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GABA^ and GABAg binding sites in the pituitary gland.
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3.1 Introduction
Synaptically-released GABA may interact with a variety of
available recognition sites. These include postsynaptic or
presynaptic receptors, or neuronal or glial high-affinity uptake
sites. Early studies of binding sites for radio!abelled GABA showed
their interaction with ligand to be Na+- dependent (Sano and
Roberts, 1963; Varon, Weinstein, Kakefuda and Roberts, 1968;
DeFeudis, 1973), a characteristic of high-affinity uptake.
Sodium-dependent binding of GABA also shows the same pharmacological
profile as GABA uptake sites (De Feudis, 1973; Enna and Snyder,
1975). By contrast, the more recently detected Na+-independent
3
binding sites for [ H]GABA show different characteristics (Enna
and Snyder, 1975) and a pharmacological profile similar to that of
postsynaptic GABA receptors, for both agonists and antagonists
(Zukin, Young and Snyder, 1974; Wong and Horng, 1977; Greenlee, Van
Ness and Olsen, 1978). GABA binding sites (Na+-independent
hereinafter) show apparent heterogeneity with two sites having
different affinities but markedly similar pharmacological profile
(Olsen, Bergman, Van Ness, Lummis, Watkins, Napias and Greenlee,
1981). These two sites have since been reported to show differences
in that membrane treatment with either ammonium thiocyanate or
diethylpyrocarbonate selectively abolished high-affinity [ H]GABA
binding, without altering low-affinity binding or GABAergic
3
enhancement of [ Hjbenzodiazepine binding (Browner, Ferkany and
Ticku, 1981; Burch, Thyagarajan and Ticku, 1982). Conversely,
3
sulfanilate treatment abolished low-affinity [ H]GABA binding and
3
GABAergic enhancement of [ H]benzodiazepine binding (Burch et al
1982).
[3H]Muscimol has also been used as a ligand for post-synaptic
GABA receptors (Snodgrass, 1978; Beaumont, Chilton, Yamamura and
Enna, 1978; Williams and Risley, 1979), and the sites thus labelled
show many of the same characteristics as those labelled with
3
[ H]GABA. Pharmacological profile, regional and subcellular
distributions of the sites labelled are similar, and, like
3 3
[ H]GABA binding, binding of [ H]muscimol is enhanced by
freezing and Triton X-100 treatment (Enna, Beaumont and Yamamura,
3
1978; De Feudis, 1980). [ H]Muscimol also appears to bind to two
sites in some reports (Beaumont et al, 1978; Williams and Risley,
1979; Jordan, Matus, Piotrowski and Wilkinson, 1982) but not others
(Snodgrass, 1978).
+
In all the studies on Na -independent GABA binding sites cited
here, the pharmacological profile has been of the GABA^ receptor.
A binding site which appears to correspond to the GABAg receptor
has been described, which can be labelled by either [ H]baclofen
or [3H]GABA (Bowery, Hill and Hudson, 1983). Interaction with
this binding site shows an absolute requirement for divalent
2+
cations: Ca is generally used and maximally enhances binding at
physiological concentrations (Bowery et al, 1983). The
pharmacological profile is clearly different from both postsynaptic
GABA^ receptors and GABA uptake sites, with only GABA, (±) and
(-)baclofen being markedly active (Hill and Bowery, 1981). In the
original studies, only one class of site was labelled using either
[^H](±)baclofen or [3H]GABA (Hill and Bowery, 1981; Bowery et
al, 1983) but subsequently, non-linear Scatchard plots have been
obtained using [ H](-)baclofen (which showed improved binding
characteristies over the racemate) (Bowery, Hill and Hudson, 1985)
3
and [ H]GABA (Bowery et al, 1985; Karbon, Durman and Enna, 1983).
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Radioligand binding studies using [^H]GABA or [^H]muscimol
to label GABA^ sites have been performed on PD from both female
rats (Grandison and Guidotti, 1979; Fiszer de Plazas, Becu,
Mitridate de Novara and Libertum, 1982; Racagni, Apud, Iuliano,
Cocchi, Locatelli and Muller, 1983; Apud, Masotto, Cocchi,
locatelli, Muller and Racagni, 1984) and humans (Grandison,
Cavagnini, Schmid, Invitti and Guidotti, 1982). Specific binding of
? rojc[JH]GABA was not detectable in male/PD (Fiszer de Plazas,
Seilicovich, Duvilanski, Gonzalez and Rettori, 1983).
In these studies on the rat, membranes were incubated in Triton
X-100 before assay. This results in the conversion or loss of the
low-affinity sites seen in untreated membranes to a single
population of sites with high affinity (Beaumont et al, 1978), and
in agreement with the results on CNS membranes, Scatchard plots of
[ H]GABA binding to Triton-treated PD membranes were linear
(Grandison and Guidotti, 1979; Fiszer de Plazas et al, 1983).
O
Scatchard plots of [ H]muscimol binding, however, were
curvilinear, with high and low affinity components (Racagni et al,
1983; Apud et al, 1984). Although some GABA-receptor mediated
effects have been demonstrated in NI (Zingg et al, 1979; Taraskevich
and Douglas, 1982; Demeneix et al, 1984) no binding studies have
previously been performed in this region. These experiments set out
to re-examine GABA^ binding sites in PD, to investigate the
presence of GABA^ sites in NI, and GABAg sites in both areas,
O o
using both [ H]GABA and [JH]muscimol as ligands.




Aminobutyric acid, y-[2,3- H]-([ H]GABA, 82.6 Ci/mmol) and
3 3
[methylene- H (N)]muscimol ([ H]muscimol, 29.4 Ci/mmol) were
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obtained from New England Nuclear, Dreiech, W. Germany. GABA,
muscimol, and imidazoleacetic acid (IAA) were obtained from Sigma,
Poole, isoguvacine was the gift of Dr. P. Krogsgaard-Larsen and
(^baclofen was the gift of Ciba Geigy, Basle, Switzerland. Other
chemicals were Analar grade, BDH, Poole.
3.2.2.Membrane preparation
Male Wistar rats (150-?50g) were stunned and decapitated, the
pituitary gland removed, and dissected into PD and NI. Cerebellum
and frontal cortex were also dissected and tissues were stored at
-20°C. Membranes were prepared by homogenisation of tissue in 100
volumes of the appropriate ice-cold buffer (see below) using a high
frequency homogeniser (Ystral, Dottingen, W.Germany) (setting 3 for
5 sec), and centrifugation at 48,000g for 10 minutes at 4°C. After
discarding the supernatant, the membrane pellet was suspended in
fresh buffer and stored at -20°C until use 1-3 days later. On the
day of assay, the membranes were thawed and the washing procedure
was repeated a further 4 times. Freeze/thaw treatment and repeated
washing have been shown to be necessary to remove the very high
levels of endogenous GABA present in brain tissue (Gardner, Klein
and Grove, 1981).
3.2.3 Radioligand binding assays
Two radioligand binding assays were used:
(1)[^H]GABA binding to GABA^ and GABAg sites. Whole brain and
pituitary region membranes were prepared in 50mM Tris HC1 buffer, pH
7.4, containing 5mM CaClg. This concentration of Ca ions has
been shown to optimise binding to GABAg sites (Bowery, Hill and
3
Hudson, 1983). [ H]GABA was used as ligand at concentrations
between 2 and 2,000nM for whole brain saturation analysis of
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binding, and at lOnM for analysis of relative binding to PD and NI.
(2 )[^H]Muscimol binding to GABA^ sites. CNS region and
pituitary membranes were prepared in 50mM Tris HC1 buffer, pH 7.1.
[ H]Muscimol was used as ligand at concentrations between 0.5 and
200nM for saturation analyses of binding to cerebellar and frontal
cortex membranes, and up to lOOnM for pituitary membranes. For
estimation of the distribution of high and low affinity sites within
the pituitary, concentrations of 2nM and 20nM were used.
In both cases, assays were carried out in duplicate on 200-600pg
of membrane protein (in a final volume of 1 ml) in 1.5 ml poly¬
propylene tubes (Sarstedt, W.Germany), and lOOyM GABA was used to
O
define non-specific binding. [ H]GABA assays were incubated at
20°C for 15 min before being cooled on ice for 5 min, and
[ H]muscimol assays were incubated on ice for 60 min. Assays were
terminated by centrifugation at 16,000g for 2 min at 4°C, the
supernatant was aspirated and the tube and pellet washed
superficially with 1.2ml of ice-cold buffer. lOOyl of Protosol (New
England Nuclear) was added to solubilise the pellet. After
neutralisation of the Protosol with 100 pi of 1M HC1, the assay tube
was placed in a scintillation counting vial and covered in 18 ml of
liquid scintillation counting fluid NE265 (Nuclear Enterprises Ltd.,
Sighthi11, Edinburgh). After thorough mixing radioactivity was
counted at =47% efficiency in a Beckman counter. Protein
determinations on aliquots of homogenates were performed as
described in Section 2.4. In both cases binding was linear with
protein concentration over the range used.
3.2.4. Calculation of results
Saturation analyses of binding of [ H]GABA to whole brain
3
membranes and [ H]muscimol binding to brain regions and whole
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pituitary membranes was analysed in two ways, both graphically after
transformation of data according to Scatchard (1949), and by a
computerised iterative least-squares method. Two computer
programmes were used:
( i) a single-site programme to fit a straight line to data, used
for analyses of [ H]GABA binding to GABAg sites in whole brain,
(ii) a two-site programme that fitted a hyperbola to the data, used
for [^H]GABA binding to GABA^ sites in whole brain and
3
[ H]muscimol binding in all regions. Both programmes generated
Kn and B values for one or two binding sites as appropriate.D max 3
For single-concentration analysis of binding of [ HjGABA and
3
[ H]muscimol to pituitary regions, results are expressed as
specific fmol bound/mg protein at that concentration.
The computer programmes were generously provided by Professor B.
Ginsborg.
3.3. Results
3.3.1. [^H]GABA assay characteristics
3
The [ H]GABA binding protocol was based on that of Bowery,
Hill and Hudson (1983) who developed it to optimise GABAg
binding. In this study the assays were chilled on ice for 5 min
before being centrifuged as this was found to increase the
reproducibility of the assay without altering the amount of specific
binding (Bowery et al, 1983). Both IAA and (±) baclofen caused
3
concentration- dependent displacement of [ HjGABA (lOnM) binding
from whole-brain membranes but neither drug caused complete
displacement at lOOyM (Figure 3.1-)• The amount of IAA-displaceable
binding at that concentration (69 ± 2%, n = 4) was equivalent to
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that resistant to baclofen (66 ± 3%) and that sensitive to 40yM
isoguvacine (66 ± 4£), the GABA^ agonist originally used to
3
discriminate [ H]GABA binding under these conditions into GABA^
and GABAd sites (Bowery et al, 1983). (Both isoguvacine and IAA
D
show a considerable margin of selectivity for GABA^ over GABAg
sites (Hill and Bowery, 1981); IAA was used here because of
restricted availability of isoguvacine). When high concentrations
of either IAA or baclofen were included in the assay to suppress
binding to one site, the other drug caused complete displacement
(Figure 3.2.). Thus in the presence of 40yM IAA, (±)baclofen
displaced the remaining binding with a Ki in the order of 200-300nM
and caused 96 ± 1% displacement at lOOyM (n = 4). Similarly, in the
presence of lOOyM (±)baclofen, IAA displaced the remaining binding
)<y £ 1
with high potency^ This demonstrates the ability of IAA and
baclofen to selectively displace [^H]GABA from GABA^ and GABAg
binding sites respectively in the protocol employed. Subsequently,
binding of [^H]GABA, displaceable by lOOyM (±)baclofen, was
defined as "GABAg" and that resistant to displacement by lOOyM
(±)baclofen but sensitive to lOOyM GABA as "GABA^".
3.3.2 [^H]GABA binding to brain and pituitary.
Saturation analysis of [ H]GABA binding to whole brain
membranes using this concentration of baclofen to discriminate
binding gave the following results (Figure 3.3.): GABA^ sites
showed two components of differing affinity, as has been previously
described for membranes prepared without Triton X-100 treatment
(Olsen et al, 1981). The high affinity component had a Kg 6.9 ±
1.8nM, Bmax 169 ± 46fmol/mg protein, and the low affinity had a Kg
256 ± 35nM, Bmax 1790 ± 160fmol/mg protein (n = 4). GABAg sites
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showed linear Scatchard plots, with KQ 28 ± 4nM, Bmax 419 ±
35fmol/mg protein (n = 4).
Specific binding of lOnM [^H]GABA was detectable in both PD
and NI, although less than in brain. In PD binding was 35%
specific, (displaceable by lOOpM GABA) accounting for
= 4,500dpm/assay, and was partly baclofen-sensitive and partly
baclofen-insensitive. The concentration (as measured) of GABA^
sites was 20.9 ± 1.7 fmol/mg protein, and of GABAg sites was 16.5
± 1.8fmol/mg protein. In NI there were found to be fewer GABA^
sites (5.5 ± 0.7 fmol/mg protein) and no detectable GABAg sites
(baclofen-sensitive binding was 0.6 ± 1.4fmol/mg protein), n = 5 in
al1 cases (Figure 3.4).
3.3.3 [^H]Muscimol binding
The results of saturation analyses of [ H]muscimol binding to
frontal cortex and cerebellum membranes are shown in Figure 3.5. and
Table 3.1. The affinity constants for the two components are
similar to those reported by Williams and Risley (1979) who used a
filtration assay. In our hands, however, the low affinity component
was greatly reduced using a filtration assay (data not shown) and
3
therefore a centrifugation method similar to that for the [ H]GABA
binding experiments described here was used.
The higher affinity and lower non-specific binding
(approximately 50% using pituitary tissue) of [ H]muscimol
compared to [ H]GABA enabled saturation analyses to be carried out
on whole pituitary membranes. The results shown in Figure 3.6 and
Table 3.1 show that the affinity constants of the two components are
similar to those found in the CNS regions, but that the Bmax values
are considerably lower.
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The distribution of [^H]muscimol binding sites within the
pituitary gland was examined using ligand concentrations of 2nM and
20nM (Figure 3.7). At 2nM, approximately 70% of binding is to the
high affinity site and at 20nM a similar fraction is to the low
affinity site (Figure 3.6). Binding at 2nM comprised 9.5 ± 0.8
fmol/mg protein in PD and 3.0 ± 0.2fmol/mg protein in NI whilst at
20nM there was 21.3 ± 1.2fmol/mg protein in PD and 6.3 ± 0.4fmol/mg
protein in NI (n = 5, PD; n = 4, NI). Thus the relative
concentration of GABA^ sites in PD found using [ H]GABA was
confirmed. The ratio of binding at 20nM to binding at 2nM was 2.2
in PD and 2.1 in NI. This suggests that the high and low affinity
[ Hjmuscimol binding sites are distributed in the same proportions
between PD and NI.
3.4 Piscussion
The presence of GABA binding sites in PD has been previously
3
investigated using [ H]GABA as ligand in both female rat
(Grandison and Guidotti, 1979; Fiszer de Plazas et al, 1982) and
human tissue (Grandison et al, 1982) although no binding sites were
apparently detectable in male rats (Fiszer de Plazas et al, 1983).
In all cases, linear Scatchard plots were reported, with values
of approximately 35nM, and Bmax values of 0.65 - 1.2pmol/mg
protein. This contrasts with the results of Olsen et al (1981) who
3
found that [ H]GABA binding to frozen/thawed brain membranes
without detergent treatment revealed two components with KQ values
of = lOnM and 300nM (similar to the values of 7nM and 250nM reported
here and by others (Jordan et al, 1982). [ H]Muscimol has also
been shown to bind to two sites with values differing by
30-fold in well-washed membranes (Beaumont et al, 1978) but after
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Triton X-100 treatment, only one site, with high affinity, was
found, although the Bmax was not altered. The results presented
3 3
here using both [ H]GABA and [ H]muscimol confirm that two
GABA^ binding sites are present on CNS membranes, when one
freeze/thaw cycle but not detergent is used during preparation and
demonstrate very similar sites in the pituitary gland. Bmax values
3 3
for [ H]GABA and [ H]muscimol binding to CNS membranes are
similar to those reported in the literature, (small differences
being attributable to the use of a whole tissue homogenate in these
studies compared with semi-purified synaptosomal membranes by some
others). However the Bmax values for [ H]muscimol binding to
pituitary membranes reported here are very much lower than the
3
values reported elsewhere: the total Bmax for [ H]muscimol here is
50fmol/mg protein, compared with values of 680fmol/mg protein
(Fiszer de Plazas et al, 1982) and 1200fmol/mg protein (Grandison
and Guidotti, 1979) using [ H]GABA, although more comparable
findings using [ H]muscimol have also been reported (Racagni et
al, 1983; Apud et al, 1984). These higher values are from
experiments on PD tissue rather than whole pituitary as reported
here, but the 'diluting' effect of NI tissue could not be sufficient
to account for the greater than 10 fold difference. Saturation
analyses of [ H]GABA binding to pituitary membranes could not be
performed, but the close parallels in ratios of sites for GABA^
3 3
sites labelled by either [ H]GABA or [ H]muscimol (Figures 3.4
and 3.7) suggest that discrepancies caused by the different ligands
cannot account for these large differences. This also suggests that
any effect of Ca^+ on [^H]GABA binding to GABA^ sites (Corda
and Guidotti, 1983) was of minor importance. A more likely
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explanation for the large discrepancy is the use of Triton X-100
during membrane preparation. Although Triton X-100 has been
3
reported to increase the Kg but not the Bmax values of [ H]GABA
3
and [ H]muscimol binding to CNS tissue (possibly by removal of
endogenous inhibitors such as GABAmodulin (Toffano, Guidotti and
Costa 1978)), it is possible that some experimental protocols may
not allow detection of a significant proportion of the lower
affinity sites until their affinity is enhanced by detergent
treatment.
The results presented here demonstrate GABA^ binding sites in
NI and Figures 3.4 and 3.7 show that both [^H]GABA and
3 3
[ H]muscimol bind specifically to NI membranes. Both [ H]GABA
3
and [ H]muscimol label fewer sites in NI compared to PD (ratio
PD:NI of 3.8 using [^H]GABA, 3.2 and 3.4 using 2nM and 20nM
[ H]muscimol respectively). The close agreement in the ratios for
the two ligands suggests that both are binding to the same sites.
A population of GABAg sites was detectable in PD, but not NI.
Functional effects of these sites on PD hormone secretion are
discussed in Chapters 5 and 7. In the present studies, [ H]GABA
binding to whole brain membranes (displaceable by lOOyM baclofen)
appeared to be a single component, with Kg28nM. No consistent
curvature was observed even at the highest comcentrations used, in
agreement with the observations by Bowery et al (1983), using both
[^H]GABA and [^HK^baclofen. Karbon et al (1983) have reported
curvilinear Scatchard plots using [ H]GABA to label GABAg sites
in rat frontal cortex and five areas of cow brain, and suggested
that the two populations were distinct, as only the low affinity
sites were reduced after lesion of the dorsal noradrenergic bundle
in the rat. The sites measured in these studies may correspond to
the high-affinity sites of Karbon et al (1983) which may explain the
apparent deficit of GABAg binding sites in NI despite postsynaptic
electrophysiological and biochemical effects of baclofen in that
area (Demeneix et al, 1984; Taraskevich and Douglas 1985), if the
two populations are anatomically and functionally distinct. Bowery
et al (1985) have also reported curved Scatchard plots, using both
C^H](-)baclofen and [^H]GABA and proposed that the inability to
measure the low affinity component in earlier experiments (Hill and
Bowery, 1981; Bowery et al, 1983) was caused by using the
radioligand at too high a concentration. If the concentration of
radioligand was kept low, and increasing concentrations of
unlabelled ligand were used, the low affinity component could be
detected. The technical difficulties of measuring a site of such
low affinity (Kp - 1.2yM) are very great and considerable further
work is required to clarify this point, particularly in view of
possible multiple mechanisms of action of baclofen.
3 +
[ H]GABA binding in Na -free buffers (to eliminate binding
to membrane uptake) meets many criteria of receptor identification
(Zukin et al, 1974; Enna and Snyder, 1975; Greenlee et al, 1978).
3
The studies here are in agreement with the view that both [ H]GABA
3
and [ H]muscimol can be used to label GABA receptors (De Feudis,
1980; Jordan et al, 1982). Table 3.1 shows the results of
saturation analysis of [ Hjmuscimol binding to membranes from
frontal cortex, cerebellum, and whole pituitary. The affinity
constants for each of the two sites are similar in the three areas
examined, and are similar to those reported by others (Beaumont et
al, 1978; Williams and Risley, 1979). However in both the pituitary
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and the frontal cortex it can be seen that the B of the highmax 3
affinity components is much less than that of the low affinity
component (a ratio of approximately 0.3) whereas in the cerebellum
the values are approximately equal. The preponderance of low
affinity sites in frontal cortex has been previously reported using
[^H]GABA (01 sen et al, 1981; Burch et al, 1983) and it has been
suggested that it is the low-affinity site which is linked to the
benzodiazepine receptor (Browner et al, 1981; Burch et al, 1983).
The significance of some regions containing a preponderance of
low-affinity, possibly benzodiazepine-1inked sites, if in fact the
two populations are discrete (Olsen et al, 1981), is unknown. A
significant point is that GABA binding sites are predominantly
localised in PD, whereas the results in Chapter 4 show that central
type benzodiazepine binding sites are approximately 4-fold more
concentrated in NI than in PD. Thus it seems most unlikely that
GABA and benzodiazepine binding sites are ubiquitously linked in a
one-to-one ratio as has been suggested by some workers from receptor
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Outline of methods used to characterise and quantify GABA bindi
sites in the pituitary gland.
- log M
In presence of 100 pM baclofen
baclofen
In presence of UO ^jM IAA
FIGURE 3.2
Displacement of [^HJGABA binding to whole brain membranes in
Ca^ -containing buffer.
(a) Displacement by IAA (•) or baclofen (O) separately.
(b) Displacement by baclofen in the presence of 40yM IAA (O) and by
IAA in the presence of lOOyM baclofen (#).
Non-specific binding defined by lOOyM GABA in all cases. Mean ±





Scatchard plot of [3h]GABA binding to GABAA and GABAg binding
sites in rat whole brain
GABAa sites (•): binding not displaced by lOOpM baclofen but
displaced by lOOyM GABA.
GABAg sites (O): binding displaced by lOOyM baclofen.
Representative experiment, performed in duplicate.
FIGURE 3.4
[3h]GABA binding to GABAA and GABAg sites in PD and NI.
[JH]GABA concentration was lOnM. GABAA (hatched columns) and
GABAg (open columns) binding sites were discriminated using lOOuM
baclofen. Mean ± n = 5.
Bound fmol /mg protein
FIGURE 3.5
(a) Scatchard plot of [3H]muscimol binding to Frontal Cortex
membranes.
(b) Scatchard plot of [3H]muscimol binding to Cerebellum membranes.
Representative experiments. The straight lines represent the high-
and low-affinity components of binding drawn independently. These





























Binding of [^Hjmuscimol to PD and NI membranes.
Open columns: binding at 2nM [3H]muscimol.
Hatched columns: binding at 20nM [3H]muscimol.
Mean ± S.E.M., n = 5, PD; n = 4, NI.
Table 3.1
KDl(nM) fynaxl (fmol/mg KD2 fy,ax2
protein)
Pituitary 1.1 ± 0.1 9.4 ± 0.4 34.7 ± 3.0 46.8 ± 6.7
Frontal cortex 3.8 ± 0.2 608 ± 14 46.6 ± 4.2 2045 ± 69
Cerebellum 4.2 ± 0.2 1003 ± 45 44.7 ± 1.9 1051 ± 75
n = 3-4 Mean ± S.E.M.
Results of Scatchard analysis of [^Hjmuscimol binding to membranes from
whole pituitary, frontal cortex and cerebellum. Kq and Bmax values
were derived from computerised least-squares analysis of Saturation data.
CHAPTER 4
Analysis of benzodiazepine binding sites in the pituitary gland
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4.1 Introduction
High-affinity binding sites for radiolabeled benzodiazepines
were originally demonstrated by Squires and Braestrup (1977) and
Mohler and Okada (1977a) on rat brain membranes, and the affinities
of many benzodiazepines correlated well with their behavioural
potency (Mohler and Okada, 1977a). Similar binding sites have been
demonstrated in human brain (Braestrup, Albrechtsen and Squires,
1977; Young and Kuhar, 1979) and the affinities of many
benzodiazepines at these sites correlate with human daily dosage.
3 3
[ H]diazepam and [ HJflunitrazepam (FNM) also bind with high
affinity to peripheral tissues, notably kidney (Braestrup and
Squires, 1977; Regan, Yamamura, Yamada and Roeski, 1981), but there
are great differences in pharmacological profile between these
peripheral-type sites and the central-type sites, in particular the
selectivity of clonazepam for central-type sites and the
behaviourally-inactive benzodiazepine Ro5-4864 for peripheral-type
sites (Gallagher, Mallorga, Oertel, Henneberry and Tallman, 1981;
Regan et al, 1981). [^H]Ro5-4864 has been used to label these
peripheral-type sites in kidney and in brain (Marangos,
Patel ,Boulenger and CIark-Rosenburg, 1982; Schoemaker, Boles, Horst
and Yamamura, 1983) and they can also be labelled by the
3
non-benzodiazepine [ H]PK11195 (Benavides, Quarteronet, Imbault,
Malgouris, Uzan, Renault, Dubroeucq, Guerency and LeFur, 1983).
While evidence is accumulating for GABAergic control over the
pituitary, it remains an open question whether GABA receptors there
are modulated by benzodiazepine-recognising components. A close
interaction between GABA receptors and sites recognising
benzodiazepines is shown by allosteric effects on equilibrium
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binding:GABA has been reported to enhance the binding of tritiated
benzodiazepines to the central type site by an increase in affinity
(Martin and Candy, 1978; Tallman, Thomas and Gallagher, 1978) but
does not affect the peripheral type site (Marangos et al, 1982).
Further to the division of benzodiazepine binding sites into
'central-' and 'peripheral-' types, it has recently been suggested
that the central type sites may not be homogenous, on the basis of
their interactions with certain non-benzodiazepine compounds. These
compounds, including triazolopyridazines such as CL 218872 (Klepner,
Lippa, Benson, Sano and Beer, 1979) and esters of e carboline-3-
carboxylate (Nielsen and Braestrup, 1980; Braestrup and Nielsen,
1981) show regional variations in affinity consistent with
populations of two distinct subtypes of receptor, BZ^ and BZ^
(Braestrup and Nielsen, 1981) or type I and type II (Young, Neihoff,
Kuhar, Beer and Lippa, 1981) being differentially distributed within
the CNS. These differences can be detected by 'in vivo' binding
studies as well as in vitro (Minchin and Nutt, 1983).
Benzodiazepines however appear to have very similar affinities
for the two putative subtypes. Kinetic analysis of the association
and dissociation of [ H]FNM have led to suggestions that
benzodiazepine binding sites have different functional states with
co-operative interactions rather than their being distinct molecular
entities (Chiu, Dryden and Rosenburgh, 1982; Doble, Iversen and
Martin, 1982; Quast and Mahlmann, 1982). Ethyl e-carboline-3-
carboxylate (ECC)-induced dissociation of [3H]FNM shows different
kinetics to when dissociation is initiated by a benzodiazepine
(Martin and Doble, 1983), and these data suggest that the binding
mechanism for ECC (and other non-benzodiazepines) may be different
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from that of benzodiazepines. This is supported by experiments
involving photoaffinity labelling of benzodiazepine sites with
[^H]FNM (Hirsch, 1982; Brown and Martin, 1983). Nevertheless
[ H]FNM has been reported to bind to two proteins in hippocampus
but only one in cerebellum (Sieghart and Karobath, 1980), and type I
and type II sites appear to be differentially distributed within the
substantia nigra and amygdala (Lo, Niehoff, Kuhar and Snyder, 1983;
Niehoff and Kuhar, 1983) and change differentially after neurotoxin
administration (Medina, Novas and De Robertis, 1983). It remains
clear that benzodiazepine binding sites exhibit different properties
in different regions and the possibility that these 'subtypes' may
have distinctly different roles in vivo points to the importance of
characterising the receptor subtypes present in the pituitary.
Experiments were therefore carried out using [ H]propyl-e-
carboline as a selective ligand for BZ^ type sites (Braestrup and
Nielsen, 1981).
There is increasing evidence that the benzodiazepine class of
drugs may exert neuroendocrine effects in addition to their well
known profile of central actions as anxiolytics, hypnotics,
anti-convulsants and muscle relaxants. For example, benzodiazepines
have been reported to modify the plasma concentration of prolactin
in the rat. A number of benzodiazepines have been shown to lower
basal concentrations of circulating prolactin in male rats, and
attenuate pharmacologically-induced increases (Grandison, 1980,
1981a; Lotz, 1982; Sibilia, Netti, Guidobono, Pagani and Pecile,
1985). The specific benzodiazepine antagonist, Rol5-1788 is
reported to effectively block several of these effects (Lotz,
1982). Furthermore, diazepam markedly attenuated stress-induced
prolactin release and the prolactin surge on the afternoon of
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proestrus in female rats (Grandison, 1982). Diazepam also causes a
prominent stimulation of GH secretion in man (Koulu, Lammintausta,
Kangas and Dahlstrom, 1979).
The possibility that benzodiazepines might be acting directly on
the anterior pituitary gland was raised by the demonstration of
3
specific binding sites for [ H]diazepam on rat pituitary cells in
3
culture (Grandison, 1981b). However, [ H]diazepam could not be
displaced from these cells by clonazepam, but could be by
Ro5-4864. Nevertheless, preincubation of these cells for 24 hours
with diazepam, although at a very high concentration, potentiated
the inhibition of prolactin release caused by receptor agonists for
the putative prolactin release-inhibiting factors dopamine and GABA
(Grandison, 1981b). Similar results have been reported by
Schettini, Cronin, O'Dell and MacLeod (1984) and are discussed
further in Chapter 6.
These studies therefore addressed the following questions.
i)Could any specific binding of [ H]FNM to pituitary membranes
be detected?
ii)Did this specific binding show a central or benzodiazepine
peripheral type pharmacology profile, or was it a mixed
population?
iii)What was the distribution of the two types of site within the
pituitary?
iv)Was there any evidence for interaction between binding sites and
GABA receptors?
v)Did the central-type sites appear to be of the BZ-^ or $1^
subtype, or a mixture?
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4.2 Materials and Methods.
4.2.1. Materials
[Methyl-3H]flunitrazepam ([3H]FNM), specific activity 70-80
Ci/mmol and [propyl-2, 3-3H]e-carboline-3-carboxylate ([3H]PCC),
specific activity 95 Ci/mmol were obtained from New England
Nuclear. Laboratory chemicals (Analar) were obtained from BDH, and
GABA from Sigma. Diazepam, clonazepam and Ro5-4864 were the gift of
Hoffmann-La Roche, and PCC of Dr. I.L. Martin.
4.2.2. Membrane preparation
Male Wistar rats (150—250g) were stunned and decapitated, the
pituitary gland removed, and dissected into PD and NI. Other CNS
and peripheral tissues were also dissected, and all were stored at
-20°C. Membranes were prepared by homogenisation of tissue in 100
volumes of ice-cold 25mM KH^PO^ buffer (pH 7.1) using an Ystral
high frequency homogeniser (setting 3 for 5 seconds). Homogenates
were centrifuged at 48,000g for 10 minutes at 4°C. After discarding
the supernatant, the membrane pellet was resuspended in fresh buffer
before centrifugation. The washing procedure was repeated a further
three times to remove endogenous GABA (Gardner et al, 1981).
The final resuspension of membrane preparations gave
concentrations of 200-600pg protein/ml for pituitary tissue
(linearity over this range is shown in Figure 4.1) and 400-500pg
(«.'■«*)
protein/ml for CNS and kidney tissues. Aliquots of 500pl^were used
for radioligand binding assays. Protein determinations on aliquots
of homogenate were performed as described in Section 2.4.
4.2.3. Radioligand binding assays.
3
The main series of experiments were carried out using [ H]FNM
as ligand at a concentration of 0.5nM or InM (see legends for
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details) in a final assay volume of 2ml. For saturation analyses
ligand concentrations between O.lnM and lOnM were used for
cerebellar and hippocampal membranes and up to 200nM for pituitary
membranes. In experiments to analyse central benzodiazepine
3
receptor subtypes [ H]PCC was used as ligand at concentrations
between 0.05nM and 5nM for saturation analyses.
Unlabelled benzodiazepines and PCC were dissolved in
dimethylformamide which was present in the assay at concentrations
between 0.0004% and 0.02% v/v and had no effect on specific binding
in this range. Nonspecific binding was defined by 10pM diazepam or
200nM clonazepam in parallel incubations.
Assays in duplicate were incubated on ice for 90-180 minutes in
the dark before being rapidly filtered through Whatman GF/B filters
under vacuum and washed with 3 x 5ml ice-cold buffer via the
incubation tube. Filters were transferred to scintillation vials
and 9ml of scintillation fluid was added. Radioactivity was counted
at - 47% efficiency in a Beckman liquid scintillation counter.
To investigate the effects of GABA on [^H]FNM binding to
pituitary membranes, tissue samples were homogenised and washed in
50mM Tris Citrate buffer, pH 7.1, final resuspension being in
phosphate buffer.
4.2.4. Radioligand purity and adsorption experiments
Radiochemical purity was tested by thin layer chromatography on
silica gel plates (Whatman LK5D) using solvent systems of
3
chloroform:acetone (9:1) for [ H]FNM and ethyl acetate:methanol:
3
ammonium hydroxide (5:1:1) for [ H]PCC according to manufacturer's
3
instructions. More than 97% of radioactivity in [ H]FNM samples
3
and more than 99% in [ H]PCC samples co-migrated with the
authentic compound (n = 5 in each case).
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Account was also taken of adsorption phenomena reducing the free
ligand/displacer concentration. Adsorption was assessed across the
ligand concentration ranges used by experiments in which assay
mixtures were carried through the standard preparation and
incubation procedures before centrifugation for 3 minutes at 16,000g
and 2°C. Tritium was counted in aliquots of supernatant. Under the
conditions described (using 600yg protein/ml membrane preparation)
3
whilst true free [ H]FNM concentration represented 71-90% of added
ligand through the range O.lnM to 200nM [^H]FNM added, the
proportion of added [ H]PCC remaining free varied from 82% at 50nM
to only 30% at 0.05nM. Adsorption of both ligands was linear with
protein concentration and appropriate corrections were made to the
true free ligand concentrations in all calculations. The marked
adsorption out of solution of some ligands such as PCC means that
such phenomena must be taken into account to avoid artefactual
distortion of kinetic binding data.
4.2.5. Calculation of results
Displacement data was also analysed as Hill and Hofstee plots.
For Hill plots, data is plotted as
1og % displacement
100-% displacement
against log concentrations of displacing drug. Points were fitted
by linear regression using a Texas programmable calculator. Hill
coefficients were calculated as the inverse of the gradient of the
1ine thus generated.
For Hofstee plots, data is plotted as:
% displacement . . „ ,
i —p—r o ..—t- . , against % displacement,concentration of displacing drug 3 K
Linear Hofstee plots were fitted by linear regression and best lines
for curved Hofstee plots were estimated by eye.
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Saturation experiments were analysed after transformation of the
data according to Scatchard (1949). Obviously linear Scatchard
plots were fitted by linear regression, with the intercept on the
abscissa giving the Bmax value, and -1/gradient giving the KQ
value. A curved Scatchard plot was obtained for
3
diazepam-displaceable binding of [ H]FNM to whole pituitary
membranes (Figure 4.5). An estimate of the best line through the
experimental points was fitted by eye. No numerical data were
derived from this.
4.3 RESULTS
4.3.1. Discrimination of central and peripheral type benzodiazepine
binding sites.
Experiments to establish suitable conditions for discrimination
3
of [ H]FNM binding to central- and peripheral-type sites were
carried out using membranes from whole brain and kidney.
Displacement of [ H]FNM from both brain and kidney membranes by
clonazepam and Ro5-4864 was concentration-dependent, showing sigmoid
curves (Figure 4.2). Hill plots gave coefficients close to unity
and Hofstee plots were linear, results entirely consistent with a
bimolecular interaction at a single population of binding sites in
both areas. In brain and kidney respectively, IC^s of 0.86nM and
5,400nM for clonazepam and 80,000nM and 2.0nM for Ro5-4864 were
obtained, demonstrating the specificity of clonazepam for the
central-type site and of Ro5-4864 for the peripheral-type site. The
curves showed that clonazepam at a concentration of 200nM caused
approximately 100% displacement of [ H]FNM from brain and
negligible displacement from kidney membranes. This concentration
was therefore used subsequently to define central-type binding.
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4.3.2. Central- and peripheral-type benzodiazepine binding sites in
the pituitary gland.
3
Specific binding of InM [ H]FNM, defined by 10yM diazepam, was
detectable in both areas of the pituitary : 28.3 ± 5.0fmol/mg
protein in PD and 101 ± 14fmol/mg protein in NI (n = 5). Clonazepam
and Ro5-4864 produced extended displacement curves with distinct
plateau regions in both areas (Figures 4.3 and 4.4). Hofstee plots
showed pronounced curvature and Hill coefficients were much less
than unity (e.g. for clonazepams.29 in PD and 0.42 in NI). Figures
4.3 and 4.4 show that under the standard assay conditions used,
central-type binding (i.e. that displaced by 200nM clonazepam)
accounted for 27% of total specific binding in PD (7.6fmol/mg
protein) and 34% in NI (34.2fmol/mg protein), a ratio PD:NI of
1:4.5. Peripheral-type (clonazepam insensitive) binding accounted
for 20.7fmol/mg protein in PD and 66.4fmol/mg protein in NI, a ratio
of 1:3.2. Under these conditions, specific binding to pituitary
regions accounted for 800-2,000 dpm/assay representing approximately
60% of total binding, with a duplicate reproducibi1ity in the order
of 7%.
Scatchard plots of [^H]FNM (0.1-200nM) binding to whole
pituitary membranes was biphasic when 10yM diazepam was used to
define non-specific binding (Figure 4.5), consistent with the
presence of two sites. Using 200nM clonazepam to discriminate
central and peripheral sites, binding was resolved into two linear
components: a small population of high affinity clonazepam-sensitive
sites and a larger population of lower affinity sites resistant to
clonazepam. The high affinity site had a of 1.9 ± 0.3nM,
32.8 ± 2.6fmol/mg protein (n = 8), and the lower-affinityiTlaX
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site had a Kn of 34.7 ± 4.9nM, Bm,„ 660 ± 16fmol/mg proteinU ITlaX
(n = 4).
The addition of lOOuM GABA increased the specific binding of InM
3
[ H]FNM to whole pituitary membranes, washed in Tris citrate
buffer, by 24% from 23.8 ± 1.1 to 29.6 ± 1.5fmol/mg protein
(P <0.02, paired t test, Figure'^-6). Central-type binding
(clonazepam-sensitive) was increased by 79% from 8.4 ± 1.1 to 15.0 ±
1.3fmol/mg protein (P < 0.05) but peripheral-type binding was not
significantly altered (17.0 ± 1.3 to 14.7 ± 0.5fmol/mg protein,
n = 4).
4.3.3. Subtypes of central benzodiazepine binding sites in pituitary
and brain regions.
3
[ H]PCC has been reported to be a high affinity specific
ligand for the BZ-^ subtype of central benzodiazepine binding site
and this ligand shows negligible binding to peripheral-type
benzodiazepine sites (Mitchell and Wilson, 1984). [^H]PCC bound
to pituitary membranes in a specific, saturable manner throughout
the concentration range 0.05-5nM. Scatchard plots of [ H]PCC
binding to whole pituitary membranes were linear (Figure 4.7) (using
200nM clonazepam to define non-specific binding), with a Kg of
0.33 ± 0.05nM, Bm3v 36.7 ± 4.8fmol/mg protein (n = 7). The Bm,vITlaX iTlaX
3
of [ H]PCC binding sites was not significantly different from that
3
of clonazepam-sensitive [ H]FNM binding. The results of control
experiments on hippocampal and cerebellar membranes are shown in
Figure 4.8 and Table 4.1.
The displacement of bound [^H]FNM (0.5nM) by unlabelled PCC
also differed between cerebellum and hippocampus. In the
cerebellum, PCC gave an IC^g of 1.3nM and clearly linear Hofstee
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plots, but in the hippocampus, the apparent affinity of PCC was
less, with an IC^q of 8.7nM and distinct curvature in Hofstee
plots (Figure 4.9a, b). Hill coefficients of this displacement data
were 0.96 and 0.71 in cerebellum and hippocampus respectively. When
similar experiments were carried out using pituitary membranes, PCC
showed a similarly high affinity to that in cerebellum (Figure 4.9a,
ICj-q of 1.1 ± 0.2nM, n = 4), giving linear Hofstee plots with no
indication of curvature (Figure 4.9b) and Hill coefficient of
0.9 ± 0.1.
4.4. Piscussion
The experiments on displacement of [^H]FNM by clonazepam and
Ro5-4864 in the brain and kidney (Figure 4.2) demonstrated the
specificity of these two drugs and revealed the conditions necessary
for the two binding sites to be differentiated in a mixed
population. Similar experiments using pituitary membranes gave very
different results from the single component Law of Mass Action
displacement seen in the prototype areas. Extended displacement
curves and non-linear Hofstee plots in both PD and NI suggested the
presence of two distinct types of binding site (Figures 4.3 and
4.4). This was supported by the clearly non-linear Scatchard plot
when diazepam is used to define non-specific binding (Figure 4.5).
From Figure 4.2 it can be seen that 200nM clonazepam causes 100%
displacement from brain and no significant displacement from
kidney. The use of 200nM clonazepam to separate specific binding
into clonazepam-sensitive (central) and -insensitive (peripheral)
sites in the pituitary revealed populations of each type (Figure
4.5) with individually linear Scatchard plots. The
clonazepam-sensitive sites showed higher affinity for [ H]FNM
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(1.9 ± 0.3nM) than the clonazepam- insensitive sites (34.7 ±
4.9nM). The affinity of [ H]FNM for the clonazepam-sensitive site
is similar to that found in CNS regions in this study (Table 4.1),
consistent with this pituitary site representing a central
benzodiazepine receptor. The affinity of [°H]FNM for the
clonazepam-insensitive sites is similar to that reported at the
peripheral benzodiazepine receptor (Regan et al, 1981), being many
fold lower than the affinity for central sites.
Further support for the idea of co-identity of clonazepam-
sensitive sites here with central benzodiazepine receptors was
provided by experiments to investigate the enhancement of tritiated
benzodiazepine binding by GABA. Figure 4.5 shows that lOOyM GABA
3
significantly enhanced the binding of [ H]FNM to well-washed
pituitary membranes. Preparation in buffers containing divalent
cation chetalors (e.g. citrate) has been reported to facilitate
observation of GABA enhancement effects, probably by more efficient
removal of endogenous GABA (Squires and Saederup, 1982). The use of
200nM clonazepam to define central-type binding sites showed that
the increase in [ H]FNM binding is limited to those sites. This
is in accordance with previous reports that in contrast to CNS
tissue GABA has no effect on [ H]FNM binding to kidney membranes
3
(Regan et al, 1981) nor on [ H]Ro5-4864 binding (Marangos et al,
1982).
The pituitary population of central-type binding sites is
clearly present in much lower concentrations than in CNS regions,
with for example even NI having only 13% of the number of sites
found in cerebellum but is similar to the number of GABA binding
sites described in Chapter 3. Nevertheless, the similar
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pharmacological properties of the sites and their interaction with
GABA in these experiments strongly suggest that they may have a
functional role in regulating local GABA receptors. The relatively
small overall population might be explained in terms of a
distribution restricted to certain cell types only, which
individually could possess reasonably dense receptor populations.
The experiments described in Chapters 5 and 7 demonstrate the
presence of benzodiazepine receptors on lactotrophes and
somatotrophes. These cell types make up approximately 60% of PD
(Frawley, Bockford and Hoeffler, 1985), suggesting that these
nonsynaptic receptors may be much less densely packed on these cell
membranes than are the synaptic receptors e.g. in cerebellum.
Benzodiazepine binding sites in the CNS display different
properties in different regions. In areas such as hippocampus and
frontal cortex, but not cerebellum, the binding sites exhibit
kinetics consistent with either a heterogeneity of sites or variable
co-operative interactions between them (Squires, Benson, Braestrup
et al. 1979; Braestrup and Nielsen, 1981; Ehlert, Roeske and
Yamamura, 1981 ;^Prestwick and Horton, 1982; Chiu «0- c<.L lc/?z.)
Furthermore, receptor solubilisation studies have shown
3
multiplicity of [ H]FNM photoaffinity-1abelled proteins in some
areas, including hippocampus and frontal cortex, but not cerebellum
(Sieghart and Karobath, 1980; Sigel, Stephenson, Mamalaki and
Barnard 1983; Asano, Yamada and Ogasawara, 1983). While evidence at
present may not be sufficient to define unequivocally the existence
v
of several distinct benzodiazepine receptor molecules (Martin, Brown
and Doble, 1983) it appears that several sites can be defined in
terms of their regionally different pharmacological properties
(Squires et al, 1979; Braestrup and Nielsen, 1981). PCC binds with
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high affinity to all benzodiazepine binding sites in cerebellum but
in hippocampus shows a similar high affinity at only some sites with
approximately 10-fold lower affinity at the remainder (Braestrup and
Nielsen, 1981). The high affinity sites in cerebellum (and
hippocampus) have been denoted BZ^ and the lower affinity BZ^
although differences between the cerebellar and hippocampal BZ^
sites are apparent in their linkage to GABA receptors (Harris and
Mitchell, 1984). It has been suggested that at low concentrations
O
[ H]PCC can be used as a selective ligand for the BZ-^ site
(Braestrup and Nielsen, 1981).
3
By comparison of the relative B . values of [ H]FNM andmax
3
[ H]PCC binding it is possible to estimate the proportion of the
two sites in an area. Thus the results of such Scatchard analyses
in Figure 4.8 and Table 4.1 suggest that the cerebellum contains
almost exclusively (= 92%) BZ, sites with similar B values1 max
3
for either ligand, whereas the B for [ HlPCC in the3 max L
hippocampus is only 50% of that for [^H]FNM (P < 0.001),
suggesting that BZ-^ and BZ^ sites are present there in
approximately equal numbers. These results on different CNS regions
are in close accordance with those reported by other groups:
Braestrup and Nielsen (1981) and Stapleton, Prestwich and Horton
(1982) found values of 57% and 58% respectively for hippocampus, and
both reported values of 91% for cerebellum.
This heterogeneity in the properties of the sites is confirmed
3
by Hofstee plots of the displacement of bound [ H]FNM by
unlabelled PCC (Figure 4.9), with a single linear component in
cerebellum but a clearly curvilinear plot in hippocampus. This
together with Hill coefficients of 0.96 for cerebellum and 0.71 for
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hippocampus, is consistent with the presence of only one site in the
cerebellum but possibly two in the hippocampus.
Application of the same approaches to characterise the type(s)
of central benzodiazepine binding site in pituitary revealed that
3 t J
[ H]PCC binds :there to a similar number of central sites to
3
[ H]FNM (Figure 4.7). This suggests that the benzodiazepine sites
present are predominantly of the BZ^ type. The results of PCC
O
displacement curves of [ H]FNM on pituitary membranes show an
ICgg of 1.1 ± 0.2nM (very similar to that in the cerebellum
(1.3nM), but rather lower than that in hippocampus (8.7nM)), linear
Hofstee plots and a Hill coefficient close to unity (0.9). These
results support those obtained by saturation analysis and strongly
suggest that the central type benzodiazepine binding sites in the
pituitary are predominantly of the BZ^ type. It therefore appears
that BZ^ receptors must mediate any facilitation of GABA effects
in the pituitary gland by benzodiazepines. The effectiveness of
benzodiazepines in such systems will thus be characteristic of
action at a specific BZ-^ type site and may be of use in the study
of compounds with allegedly selective actions.
The presence of binding sites for [ H]diazepam has been
previously reported in both rat and human PD tissue (Grandison,
1981b; Grandison, Cavagnini, Schmid, Invitti and Guidotti, 198Z;
Voigt, Davis and Wyche, 1984) but clonazepam was reported not to
cause any displacement in either tissue. In contrast, the results
reported here have revealed a population of central type sites in
both PD and NI, and suggest that the distribution of these sites
with GABA receptors is not confined to the CNS.
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Benzodiazepines have been reported to modify plasma prolactin
concentrations, and the pharmacological profile reported (Grandison,
1982; Lotz, 1982) suggest that central-type rather than
peripheral-type receptors are involved. The effects of
benzodiazepines on prolactin secretion and interactions with GABA
are discussed further in Chapter 6.
In addition to PD, benzodiazepine binding sites were found in
NI, with both central and peripheral type binding sites being
concentrated in NI rather than PD. The electrophysiological
properties of PI cells have been reported to be affected by GABA and
these effects were potentiated by diazepam (Taraskevich and Douglas,
1982). No other benzodiazepines were tested but as diazepam had no
effect alone and only potentiated the effect of GABA, it seems
unlikely that peripheral type sites were involved. Although GABA
has been reported to have other effects on NI (Dyball and Shaw,
1979; Zingg et al, 1979; Demeneix et al, 1984-), there are no reports
on the involvement of benzodiazepines. There are clearly,
therefore, likely to be a number of further actions of central type
benzodiazepine sites in the pituitary not yet identified.
Since this work was carried out, an autoradiographic study has
confirmed the presence of central-type benzodiazepine binding sites
in the pituitary (Brown and Martin, 1984). These authors
3
demonstrated (using [ H]Rol5-1788) a minor population of sites in
the PD but a dense population in PI. PN appeared devoid of sites.
[ H]Ro5-4864 has been reported to bind to pituitary tissue
with high affinity very similar to that in kidney and to that of a
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minor population of peripheral type sites in the CNS (Schoemaker et
al, 1983). The B of [^H]Ro5-4864 in pituitary (436 ± 43iii Cl A
fmol/mg protein) is comparable to that reported here for
3
clonazepam-insensitive [ h]FNM binding (660 ± 16 fmol/mg
protein). Schoemaker et al. (1983) reported that the affinity of
FNM for [ H]Ro5-4864 sites is approximately 20-fold lower than
that of Ro5-4864 itself and in accordance with this the Kg value
of 34.7 nM for clonazepam-insensitive [ H]FNM binding here shows a
similar ratio to the Kg values of 0.6 - 1.6 nM for [^H]Ro5-4864
(Marangos et al, 1982; Schoemaker et al, 1983). The results
reported here show that the peripheral type sites are predominantly
localised in NI, in agreement with autoradiographic studies using
[^H]Ro5-4864 (Mohler and Richards, 1983; De Souza, Anholt, Murphy
Snyder and Kuhar, 1985).
Ro5-4864 differs in structure from diazepam by only one
substituent but lacks the classical benzodiazepine profile in
behavioural tests in rodents (Zbinden and Randall, 1967). It has
been reported to possess anticonvulsant activity against maximum
electroshock in mice (deLorenzo, Burdette and Holderness, 1981) but
others have found it to be inactive in that test (Pieri, Pole,
Bonetti, Cumin, Scherschlicht and Haefely, 1983) or recently,
proconvulsant in mice, guinea-pigs and rats (File and Mabutt, 1983;
S
Pieri et al., 1983; Weisman, Cott, Paul and Skolnick, 1983).
/>
Benzodiazepines have been reported to exert various metabolic
effects on transformed cells through peripheral type receptors
(Strittmatter, Hirata, Axelrod, Mallorga, Tallman and Henneberry,
1979; Matthew, Laskin, Zimmerman, Weinstein, Hsu and Engelhardt,
1981; Wang, Morgan and Spector, 1982) and alterations in renal
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benzodiazepine binding have been demonstrated in
experimentally-induced and genetically linked states (Regan et al.,
1981; Taniguchi, Wang and Spector, 1981; Del Zompo, Cherillard,
Saavedra, Post and Tallman, 1982). One important feature of
O
[ H]Ro5-4864 binding sites, however, is that on subcellular
fractionation they sediment in the nuclear rather than
mitochondrial/piasma membrane fraction (Marangos et al., 1982) and
are therefore unlikely to represent cell-surface receptors.
O
[ H]FNM has also been reported to bind to purified frontal
cortical nuclear membranes with a of 28nM (Bormann, Penney,
Case and Averill, 1980), a value which is similar to that of
clonazepam- insensitive binding in the pituitary reported here.
Furthermore, when such binding sites have been described in the CNS,
they appear to be relatively restricted to glial than neuronal
elements (Gallagher et al., 1981; Marangos et al., 1982; Mohler and
Richards, 1983). In contrast, recent electrophysiological studies
have shown interaction of high (30uM) concentrations of Ro5-4864
with the GABA^ receptor complex (Simmonds, 1984); Ro5-4864
antagonised both the effect of muscimol and the potentiation by
phenobarbitone of the effect of muscimol but enhanced the potency of
picrotoxin. Lower concentrations reduced the potentiation of the
response to muscimol by flurazepam (Simmonds 1984) and it was
suggested that Ro5-4864 was acting at sites not previously
characterised in binding studies as a benzodiazepine antagonist
(Pellow, File and Simmonds, 1984).
These studies have defined the distribution of benzodiazepine
binding sites within the pituitary gland, revealing the presence of
central-type (GABA-1inked) sites in addition to the peripheral-type
sites which seem unlikely to relate to specific neurotransmitter
function. The central sites present in pituitary have been further
characterised as the BZ^ subtype, which in other areas such as
cerebellum shows prominent interaction with GABA receptors (Harris
and Mitchell, 1984). Functional effects of the central-type sites
in PD are described in Chapters 6 and 7.
mg protein
FIGURE 4.1
Linearity of binding of InM [^H]FNM to whole pituitary membranes with
protein concentration.
(□) Total binding.
(A) Non-specific binding (luM diazepam)
(•) Specific binding





Displacement of InM [^HJFNM by clonazepam (■) and Ro5-4864(0) from a)
whole brain and b) kidney membranes. Assays were incubated at 0°C for 90
minutes. 10pM diazepam was used to define non-specific binding. Mean ±
S.E.M., n = 4.
FIGURE4.3 DisplacementoflyM[]FNMfrPDmembranesbyc onazepam(■)a d Ro5-4864(•). (a)DisplacementcurvesndbHofst elotfthd ta.Assayw r incubateda0°Cfor90minu s.10UMdiazepamwsetoefine non-specificbinding.Mean±S.E.M.,=4









Representative Scatchard plot of [3(H]FNM binding to whole pituitary
membran es.
(H) non-specific binding defined by 10yM diazepam.
(•) non-specific binding defined by 200nM clonazepam.
(O) binding in the presence of 200nM clonazepam, non-specific binding
defined by 10yM diazepam.














of GABA on binding of InM [3h]FNM to whole pituitary
Columns represent specific binding of InM [3h]FNM in absence
lumns) and presence (solid columns) of lOOyM GABA.
specific binding defined by 10yM diazepam;
SENSITIVE:non-specific binding defined by 200nM clonazepam;
INSENSITIVE: binding in the presence of 200nM clonazepam,
c binding defined by 10yM diazepam,
incubated at 0°C for 90 minutes. Levels of significance




Representative Scatchard analysis of [^h]FNM (#) and [3h]PCC (O)
binding to whole pituitary membranes. Assays were incubated at 0°C
for 120 minutes. Non-specific binding was defined by 200nM
clonazepam in both cases. Lines were fitted by linear regression.
a.b. Boundfmol/mgpr teinBoundfmol/mgpr tein FIGURE4.8 RepresentativeScatchardnalysisof[3h]FNM(•)a d[^HJPCCObindi gt( cerebellumand(b)hippocamp smembranes. Assayswereincub teda0°Cfo120minutes.Non- pecificbi dingwasdefinedy200 M clonazepamiallas s,[^h]PCCwusedinconce trationsptlO Mfo cerebellum,5nMforhippocampus.Li sfitt dbylineregression.
-LogM[PC.cJ%Displacement
FIGURE4.9. a)Displacementcurb sofb nding0.5nM[^H]FNyPCCfr m (•)cerebellum,■hippocampusand(▲wholituitarymembr nes. b)Hofsteeplotsftheresultin(a).Assayswerincubat d0°Cfor 180minutes.200 Mclonazepamw susedtdefinon-sp cificbi dingi allcases.Resultrmeanoftwoexperim ntsp rfo dindupli tfo cerebellumandhippocampus,repr s ntativeoffourperf rmedin duplicate,forpituitary.Line rHofsteeplo sw rfittedbylinea regression.
Bound fmol/mg protein
FIGURE 4.7
Representative Scatchard analysis of [3h]FNM (#) and [3h]PCC (O)
binding to whole pituitary membranes. Assays were incubated at 0°C
for 120 minutes. Non-specific binding was defined by 200nM






















Results of Scatchard analysis of [3h]FNM and [3h]pcc binding to
whole pituitary, cerebellum and hippocampal membranes. Mean ±
S.E.M., n = 7-8 for pituitary, n = 4 for cerebellum and hippocampus.
CHAPTER 5
GABAa - and GABAg - receptor mediated effects
on prolactin secretion in vitro
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5.1 Introduction
Investigations of the involvement of GABA in the control of
prolactin secretion do not date back as early as studies on other PD
hormones (Makara and Stark, 1974; Ondo, 1974) but have since
provided a wealth of data, at times conflicting, reflecting the
variety of animal models, drugs and their routes of administration
studied. GABA was originally reported to stimulate prolactin
secretion after i.e.v. injection in both conscious female and
anaesthetized and conscious male rats (Mioduszewski, Grandison and
Meites, 1976; Ondo and Pass, 1976; Pass and Ondo, 1977) but
intrapituitary injection was without effect (Ondo and Pass, 1976).
This has been confirmed by others (Vijayan and McCann, 1979; Donoso
and Zarate, 1981; Lamberts, Vijayan, Graf, Mansky and Wuttke,
1983). In contrast to these results, Schally et al isolated a PIF
from porcine hypothalami which was distinct from catecholamines and
which they identified as GABA (Schally, Redding, Arimura, Dupont and
Linthicum, 1977). They found that GABA inhibited basal prolactin
secretion in vitro and in vivo when administered intravenously
(i.v.) after elevation of secretion by monoiodotyrosine or
neuroleptics. These findings were supported by the demonstration
that basal or elevated prolactin secretion could be inhibited
in vivo by the GABA-transaminase inhibitors ethanolamine-o-sulphate
(EOS), Y-acetylenic GABA (GAG) and amino-oxyacetic acid (AOAA) or
muscimol (i.v.) (Locatelli, Cocchi, Racagni, Cattabeni, Maggi,
Krogsgaard-Larsen and Muller, 1978; Racagni et al, 1979; Libertun,
Arakelian, Larrea and Foglia, 1979; Locatelli, Cocchi, Frigerio,
Betti, Krogsgaard-Larsen, Racagni and Muller, 1979; Grandison and
Guidotti, 1979; Grandison, 1980; Debeljuk, Goijman, Seilicovich,
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Diaz and Rettori, 1980; Apud, Racagni, Iuliano, Cocchi, Casanueva
and Muller, 1981; Donoso and Zarate, 1981). An inhibitory action
in vitro has also been confirmed (Lamberts and MacLeod, 1978;
Enjalbert et al, 1979a; Grandison and Guidotti, 1979; Grossman,
Delitala, Yeo and Besser, 1981; Matsushita, Kato, Shimatsu,
Katakami, Yanaihara and Imura, 1983), and GABA was shown to inhibit
spontaneous action potential firing in GH^ cells (Israel, Dufy,
Gourdji and Vincent, 1981), but it has been a consistent finding
that GABA and muscimol do not inhibit prolactin secretion from
ectopic PD transplants (Locatelli et al. 1978, 1979; Shin,
Obonsaurin and Bates, 1984). This may be because of a long-term
change in responsiveness of PD when removed from its normal
environment and control mechanisms.
There is therefore considerable evidence that GABA can act
directly on PD to inhibit prolactin secretion and specific binding
3 3
sites for [ H]GABA and [ H]muscimol have been demonstrated in PD
(Grandison and Guidotti, 1979; Chapter 3). A physiological role of
GABA is supported by experiments which showed that bicuculline and
allylglycine (an inhibitor of GAD) given i.v., potentiated the rise
in plasma concentration of prolactin in male rats in response to
injection of sulpiride (Debeljuk et al, 1980; Debeljuk, Seilicovich
and Diaz, 1981). Other studies using bicuculline (i.v.) have
yielded conflicting reports: it was found to have no effect in male
rats after injection of pimozide (Shin et al, 1984) but in
oestrogen-primed, ovariectomized rats, bicuculline methiodide
reduced prolactin secretion (Locatelli et al, 1979; Casanueva, Apud,
Locatelli, Martinez-Campos, Civati, Racagni, Cocchi and Muller,
1981).
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Recently, bicuculline (i.v.) was reported to cause a transient
stimulation of prolactin secretion followed by an inhibition in both
male and ovariectomized female rats (McCann, Vijayan, Negro-Vilar,
Mizunuma and Mangat, 1984) but no data was provided to support this.
In addition to reducing plasma prolactin concentrations, EOS
(i.c.v.) increases the concentration of GABA in hypophysial portal
blood (Gudelsky, Apud, Masotto, Locatelli, Cocchi, Racagni and
Muller, 1983) and in PD (Racagni et al, 1979; Casanueva et al,
1981). The concentration of GABA in PD has also been used as an
index of tuberoinfundibular GABAergic activity to investigate the
possibility of a physiological role for GABA in suckling (Racagni
and Apud, 1982). Pup separation caused a parallel fall in PD GABA
concentration and plasma prolactin concentration, (i.e. an inverse
correlation to that observed after EOS administration). Suckling
caused an approximately 10-fold increase in plasma prolactin
concentration within 30 min, at which time PD GABA was unchanged.
After 2 hours, PD GABA concentrations were elevated, reaching their
highest value during continuous suckling. From these results it was
suggested (Racagni and Apud, 1982) that GABA may be involved in
feedback mechanisms rather than in tonic regulation of prolactin
secretion. AOAA has been reported to prevent suckling-induced
prolactin secretion (Libertun et al, 1979) and sodium valproate
administration to puerperal women prevented breast stimulation-
induced prolactin secretion (Melis, Fruzzetti, Paoletti, Mais,
Kemeney, Stringini, Boldrini and Fioretti, 1984) with little (Melis
et al, 1984) or no (Libertun et al, 1979) effect on basal prolactin
secretion. These studies, together with those discussed above, show
the inhibitory potential of endogenous GABA, particularly when
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prolactin secretion is elevated. GAD activity in MBH is decreased
by apomorphine, and increased by neuroleptics (Prato, Clementi,
Nicoletti, Canonico, Patti, Condorelli, DiGiorgio and Drazo, 1981;
Nicoletti, Clementi, Prato, Canonico, Rampello, Patti, DiGiorgio and
Scapagnini, 1983), treatments which decreased and increased plasma
prolactin concentrations respectively. As the effect of sulpiride
was prevented by hypophysectomy and to some extent mimicked by a
pituitary graft (Nicoletti et al, 1983) it was proposed that the
effects on GAD were mediated by prolactin, acting in a negative
feedback manner. Similar experiments have been performed on DA
turnover in MBH and ME (Moore, Demarest and Johnston, 1980).
Prolactin itself has also been found to increase GAD activity in
MBH, and the concentration of GABA in hypophysial portal blood after
i.c.v. administration, but only after a delay of 16 hours (Apud et
al, 1984).
While it is clear that GABA can stimulate prolactin secretion at
a central site, possibly by inhibiting DA release into hypophysial
portal blood (Vijayan and McCann, 1979; Casanueva et al, 1981;
Racagni and Apud, 1982; see also Chapter 11) and can inhibit
prolactin secretion by an action at the pituitary, a physiological
role of GABA either in tonic inhibition or in feedback regulation
remains unproven.
A transient stimulatory effect of GABA on electrical activity of
cultured pars intermedia cells and on aMSH secretion (Taraskevich
and Douglas, 1982; Tomiko et al, 1983; Demeneix et al, 1984) has
been reported. The purely stimulatory GABA^ receptor response on
aMSH secretion and the inhibitory GABAg receptor response
(Demeneix et al, 1984) contrasts with the inhibitory effect of GABA
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and muscimol on prolactin secretion, even in superfusion systems
when transient effects might be apparent (Grossman et al, 1981;
Matusushita et al, 1983). The present studies were therefore
undertaken to examine the effects of GABA^ and GABAg receptor
activation on prolactin secretion, using a superfusion system but
avoiding the use of trypsin to disperse cells, as it abolishes
spontaneous electrical activity in PD cells for several days
(Israel, personal communication.).
5.2 Materials and Methods
5.2.1. Apparatus and materials
The superfusion chamber consisted of a Swinnex filter unit
(Millipore, Harrow) containing a Millipore AP20 prefilter to support
the tissue. The inlet at the top was attached to a length of 1mm
bore silicone rubber tubing, the end of which was immersed in the
superfusion medium. The outlet was attached by similar tubing to a
peristaltic pump (model 510, Watson Marlow) and from this tubing
passed to a fraction collector (model 2070 Ultrorac 11, LKB, Sweden).
All chemicals used in the superfusion medium and tetraethyl
ammonium bromide (TEA) were obtained from BDH, Poole, except
bacitracin and bovine serum albumin (BSA) which were obtained from
Sigma. The following were also obtained from Sigma: GABA, muscimol,
homocarnosine, IAA, picrotoxinin (PTX), strychnine, glycine,
taurine, 3-isobutyl-l-methyl xanthine (IBMX), N®-2°-0-dibutyryl
adenosine 3'5'cyclic monophosphate (dbcAMP), VIP, sodium propionate,
propionic acid, 4-aminopyridine (4AP), collagenase, hyaluronidase,
deoxyribonuclease and cholera toxin. Isoguvacine was obtained from
Cambridge Research Biochemicals (Cambridge), 3-aminopropane
sulphonic acid (APS) from Aldrich Chemical Co. (Milwaukee, WI, USA),
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bicuculline methiodide (BMI) from Pierce Chemical Co., (Rockford,
IL, USA), forskolin from Behring Diagnostics (La Jolla, CA, USA),
4,4'-diiso-thiocyano- 2,2'-disulphonic acid stilbene (DIDS) from
Calbiochem Behring Corpn. (La Jolla, CA, USA). The following were
generous gifts of the individuals or organisations named:
(±)baclofen and its stereoisomers from Ciba-Geigy (Basel,
Switzerland), piperidine-4-sulphonic acid (P4S) and 4,5,6,7-
tetrahydroisoxazolo [5,4—c] pyridin-3-ol (THIP) from Dr. P.
Krogsgaard- Larsen (Copenhagen).
5.2.2. Methods
Male Wistar rats (200-300g) were stunned, decapitated, and the
pituitary gland removed (Section 2.3). NI was discarded, and PD was
mechanically chopped (Macllwain Tissue Chopper, Mickle Laboratory
Engineering Co., Gomshall, Surrey) at 500uM intervals in two
directions at 90°. Tissue was then transferred to a polystyrene
tube (Luckham) containing = 10ml of Krebs Bicarbonate medium
(composition in mM: NaCl,127; KC1,3.83; CaCl^.l.S; MgCl^.l.lS;
KH^PO^.l.lS; NaHCO^^O; with 2g/l glucose, 30mg/l bacitracin
and 0.1% BSA, pH 7.4) equilibrated with an atmosphere of
95^0^/5^COg at 37°C. Tissue was incubated for 1 hr under these
conditions. Aliquots corresponding to tissue from 1-2 rats were
then transferred into each superfusion chamber. The inlet line was
reconnected, and superfusion with constantly- oxygenated medium at
37°C at a rate of 0.5ml/min was started. A diagram of this method
is shown in Figure 5.1. After a period of 75 min, the collection of
2 min fractions was begun, and after a further 15 min the inlet
lines were changed to medium containing drugs as appropriate. When
antagonists were used, they were introduced 30 min before the
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agonists. Fractions were collected into polypropylene scintillation
vial inserts (Sterilin) and were stored at -20°C until assay
(Section 2.3).
5.2.3 Preparation of dispersed cells
PD from male rats were roughly chopped using a razor blade and
2+ 2+
incubated in Earles Balanced Salt solution (Ca - and Mg - free
with 1% BSA, Gibco) containing 0.1% collagenase, 0.1% hyaluronidase,
and 0.02% deoxyribonuclease in a shaking waterbath at 37°C under an
atmosphere of 95%02» 5% C^. Tissue was repeatedly triturated
using fine, siliconised Pasteur pipettes to aid. dispersal. After 45
min, the medium was centrifuged for lOmin at 600g at 4°C, the
supernatant discarded, and the cells resuspended in medium without
the enzymes. The suspension was then filtered through a nylon mesh
(80uM pore size) and mixed with Biogel P2 pre-equi1ibrated with
perfusion medium. The resultant slurry was then introduced into the
superfusion chambers, where it was supported on Whatman GF/B
filters, and superfused as described above. Normal protocol was
subsequently followed.
5.2.4 Calculation of results and statistical comparisons
Results were generally calculated as percentage changes from
pre-drug basal secretion rate. Basal rate was obtained from the
mean of 5 fractions immediately before addition of drugs, and peak
values were used to express percentage stimulation. Inhibitory
effects were quantified using a mean of 4-6 fractions when release
appeared to have stabilised. In some cases, the prolactin
concentration in each fraction is expressed as a percentage of mean
pre-drug concentration. The results from experiments using
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antagonists are expressed as percent antagonism of a control
response carried out at the same time on a parallel superfusion.
Statistical comparisons were made using the Mann-Whitney U test.
5.3 Results
5.3.1. Effects of muscimol and baclofen on basal prolactin secretion.
The GABA^ receptor agonist muscimol was found to have a
biphasic effect on prolactin secretion, which consisted of an
immediate, transient stimulation of secretion, followed by a
sustained inhibition. An example of such a response to lOyM
muscimol is shown in Figure 5.2. On washout of the muscimol,
prolactin secretion recovered towards pre-drug baseline. A similar
biphasic response to muscimol was also observed using collagenase-
dispersed cells, in which 10pM muscimol caused 44 ± 8% stimulation
and 45 ± 5% inhibition of prolactin secretion (n = 3).
To investigate the specificity of this effect, the established
PIF DA was investigated in this system. O.lyM DA caused a prompt
inhibition of secretion (71 ± 3%, n = 3) without any transient
stimulatory effect (Figure 5.3). The GABAg receptor agonist
(^baclofen had no effect on basal prolactin secretion at a
concentration of lOOuM (Figure 5.2). The results of further
experiments investigating effects of baclofen on prolactin secretion
are described in section 5.3.7.
5.3.2. Effects of other GABA agonists
GABA itself also had a biphasic effect on prolactin secretion,
qualitatively the same as that of muscimol (Figure 5.4.). A
quantitative analysis, using GABA and muscimol concentrations from
lOnM to 30yM showed that muscimol was approximately 10-fold more
potent than GABA at both effects (Figure 5.5). Figure 5.5 also shows
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concentration-response results for isoguvacine and homocarnosine.
Results for P4S, THIP and APS were similar to those for
isoguvacine. From this figure it can be seen that both components
of the response to muscimol and GABA are quantitatively similar at
each concentration i.e. the stimulatory and inhibitory curves are
nearly superimposed. By contrast, the curves for isoguvacine are
well separated, only the inhibitory effect showing a clear
concentration-dependence, the stimulatory effect being very small.
The effects of homocarnosine are discussed further below. Therefore
several analogues appeared to be less potent than GABA at causing
stimulation of prolactin secretion, but were equipotent to GABA on
the inhibitory response. This is illustrated by the responses to
each of the agonists at a concentration of lOpM (Figure 5.6). At
this concentration, GABA caused more than double the percent
stimulation of prolactin secretion that the other agonists caused (
P < 0.05 in each case) but there were no significant differences in
the amount of inhibition.
5.3.3 Effect of homocarnosine and interaction with GABA.
Homocarnosine was not found to have a biphasic effect on
prolactin secretion, but at ImM, caused a prompt and sustained
inhibition (28 ± 4%) (Figure 5.4). This effect was
concentration-dependent (Figure 5.5), homocarnosine being
approximately 100-fold less potent than GABA. The absence of any
stimulatory effect, even at 2mM, despite a considerable inhibitory
effect suggested that homocarnosine might not be acting specifically
on GABA receptors. However, lOpM BMI was found to cause significant
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antagonism of the effect of ImM homocarnosine (28 ± M inhibition,
ImM homocarnosine alone, 17 ± 2% inhibition in the presence of lOpM
BMI, n = 5, P < 0.05) (Fig. 5.7a) demonstrating that homocarnosine
was indeed acting as a GABA^ receptor agonist.
A further series of experiments was carried out to investigate
the interaction between homocarnosine and GABA. Concentrations of
GABA and homocarnosine were chosen that gave similar inhibitory
effects. 3pM GABA caused 28 ± 2% inhibition, and ImM homocarnosine
caused 28 ± 4% inhibition. This concentration of GABA caused 14 ±
2% stimulation of secretion over pre-drug rate, but when
recalculated to take into account the superimposed inhibitory effect
(estimated as the mean response to ImM homocarnosine at the fraction
of peak stimulation), this value was 21 ± 3%. The combination of
3pM GABA and ImM homocarnosine caused 32 ± 3% inhibition, and 2mM
homocarnosine alone caused 31 ± 2% inhibition demonstrating
compilation rather than addition of effects, consistent with a
single site of action. The combination caused no stimulation of
secretion above baseline, but secretion declined less rapidly. At
the fraction previously observed to demonstrate peak stimulation,
the combination caused 7 ± 3% stimulation over the effect of 2mM
homocarnosine (mean response) (Figure 5.7b). This value was
significantly less (P < 0.05) than that for GABA alone, suggesting
that homocarnosine specifically antagonised the stimulatory effect
of GABA, and that the response to the combination was not merely the
arithmetical sum of the two responses.
To investigate whether significant contamination by GABA could
in part account for sone of the inhibitory activity of
homocarnosine, the sample of homocarnosine was subjected to analysis
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by high pressure liquid chromatography with pre-injection
derivatisation with 0-phthalaldehyde and fluorescence detection.
Using a method similar to that of Turnell and Cooper (1982),
standards of GABA and homocarnosine were clearly separated.
Homocarnosine was found to contain <0.03% free GABA. Furthermore,
PD tissue was found to contain no detectable homocarnosinase
activity (Chapter 12), suggesting that homocarnosine was not
degraded by the tissue during the experiment. This was further
checked by incubating chopped PD tissue at 37°C in oxygenated medium
with ImM homocarnosine. After lhr, aliquots of medium were taken
for determination of GABA by radioreceptor assay (Section 12.2.3).
Under these conditions no GABA was detectable (< lOnM in tissue
incubation medium). These results provide further evidence for the
au<r^€^trcccof the effect of homocarnosine.
5.3.4 Effects of glycine and taurine on prolactin secretion
Glycine (100yM) and taurine (ImM) were found to have no effect
on basal prolactin secretion (Figure 5.8). Co-introduction of lOOpM
glycine increased the stimulatory response to lOpM muscimol from
65 ± 10% to 97 ± 4% (P < 0.05, n = 5) but did not alter the
inhibitory effect: 51 ± 3% inhibition by muscimol alone, 50 ± 2%
with glycine (Figure 5.8).
5.3.5 Antagonism of the effects of muscimol
BMI, PTX and strychnine were investigated as antagonists of the
effects of muscimol. Two series of experiments were performed,
using concentrations of muscimol of 10yM and 30yM. All three
antagonists at 10yM antagonised the stimulatory effect of 10pM
muscimol, with PTX and strychnine appearing especially potent
(Figure 5.9). At this antagonist concentration, only BMI caused
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significant inhibition of the inhibitory effect of muscimol,
reducing it by =50% while PTX and strychnine were ineffective. At
lOOviM antagonist, all three virtually or completely abolished the
stimulatory response, and all caused significant antagonism of the
inhibitory response (Figure 5.9). In the second series of
experiments, concentration-effect data was obtained for the three
antagonists. 30yM muscimol alone caused 139 ± 23% stimulation and
57 ± 4% inhibition (n =6). Figure 5.9 shows that PTX was
approximately 3-fold more potent than BMI as an antagonist of the
stimulatory response, with strychnine being of intermediate potency
perhaps with a steeper concentration-response curve. The limits of
accuracy of the results however prevent detailed interpretation of
this. In agreement with the first series of experiments showing
selective antagonism of the stimulatory response by PTX and
strychnine, neither antagonist at any of the concentrations tested
(i.e. up to 30pM for PTX and lOOviM for strychnine) caused
significant antagonism of the inhibitory response to 30yM muscimol.
30viM muscimol alone caused 57 ± 4% inhibition, 42 ± 4% in the
presence of 30pM PTX and 52 ± 5% in the presence of lOOpM strychnine
(n = 5-6). BMI however, was an effective antagonist, reducing the
response to 25 ± 5% at lOOuM.
5.3.6. Effects of ionic substitution and ion channel blockade.
Two approaches were taken to investigate whether both components
of the biphasic response to muscimol were mediated by increased
chloride channel conductance. In the first, sodium propionate was
substituted for NaCl in the medium, giving a residual [Cl—] of
r
=6mM (4.5% of normal). In the second, the chloride channel blocker
DIDS (Cabantchick, Kauf and Rothstein, 1978) was present in the
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superfusate at a concentration of lOOyM for 45 min before muscimol
was introduced. Low-chloride medium caused a slight, = 25%
reduction in basal prolactin secretion which largely recovered in 30
min, before muscimol was introduced. In this medium, 10yM muscimol
caused only 9 ± 2% stimulation and 24 ± 2% inhibition (n = 5, both
P < 0.05 vs control, Figures 5.9 and 5.11). lOOpM DIDS caused a
delayed but sustained increase in prolactin secretion of 45 ± 5%
(n = 5), and after this treatment, 10yM muscimol caused only 33 ± 1%
stimulation and 26 ± 3% inhibition (n = 5, both P < 0.05 vs control,
Figures 5.9 and 5.11). In neither case was the response to 30mM
K+ (using K^SO^) affected: 176 ± 12% control stimulation, 182
± 10% in low-chloride medium, and 151 ± 13% in the presence of DIDS
(n = 5 in each case).
Experiments were also carried out to investigate the effect of
K+-channel blockade by 4AP and TEA on the response to muscimol.
Channel blockers were introduced 60 min before muscimol, and both
caused a transient stimulation of secretion (Figure 5.15). In the
presence of ImM 4AP the stimulatory effect of 10yM muscimol
increased to 110 ± 8% (P < 0.05 vs control, 65 ± 10%) while the
inhibitory effect was unaltered (48 ± 5%, n = 5, control 51 ± 3%)
(Figure 5.15). Both reponses to 10yM muscimol were unaffected in
the presence of lOmM TEA; the agonist causing 60 ± 2% stimulation
and 40 ± 2% inhibition (n = 5, figure 5.11).
5.3.7. Evidence for GABAg receptor effects on prolactin secretion.
As described in section 5.3.1., 100yM (±)baclofen had no effect
on basal prolactin secretion (Figure 5.1.). This concentration of
(±)baclofen also did not affect the stimulation of secretion caused
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by 30mM K+ or 3mM Ba^+ (Figure 5.12). 30mM K+ caused 176 ±
2+
12% stimulation alone, and 193 ± 7% with baclofen; 3mM Ba caused
226 ± 34% stimulation alone, and 256 ± 35% with baclofen (n = 5 in
each case). When tested on the stimulation of secretion caused by
VIP however, an inhibitory effect was revealed. lOnM VIP caused a
peak of 91 ± 4% stimulation of secretion, which was reduced to
62 ± 5% when lOOpM (±)baclofen was cointroduced (n = 5, P < 0.05)
(Figure 5.13). This effect was stereospecific: lOOviM ( + )baclofen
had no effect on the response to 7.5nM VIP (92 ± 15% of control
stimulation) but lOOpM (-)baclofen caused a significant reduction to
59 ± 5% of control (P < 0.05, c.f. 68 ± 5% of control for
(±)baclofen) (Figure 5.13).
VIP has been proposed to stimulate prolactin secretion by
activation of adenylate cyclase (Dorflinger and Schonbrunn, 1983)
and therefore the effect of baclofen was studied following
superfusion with various substances that elevate intracellular cAMP
concentrations. Forskolin, cholera toxin, IBMX and dbcAMP (the last
two in combination as well as separately) were used. 10pM forskolin
caused a slight, = 30% stimulation of prolactin secretion which was
transient, but neither 30ng/ml cholera toxin, 2mM dbcAMP nor 2mM
IBMX had any apparent effect on prolactin secretion over the
time-period studied. All were superfused for 40 min before the
introduction of lOOyM (±)baclofen, but under none of these
conditions did baclofen have any effect (Figure 5.14).
Any possible interaction of baclofen with the transient
stimulation of secretion caused by K+ channel blockers was also
investigated. lOOpM (±)baclofen reduced the stimulation caused by
ImM 4AP from 99 ± 5% to 66 ± 6% (p < 0.05, n = 5, Figure 5.15)
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without affecting the response to lOmM TEA (57 ± 10% alone, 67 ± 1%
in the presence of baclofen). This effect of baclofen on
4AP-stimulated secretion was stereospecific: lOOyM (+)baclofen had
no effect (83 ± 10% stimulation) whereas lOOyM (-)baclofen caused
significant reduction of the stimulation (51 ± 6%, n = 5, p < 0.05,
Figure 5.15).
5.4 Piscussion
5.4.1 GABA^ receptor effects
The transient stimulation of prolactin secretion, followed by a
sustained inhibition (from which recovery could be demonstrated)
caused by GABA and muscimol is different to any other GABA^
receptor effect on pituitary hormone secretion. A purely
stimulatory GABA^ effect has been reported on ctMSH secretion
(Demeneix et al, 1984) and on LH, GH and ACTH secretion (Chapter
7). The inhibitory effect of GABA on aMSH secretion (Tomiko et al,
1983) has since been shown to be GABAg receptor mediated (Demeniex
et al, 1984). Previous studies on the effects of GABA on prolactin
secretion in vitro have used either static incubations (Lamberts and
MacLeod, 1978; Enjalbert et al, 1979a; Grandison and Guidotti, 1979)
under which conditions transient effects will not be apparent, or
trypsin-dispersed cells which were subsequently superfused either
immediately (Grossman et al, 1981) or the following day (Matsushita
et al, 1983). Trypsin causes considerable damage to PD cells and
abolishes spontaneous electrical activity for several days (Israel,
personal communication), and this may be the reason why these groups
were unable to detect the transient stimulatory effect. In this
study, collagenase-dispersed cells responded very similarly to the
chopped tissue preparation routinely used.
The electrophysiological responses of PI cells observed by
Taraskevich and Douglas (1982) were suggested to correlate with the
biphasic effect of GABA on aMSH secretion (Tomiko et al, 1983): thus
GABA was considered to transiently depolarise the cells by an
increase in chloride conductance, causing a transient burst of
action potentials whose amplitude declined rapidly, with subsequent
quiescence of the cells. The quiescence was attributed to the
collapsed membrane resistance, rendering generation of spontaneous
action potentials impossible (and, by implication, inhibiting
hormone secretion). In these studies both components of the effect
of muscimol were diminished in low CI" medium or in the presence
of the anion channel blocker DIDS (Figure 5.9) suggesting that both
components are the result of increased chloride channel opening, and
therefore show close parallels with the results of Taraskevich and
Douglas (1982). Spontaneous action potentials have been observed in
normal PD cells (Ozawa and Sand, 1978; Taraskevich and Douglas 1977)
as well as in transformed cells (Kidokoro, 1975; Dufy et al, 1979;
Israel et al, 1981) which were stimulated by TRH and inhibited by
DA, consistent with this hypothesis, and they have recently been
directly demonstrated in lactotrophes (Ingram and Mason, 1985).
There are, however, various results presented here which suggest
that this relatively simple explanation for the biphasic effect of
GABA and muscimol is inadequate, and that two different populations
of GABA^ receptors (or at least, two types or states of GABA^
receptor complex), which cause a pure stimulation or inhibition of
prolactin secretion are present.
The first indications of pharmacological discrepancies in the
two effects was provided by the study of a range of GABA analogues:
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THIP, P4S, isoguvacine and APS. These analogues have a rather more
rigid structure than GABA or muscimol and are generally potent
agonists (Krogsgaard-Larsen, Johnston, Lodge and Curtis, 1977;
Krogsgaard-Larsen and Falch, 1981). They do show some differences
in their effects, notably their reduced efficacy in vitro at
stimulating benzodiazepine binding under certain conditions
(Karobath and Lippitsch, 1979; Braestrup, Nielsen, Krogsgaard-Larsen
and Falch, 1979; Wong and Iversen, 1985). These four GABA^
agonists had a biphasic effect on prolactin secretion, but the
amount of stimulation produced was low, relative to the amount of
inhibition. Thus at 10pM these agonists produced less than half the
amount of stimulation caused by equimolar GABA, but similar amounts
of inhibition (Figure 5.5 and 5.6). This suggests a somewhat
selective potency of these compounds for the inhibitory effect, in
contrast with the non-selective action of GABA and muscimol, which
retained a 10 fold difference in potency on both effects. This
contrasts with the 'atypical' agonists potency both at displacing
O
[ H]GABA binding and at depressing cat dorsal horn interneurone
firing (Krogsgaard-Larsen and Falch, 1981), in both of which models
they are considerably more potent than GABA itself, but the
percentage stimulation of secretion caused by these six agonists (at
10pM) correlates very well (r = 0.96) with channel lifetime recorded
in fluctuation analysis experiments on cultured mouse spinal
neurones (Barker and Mathers, 1981).
Dual GABA^ effects of depolarisation at dendrites and
hyperpolarisation at somata have been reported in studies on both
hippocampal slices (Alger and Nicoll, 1979; 1982) and cultured mouse
spinal neurones (Barker and Ransom, 1978a). Alger and Nicoll (1982)
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found that THIP was surprisingly weak at causing depolarisation
relative to its potency at causing hyperpolarisation, and concluded
that two distinct GABA receptors may be involved. The demonstration
here of two distinct types of GABA^ response simultaneously on the
same secretory cells obviates the possibility that in other models
differences in the observed properties of GABA^ responses may
result from differences in agonist uptake or in ion gradients of the
cells and their processes studied.
The GABA-containing dipeptide homocarnosine is present in
hypophysial portal blood in high concentration (Mitchell et al,
1983) and has previously been briefly reported to inhibit prolactin
secretion in vitro (Schally et al, 1977). In these experiments,
homocarnosine differed from all the other GABA^ agonists tested in
that it caused no stimulation of secretion, even at a concentration
of 2mM. Instead, a prompt and sustained inhibition of secretion was
observed (Figures 5.4 and 5.5). This effect was both
concentration-dependent and antagonised by BMI. Further evidence
for the specificity of this effect despite the low potency is
provided by the demonstration that neither glycine (lOOpM) or
taurine (ImM) had any effect on prolactin secretion (Figure 5.8).
One interpretation of the action of homocarnosine is that there
are two types or states of GABA^ receptor complex on lactotrophes
which mediate the two observed responses independently. In this
analysis, homocarnosine is selective for the "receptor" mediating
inhibition of secretion. The absence of the stimulatory effect
could be explained in two ways, the first being that homocarnosine
does not bind to the stimulatory GABA^ site i.e. has no affinity
for it, and the second being that homocarnosine binds but does not
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1 activate' it i.e. has affinity but no efficacy, and thus acts as an
antagonist. As GABA and other agonists have efficacy at both sites,
the response observed experimentally is the sum of two (independent)
responses, while the response to homocarnosine is a 'pure' response
to activation of one type. Therefore taking into account the
inhibitory effect of homocarnosine allows reanalysis of the
stimulatory effects of full or partial agonists. This was attempted
using concentrations of GABA and homocarnosine which gave equal
inhibitory responses. 3pM GABA caused 21% stimulation over the
response to ImM homocarnosine, but the combination caused only 7%
stimulation over the effect of 2mM homocarnosine (Figure 5.7). If
homocarnosine did not bind to the stimulatory site, then the
combination would be expected to give a very similar result to GABA
alone, as there is already an inhibitory effect equivalent to ImM
homocarnosine in the response to GABA. This was not the case, and
these results suggest that homocarnosine specifically antagonised
the stimulatory effect of GABA.
Agonists are not a powerful tool to demonstrate receptor
multiplicity, and although homocarnosine appears able to act as an
antagonist of one response and an agonist of the other, further
pharmacological characterisation is required.
Bicuculline and PTX are both wel1-recognised GABA^ antagonists
(Curtis et al, 1971a; Gallindo, 1969; Hill, Simmonds and Straughan
1972) and strychnine is regarded as a glycine antagonist (Curtis et
al, 1971b; Kelly and Renaud, 1973; Simmonds, 1983). In these
experiments the quaternary N-methylated bicuculline methiodide was
used as bicuculline itself is very unstable in solution (Olsen, Ban,
Miller and Johnston, 1975). [^H]BMI has been used to label GABA
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binding sites (Mohler and Okada, 1977b), and in support of a direct
interaction at the GABA receptor, bicuculline antagonises GABA
responses competitively in the mammalian CNS (Simmonds, 1980b). The
PTX binding site (using [ H]dihydropicrotoxinin) (Ticku, Ban and
Olsen, 1978) appears distinct, and PTX antagonises mammalian CNS
GABA responses noncompetitively (Simmonds, 1980b) although 'mixed'
effects are seen in lobster (Constanti, 1978). Strychnine has been
reported to be approximately twenty times more selective an
antagonist at glycine than GABA receptors (Simmonds, 1983), but
appears to act competitively as a GABA antagonist, at the same site
as bicuculline (Simmonds, 1982).
When tested against lO^M muscimol at an equimolar concentration,
only BMI antagonised the inhibitory effect, and PTX and strychnine
appeared especially potent at blocking the stimulatory effect
(Figure 5.9). At higher concentrations of antagonist, all caused
significant antagonism of the inhibitory effect. A more detailed
comparison of the three as antagonists of the stimulatory effect of
muscimol was carried out using a higher concentration of muscimol,
30yM, as the larger effect thus produced enables percent antagonism
to be determined more accurately. These results confirmed the
greater potency of PTX than BMI, and strychnine appeared
intermediate (Figure 5.10). The selectivity of PTX and strychnine
was also confirmed, as even at concentrations as high as 100pM, no
antagonism of the inhibitory effect was observed. At this
concentration of strychnine the stimulatory effect of muscimol was
totally abolished, such that the response started to resemble that
to homocarnosine i.e. an immediate inhibition of secretion.
Lamberts and MacLeod (1978) also found that PTX was ineffective as
-78-
an antagonist of GABAergic inhibition of prolactin secretion in
vitro, but others have found that it did antagonise the effect of
GABA (Enjalbert et al, 1979a). These results, showing selective
antagonism by strychnine (and to a lesser extent by PTX, as 30yM PTX
caused a slight but not significant antagonism of the inhibitory
response to 30pM muscimol) provide further evidence that the two
components of the biphasic response to muscimol are mediated by
*vy
independent receptor complexes with different pharacological
K
properties.
Glycine was found to have no effect on prolactin secretion alone
at IOOmM, but when co-introduced with lOpM muscimol significantly
potentiated the stimulatory effect, without altering the inhibitory
effect (Figure 5.8). Glycine and GABA act very similarly by opening
anion channels (Barker and McBurney 1979a) but several lines of
evidence suggest that independent receptor sites are involved:
effects of GABA and glycine are selectively antagonised (Curtis et
al, 1971a, b; Nicoll, Padjen and Barker, 1976), GABA is a very weak
3
displacer of [ H]strychnine binding (Muller and Snyder, 1978) and
3
glycine is a very weak displacer of [ H]GABA binding (Zukin et al,
1974), and cultured spinal cord neurones grown in the presence of
one of the amino acids become unresponsive to that one, without
responsiveness to the other being affected (Nelson, Ransom, Henkart
and Bullock, 1977). Furthermore, if the amino acids shared one
receptor, glycine, being inactive here, would be expected to
antagonise, not potentiate, the response to muscimol. Barker and
McBurney (1979a) found some cross-desensitisation, and suggested
that the two independent receptors may share a common channel, which
could still be activated by glycine when GABA receptors were largely
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desensitised but which was resistant to activation by GABA when
glycine receptors were only partially desensitised. If
desensitisation contributes substantially to limiting the
stimulatory response to muscimol, then a similar mechanism may
contribute to the potentiation by glycine of the response observed
here. These results suggest that glycine receptors can modulate
GABAergic responses on 1actotrophes, glycine itself potentiating the
response and strychnine antagonising it. This modulation appears
selective for the stimulatory response.
Strychnine is a potent antagonist of GABA-receptor stimulated
benzodiazepine binding at some, but not all GABA/benzodiazepine
receptor complexes (Braestrup and Nielsen, 1980), and
benzodiazepines (and barbiturates) potentiate the stimulatory effect
of muscimol on prolactin secretion without altering the inhibitory
effect (Chapter 6). Furthermore, the agonists THIP, P4S, APS and
isoguvacine are only weakly active as stimulators of both prolactin
secretion (here) and benzodiazepine binding (Karobath et al, 1979;
Braestrup, et al, 1979). The selective inhibitor of prolactin
secretion, homocarnosine is inactive on benzodiazepine binding
(Karobath et al, 1979).
It therefore appears that the GABA^ receptor complex which
upon activation causes a stimulation of prolactin secretion is
associated with a variety of modulatory sites while the complex
which causes inhibition of prolactin secretion is much simpler,
having none of these. Despite these differences, both are
chloride-dependent effects, and the GABA-binding part of the
receptor complex may have similar properties in both cases, as BMI
did not show any selectivity and muscimol and GABA showed similar
potency ratios for both effects. Although both components of the
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response to muscimol were found to be chloride-dependent, the
possibility that other ion channels are involved exists. Potassium
channels are of great importance in the regulation of membrane
excitability, and a series of experiments were carried out to
+
investigate the effect of K channel block on the response to
muscimol.
Potassium channels and their properties have been the subject of
several recent reviews (Adams, Smith and Thompson, 1980; LaTorre and
Miller, 1983; Petersen and Maruyama, 1984). 4AP blocks the
transient K+ current, 1^ (Thompson, 1977) in molluscs and a
similar current in hippocampus (Gustaffson, Galvan, Grafe and
Wigstrom, 1982). This current is considered to have a major
influence on excitability, as it is active at a more negative
+
voltage than other K currents, and slows the rate of
depolarisation thus delaying generation of the action potential.
Blockade of this channel by 4AP would therefore be expected to
increase the frequency and duration of action potentials, and this
has been observed in GH^ cells (Ozawa and Kimura, 1979; Sand, Haug
and Gautvik, 1980). 4AP was found to cause a stimulation of
prolactin secretion (Figure 5.15) and subsequently, introduction of
10pM muscimol caused a considerably greater stimulation of secretion
than in controls, but no change in the amount of inhibition (Figure
5.11). TEA blocks the voltage-activated late K+ current, 1^
(the delayed rectifier) (Hille, 1957) and in vertebrates, but not
2+ +
molluscs, the Ca -activated K current, 1^, (Thompson, 1977;
Adams, Constanti, Brown and Clark, 1982b). The main function of
appears to be to provide outward current to repolarize the
membrane during a spike, and 1^ is activated by increased
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intracellular Ca concentration, thus also contributing to
repolarisation. TEA would therefore be expected to increase the
duration of action potentials, which has been observed in GH cells
(Taraskevich and Douglas, 1980). TEA caused a transient stimulation
of prolactin secretion (Figure 5.15) but did not affect either the
stimulatory or the inhibitory component of the response to 10yM
muscimol (Figure 5.11). These results suggest that a current
similar to 1^ is of importance in limiting the stimulation of
secretion caused by muscimol. This result is not unexpected, as
1^ is a major influence on excitability in the mollusc (Adams et
al, 1980) but demonstrates the ubiquity of both the channel and its
effect. In similar experiments 4AP potentiated acetylcholine-
86 "**
induced GH release and Rb efflux (a marker for K ) (Schofield
and Smith, 1981). The lack of effect of 1^ block may reflect the
more reluctant activation of this current in response to partial
depolarisation (compared to 1^). Alternatively spike frequency
rather than duration may be a more important factor in stumulus-
secretion coupling (at least as measured here). 1^ has been
demonstrated in an ACTH-secreting cell line (Wong, Lecar and Adler,
1982) and may be of considerable importance in the control of
secretion in both endocrine and exocrine glands (Petersen and
Maruyama, 1984). The lack of effect of TEA on the response to
muscimol is therefore perhaps surprising but indicates that in
practice 1^ and I are unlikely to be of importance in either
modulating or even mediating any component of the GABA^
responses. The lack of effect of TEA here contrasts with the
potentiation of the stimulatory effect of TRH on GH secretion by TEA
(Saith, Bicknell and Scholfield, 1982). TRH may act directly on
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K+ channels (Ozawa and Kimura 1979; Kaczorowski, Vandlen, Katz and
Reuben, 1983; Barker, Dufy, Owen and Segal, 1983) which would
explain this. Any further explanation of the present results is
impossible without electrophysiological studies of the effect of
muscimol and the properties of K+ currents in lactotrophes.
Similarly, the mechanism underlying the inhibitory effect of
muscimol on prolactin secretion, and its apparent independence of
K+ currents, must await electrophysiological study.
In conclusion, the experiments using 4AP and TEA demonstrated
that both are prolactin secretagogues. It was not possible to
establish involvement of another channel type in the response to
muscimol because of the importance of the currents blocked by 4AP
and TEA in the regulation of membrane excitability and therefore
basal hormone secretion, and similar problems would beset any
2+
investigation into the involvement of Ca channels using a
simi1ar model.
5.4.2. GABAg receptor effects
lOOyM baclofen had no effect on basal prolactin secretion
(Figure 5.2) or the stimulation of secretion caused by 30mM K+ or
2+ 2+3mM Ba (Figure 5.12). Ba prolongs action potential duration
in normal and transformed PD cells (Ozawa and Sand, 1978;
Taraskevich and Douglas, 1980) possibly by blockade of 1^ K+
currents (Fatt and Ginsborg, 1958; Adams, Brown and Constanti,
2+
1982a), and can also pass through Ca channels more easily than
2+
Ca itself (Hagiwara and Byerly, 1981). Both these effects have
been observed in melanotrophes (Douglas and Taraskevich, 1980,
o+
1982), where Ba has been demonstrated to be a potent
2 +
secretagogue (Douglas, Taraskevich and Tomiko, 1983). Ba has
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been used to demonstrate GABAD receptor-mediated inhibition of
D
aMSH secretion (Demeneix et al, 1984). Baclofen was found to
0+
inhibit basal aMSH secretion by =25% and Ba -induced secretion by
up to 60%. These effects were interpreted primarily as a reduction
2+
in the Ca component of each action potential, as observed
electrophysiologically both in PI and on sensory neurones (Dunlap,
1981; Desarmenien, Santangelo, Occhipinti, Schlichter, Loeffler,
Desaulles, Demeneix and Feltz, 1983). There was no such effect on
prolactin secretion, implying that lactotrophes do not have GABAg
receptors, or that if they do, they do not affect basal or
2+ 2+
Ba -induced secretion through an apparent regulation of Ca
currents as in melanotrophes.
Early studies on GABAg receptors were concerned with their
presynaptic mechanism of action (Bowery et al, 1980), in particular
2+
their effect on Ca components of action potentials, as mentioned
above (Dunlap, 1981; Desarmenien, Feltz, Occhipinti, Santangelo and
Schlichter, 1984; Cherubini and North, 1984). More recently other
mechanisms of action of baclofen have been investigated,
particularly interactions with adenylate cyclase (Wojcik and Neff,
1984; Hill, 1985) and K+ channels (Newberry and Nicoll, 1984a;
Inoue, Matsuo and Ogata, 1985). These possible mechanisms of action
are by no means mutually exclusive, as will be discussed below.
GABAg receptor binding is depressed by GTP (Hill, Bowery and
Hudson, 1984), an essential cofactor in the activation or inhibition
of adenylate cyclase (Rodbell, 1980). Investigations into the
effects of baclofen on adenylate cyclase activity have been
apparently conflicting: baclofen has been shown to potentiate the
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stimulatory effect of catecholamines, histamine and VIP (Hill, 1985;
Karbon and Enna, 1985). In contrast, baclofen inhibited the
stimulatory effect of forskolin (Wojcik and Neff, 1984; Hill, 1985;
Karbon and Enna, 1985). This inhibitory effect was shown to be
dependent on GTP (Wojcik and Neff, 1984) and baclofen activated
high-affinity guanosine 5'-triphosphatase (Wojcik, Cavella and Neff,
1985), suggesting involvement of N^, the GTP binding protein that
is inhibitory to adenylate cyclase. VIP is well recognised to
stimulate prolactin secretion in vitro (Ruberg et al, 1978;
Enjalbert, Arancibia, Ruberg, Priam, Bluet-Pajot, Rotsztejn and
Kordon 1980). VIP activates PD adenylate cyclase (Robberecht,
Deschodt-Lanckman, Camus, De Neef, Lambert and Christophe 1979;
Giachetti, Borghi, Nicosia and Said, 1979) which has been proposed
to be the mechanism of the biological effects of VIP (Dorflinger and
Schonbrunn, 1983). Therefore if baclofen affects adenylate cyclase
activity in 1actotrophes, this might be reflected by an alteration
in the prolactin-releasing effect of VIP: a potentiation if baclofen
enhances the cAMP-producing effect of VIP and a reduction if the
converse is true. When co4ntroduced, 100pM baclofen reduced the
response to VIP by = 35%, in a stereospecific manner (Figure 5.13).
This suggested that baclofen might indeed be inhibitory to the
activation of adenylate cyclase, but if that is so then baclofen
might also cause an inhibition of prolactin secretion under other
circumstances in which cAMP concentrations are elevated. In
comparison, somatostatin has been shown to inhibit both
receptor-mediated and non-receptor- mediated increases in cAMP and
ACTH secretion (Heisler, Reisine, Hook and Axelrod, 1982). This was
investigated using dbcAMP and the phosphodiesterase inhibitor IBMX,
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and forskolin and cholera toxin. Forskolin is believed to act
directly on the catalytic subunit of adenylate cyclase (Seamon and
Daly, 1981) whereas cholera toxin acts on the GTP binding
protein (Bokoch, Katada, Northrup, Hewlett and Gilman, 1983). Both
substances have been shown to cause very large and rapid increases
in PD cAMP content, but inconsistent effects on the secretion of
prolactin (Thorner, Hackett, Murad and MacLeod, 1980; Cronin, Myers,
MacLeod and Hewlett, 1983). In these experiments, no marked effect
of any of these treatments was observed, and lOO^M baclofen,
introduced 40 min later, was in no case observed to inhibit
prolactin secretion (Figure 5.14). These results suggest two things:
1) the increase in cAMP caused by VIP may not be the major
mechanism of the rapid stimulation of secretion observed in
these cells.
2) consequently, any inhibitory effect of baclofen on cAMP
accumulation is unlikely to be the cause of the observed
inhibition of VIP-induced prolactin secretion.
These experiments in themselves do not provide any evidence for
or against an effect of baclofen on adenylate cyclase activity in
PD. TRH also increases cAMP accumulation in PD cells (Gautvik,
Iversen and Sand, 1980) but its effect on prolactin secretion is
likely to be a result of inhibition of 1^ (Barker et al, 1983).
Baclofen has recently been reported to directly increase
postsynaptic K+ conductance in hippocampus (Newberry and Nicoll,
1984a; Inoue et al, 1985) and in the dorsolateral septal nucleus
(Gallagher, Stevens and Shinnick-Gallagher, 1984). This effect (in
hippocampus) could be antagonised by 4AP and was unaffected by TEA
(Inoue et al, 1985), suggesting that it might be mediated by
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facilitation of I^-like currents. Both 4AP and TEA are prolactin
secretagogues (see above) suggesting the involvement of currents
equivalent or identical to 1^, IK and 1^ in the regulation of
lactotrophe excitability. When cointroduced, lOOviM baclofen reduced
the prolactin-stimulating effect of 4AP in a stereospecific manner,
without affecting the response to TEA (Figure 5.15). This suggests
that baclofen can open K+ (probably 1^—1 ike) channels on
lactotrophes, and parallels the results obtained using hippocampal
slices. Although it is tempting to speculate as to the identity of
the channel involved based on the pharmacological specificity of 4AP
(Adams et al, 1980), discrepancies in the results obtained in the
hippocampus between the baclofen-associated current and 1^ (Inoue
et al, 1985) prevent direct comparisons from being made.
These results provide a basis for a reexamination of the effects
+
of VIP. Many other peptides have effects on K currents e.g. TRH
(Barker et al, 1983), opioids (Werz and Macdonald, 1983) and
Substance P (Nowak and Macdonald 1982). This in turn may affect
2+
Ca conductance (Werz and MacDonald, 1983; North and Williams,
1983). An alternative mechanism is suggested by the dependence of
K+ currents in Aplysia on transmitter-linked adenylate cyclase
(Siegelbaum, Camardo and Kandel, 1982), and the ability of 8-bromo
cAMP to inhibit (Madison and Nicoll, 1982). In such a model
the response to VIP may be produced by inactivation of a K+
current mediated by an increase in cAMP. Baclofen might reduce
2+
either component but both the effect on Ca conductance in
sensory neurons and on K+ currents in hippocampus appear to be
independent of cyclic nucleotides (Dun'lap and Fishbach, 1981;
Newberry and Nicoll, 1984b; Dunlap, 1985). The inability of
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non-receptor mediated increases in cAMP to cause a rapid prolactin
response may reflect the importance of subcellular localization. In
conclusion, these results provide evidence for GABAg receptors on
lactotrophes which are capable of regulating the response to a
physiological secretagogue. The inability of baclofen to inhibit
2+
basal or Ba induced secretion of prolactin may reflect lack of
2+
association with Ca conductances, and the reduction in response
to 4AP (and VIP) suggests a direct involvement with a K+ current
(with or without an effect on adenylate cyclase).
METHOD





Method for preparation and superfusion of PD prisms.
FIGURE 5.2
Effect of lOiiM muscimol (•) and lOOyM (±) baclofen (O) on prolactin
secretion from PD prisms.






Comparison of the effects of 10pM muscimol (•) and lOOnM DA (O) on
prolactin secretion. Drugs were introduced at the arrow. Prolactin
concentrations have been expressed as a percentage of pre-drug
baseline concentration.
300-




Effects of 10uM GABA (#) and ImM homocarnosine (O) on prolactin
secretion. Drugs were introduced at the arrow. Representative
experiments.
Figure 5.5
Concentration-response curves of the effects of some GABA agonists
on prolactin secretion.
Results are expressed as percentage change from baseline,
(o) percentage stimulation
(•) percentage inhibition
Drugs: muscimol (MUSC); GABA; isogu vacine (ISO); homocarnosine (HC)
Mean ± S.E.M. n = 5-6 in each case.
40-
FIGURE 5.6
The effect of some GABAergic agonists on prolactin secretion. GABA,
APS, THIP, P4S and Isoguvacine (ISO) were tested at 10uM.
Open bars: percentage stimulation of secretion
Hatched bars: percentage inhibition of secretion
*:p<0.05 vs response to GABA. Mean ± S.E.M., n = 5 in each case.
b
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FIGURE 5.8
Effects of glycine and taurine on prolactin secretion and modulation
of the effect of muscimol by glycine.
(O) lOOyM glycine
(■) ImM taurine
(#) lOOyM glycine with 10yM muscimol
The dotted line shows a control response to 10yM muscimol.

























































Antagonism of the stimulatory effect of 30yM muscimol on prolactin
secretion. Antagonism by BMI (O)
PTX (□)
strychnine (A).
Results were calculated as percentage antagonism of control
responses. Mean ± S.E.M., n = 5.
FIGURE 5.11
The effect of ionic manipulation on the effect of muscimol on






Representative experiments. The response in the presence of TEA is


















EffectofbaclofennK+andB 2+stimulatedprolac insecre ion. (O)30mMK+alone (•)30mMK+withlOOy(±)baclofen. (□)3mMBa2+ lone (■)3mMBa2+withlOOyM(±)baclofen Representativeexp riments.
serial fractions
FIGURE 5.13
Inhibition of VIP stimulated prolactin secretion by baclofen.
(•) Effect of lOnM VIP
(■) Effect of lOnM VIP with lOOyM (±)baclofen
(O) Effect of 7.5nM VIP
(□) Effect of 7.5nM VIP with lOOyM (-)baclofen
(A) Effect of 7.5nM VIP with lOOuM (+)baclofen
Representative experiments. Drugs were introduced at the arrows.
Fraction no.
FIGURE 5.14
The effect of baclofen on prolactin secretion following treatment
with drugs which alter intracellul ar cAMP concentrations. IOOuM (±)
baclofen was introduced at the arrow.
Treatments: (•) lOng/ml cholera toxin
( ■ ) I0yM forskolin
(A) 2mM IB MX with 2mM dbcAMP













ImM 4AP with lOOpM (^baclofen
ImM 4AP with lOOpM (-)baclofen
ImM 4AP with lOOpM (+)baclofen
lOmM TEA
lOmM TEA with lOOpM (±)baclofen
Representative experiments. Drugs were introduced at the arrows.
CHAPTER 6.
Modulation of GABA^ receptor effects on prolactin secretion
by benzodiazepines and barbiturates.
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6.1 Introduction
The hypothesis that the main mechanism of action of
benzodiazepines is a facilitation of GABAergic effects is supported
by a wealth of evidence. Schmidt, Vogel and Zimmermann (1967)
provided the first report which, in retrospect, demonstrated a
relevant synaptic mode of action of benzodiazepines. They found
that diazepam facilitated primary afferent depolarisation in the
spinal cord. Considerable evidence was subsequently provided that
this presynaptic inhibition was mediated by GABA (Barker and Nicoll,
1972: Curtis and Johnston, 1974), enabling the work of Schmidt et al
(1967) to be confirmed and enlarged upon (Pole, Mohler and Haefely,
1974). The effect of diazepam could be antagonised by bicuculline
and by depletion of endogenous GABA by thiosemicarbazide (Pole et
al, 1974), supporting the hypothesis that diazepam acted by
facilitation of GABAergic transmission. Picrotoxin was also found
to antagonise the action of diazepam in the spinal cord (Stratten
and Barnes, 1971) and in the geniculate nucleus, another site of
potentiation of presynaptic inhibition (Barnes and Moolenaar, 1971).
Benzodiazepines have also been reported to antagonise effects of
GABA (Steiner and Felix, 1976; Gahwiler, 1976) or to be unable to
potentiate responses to GABA (Dray and Straughan, 1976) although in
this last study, the depressant effect of benzodiazepines alone was
antagonised by bicuculline but not strychnine. Others have found
that diazepam did not modify responses to exogenous GABA, but
appeared to potentiate GABAergic transmission (Curtis, Lodge,
Johnston and Brand, 1976). This is consistent with observations
that inhibition of GAD by isoniazid or thiosemicarbazide prevented
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the effects of benzodiazepines (Pole et al, 1974; Mao, Guidotti and
Costa, 1974; Haefely, Kulcsar, Mohler, Pieri, Pole and Schaffner,
1975). It therefore appears that benzodiazepines are more easily
able to potentiate the effect of endogenous, synaptically-released
than exogenous GABA.
The facilitatory action of benzodiazepines on GABAergic synapses
is now well documented, and current investigations are therefore
aimed at determining the mechanism of this facilitation.
There are several possible sites of action within the GABAergic
synapse: presynaptic effects on the release or reuptake of GABA, or
on enzymes of synthesis and degradation, or post-synaptically on the
GABA receptor and associated ion channels. Benzodiazepines have no
effect on GABA uptake (Iversen and Johnston, 1971; Curtis et al,
1975), and although flurazepam appears to have some direct effect
enhancing release of GABA (Nestoros and Nistri, 1978; Mitchell and
Martin, 1978b) this was not observed with other benzodiazepines
(Mitchell, 1979). Diazepam has been found to have no effect on GABA
synthesis or degradation (Sawaya, Horton and Meldrum, 1975; Haefely
et al, 1975), which argues against any major presynaptic effect of
benzodiazepines. A direct postsynaptic action on GABA receptors is
also unlikely as the effect of benzodiazepines can be prevented by
depletion of endogenous GABA (see above) but more importantly
benzodiazepines have been shown to be unable to displace [ H]GABA
from high- (or indeed, lower-) affinity binding sites (Snyder and
Enna, 1975; Olsen, Ticku, Van Ness and Greenlee, 1978). Conversely,
benzodiazepines have been shown to potentiate the effect of GABA in
a synergistic manner (Kozhechkin and Ostrovskya, 1977), an effect
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that was selective for GABA and not glycine (Choi, Farb and
Fishbach, 1977). Similar results were obtained by Macdonald and
Barker (1978) who proposed an allosteric mechanism of action
equivalent to that frequently observed in enzyme biochemistry.
These electrophysiological results are compatible with three
potential mechanisms of action of benzodiazepines: to increase GABA
receptor affinity, the number of available receptors, or to improve
coupling between GABA receptor and chloride channel.
The demonstration of specific high-affinity binding sites for
benzodiazepines (Mohler and Okada, 1977a; Squires and Braestrup,
1977) distinct from, but allosterically linked to GABA receptors
(Tallman, Thomas and Gallagher, 1978), has provided a fresh model
for the investigation of the mechanism of action of benzodiazepines
(see Chapter 4). Although benzodiazepines were shown not to affect
high-affinity [ H]GABA binding, Guidotti, Toffano, Grandison and
Costa (1978) showed that if fresh membranes were used (which show
3
low-affinity [ H]GABA binding), addition of benzodiazepines
revealed a high-affinity component. Subsequently, these workers
were able to purify an endogenous protein 'GABA modulin', which
appeared to regulate high affinity GABA binding (Guidotti, Toffano
and Costa, 1978; Toffano et al, 1978). More recently,
benzodiazepines have been confirmed to increase low-affinity
[^H]GABA binding (Skerritt, Willow and Johnston, 1982; Skerritt
and Johnston, 1983), although this result has not been readily
reproduced by other groups.
These results therefore support a direct postsynaptic effect of
benzodiazepines on the GABA-chloride channel complex, possibly by
increasing receptor affinity.
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Barbiturates also act to enhance synaptic GABAergic transmission
and the effects of exogenous GABA but not glycine (Nicoll, 1975;
Nicoll, Eccles, Oshima and Rubia, 1975; Ransom and Barker, 1976;
Bowery and Dray, 1976; Barker and Ransom, 1978b), and their direct
effects can be antagonised by picrotoxin (Nicoll, 1975). The
application of fluctuation analysis has demonstrated that
pentobarbital opens identical channels to those opened by GABA, but
for much longer (Mathers and Barker, 1980), and that phenobarbitone
can prolong the lifetime of the elementary conductance event
activated by GABA and the time constant of decay of one population
of spontaneous synaptic currents recorded in cultured spinal cord
neurones (Barker and McBurney, 1979b). In this respect barbiturates
differ from diazepam which is reported to have little effect on
channel lifetime but increases the frequency of channel openings (a
parameter which was somewhat decreased by pentobarbital)(Study and
Barker, 1981). Furthermore, benzodiazepines and barbiturates bind
to independent sites: barbiturates were found not to displace
3
[ H]diazepam binding (Squires and Braestrup, 1977) but potently
displaced [^H]dihydro-picrotoxinin ([^H]DHP) and
[^S]t-butylphosphorothionate ([^S]TBPS) binding, believed to
be associated with the chloride channel (Ticku and Olsen, 1978;
Squires, Cassida, Richardson and Saederup, 1983). In general,
3
benzodiazepines do not displace [ H]DHP binding with high affinity
(Ticku, Ban and Olsen, 1978). Barbiturates interact allosterically
3 3
with both [ HjGABA and [ H]bicuculline methochloride binding
(Willow and Johnston, 1981; Olsen and Wong, 1984), the effect on
3
[ H]GABA binding being a slowing of dissociation from high
affinity sites (Willow and Johnston, 1981).
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The present studies were carried out to investigate whether any
component of the GABA^ receptor effect on prolactin secretion
demonstrated in Chapter 5 could be modulated by benzodiazepines or
barbiturates, which would provide functional evidence for the
existence of the GABA receptor/effector complex with associated
regulatory components (Olsen 1982) at a non-synaptic site outside
the CNS. Benzodiazepines have been previously shown to inhibit
prolactin secretion in vivo in a number of animal models (Grandison,
1980, 1982; Lotz, 1982) but the results of in vitro experiments were
equivocal: benzodiazepines were found to have no GABA-potentiating
effect in a dispersed cell superfusion system (Grossman et al, 1981)
but potentiated the effect of GABA on prolactin secretion from
statically incubated pituitary halves (Clemens and Shaar, 1981).
More recently diazepam has been shown to potentiate the inhibitory
effect of muscimol on prolactin secretion from cultured pituitary
cells and to directly inhibit secretion at higher concentrations
(Schettini, Cronin, O'Dell and Macleod, 1984).
The interaction between effects of benzodiazepines and GABA
antagonists has been used to investigate their site of action within
the GABA response mechanism (Simmonds, 1980a). As the effect of
muscimol on prolactin secretion is reproducible and quantifiable, a
similar series of experiments were carried out to examine whether
the model proposed by Simmonds (1980a) could be supported.
6.2 Materials and Methods.
6.2.1 Materials
Muscimol, secobarbital and picrotoxinin (PTX) were obtained from
Sigma, (Poole); bicuculline methiodide (BMI) from Pierce Chemical
Co. (Rockford, IL, USA) and the benzodiazepines clonazepam,
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flurazepam, Ro5-4864, Rol5-1788 and Roll-6896 were the generous gift
of Hoffmann La Roche (Basel, Switzerland).
6.2.2 Methods
The materials and methodology used in these experiments were as
described in Chapter 5. Chopped PD tissue was superfused with
oxygenated Krebs Bicarbonate medium at 37°C. Fractions were
collected and assayed for prolactin by RIA (section 2.3). In most
experiments 2 min fractions were collected, except in one series
(results depicted in Figure 6.6) when 24sec fractions were collected.
After 90 min of superfusion, inlet lines were changed to medium
containing muscimol, with benzodiazepines or secobarbital as
appropriate. When antagonists were used, they were introduced 30
min before muscimol.
6.2.3 Calculation of results
The response to muscimol was calculated as percentage
stimulation and inhibition, as in Chapter 5, using the mean of 5
pre-drug samples for baseline. When the rapid collection protocol
was used, the prolactin concentration of each fraction after
addition of drugs was also expressed as a percentage of pre-drug
concentration, and the results in Figure 6.6 are plotted in this
form. A line was fitted through the 5-6 fractions of the rising
phase of the response in each experiment by linear regression, and
the slope was taken as an index of the rate of increase in prolactin
secretion. Correlation coefficients (for individual experiments)
were >0.9 for muscimol alone and muscimol with secobarbital, and
>0.75 for muscimol with Roll-6896.
The results from experiments using antagonists are expressed as
percent antagonism of a control response carried out at the same
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time on a parallel superfusion line.
All data^-c expressed as mean ± S.E.M., from 5-6 experiments.
6.3 Results
Muscimol itself was found to have a biphasic effect on prolactin
secretion (Chapter 5) which consisted of a transient stimulation of
secretion followed by sustained inhibition. The effect of lyM
clonazepam was tested on a wide range of muscimol concentrations,
from lOnM to 30yM. No effect was found on the inhibitory component
of the response to muscimol at any concentration, but a potentiation
of the stimulatory response was seen at low concentrations of
muscimol. Thus the stimulatory response to lOOnM muscimol was
increased from 11 ± 1% to 27 ± 3% (n = 5, P < 0.05) (Figure 6.1)
while the inhibitory response was 16 ± 2% alone and 13 ± 2% in the
presence of clonazepam. The pharmacology of this potentiation was
further investigated, and the results are shown in Figure 6.2. 10yM
Rol5-1788 antagonised the effect of lyM clonazepam, while having no
effect on the response to muscimol itself. lyM Rol5-1788 caused
partial antagonism. lyM Ro5-4864 did not affect either the
stimulatory or inhibitory components of the response. These results
suggest the involvement of the central- but not the peripheral-type
benzodiazepine receptors, whose presence within the anterior
pituitary gland was demonstrated by binding studies described in
Chapter 4.
The effect of lyM clonazepam was also investigated on the
antagonism of the stimulatory response to 30yM muscimol by PTX and
BMI. This concentration of muscimol gave a control response of
143 ± 15% (n = 6), which itself was unaltered by lyM clonazepam, the
combination causing 152 ± 18% stimulation. Concentration-response
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curves for the antagonists are shown in Figure 5.3, results being
expressed as % antagonism of a control response. Clonazepam shifted
the curve for BMI to the right, such that BMI caused significantly
less antagonism at 3uM and 10yM in the presence of lyM clonazepam.
The effect of PTX was clearly unaltered at 3, 10 or 30yM. Examples
of individual experiments are shown in Figure 6.4. The discrepancy
between these results and those of Simmonds (1980a) (using
flurazepam) caused us to investigate the effect of flurazepam on
this system. Flurazepam (lyM) reduced the antagonism caused by 3yM
PTX from 54 ± 5% to 29 ± 6% (compared with 56 ± 4% in the presence
of clonazepam) and that caused by 10yM BMI from 62 ± 2% to 39 ± 6%
(n = 5, P < 0.05 in both cases)(compared with 47 ± 5% in the
presence of clonazepam). Examples are shown in Figure 6.5.
The effects of the barbiturate secobarbital were investigated on
the responses to muscimol using both the normal protocol and also in
a series of experiments in which 24 sec (rather than the usual
2 min) fractions were collected. The effect of the benzodiazepine
Roll-6896 was also investigated in these experiments. Using the
normal protocol, both lOOyM secobarbital and lyM Roll-6896
potentiated the stimulatory response to lyM muscimol from 20 ± 3% to
74 ± M (secobarbital) and 51 ± 6% (Roll-6896) (P < 0.05, n = 5 in
each case) while not affecting the inhibitory component: 43 ± 2%
muscimol alone, 40 ± 4% with secobarbital and 43 ± 5% with
Roll-6896. Representative experiments are shown in Figure 6.6.
Similar results were found using the rapid collection protocol: the
peak stimulatory response of 23 ± 2% to muscimol was increased to
37 ± 2% by secobarbital and 54 ± 8% by Roll-6896 (P < 0.05, n = 5 in
each case, Figure 6.7). This protocol allowed the response to be
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analysed in greater detail, as the rising phase of the response was
spread over 5-6 fractions. The prolactin concentrations in these
fractions were expressed as a percentage of baseline secretion (mean
of 6 predrug fractions). The slope of the mean line constructed
through these values gives a measure of the rate of increase in
prolactin secretion, and was found to be
2.9 ± 0.6% per fraction with lyM muscimol. This was increased to
6.8 ± 0.9 by lOOyM secobarbital and 7.1 ± 1.4 by lyM Roll-6896 (P <
0.05, n = 5 in each case). Therefore both drugs were found not only
to increase the peak response to muscimol but also the rate of
increase in prolactin concentration, but as with clonazepam, no
effect on the inhibitory response to muscimol was observed. None of
the benzodiazepines or secobarbital were found to have any effect on
prolactin secretion alone.
6.4 Piscussion
The results presented here in Figures 6.1 and 6.6 demonstrate
potentiation of a GABA^ receptor effect by the benzodiazepines
clonazepam and Roll-6896, which were without effect alone. This
demonstrates that benzodiazepine receptors can be functional at
non-neuronal, non-synaptic locations and supports the hypothesis of
a widespread presence of this interaction (Olsen, 1982). PI cells
are also responsive to diazepam (Taraskevich and Douglas, 1982) at
what is probably a synaptic location (Oertel et al, 1982).
Two other observations were made:
a) that the benzodiazepine receptor involved showed central-type
phamacology and
b) that only one part of the response to muscimol was potentiated.
The basis for conclusion (a) is that clonazepam and Ro5-4864
-97-
show great selectivity for the central-type and peripheral-type
sites respectively (see Figure 4.2) and that the effect was
antagonised by Rol5-1788. Rol5-1788 is a potent displacer of
[ H]diazepam binding, but in a variety of models showed no
benzodiazepine-1ike action: it did, however, antagonise behavioural
effects of benzodiazepines (Hunkeler, Mohler, Pieri, Pole, Bonetti,
Cumin, Schaffner and Haefely, 1981). In situations in which
GABAergic activity is compromised, eg after isoniazid treatment,
Rol5-1788 has been reported to have anxiogenic activity and to cause
convulsions (Corda, Guidotti and Costa, 1982), suggesting that it
has some intrinsic e-carboline-1ike "inverse agonist" action
(Braestrup, Nielsen and Honore, 1983). In electrophysiological
studies it has been shown to have some partial agonist action
(Macdonald, Skerritt and McLean 1984). Rol5-1788 did not affect the
response to muscimol alone (Figure 6.2), and therefore appeared to
have no detectable efficacy in this model. Peripheral-type
benzodiazepine sites are present in PD in far greater abundance than
the central sites (Chapter 4) but as yet no function can be ascribed
2+
to them. An association with Ca channels has been suggested in
the heart (Mestre, Carriot, Belin, Uzan, Dubroeucq, Gueremy, Doble
and LeFur, 1985) and spinal cord (Skerritt, Werz, McLean and
Macdonald, 1984). Ro5-4864 has recently been shown to reduce
45 2+
Ca uptake in GH^ cells, an effect that was antagonised by
PK 11195 but not mimicked by clonazepam, suggesting the involvement
of a peripheral-type benzodiazepine receptor (Benavides, Burgevin,
Doble, LeFur and Uzan, 1985). By this reasoning Ro5-4864 might be
expected to influence stimulus-secretion coupling, but this was not
demonstrated here at the concentrations required to exclude action
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at central type sites. Ro5-4864-sensitive sites have also been
associated (along with a putative GABA receptor) with activation of
phospholipase A^ (Majewska and Chuang, 1985): this involved
potentiation of the effect of muscimol acting at a bicuculline-
sensitive but picrotoxin-insensitive GABA receptor, and Ro5-4864
appeared to be an antagonist of the effects of other benzodiazepines
e.g. diazepam. Ro5-4864 has also been reported to antagonise the
effect of muscimol in the cuneate nucleus (Simmonds, 1984), although
the mechanism for this is not entirely clear.
The second observation, the selectivity of the potentiation by
both benzodiazepines and secobarbital of the stimulatory part of the
response to muscimol is of interest in the light of the observations
of the differential pharmacology of the two parts of the response
described in Chapter 5. Strychnine was found to be a selective
antagonist of the stimulatory part of the response, and has also
been reported to be a potent antagonist of GABAergic stimulation of
benzodiazepine binding in some regions (Braestrup and Nielsen,
1980). There are distinct differences between the mechanisms of
action of benzodiazepines and barbiturates and the two classes of
drug are recognised by distinctly different although interacting
sites. It therefore appears that two different types of GABA^
receptor/channel complex may be involved in producing the two
effects on prolactin secretion:
(I) a benzodiazepine/barbiturate-1inked complex, which also has
associated sites for glycine and strychnine but at which
homocarnosine apparently lacks efficacy,
(II) a complex that appears to be insensitive to these modulators,
and glycine and strychnine, yet is activated by homocarnosine.
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These results do not confirm the results others have previously
obtained in vitro. The absence of an effect of benzodiazepines
reported by Grossman et al (1981) may be attributed to the absence
of a transient stimulation of prolactin secretion observed in their
study. A potentiation of the inhibitory effect of GABA or muscimol
was observed by Clemens and Shaar (1981) using hemipituitaries and
by Schettini et al (1984) using cell cultures. The static
incubation protocol used by these groups precludes the demonstration
of transient effects, but nevertheless there is no ready explanation
for the discrepancy. One possibility is that the effect of diazepam
2+
in those studies is related to its ability to depress Ca action
potentials (Skeritt et al, 1984; Cherubini and North, 1985) which
occur in PD cells (Taraskevich and Douglas,1977) and therefore the
potentiation of GABA effects is apparent rather than real. This
would also explain the direct inhibitory effect of diazepam on basal
and stimulated prolactin secretion (Schettini et al, 1984).
Clarification must await further study, but the results presented
here are consistent with the demonstration by Taraskevich and
Douglas (1982) that diazepam potentiated the electrophysiological
responses of PI cells to GABA, and GABA^ receptor activation
causes a stimulation of aMSH secretion (Tomiko et al, 1983; Demeneix
et al, 1984). Roll-6896 and secobarbital were also found to
potentiate the stimulatory effect of muscimol on GH secretion
(Chapter 7).
Despite the volume of research devoted to benzodiazepines, the
mechanism by which they potentiate GABAergic responses is not fully
understood. This problem was investigated by examining the effect
of clonazepam on the ability of PTX and BMI to antagonise the
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response to a fixed concentration of muscimol. Clonazepam was found
to reduce the ability of BMI but not PTX to antagonise the response
to muscimol (Figures 6.3 and 6.4) while not affecting the response
to muscimol alone. This approach has been previously employed in
electrophysiological experiments with brain slice preparations
(Simmonds, 1980a). In that case however, (using flurazepam as the
benzodiazepine) the potency of PTX but not BMI was reported to be
selectively reduced. The lack of influence on the potency of BMI
was suggested to reflect no change in the properties of the receptor
itself while the reduced potency of PTX was suggested to reflect
increased receptor-effector coupling or prolonged channel opening.
Repeated series of experiments with that model have shown
considerable variation in the interaction between muscimol,
flurazepam and PTX (Simmonds, 1983b) and prolongation of channel
open time has been shown to be a minor effect of diazepam (Study and
Barker, 1981). Furthermore, results from binding studies have
suggested instead, that alterations in binding site properties may
be more crucial, in that a variety of benzodiazepines enhance the
affinity of the low-affinity GABA binding site (Guidotti et al,
1978; Skerritt and Johnston, 1983). Recent patch-clamp experiments
have supported this interpretation, suggesting that diazepam
increases either the affinity of the GABA receptor or the number of
available receptors, without affecting conductance or gating
properties of GABA-activated channels (Bormann and Sakmann, 1984).
The results presented here in Figure 6.3 are consistent with
clonazepam enhancing the GABA receptor affinity, thus reducing the
potency of BMI without altering the receptor-effector coupling.
This is reflected in the lack of change of PTX potency, and the
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absence of any potentiation of the effect of muscimol alone at this
relatively high agonist concentration. It seems likely that a major
contribution to this discrepancy, between the present results which
support the ligand binding and patch clamp data and those of
Simmonds (1980a), beside differences in the properties of the model
used, is the use of flurazepam as opposed to clonazepam. Flurazepam
is a relatively potent and apparently competitive displacer of
[^H]DHP binding (Leeb-Lundberg, Napias and Olsen, 1981) in
comparison with its affinity for benzodiazepine receptors.
Clonazepam (and Roll-6896, also used here) are more selective
compounds as they are less potent (and non-competitive) displacers
of [^H]DHP binding (Leeb-Lundberg et al, 1981) whilst they are
3
more potent displacers of [ Hjbenzodiazepine binding. Such an
3
atypical action of flurazepam at [ H]DHP binding sites could
enhance its apparent effect on PTX potency. Indeed, such an effect
was observed here as flurazepam considerably reduced the antagonism
caused by both PTX and BMI. High concentrations of flurazepam have
also been reported to antagonise GABA responses (Nistri and
Constanti, 1978).
Another possible contributory factor is differences in the
methodology used. In the cuneate slice, the lower part of the
muscimol concentration-response curve was examined in the presence
and absence of flurazepam and the antagonists (which is the part of
the curve most sensitive to potentiation of the effect of muscimol
(Simmonds, 1980a). In the studies presented here, a high
concentration of muscimol was used to enable more accurate values
for percent antagonism to be calculated, and the response to this
concentration of muscimol was unaffected by clonazepam. The
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experimental protocol used here does not allow more than one
response to be measured on each set of superfused tissue, whereas
many responses in the presence of different drugs can be measured in
one cuneate slice. The use of part of the response curve sensitive
to flurazepam may have contributed to the variation encountered
(Simmonds, 1983b).
Lorazepam has also been found to reduce the potency of PTX in
the cuneate slice (Simmonds, 1981). Lorazepam is not potent at
displacing [^H]DHP binding (Leeb-Lundberg et al, 1981) but is
anomalously weak in antipunishment tests (Stephens, Kehr, Schneider
and Braestrup, 1984). These discrepancies may reside with the model
studied. One possibly important difference is the potency of
strychnine to antagonise muscimol in these studies (Chapter 5)
whereas it is much weaker than bicuculline in the cuneate slice
(Simmonds, 1982).
Further experiments to confirm these findings could be carried
out using e-carboline 'inverse agonists' which would be expected to
reduce the effect of muscimol and enhance the potency of BMI in this
model, paralleling their anxiogenic effects (Corda, Blaker,
Mendeson, Guidotti and Costa, 1983).
In conclusion, these results demonstrate the potentiation of a
GABA^ receptor effect by benzodiazepines and a barbiturate. The
interactions between clonazepam and the antagonists BMI and PTX are
consistent with benzodiazepines enhancing GABA receptor affinity or
the number of available receptors, without affecting the linkage
between receptor and ion channel. These results also support the
proposal that two separate types of GABA^ receptor complex are




Potentiation of the stimulatory effect of muscimol on prolactin
secretion by clonazepam. lOOnM muscimol alone (•) or with lpM
clonazepam (O) was introduced at the arrow.
%Inhibition
FIGURE 6.3
Interaction of clonazepam with antagonists.
Antagonism of the stimulatory effect of 30uM muscimol on prolactin
secretion by (□)PTX and (O) BMI.
Antagonism in the presence of lpM clonazepam: (0) PTX and (•) BMI.
Results expressed as percentage antagonism against antagonist
concentration. Mean ± S.E.M., n = 5.




Example of the interaction of clonazepam with antagonism of the
stimulatory effect of muscimol on prolactin secretion by BMI.
( • ) 30pM muscimol
(O) 30uM muscimol + luM clonazepam
(■) 30yM muscimol + 10pM BMI
(□) 30 uM muscimol + 10pM BMI + l^M clonazepam
Muscimol and clonazepam were introduced at the arrow, BMI was





Example of interactions of flurazepam with antagonism of the
stimulatory effect of muscimol on prolactin secretion by PTX.
( •) 30yM muscimol
(■) 30yM muscimol + 3yM PTX
(□) 30yM muscimol + 3yM PTX + lyM flurazepam
Muscimol and flurazepam were introduced at the arrow, PTX was
introduced 30 min previously.
!,r
10230 Fractionno.
FIGURE6.6 EffectsoflyMRoll—6896andlOOyMsecobarbitalthresponse luMmuscimol. (A)control,lyMmuscimolal e (X)lyMmuscimol+lpRoll—6896 (O)luMmuscimol+lO yMsecobarbital Drugswereintrod cedatthrow.Rep esentativexpe iments
FIGURE 6.7
Effects of lpM Roll-6896 and lOOyM secobarbital on the stimulatory
effect of lpM muscimol on prolactin secretion.
24 sec fractions were collected. Results are mean of prolactin
concentration in each fraction as a percentage of pre-drug
concentrations.
(A) luM muscimol alone
( X ) luM muscimol + lpM Roll -6896
(O) luM muscimol + lOOpM secobarbital
Drugs were introduced at the arrow. Standard errors (4 4%) are
omitted for clarity, n = 5.
CHAPTER 7
Effects of GABA receptor agonists on the secretion of GH, LH,
ACTH and TSH in vitro
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7.1 Introduction
Although prolactin has been the PD hormone most subject to
investigation in this field, there is considerable evidence that
GABA is involved in some way in the control of the other PD
hormones, GH, LH, ACTH and TSH. There are reports of no apparent
effect of GABA on follicle-stimulating hormone (FSH) secretion
(Ondo, 1974; Pass and Ondo, 1977; Vijayan and McCann, 1978a). As
the results of experiments on these hormones are often conflicting,
they will be discussed separately.
7.1.1. GABA and Growth Hormone Secretion
Vijayan and McCann (1978b) found that i.e.v. administration of
GABA to conscious female rats caused a rapid increase in GH
secretion, which was antagonised by bicuculline. This failed to
confirm an earlier report that GABA i.c.v reduced plasma GH
concentration in anaesthetized male rats (Bruni, Mioduszowski,
Grandison, Simkins and Meites, 1977), but supported the results of
Martin, Durand, Gurd, Faille, Audet and Brazeau (1978) who found
that picrotoxin suppressed episodic GH secretion, providing evidence
for a physiological stimulatory role for GABA. Bicuculline and
picrotoxin have also been shown to prevent both the stimulation of
GH secretion by a met-enkephalin analogue in conscious male rats
(Katakami, Kato, Matsushita, Shimatsu and Imura 1981) and the
ability of muscimol to stimulate GH secretion in man (Tamminga,
Neophytides, Chase and Frohman, 1978). Administration of AOAA to
elevate brain GABA concentrations also stimulated GH secretion
(Turnbull and SIater,1970). This stimulatory GABAergic effect may
be mediated, at least partly, by reduced release of somatostatin
into hypophysial portal blood (Gamse et al, 1980; Takahara, Yunoki,
Hosogi, Yakushiji, Kageyama and Ofuji, 1980).
-104-
Other results supporting those of Bruni et al (1977) of an
inhibitory effect on GH secretion have also been obtained.
Intraperitoneal injection of muscimol has been reported to inhibit
GH secretion in female rats (Cocchi, Casanuva, Locatelli, Apud,
Martinez-Campos, Civati, Racagni and Muller, 1981) but this was
enhanced by bicuculline. Blockade of GABA synthesis or receptors
stimulated GH secretion, and inhibition of GABA degredation
inhibited GH secretion (Fiok, Acs and Stark, 1981a). These
conflicting results may have been resolved by a recent study by
Fiok, Acs, Makara and Erdo (1984). These authors demonstrated that
systemic administration of muscimol inhibited anticipated GH surges
in conscious male rats, an effect also produced by elevating brain
GABA with GAG. Conversely, BMI triggered an early secretory peak.
Muscimol also inhibited GH secretion in rats with anterolateral
deafferentation of the medial basal hypothalamus, a procedure which
elevates GH secretion by removing the influence of somatostatin
(Brownstein, Arimura, Fernandez-Durango, Schally, Palkovits and
Kizer, 1977; Karteszi, Fiok and Makara, 1982; Makara, Palkovits,
Antoni and Kiss, 1983) and which therefore suggested that muscimol
was acting by inhibition of GH-releasing hormone (GHRH) secretion.
Fiok et al (1984) also suggested that the reason for the apparent
discrepancy between these results obtained after peripheral
administration of muscimol and BMI and those obtained after central
administration is the anatomical localisation of somatostatin-
containing and GHRH-containing cell bodies: the former, being in
anterior periventricular regions (Hokfelt, Hellerstrom, Johnson,
Luft and Arimura, 1975; Elde and Parsons, 1975; Dierickx and
Vandersande, 1979) may be preferentially influenced by i.e.v. GABA
(Makara et al, 1975) whereas GHRH-containing cells are found in
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arcuate and ventromedial nuclei of the hypothalamus (Frohman,
Bernardis and Kant, 1968; Martin, 1976; Block, Brazeau, Ling,
Bohlen, Esch, Wehrenberg, Benoit, Bloom and Guillemin, 1983) and
will therefore be more susceptible to the effects of
peripherally-administered substances which only cross the
blood-brain barrier poorly.
Taken in toto, these results suggest two centrally-mediated
effects of GABA on GH secretion. The stimulation of GH secretion by
BMI, and the inhibition by picrotoxin and bicuculline suggest that
both may be tonically active. This explanation may underly the
apparently paradoxical demonstration that diazepam-stimulated GH
secretion in man is abolished by the GABA-transaminase inhibitor
sodium valproate (Koulu, Lammintausta, Kanga and Dahlstrom, 1979).
Baclofen has been reported to inhibit stimulated GH secretion in
man (Cavagnini, Invitti, DiLandro, Tenconi, Maraschini and Girotte,
1977) but others have reported rapid stimulatory effects in both man
and rats (Koulu, Lammintausta and Dahlstrom, 1979, Fiok, Acs and
Stark, 1981b).
Both GABA and muscimol have been reported to have no effect on
GH secretion in vitro using hemipituitaries or dispersed cells
(Tsushima, Irie and Sakuma, 1971; Vijayan and McCann, 1978b; Fiok et
al, 1981a; 1984). Peripheral administration of GABA to neonate rats
was observed to stimulate GH secretion (Acs, Makara and Stark,
1984), whereas in the adult muscimol inhibited GH secretion (Fiok et
al, 1984). Subsequent study showed that this effect could be
demonstrated in vitro using either GABA or muscimol, but only up to
the 9th day post-partum (Acs et al, 1984).
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7.1.2 GABA and Luteinizing Hormone secretion
Ondo (1974) demonstrated that i.e.v. GABA stimulated LH
secretion in anaesthetized male rats. This was subsequently
confirmed and enlarged upon (Pass and Ondo, 1977; Vijayan and
McCann, 1978a, 1979), but more recently inhibitory effects of i.e.v.
GABA and muscimol have been demonstrated (Lamberts, Vijayan, Graf,
Mansky and Wuttke, 1983). This effect of muscimol was dependent on
the steroid status of the animal, as it was present in
ovariectomized rats, but not if they were treated restoratively with
steroids (Lamberts et al, 1983). From this and results of
measurements of catecholamine and GABA turnover after endocrine
manipulations, it has been proposed that oestrogen-sensitive GABA
neurones in the preoptic area/anterior hypothalamus modulate the
stimulatory effect of noradrenergic neurones on LHRH neurones
(Mansky, Mestres-Ventura and Wuttke, 1982; Fuchs, Mansky, Stock,
Vijayan and Wuttke, 1984). A direct action of GABA on LHRH neurones
was suggested to be unlikely as steroid-primed rats show great
sensitivity to LHRH (Ramirez and McCann, 1963) and any direct effect
would be reflected by changes in LH which was not observed (Lamberts
et al, 1983). However, GAD-IR axons have recently been demonstrated
to synapse directly onto LHRH-containing neurones (Leranth,
MacLusky, Sakamoto, Shonabrough and Naftolin, 1985).
GABA has been reported to have no effect on LH secretion
following direct injection into the pituitary (Ondo, 1974; Pass and
Ondo, 1977).
7.1.3 GABA and Adrenocorticotrophic hormone secretion
Studies on ACTH secretion have been less conflicting, and have
been of some therapeutic value. GABA i.e.v. inhibited
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trauma-iinduced increases in plasma corticosterone, and picrotoxin
and BMI elevated corticosterone concentrations when given i.e.v. to
rats with hypothalamic deafferentation (Makara and Stark, 1974).
GABA also inhibited the acetylcholine- or 5HT-stimulated release of
bioassayable CRH from hypothalamic slices (Burden et al, 1974). An
inhibitory involvement in the feedback of steroids or stress is
suggested by several lines of evidence: bicuculline potentiated the
stress-induced increase in plasma corticosterone, and prevented the
dexamethasone-induced decrease in plasma corticosterone (Kameyama,
Nabeshima, Banno and Kamata, 1983). Inhibition of GAD by
mercaptopropionic acid reduced the effect of dexamethasone on basal
and stressed corticosterone concentrations (Acs and Stark, 1978),
and dexamethasone increased, whereas stress decreased, diencephalic
GABA concentrations (Kameyama et al, 1983). A stimulatory effect of
dexamethasone on GAD activity has been localised to the supraoptic
nucleus (Acs, Palkovits and Stark, 1980) which may contain the cell
bodies of part of the CRF innervation of the ME (Cummings, Elde,
Ells and Linda!1, 1983).
Sodium valproate given to rats for 3 months blunted
stress-induced rises in plasma ACTH concentration, and this drug has
proved to be of value in the treatment of Nelson's Syndrome, as has
diazepam (Jones, Gillham, Attaher, Nicholson, Campbell, Watts and
Thody, 1984). GABA and sodium valproate were without effect on ACTH
secretion from human pituitary adenoma in vitro (Jones et al, 1984)
suggesting that the effect of sodium valproate was to potentiate
GABAergic inhibition of CRF secretion.
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7.1.4 GABA and Thyroid Stimulating Hormone secretion
The existence of a centrally-mediated inhibitory effect of GABA
on TSH secretion is suggested by the fall in plasma TSH
concentration following i.e.v. administration of GABA (Vijayan and
McCann, 1978b; Jordan, Poncet, Veisseire and Mornex, 1983).
Picrotoxin and the GAD inhibitor semicarbazide were found to elevate
the nocturnal low concentrations of TSH without affecting the
diurnal peak, suggesting an involvement of GABA in the circadian
rhythm (Jordan et al, 1983). AOAA also decreased plasma TSH
concentrations (Mat ilia and Mannisto, 1980).
There is no evidence for a direct effect of GABA on TSH
secretion. GABA was found to be without effect on TSH secretion
from hemipituitaries (Vijayan and McCann, 1978b; Jordan et al, 1983)
or on TRH-stimulated TSH secretion in vivo, although it was able to
inhibit cold-induced TSH secretion (Matilla and Mannisto, 1980).
The results discussed above demonstrate pharmacological effects
of GABAergic drugs on GH, LH, ACTH and TSH. Physiological
involvement of GABAergic neurones is suggested for GH, ACTH and TSH
by the effects of antagonists alone, and for LH by the
steroid-dependency of the effect. Given the ubiquity of GABAergic
neurones within the hypothalamus and the complexity of neurochemical
control of these hormones, action at multiple sites (and hence
conflicting experimental observations) appears near unavoidable.
This is perhaps best illustrated by the evidence for GABAergic
control of both somatostatin and GHRH secretion. Despite this
wealth of possible function within the hypothalamus, the only report
of a direct action on PD concerns GH secretion in neonate rats.
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Th e aim of this study was to reassess the effect of GABA
receptor agonists on GH, LH, ACTH and TSH secretion in vitro using
the superfusion method demonstrated in Chapter 5 to have the
resolution capable of revealing novel effects on prolactin
secretion. The influence of both GABA^ and GABAg receptors was
investigated, as both are found in PD (Chapter 3) and may have
opposing effects, as demonstrated on aMSH secretion from PI
(Demeneix et al, 1984).
7.2 Materials and Methods
Materials were as described in Chapters 5 and 6; LHRH was
obtained from Cambridge Research Biochemicals. Methods were also
the same. Hormones were measured in aliquots of superfusate as
described in Section 2.3.
Results were calculated as peak percentage changes from pre-drug
baseline, and are expressed as mean ± S.E.M. Statistical
comparisons were made by the Mann-Whitney U test.
7.3 Results
7.3.1 Growth Hormone
GABA and muscimol both produced a large, transient stimulation
of GH secretion which peaked within 4 min and then rapidly declined,
reaching approximately pre-drug concentrations in about 20 min
(Figures 7.1, 7.3). At the end of the routine collection period, 30
min after drug addition, secretion was within 20% of pre-drug
concentrations and no inhibitory effect was observed. The effect of
muscimol was found to be concentration dependent from 0.1-10uM
(Figure 7.2) and the effect of 10pM muscimol was reduced from
186 ± 21% to 20 ± 2% (n = 5, P < 0.05) by 10pM BMI, indicating
mediation of the effect by a GABA^ receptor (Figures 7.2, 7.3).
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The selective GABAg receptor agonist baclofen (100uM) had no
9+
effect on basal GH secretion(Figure 7.1 ). 3mM Ba was found to
be a very potent secretagogue for GH, and caused 673 ± 53%
stimulation of secretion alone. When lOOuM (±)baclofen was
co-introduced, the response was unaffected (659 ± 57% stimulation,
n = 5 in each case).
The pharmacology of the GABA^-receptor mediated stimulation of
GH secretion was further investigated using drugs previously found
of interest in the study of GABA receptor effects on prolactin
secretion. The effect of lyM muscimol was potentiated by both the
benzodiazepine Ro11—6896 and the barbiturate secobarbital: lpM
muscimol caused 117 ± 21% stimulation alone, 186 ± 9% in the
presence of lpM Rol 1-6896 and 260 ± 40% in the presence of IOOjiM
secobarbital (P<0.05 in both cases, n=5-6, drugs introduced
simultaneously, Figure 7.3). 10pM strychnine did not antagonise the
response to 10yM muscimol, the combination causing 162 ± 35%
stimulation(Figure 7.<ta). Homocarnosine (ImM) had no effect alone
on GH secretion, nor did it significantly affect the response to
GABA. 10pM GABA caused 128 ± 12% stimulation alone, and 96 ± 19% in
the presence of homocarnosine (Figure 7.A-b).
7.3.2 Luteinizing Hormone
lOyM muscimol caused a small transient stimulation of LH
secretion (17 ± 2%, n = 5)(Figure 7.5) which rapidly returned to
pre-drug concentrations. No subsequent inhibition was observed.
Neither baclofen (lOOpM)(Figure 7.6) nor GABA itself (10yM) had any
effect on basal secretion. This effect of muscimol was abolished by
lOpM BMI (no stimulation of release could be observed), suggesting
the involvement of a GABA^ receptor, but the lack of effect of
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GABA itself, probably because of its lower potency than muscimol,
suggested the importance of studying stimulus-induced release. LHRH
was used, being the physiological secretagogue, and caused a prompt,
concentration-dependent stimulation of secretion that peaked in 4-6
minutes with a gradual subsequent decline. 10pM muscimol
significantly potentiated the peak response to 300nM LHRH in a
greater than additive manner when added simultaneously, from 117 ±
\% to 164 ± 6% (n=5, P<0.05), and this potentiation was antagonised
by 10yM BMI (Table 7.1, Figure 7.5). 10yM GABA potentiated the
response to 3nM LHRH but had no effect on the response to 300nM
LHRH, although there was a trend towards an inhibition (Table 7.1).
lOpM BMI antagonised the stimulatory effect of 10uM GABA on the
response to 3nM LHRH, but in the presence of lOpM BMI, 10pM GABA
caused a significant inhibition of the response to 300nM LHRH (Table
7.1). The effect of baclofen was investigated in parallel
experiments. lOOpM (±)baclofen had no effect on basal LH secretion,
but reduced the response to 300nM LHRH from 117 ± M to 82 ± 8% (n =
5, P < 0.05, Figure 7.6, Table 7.1). These results suggest that an
inhibitory GABAg response determines the effects of GABA at high
LHRH concentrations, but a stimulatory GABA^ receptor effect is
predominant at lower LHRH concentrations. An alternative putative
2+
secretagogue, Ba (3mM) was found to have no effect on secretion
of LH in contrast to other hormones, although 50mM K+ caused a
similar response to 300nM LHRH (Figure 7.7). Subsequent studies
2
have shown this to be a sex-dependent effect, as Ba stimulates




10uM Muscimol caused a transient stimulation of ACTH secretion
rising to a peak of 39 ± 5% (n = 5)above baseline (Figure 7.8a).
Secretion returned to approximately pre-drug rates within 20 min,
and no subsequent inhibition was seen. 10uM BMI reduced this effect
to 13 ± 3% (P < 0.05, n = 5). lOOpM (±)baclofen had no consistent
effect on basal ACTH secretion (although sometimes a transient
inhibition was observed (Figure 7.8a), but reduced the peak
stimulation caused by 3mM Ba^+ from 255 ± 23% to 152 ± 17% (n = 5,
"t*
P < 0.05 Figure 7.8b). The response to K (substituted for Na
in the medium) was also inhibited by baclofen: 50mM K+ caused
170±10% stimulation alone and 104^7% in the presence of lOOpM
baclofen (p<0.05, n = 5), suggesting that on corticotrophes a
GABAg receptor (as well as GABA^) can be functionally active,
but only in the stimulated condition.
7.3.4 TSH
Neither muscimol (10uM) nor baclofen (lOOpM) had any effect on
9+
basal TSH secretion (Figure 7.9). The effect of 3mM Ba was also
unaffected by baclofen, causing 88 ± 10% peak stimulation alone, and
91± 13% in the presence of lOOyM baclofen (n = 5, Figure 7.9).
Piscussion
These results demonstrate the apparent presence of GABA
receptors on somatotrophes, gonadotrophes, and corticotrophes but
not thyrotrophes. The possibility exists that the effects of
muscimol demonstrated here are not direct in each case, but may be
indirect, by a paracrine interaction between different cell types.
Such an interaction between gonadotrophes and lactotrophes has been
demonstrated (Denef and Andries, 1983), and could be investigated
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using purified and cultured cell types. There are, however,
differences in the responses of the various celltypes, with only LH
and ACTH secretion following the same pattern (i.e. stimulatory
GABA. response and inhibitory GABAD response) which perhapsA D
suggests that such an interaction is not of major importance. An
+
alternative possibility is that GABA^ depolarisation-induced K
efflux (Deschenes and Feltz, 1976; Loeffler et al, 1982) for
example, from somatotrophes, may account for the slightly increased
release of LH (and ACTH).
GABA^ receptor activation in these experiments (being a
BMI-sensitive response to muscimol) was found to cause a transient
stimulation of GH, LH and ACTH secretion. This is similar to that
seen on aMSH secretion (Demeneix et al, 1984), but somewhat in
contrast to prolactin secretion where a biphasic GABA^ response is
seen, with inhibition subsequent to the transient stimulation
(Chapter 5). This purely stimulatory effect was clearest on GH
secretion (Figure 7.1), suggesting that the inhibitory effect of
GABA^ agonists on prolactin secretion is not purely a consequence
of the stimulation (Taraskevich & Douglas, 1982), but involves a
quite distinct response mechanism that can be present or absent in
different cell types.
Previous experiments have been unable to show any effect of GABA
or, where investigated, muscimol on in vitro secretion of any of the
hormones here examined (Fiok et al, 1981a, 1984; Jones et al, 1984;
Vijayan & McCann, 1978b; Jordan et al, 1983), the only exception
being that a stimulatory effect has been reported on GH secretion
from neonate rat pituitaries, although the same authors were unable
to find this effect using adult tissue (Acs et al, 1984). One
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possible contributory factor, other than the inherent unsuitabi1ity
of static incubations for the detection of transient events, is the
high concentration of GABA-transaminase in PD (Racagni et al, 1979),
which can prevent the inhibitory effect of GABA on prolactin
secretion from being observed (Racagni et al, 1983). None of these
reports used a superfusion system.
The mechanisms of action of GABA^ and GABAg receptors on
stimulus-secretion coupling are different. GABA^ receptor
activation results in an increased Cl~ conductance which (at least
transiently) may depolarise the secretory cell membrane and cause a
flurry of action potentials (Taraskevich & Douglas, 1982). This in
turn will facilitate (again probably transiently) the release of
hormone, and may be the mechanism underlying the effect of muscimol
on the secretion of GH and ACTH. As gonadotrophes apparently show
no spontaneous action potentials (Mason and Waring, 1984) but only
/
an increased membrane electrical 'noise', even in response to LHRH
(Mason and Waring, 1984) another mechanism may possibly be
involved. Nevertheless, depolarisation with K+ is an effective
secretagogue in gonadotrophes, so partial depolarisation from
GABA^ receptor induced Cl~ movement may well promote the
secretory mechanism. The transient nature of these responses may be
2
a result of inactivation of voltage-dependent Ca channels
(Tomiko et al, 1981).
Evidence for endocrine responses to GABAg receptor activation
is scanty, but stimulatory effects of baclofen on GH secretion in
man and rat have been reported (Koulu et al., 1979; Fiok et al.,
1981b). GABAg receptor activation results in inhibition of
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neurotransmitter (Bowery et al, 1980) or hormone (Demeneix et al,
1984) release and blockade of calcium channels has been proposed as
a mechanism of action (Dunlap, 1981; Dunlap and Fischbach, 1981). A
hyperpolarising postsynaptic response to baclofen (as a result of
increased K conductance) (Newberry and Nicoll, 1984a) has also
been reported in the hippocampus. Both of these type of effects
would tend to inhibit secretion particularly in the stimulated
situation. No effects of baclofen were found on basal secretion of
any of the hormones here investigated, but baclofen was found to
inhibit Ba^+- and K+-induced secretion of ACTH but not GH or TSH
(or prolactin, Chapter 5) and LHRH-induced secretion of LH.
Previous studies (Demeneix et al, 1984) have also shown greater
effects of baclofen on stimulated than on basal secretion. Other
possible mechanisms of action of GABAg receptors are discussed in
Chapter 5, but no relevant experiments were carried out in this
Chapter.
Barium is a potent secretagogue in PD, as shown here, and also
in PI, where it has been used previously in the demonstration of a
GABAg receptor effect. Barium is considered to act by
facilitating sustained cell firing and the development of
long-lasting action potentials by penetrating voltage dependent
2+ + .
Ca channels and blocking K channels (Taraskevich and Douglas,
1980; Hagiwara and Byerly, 1981; Douglas et al, 1983; Adams et al,
1982a). Spontaneous action potentials have been detected in
anterior pituitary tissue in vitro (Douglas and Taraskevich, 1978;
Ozawa and Sand, 1978) and in cultures of purified somatotrophes
provided that they have been cultured long enough to recover from
the effects of trypsin used in preparation (Israel, personal
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communication). LH secretion (from male tissue) was found to be
2+
unaffected by 3mM Ba , which supports the above mechanism of
2+
action of Ba in that ovine pars tuberalis gonadotrophes do not
/
"show action potentials, even in response to LHRH (Mason and Waring,
1984). This result does not provide evidence that LHRH acts
ubiquitously by inhibition of the M current, an action which has
been proposed to account entirely for its effect on bullfrog ganglia
2+
(Adams et al, 1982a) because Ba also blocks this current.
The action of GABA in facilitating the LH response to a low
(3nM) concentration of LHRH, but reducing the response to a high
(300nM) concentration is potentially important in terms of a
regulatory role. These effects appeared to be mediated by separate
receptors, the potentiation of the response to LHRH being mediated
by a GABA^ receptor, but the inhibition of the response to LHRH
being mediated by a GABAg receptor. If these results can be
extrapolated to in vivo, the physiological role of GABA may be to
sensitise gonadotrophes to low LHRH concentrations while suppressing
the effects of high concentrations, and this perhaps only occurs
under particular conditions in which the secretion of GABA into
hypophysial portal blood is elevated. Similar effects of GABA
acting at GABA^ receptors to enhance neurotransmitter release at
low secretagogue concentrations and at GABAg receptors to reduce
release at high secretagogue concentrations, have been previously
observed in the CNS (Bowery et al, 1980). The number of GABA^
binding sites in the PD can be altered by steroid treatment (Racagni
et al, 1983), which also increased GABA concentration in PD and GAD
activity in ME (Nicoletti, Grandison and Meek, 1985) and this may
support the idea of a variable GABAergic influence of gonadotrophe
function.
-117-
Benzodiazepines and barbiturates commonly potentiate GABAergic
responses (Ransom and Barker, 1976; Choi et al., 1977; Macdonald and
Barker, 1978; 1979). Benzodiazepines potentiate the stimulatory
effect of muscimol on prolactin secretion (Chapter 5), and there are
central-type benzodiazepine binding sites in the PD (Chapter 4).
Both the benzodiazepine Roll-6896 and the barbiturate secobarbital
were found to potentiate the stimulation of GH secretion caused by
muscimol, demonstrating a further cellular location for GABA^
receptor/modulator/chloride channel complexes (Olsen, 1982) outside
the CNS. These complexes are therefore found on a large proportion
of PD cells. The number of GABA^ and central-type benzodiazepine
binding sites in PD is much less than that found in CNS regions
(Chapters 3 and 4) suggesting that their concentration on receptive
cell membranes is much less at non-synaptic PD sites that at
synaptic sites within the CNS. Benzodiazepines can modify plasma
prolactin concentrations (Grandison, 1982; Lotz, 1982), and these
results suggest that GH concentrations may also be affected.
In these experiments strychnine was found to be ineffective at
antagonising the effect of muscimol on GH secretion. In contrast,
muscimol-induced stimulation of prolactin secretion was very
potently antagonised by strychnine, which was found to be slightly
more potent than BMI (Chapter 5). The GABA-containing dipeptide
homocarnosine, present in hypophysial portal blood in high
concentrations (Mitchell et al, 1983) was without effect on GH
secretion. Homocarnosine has modest affinity for GABA^ receptors
(Mitchell et al, 1983), but causes significant inhibition of
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prolactin secretion in vitro (Schally et al, 1977; Chapter 5). Its
lack of either agonist or antagonist action on GH secretion suggests
that it has neither affinity nor efficacy at this particular GABA^
receptor. The GABA^ receptor mediating stimulation of GH
secretion therefore shows both similarities and differences to the
GABA^ receptor mediating stimulation of prolactin secretion, being
benzodiazepine- and barbiturate-linked but insensitive to strychnine
and homocarnosine. This further emphasizes the novelty of the
GABA^ receptor effects on prolactin secretion, being the only
pituitary hormone so far studied from the anterior or intermediate
lobes which can be inhibited by GABA^ agonists in addition to what
must be now regarded as a near-ubiquitous stimulatory effect. If
any of the responses demonstrated here are indirect, e.g. mediated
by increased extracellular K+, this might be a consequence of the
ability of this tissue preparation to reveal such effects, as the
structure of the tissue is largely preserved. If these responses
were not observed using a dispersed cell preparation, this in turn
might reflect the physiological importance of intercellular
interactions of this kind.
These results provide further evidence for a neuroendocrine role
of GABA in PD. Previously GABA has been associated only with the
control of prolactin secretion at the level of the pituitary
(Schally et al, 1977; Enjalbert et al, 1979) but these results
demonstrate that both stimulatory and inhibitory GABAergic
influences on other hormones require consideration in in vivo
experiments.
FIGURE 7.1
Effects of lOpM muscimol (•) and 100yM(±) baclofen (O) on basal GH
secretion. Drugs were introduced at the arrow. Representative
experiments.
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FIGURE 7.2
Stimulation of GH secretion by muscimol and GABA, and antagonism
BMI.
(•) Concentration-response curve for muscimol
(O) Effect of 10pM muscimol in the presence of 10uM BMI
(■) Effect of 10uM GABA.
Results are expressed as percentage increase in secretion, mean
± S.E.M., n = 5 in each case.
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FIGURE 7.3
Modulation of the effect of muscimol on GH secretion by
benzodiazepines and barbiturates.
(O) Effect of IjjM muscimol
(A) Effect of lyM muscimol + lpM Rol 1-6896
(■) Effect of lpM muscimol + 100pM secobarbital

















a) Selective antagonism of the effect of muscimol on GH secretion
by BMI but not strychnine.
(•) Effect of 10pM muscimol
(O) Effect of 10uM muscimol in the presence of 10pM BMI
(A) Effect of 10uM muscimol in the presence of 10uM strychnine
Muscimol was introduced at the arrow. Antagonists were introduced
30 mins previously.
b) Effect of GABA and homocarnosine on GH secretion.
(•) Effect of 10UM GABA
(A) Effect of ImM homocarnosi ne
(a) Effect of 10yM GABA + ImM homocarnosine







Interaction of GABA/\ receptors with LHRH-stimulated LH secretion.
(a) Effect of 10uM muscimol
( □) Effect of 300nM LHRH
(O) Effect of 10yM muscimol + 300nM LHRH
(•) Effect of 10yM muscimol + 300nM LHRH in the presence of
lOuM BMI.
Muscimol and LHRH were introduced at the arrow. BMI was introduced




Interaction of GABAg receptors with LHRH - stimulated LH secreti
(O) Effect of 100yM (±)baclofen
(□) Effect of 300«M LHRH
(#) Effect of lOOyM (±)baclofen + 300nM LHRH
Baclofen and LHRH were introduced at the arrow. Representative
experiments.
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FIGURE7.7 SecretagogueactionofK+butno8a2+onLHsecretion. (O)Effectof50mMK+ (□)Effectof3mMBa^"1" (•)Effectof300nMLHRH Ionic-substitutedmediumrLHRHw reintr ducedattharrow. Representativeexp riments.
FIGURE 7.8
Effects of muscimol and baclofen on ACTH secretion.
a)(A) Effect of 10pM muscimol
(A) Effect of lOOyM (±) baclofen
b)(0) Effect of 3mM Ba^"1"
(•) Effect of 3mM Ba2+ with lOOpM (±) baclofen
Representative experiments. Muscimol, baclofen and Ba2+ were













(•) 3mM Ba2+ + 100yM (±)baclofen
Representative experiments. Muscimol, baclofen and Ba^+ were
introduced at the arrow.
TABLE 7.1
GABA/\ and GABAg receptor modulation of the effect of LHRH on LH
secretion.
LHRH 3nM 300nM
Control 45 ± 5 117 ± 4
+ 10pM Muscimol - 164 ± 6*
+ 10yM Muscimol + 10yM BMI - 91 ± H
+ lOOyM Baclofen - 82 ± 8*
+ 10yM GABA 75 ± 7* 78 ± 11
+ 10yM GABA + lOyM BMI 42 ± 5* 52 ± 4*
Values are peak percentage stimulation of secretion.
* P < 0.05 vs control
4 P < 0.05 vs Agonist alone
Mean ± S.E.M., n = 5 in each case.
CHAPTER 8
3Characteristics of the uptake and release of [ H]GABA by the
median eminence and the neurointermediate lobe of the pituitary
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8.1 Introduction
The median eminence (ME) contains very high metabolic activity
corresponding to the GABA-synthesising enzyme GAD (Tappaz,
Brownstein and Palkovits, 1976) and high concentrations of GABA
itself (Van der Heyden, DeKloet, Koft and Versteeg, 1979). ME GAD
activity is unaltered following deafferentiation of MBH (Tappaz and
Brownstein, 1977) suggesting that it is present in neurones
intrinsic to that area. Much lower GAD activity is present in the
posterior pituitary and it was originally suggested to be confined
to glial cells (Beart, Kelly and Schon, 1974). This was supported
O
by autoradiographic localisation of [ H]GABA accummulated in the
posterior pituitary (Beart et al, 1974; Hamberger, Norstrom,
Sandberg and Svanberg 1979). Release of [^H]GABA from the
posterior pituitary also showed glial characteristics (Minchin and
Nordman, 1975). Similar experiments using ME tissue following
either in vitro or in vivo accummulation of [ H]GABA showed that
it was taken up predominantly by neurones in the external layer of
ME (Tappaz, Aguera, Bel in and Pujol, 1980).
More recently, immunohistochemical studies using antisera to
purified GAD as a marker for GABAergic neurones have been used to
describe a dense plexus of GAD-like immunoreactivity in both the
external layer of ME and the intermediate lobe of the pituitary,
with a less dense innervation of the posterior lobe (Vincent et al,
1982; Tappaz et al, 1983). GAD activity and immunoreactivity in NI
was virtually abolished by transection of the pituitary stalk
(Oertel et al, 1982) suggesting that it is of central origin, but
the precise location of the cell bodies remains unknown.
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These studies were undertaken to examine the uptake and release
of [^H]GABA in ME and NI with the aim of establishing
neurochemically the presence of GABA nerve terminals and revealing
their characteristics.
One characteristic of GABA nerve terminals in several CNS
regions is the presence of presynaptic autoreceptors (Mitchell and
Martin, 1978a; Arbilla, Kamal and Langer, 1979). GABAergic nerve
terminals in ME might be expected not to be subject to autoreceptor
control if GABA is not released into a synaptic environment but into
hypophysial portal blood (Mitchell et al, 1983). Similarly, DA
terminals in ME have been shown to have a lower affinity uptake
mechanism than in striatum (Demarest and Moore, 1979) and DA release
was not influenced by autoreceptors (Annunziato, Cerrito and
Raiteri, 1981). Others have reported the existence of DA
autoreceptors, using the larger whole ME preparation (Sarkar,
Gottshall, Meites, Horn, Dow, Fink and Cuello, 1983).
The role of DA as a major PIF is better established than that of
GABA (Leong et al, 1983) and the apparent coexistence of tyrosine
hydroxylase-immunoreactivity and GAD-IR has been described in some
neurones projecting to ME (Everitt et al, 1984). Serotonin (5-HT)
is present in the ME in both tanocytes (Sladek and Sladek, 1981) and
y
nerve fibres (Bjorklund, Flack, Hromek, Owman and Wert, 1970;
Palkovits, Saavedra, Jacobowitz, Kizer, Zaborsky and Brownstein,
1977) and may interact with GABA and DA in the control of prolactin
secretion (Caligaris and Taleisnik, 1974; Wehrenburg, McNicol,
Frantz and Ferin, 1980). Indeed the effect of 5-HT on plasma
prolactin concentration can be antagonised by picrotoxin (Caligaris
and Taleisnik, 1974). Similarly, there is both a dopaminergic and
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serotonergic innervation of NI (Leranth, Paikovits and Kreiger,
1983) and both of these transmitters can affect hormone secretion
from the PI in vitro (Bower, Hadley and Hruby, 1974). Therefore, in
view of the morphological and functional connections between systems
of these two transmitters and GABA, their effects on GABA release in
both ME and NI were examined. Similar experiments have been carried
out to determine whether prolactin, which may have a feedback effect
on GABA synthesis in MBH (Nicoletti et al, 1983), also increases
GABA release.
Vasopressin is found in ME as well as the posterior pituitary
(Zimmerman, Stillman, Recht, Antunes and Carmel, 1977) in terminals
of neurones of the paraventricular nucleus (Alonso and Assenmacher,
1981). This projection appears distinct from that to PN, both
anatomically (Swanson and Sawchenko, 1980) and functionally, being
involved in the control of ACTH secretion (Zimmerman et al, 1977;
Gillies and Lowry, 1979; Rivier and Vale, 1983). An electro¬
physiological study, however, provided evidence that the ME
projection consisted of axon collaterals of the neurohypophysial
projection (Pittman, Blume and Renaud, 1978). The density of
vasopressin binding sites in ME and PN (Brinton, Gee, Wamsley, Davis
and Yamamura, 1984) suggests that vasopressin may be involved in the
local control of release of other transmitters/releasing factors in
both areas. ctMSH is also found in nerve terminals in ME (O'Donohue,
Miller and Jacobowitz, 1979), and may be involved in the control of
prolactin (Khorram, Mizunuma and McCann, 1982) and LH secretion
(Aide and Celis, 1980; Khorram, De Platis and McCann, 1984). The
release of both vasopressin and aMSH from the pituitary can be
affected by GABA, that of aMSH by a direct action (Tomiko et al,
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1983) and that of vasopressin both centrally, possibly by an action
within the supraoptic nucleus (Knepel et al, 1980; Arnauld, Cirino,
Layton and Renaud, 1983) and directly (Knepel et al, 1984). An
interaction within the neurohypophysis may be supported by the
demonstration of increased [ H]GABA uptake by that area following
water deprivation (Hamberger et al, 1979). The possible influence
of these hormones on [ H]GABA release from ME and NI was therefore
investigated.
8.2. Materials and methods
8.2.1. Materials
[^H]GABA (aminobutyric acid, y-[2,3-^H]-), specific activity
80-83 Ci/mmol was obtained from New England Nuclear. The medium
consisted of NaCl (133mM), KC1 (5mM), CaCl2(2.7mM), MgSO^
(1.2mM), Tris (lOmM) and glucose (lOmM) pH 7.4, all Analar, BDH, and
was equilibrated with 100% O2.
e alanine, L-2,4 diaminobutyric acid, muscimol, dopamine,
serotonin, aMSH, arginine vasopressin, ovine prolactin, and amino
oxyacetic acid (AOAA) were obtained from Sigma. Bicuculline
methiodide (BMI) was obtained from Pierce Chemical Co.
8.2.2. Tissue preparation
Male Wistar rats (200-250g) were decapitated and the brain
rapidly removed. The pituitary gland was removed and NI separated
from PD. The ME (including a small part of the pituitary stalk) was
dissected from the brain on an ice-cold platform under a binocular
microscope as described in section 2.2. Tissue was collected into
cold oxygenated Krebs medium then transferred to a teflon/glass
homogeniser. Pooled samples of ME or NI were homogenised in cold
0.32 M sucrose to produce a crude synaptosomal preparation of
neurone terminals (Gray and Whittaker, 1960).
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8.2.3. Uptake studies
NI and ME were homogenised in sucrose at a tissue concentration
of one area/lOOyl (60-100yg protein for NI, 12-25yg protein for
ME). lOOyl aliquots were taken for individual determination of
[ H]GABA uptake and added to 8 volumes of cold Krebs medium.
Samples were then preincubated at 25°C for 20 min before the
3
addition of [ H]GABA in 1 additional volume to give a final
concentration of luM and sucrose dilution to 32 mM, in a final
volume of 1 ml. After a further 5 min incubation, samples were
filtered through Whatman GF/B filters under vacuum and washed with 3
x 5 ml medium at 25°C. Radioactivity incorporated into the filters
was subsequently measured by LSC after overnight extraction into
10ml NE265 scintillation fluid. This standard protocol was adapted
3
as follows to characterise the properties of [ H]GABA uptake into
the two regions:
a) Time-dependence: incubations were carried out for 1,2,5 or
10 min.
b) Temperature-dependence: control incubations were carried out on
ice throughout, and filters were washed with cold medium.
c) Sodium dependence: choline chloride was substituted for NaCl in
the medium.
d) Pharmacological properties: 3 alanine (1 mM) or L-2, 4
diaminobutyric acid (DABA) (500 yM) were present from the
beginning of the preincubation period.
3
e) Kinetic analysis: a range of [ H]GABA concentrations
(1.0-20 yM) were used.
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Appropriate blanks were subtracted in all cases derived either
from detergent lysed preparations (1% Triton X-100) or tissue free
incubation, which gave essentially identical results (approximately
30% of apparent uptake at 5 min in ME, 50% in NI). Aliquots of
homogenate were taken for determination of protein content according
to section 2.4.
8.2.4 Release experiments
Sucrose homogenates were diluted into medium to give a tissue
concentration of 10 areas/4 ml and preincubated at 37°C for 15 min.
50nM [^H]GABA was then added, with 10yM AOAA to inhibit catabolism
of the accumulated transmitter through the longer time course of
these experiments. After a further 15 min, aliquots corresponding
to one dissected tissue area were transferred on to Whatman GF/B
filters in parallel superfusion chambers and continuously perfused
with oxygenated medium at 37°C at 0.5 ml/min. The superfusion
apparatus was the same as that used for hormone secretion studies,
and is described in section 5.2. After 30 min washout, 1 min
fractions were collected. At the beginning of the 5th or 7th
fraction, superfusion intake lines were transferred to medium
containing depolarising concentrations of potassium ions and/or
drugs as appropriate. After 12 fractions had been collected,
radioactivity in each fraction and that remaining in the tissue was
measured by LSC.
8.2.5. Chemical identity of released tritium
Aliquots of superfusate from both basal and K+ pulse samples
were passed through 3 x 0.6 cm columns of Dowex 50W (100-200) mesh
in the H+ form according to Iversen and Kravitz (1968). Acidic
metabolites were eluted with 2 ml F^O and were found to account
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for only a few per cent of total radioactivity under these
conditions. The remaining radioactivity (> 90%) was retained, to be
eluted by 5ml of 1.5M NH^OH indicating that its probable identity
3
was unchanged authentic [ H]GABA (n = 3-5 in each case).
8.2.6. Calculation of results and statistics
The results of uptake experiments were calculated as pmol GABA
transported/mg protein/min. Kinetic data was derived by a
computerised iterative least-squares program, as used in Chapter 3.
Release data was calculated as fractional release coefficient (FRC)
(i.e. radioactivity in a fraction as a percentage of tissue
radioactivity at the beginning of that fraction). Values for
percentage stimulation of release were obtained from the peak
release coefficient and the mean of the two basal release fractions
immediately preceding the stimulus. Significance of difference for
uptake studies was by Students paired t-test, and for release
studies was by Mann-Whitney U test, using values for peak percentage
stimulation. In some cases percent stimulation of release was
recalculated as a percentage of a control stimulation carried out at
the same time on a parallel superfusion.
8.3 Results
8.3.1 Uptake of f3HlGABA
Tritium was rapidly accumulated by both tissues when incubated
3
with lpM [ H]GABA and uptake was approximately linear for 10 min
(Figure 8.2) at these tissue concentrations, although ME showed a 20
fold greater capacity for uptake. Uptake was markedly reduced in
sodium-free medium, by a mean of 89% in NI and 98% in ME, and also
showed temperature-dependence, being reduced by a mean of 81% in NI
and 90% in ME when incubations were performed on ice (Figure 8.3).
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The pharmacological profiles of the uptake sites involved were
investigated using s alanine and DABA as selective inhibitors of
glial and neuronal [°H]GABA uptake respectively (Iversen and
Johnston, 1971; Schon and Kelly, 1974). Uptake was not
significantly reduced in the presence of ImM e alanine, but 500pM
DABA inhibited uptake by 46% (p < 0.001) in NI and 56% (p < 0.005)
in ME (Figure 8.3).
3
Kinetic analysis of [ H]GABA uptake was carried out using a
3
5 min incubation period with [ HjGABA concentrations between 1 and
20pM. For both areas, a double reciprocal plot gave a good fit to a
single straight line component fitted by a computerised least
squares method (Figure 8.4). Mean K^ values were 5.4pM and 5.0)jM
and Vmax values 17.2 pmoles/mg protein/min and 340 pmoles/mg/
protein/min for NI and ME respectively, confirming the greater
capacity of the GABA uptake carrier in ME.
8.3.2 Release of [3HlGABA:
After an initial rapid washout phase, basal release of tritium
was approximately constant within 30 min, with an FRC of
approximately 0.5% in both regions. Depolarisation with 10-60mM
+ +
K replacing Na ) rapidly caused a marked increase in the
3
release of [ H]GABA in a concentration-dependent manner (Figure
2+ 2+
8.5). In Ca free, Mg - substituted medium (without any
chelating agents) the response to 15mM K+ was greatly reduced
(Figure 8.6) and basal release was slightly elevated. Thus the
response to 15mM K+ was reduced from 211 ± 8% to 33 ± 5% increase in
NI and from 129 ± 6% to 33 ± 3% in ME (n = 5 in each case, P < 0.05).
To investigate the presence of presynaptic GABA autoreceptors
controlling transmitter release, the effect of the potent GABA^
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receptor agonist muscimol was investigated on stimulus-evoked
release. lOOnM muscimol was found to have no effect on basal
3
release of [ H]GABA (Figure 8.7) although higher concentrations
caused some heteroexchange. A submaximal depolarising stimulus of
15mM K+ was used, and muscimol and/or BMI were introduced at the
same time as the K+ stimulus. Muscimol (lOOnM) was found to
reduce the peak response to 15mM K by 24% in NI and by 26% in ME
(P < 0.05, n = 5 in each case, Mann Whitney U test). This effect of
muscimol was prevented by 10yM BMI (Figure 8.7, Table 8.1).
Effects of the neurotransmitters DA and 5-HT, and the peptide
hormones prolactin, vasopressin and aMSH, were also investigated on
stimulus-evoked release, and the results are shown in Table 8.2.
3
None of these substances was found to affect [ H]GABA release in
either ME or NI.
8.4 Discussion
8.4.1 Uptake of f3HlGABA
Previous studies have shown that when studying uptake of
3
[ H]GABA, it is necessary to use small (0.2mm x 0.1mm) slices or
subcellular particles to reveal high-affinity uptake, as this is
masked in larger slices by low-affinity uptake (Levi and Raiteri,
1973). The very small size of the tissue areas studied here
precludes the use of slices, so a sucrose homogenate preparation was
used. This preparation has been shown previously to accumulate
[ H]GABA with kinetics and inhibitor specificity similar to that
of slices, into particles sensitive to osmotic lysis and with the
density gradient characteristies of synaptosomes (Iversen and
Johnston, 1971). The sub-physiological temperature of 25°C was used
in these studies because it is the temperature at which [ H]GABA
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uptake is maximal in the absence of inhibitors of GABA catabolism
(Iversen and Neal, 1968). AOAA was not used because there is
evidence that it may modify kinetic measurements made on the uptake
carrier (Snodgrass and Iversen, 1973). The results presented here
show that both ME and NI tissue can accumulate [ H]GABA in a
temperature- and sodium-dependent manner, characteristic of
3
[ H]GABA uptake in other areas (Weinstein, Varon, Muhleman and
Roberts, 1965; Iversen and Neal, 1968; Bennet et al, 1972; Martin
and Smith, 1972; Jaffe and Cuello, 1980) and also of other
neurotransmitter uptake systems (Bogdanski, Blaszkowski and Tissari,
1970; Baldessarini and Vogt, 1971; Sarkar et al, 1983). Uptake of
[ H]GABA was sensitive to inhibition by DABA but not by 3 alanine
in both areas. The reported selectivity of these substances for
neuronal and glial [ H]GABA uptake (Iversen and Johnston, 1971;
Schon and Kelly, 1974; Jaffe and Cuello, 1980), (with DABA about
20-fold selective for neuronal uptake and 3 alanine 200-fold
selective for glial) predicts that the DABA concentration used here
3
should inhibit neuronal uptake of luM [ H]GABA by around 50%. It
3
therefore appears that the uptake of [ H]GABA described here shows
neuronal specificity in both areas. These two substances do not
have the lowest IC^g values reported (e.g. homo-3-proline has an
ICgg value of 20pM for glial uptake and chlorpromazine has an
ICgg value of 32pM for neuronal uptake (Iversen and Johnston,
1971; Larsson, Thorbek, Krogsgaard-Larsen and Schousboe, 1981) but
they have the greatest selectivity ratios. Aminocyclohexane
carboxylic acid is a rather more potent and selective inhibitor of
neuronal GABA uptake than DABA (Bowery, Jones and Neal, 1976) but is
not commercially available. These results are in agreement with
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3
autoradiographic studies of in vivo uptake of [ H]GABA into ME
(Tappaz et al, 1980) which showed that label was accumulated over
the external layer of ME with neuronal-uptake specificity. However
autoradiography following in vitro uptake of [ H]GABA into the
posterior pituitary indicated that the label was localised almost
exclusively over glial cell bodies and their processes (Beart et al,
1972; Hamberger et al, 1979). Subsequent immunohistochemical
studies showed a plexus of GAD-IR nerve terminals in the external
layer of ME and in PI with a less dense innervation of the PN
(Vincent et al, 1982; Oertel et al 1982). The results presented
here suggest that neurons in both ME and NI can accumulate
[ H]GABA, but the relative contributions of the intermediate and
posterior lobes of the pituitary have not been investigated.
Kinetic analysis showed that the uptake mechanism had very
similar Km values in the two areas, but the ME showed a considerably
larger Vmax value. The Km values are in agreement with other
reported values for both neuronal (Iversen and Neal, 1968; Jaffe and
Cuello, 1980) and also glial uptake (Bowery and Brown, 1972; Schon
and Kelly, 1974). The Vmax value for ME is approximately 1/5 that
for frontal cortical tissue and rather greater than that of spinal
cord (Iversen and Johnston, 1971). By contrast NI has a very low
Vmax, in the same order as that of [ H]GABA uptake in sensory
ganglia (Schon and Kelly, 1974).
3
In these studies uptake of exogenous [ H]GABA has been
measured. There is evidence both for and against this high-affinity
uptake system representing a homoexchange process. Iversen and Neal
(1968) demonstrated a net uptake of GABA into cortical slices
following incubation in medium containing [ H]GABA, but that it
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3
was smaller than the apparent uptake when only [ H]GABA was
measured. Others were unable to demonstrate a significant
contribution to uptake from heteroexchange for GABA but could for
glutamate (Levi, Bertollini, Chen and Raiteri, 1974). Net uptake
could be greatly increased by prior depletion of GABA by cold-shock
or high-molarity K+ (Levi, Coletti, Poce and Raiteri, 1976; Regan
and Roskoski, 1977), but preloaded [ H]GABA could be released by
unlabelled GABA with similar characteristics to those shown by high
affinity uptake (Levi and Raiteri, 1974; Roberts, 1976). It is
possible that the ability of tissue to retain GABA is disturbed j_n
vitro, and interpretations of experiments using [ H]GABA should
therefore retain a degree of caution. More recent in vitro studies
using nipecotic acid as an uptake inhibitor and measuring release of
endogenous as well as tritiated GABA have provided evidence that
reuptake is of major importance in removing GABA from extracellular
spaces (Szerb, 1982). In vivo experiments collecting GABA released
from the cerebral cortical surface also support neuronal uptake
rather than metabolism as the physiological mechanism of removal of
GABA (Moroni, Mulas, Moneti and Pepen, 1982, see also Chapter 1).
If this is the case, then the use of exogenous GABA may be an
equally valid technique to the measurement of released endogenous
GABA because it will tend to label the same stores as released then
reaccumulated transmitter. As demonstrated here, this type of
experiment has revealed uptake kinetics in the areas of interest,
closely similar to those of other CNS regions where the presence of
GABA-releasing neurone terminals is well established.
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8.4.2 Release of f3H"]GABA
3
The low and steady basal release of [ H]GABA observed after an
initial washout period was similar to that observed with other
regions containing GABA neurone terminals. Both tissues here showed
a prompt and sensitive response to K+ (Figure 8.5), especially NI,
and the effect of 15mM K+ was largely abolished by perfusion with
2+
Ca -free medium (Figure 8.6). This is in contrast to studies
using whole neurohypophyses, in which K+ was only able to
stimulate release at very high concentrations (Minchin and Nordmann,
1974; Hamberger et al, 1979). Sellstrom and Hamberger (1977)
2+demonstrated that such Ca dependency was a characteristic of
+ 3
K induced [ H]GABA release from synaptosomes, but not from
neuronal perikarya or glia, and Neal and Bowery (1979) found that
glial [3H]GABA release was insensitive to 25mM K+. It thus
appears that uptake and release of [ H]GABA by the intact
neurohypophysis is predominantly glial (Beart et al, 1974; Hamberger
et al, 1979) whereas in the preparation of NI used here, uptake and
release are mainly neuronal. This may be because most of the nerve
terminals in the pituitary showing GAD-IR are in PI, and glial cells
tightly-wrapped around neuronal terminals may also constitute a
barrier to [ H]GABA (Iversen and Kelly, 1975), which would be
disrupted in the preparation used here.
+ 2+
The lack of complete dependency of K -evoked release on Ca
2+
may be a result of residual Ca in the tissue (Srinivasan, Neal
and Mitchell, 1969) as cation chelators were not present in the
2 +
superfusion medium. Ca -dependency of evoked release has been
the subject of considerable investigation, and has been consistently
demonstrated for both endogenous and exogenous GABA (Mulder and
-132-
Snyder, 1974; Nadler, White, Vaca and Cotman, 1977; Potashner,
1978a). Basal release of [ H]GABA from both areas was observed to
2+
be elevated in Ca -free medium (Figure 8.6). This has also been
observed for endogenous GABA (Potashner, 1978a) and may be the
result of increased influx of Na through a Na /Ca exchanger
o+
(Szerb, 1979) causing release of Ca from intracel1u1ar stores
and thereby elevating secretion.
Presynaptic autoreceptors controlling the release of
neurotransmitters have been demonstrated for a variety of
neurotransmitters in both the central and peripheral nervous systems
(Farnebo and Hamberger, 1971; Szerb and Somogyi, 1973; Starke and
Montel, 1973; Starke, Reimann, Zumstein and Hertting, 1978; Langer,
1980). This interpretation is based on the inhibition by specific
agonists and enhancement by antagonists of the release of previously
accumulated radiolabeled transmitter in response to electrical or
K+ stimulation. Depending on the preparation used, a released
transmitter may or may not (as here) accumulate around the terminals
to concentrations sufficient to exert a tonic effect and therefore
reveal an enhancement of control release by antagonists.
Additionally, presynaptic autoreceptors may control the synthesis of
neurotransmitter (Kehr, Carlsson, Linquist, Magnusson and Atack,
1972; Iversen, Rogawski and Miller, 1976). Similar studies using
3
[ H]GABA have led to the suggestion that GABAergic nerve terminals
in frontal cortex and substantia nigra have presynaptic
autoreceptors which, upon activation, inhibit release of the
neurotransmitter (Mitchell and Martin, 1978a; Snodgrass, 1978;
Arbilla et al, 1979; Brennan and Cantrill, 1979). These
autoreceptors show similar pharmacology to postsynaptic GABA^
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receptors, for both agonists and antagonists (Mitchell and Martin,
1978a; Brennan, Cantrill, Oldfield and Krogsgaard-Larsen, 1981).
This makes the demonstration of GABA autoreceptors in vivo very
difficult, but action at such receptors by endogenous 6-amino-
laevulinic acid has been suggested to account for some of the
symptoms of porphyrias, which include hyperexcitabi1ity and
convulsions (Brennan and Cantrill, 1979). It has also been proposed
that GABA autoreceptors control synthesis of the amino acid
(Carmona, Gomes and Trolin, 1981; de Mello, 1984). To demonstrate
presynaptic receptor involvement in control of release, it is
essential to use drugs that do not exchange with the transmitter
i.e. are not substrates for the uptake system. The potent GABA
receptor agonist muscimol is only a poor substrate for the GABA
uptake system (Krogsgaard-Larsen and Johnston, 1975), and at the low
concentration used here (lOOnM) effectively activated presynaptic
receptors in both ME and NI without causing exchange (Figure 8.7).
Higher concentrations induced significant elevation of basal
[^H]GABA release. Muscimol reduced the amount of stimulus-induced
[^H]GABA release in a bicuculline-sensitive manner, in both ME and
NI (Figure 8.7, Table 8.1) by amounts similar to that in frontal
cortex (Mitchell and Martin, 1978a). In contrast to the results of
Brennan and Cantrill (1981), concentrations of muscimol activating
the autoreceptor in ME and NI would never produce more than about
30% reduction of stimulated release before exchange distorted the
results (even when repeating the 55mM K+ stimulus used by these
workers). The lack of effect of BMI on basal release, or on the
response to 15mM K+ suggests that the rapid superfusion system
used here prevents released [ H]GABA from re-accumulating
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sufficiently to activate the presynaptic receptors. 6ABA receptor
binding sites have been demonstrated in rat hypothalamus (Beaumont
et al, 1978; Fiszer de Plazas et al, 1982) (although ME has not been
specifically investigated) and also in NI (Chapter 3). These
studies do not discriminate presynaptic and postsynaptic sites and
it is not therefore possible to estimate the numerical contribution
of the presynaptic receptors described here.
The results in Table 8.2 suggest that GABA release from
terminals in both areas is independent of any of the several other
transmitters investigated and also free from direct hormonal
effects. The lack of effect of 5-HT on [^H]GABA release from ME
suggests that if its stimulatory effect on prolactin secretion is
mediated by GABA (Caligaris and Taleisnik, 1974) then it may be
acting indirectly or at the level of the cell body rather than the
terminals in ME.
The PIF effects of both GABA and DA raise the possibility that
they will be involved physiologically in the feedback regulation of
prolactin secretion. Neuroleptic treatment causes a rapid increase
in MBH GAD activity, and conversely apomorphine reduces MBH GAD
activity (Prato et al, 1981). That the effects of these drugs might
be mediated by changes in prolactin concentration was supported by
the demonstration that hypophysectomy prevented the changes in GAD
activity, and anterior pituitary grafts caused an elevation in GAD
activity (Nicoletti et al, 1983). Direct injection of prolactin
(i.c.v.) elevated MBH GAD activity and GABA secretion into
hypophysial portal blood, but this was only observed after 16hr, and
not after 4hr (Apud et al, 1984a). Similarly delayed effects on ME
DA turnover have been reported (Moore, Demarest and Johnston,
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1980). The present results show no direct effect of prolactin on
O
[ H]GABA release from ME and therefore do not support a rapid
feedback mechanism at the level of the nerve terminals, although an
effect on the cell bodies cannot be excluded. Prolactin has been
shown to increase the release of both endogenous and tritiated DA
from MBH slices (Perkins and Westfall, 1978; Foreman and Porter,
3
1981) but to have no effect on release of [ H]DA from specifically
ME tissue (Horn, 1984).
Immunohistochemical studies have shown presumed GABAergic
neurones in close contact with other neurosecretory terminals in
both ME and PN and with secretory cells in PI, as well as in the
neurohaemal contact zone of ME (Oertel et al, 1982; Tappaz et al,
1983). There are therefore several sites at which GABA released
from the nerve terminals in ME and NI investigated here might
participate in neuroendocrine control and GABA has been demonstrated
to affect the secretion of somatostatin (Gamse et al, 1980), CRH
(Burden et al, 1974) and DA (Chapter 11) from MBH or ME. These
neuroendocrine GABA systems (even that in ME, where GABA is not only
secreted into a synaptic environment but also into hypophysial
portal blood) appear to be similar to other CNS GABA neurones in
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Outline of the methods used for the study of [3h]GABA uptake and
release by ME and NI crude synaptosomal preparation.
a
FIGURE 8.2
Accumulation of [3H]GABA by a) ME and b) NI for different periods
of time at 25°C. Values represent uptake of [3H]GABA after
subtracting tissue-free blanks. Blanks were ~ 20% of total uptake
at 5min in ME and ~ 50% in NI. Mean ± S.E.M., n = 4.
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Accumulation of [3h]GABA by a) ME and b) NI under various
conditions. 5min incubation periods were used.
Total: total specific uptake over the 5min period.
ImM 3 alanine, 500nM DABA: incubations were carried out in the
presence of these compounds.
4°C: incubations were carried out on ice throughout.
Na+- free: choline was substituted for sodium in the medium.




Kinetic analysis of [3h]GABA uptake by a) ME and b) NI. Values
are plotted in a reciprocal form.
S: [^HjGABA concentration, from 1.0 to 20pM.
V: rate of specific accumulation of [3r]GABA. Points were fitted
by a computerised least squares method. Mean ± S.E.M., n = 4.
FIGURE 8.5
Concentration-dependence of the stimulation of [3h]GABA release by
K+. Percentage stimulation of release from ME and NI by various
K+ concentrations (replacing equimolar Na+). Mean ± S.E.M.,n = 5.
• Control





















Release of [3h]GABA by a] me
medium, open circles: Ca^+-f
ME and b) NI. Filled circles: normal
free medium. Superfusion medium was
changed to one containing 15mM K+ at the arrow. Release is
expressed as FRC. Mean ± S.E.M., n = 5.
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FIGURE 8.7
Autoreceptor-control of [^HjGABA release from a) ME and b) NI.
Medium was changed at the arrow from normal to:
(A) normal + lOOnM muscimol
(•) 15mM K+
(O) 15mM K+ + lOOnM muscimol
(A) 15mM K+ + lOOnM muscimol + lOyM BMI
Mean ± S.E.M., n = 5.
Table 8.1
Evidence for GABA/\ autoreceptors in ME and NI.
a) % Stimulation of [^H]GABA release from NI
15mM K+ 211 ± 8%
15mM K+ + lOOnM muscimol 161 ± 15%*
15mM K+ + lOOnM muscimol
+ lOpM bicuculline methiodide 229 * 10%**
15mK+ + 10pM bicuculline
methiodide 210 ± 12%
* P < 0.05 vs K+ alone
** P < 0.05 vs K+ + muscimol
n = 5 in each case. Mean ± S.E.M.
b) % Stimulation of [^HJGABA release from ME
15mM K+ 154 ± 10%
15mM K+ + lOOnM muscimol 114 ± 8%*
15mM K+ + lOOnM muscimol
+ lOyM bicuculline methiodide 125 ± 3%**
* P < 0.05 vs K+ alone
** P < 0.05 vs K+ + muscimol
n = 5 Mean ± S.E.M.
Values are peak percentage stimulation of release (expressed in
terms of FRC) above basal. Drugs were introduced simultaneously
with the K+ pulse.
Table 8.2:
Effects of other neurotransmitters and neuropeptides on
[3H]GABA release
ME NI
prolactin (lug/ml) 98 ± 5%
aMSH (1UM) 110 ± 7% 102 ± 7%
vasopressin (luM) 90 ± n 108 ± 6%
dopamine (10uM) 96 ± 7% 98 ± 4 %
serotonin (IOmM) 99 ± 5% 98 ± 6 %
Results are expressed as a percentage of the control K+-induced
stimulation of release of [3H]GABA which represented some 129 ± 6%
and 211 ± 8% increase over basal efflux, in ME and NI respectively,
(mean ± SEM, n = 5 in all cases).
CHAPTER 9
Evidence for GABAg autoreceptors in the median eminence.
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9.1 Introduction
The clinical use of the GABA analogue baclofen in the treatment
of spasticity has prompted many studies on its actions on synaptic
transmission, particularly in the spinal cord. Baclofen was found
to cause a potent and long-lasting depression of cell firing of
spinal cord, cerebral and cerebellar neurones, which was however
bicuculline-insensitive (Curtis, Game, Johnston and McCulloch, 1974;
Davies and Watkins, 1974), implying that the effect was not mediated
by GABA receptors despite the structural similarities between the
two compounds. On the basis of the depression of synaptic reflexes
in the absence of effects on motorneurones, baclofen was proposed to
act presynaptically to reduce the release of neurotransmitter
(Davidoff and Sears, 1974), a suggestion which has received
considerable support (Fox, Krnjevic, Morris, Puil and Werman, 1978;
Curtis, Lodge, Bornstein and Peet, 1981). Neurochemical studies
have also provided evidence that this may be a major effect of
baclofen: Potashner (1978b) demonstrated that baclofen inhibited
electrically- evoked release of endogenous aspartate and glutamate
(but not GABA) from guinea-pig cortex, and similar results have been
obtained in the rat olfactory cortex (Collins, Anson and Kelly,
1982) and cat spinal cord (Johnston, Hailstone and Freeman, 1980).
The possibility that these effects of baclofen were mediated by a
novel type of GABA receptor was proposed on the basis of experiments
in which GABA and baclofen inhibited stimulated [ Hjnoradrenaline
release from rat atria in a bicuculline-insensitive manner, and
subsequent studies identified specific recognition sites with
similar properties within the CNS (Bowery and Hudson, 1979; Bowery
et al, 1980). This apparently novel receptor site was designated
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'GABA ' in contrast to classical, chloride-channel-linked
D
'GABA^' receptors, and its major characteristics are
stereospecific activity of baclofen, (-) baclofen being
approximately equipotent to GABA, and insensitivity to muscimol and
bicuculline (Hill and Bowery, 1981; Bowery et al, 1983).
GABAg receptors are found on sensory neurones (Dunlap, 1981)
where electrophysiological studies have been carried out to clarify
their mechanism of action. Baclofen reduced action potential
duration in these cells, an effect common to several neuro-
2+
transmitters which appeared to be a direct effect on Ca
conductance (Dunlap and Fischbach, 1981). The possibility that the
?+
observed effect on Ca conductance might be secondary to
+
increased K conductance was suggested by the results of
Desarmenien et al (1984), who showed that this effect of baclofen
+
and GABA was prevented by loading cells with Cs . Similar results
have been obtained using guinea-pig myenteric plexus (Cherubini and
North, 1984) and such actions could provide a mechanistic
explanation for GABAg receptor-mediated inhibition of transmitter
release.
In the present experiments the presence of presynaptic GABAg
receptors on GABAergic terminals in ME and NI was investigated:
although presynaptic GABAg receptors are present on nerve
terminals containing a variety of transmitters in different areas of
the CNS, there have been no demonstrations of their presence on
GABAergic terminals (Potashner, 1978b; Bowery et al, 1980; Collins
et al, 1982). Few pharmacological tools other than the isomers of
baclofen are available for the investigation of GABAg receptors; a
major problem being the lack of a potent and specific antagonist.
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Nevertheless 6-aminovaleric acid has been suggested to be a weak
GABAg antagonist (Muhyaddin, Roberts and Woodruff, 1982) and its
action in ME was also investigated.
9.2 Materials and methods
Materials and methods used in this chapter for the study of
[ H]GABA release from ME and NI were identical to those described
in Chapter 8. (^Baclofen and its stereoisomers were the gift of
Ciba-Geigy, and s-aminovaleric acid (6AVA) was obtained from Sigma.
Results were calculated as FRC, and hence values for percentage
stimulation of release were obtained. Results were further analysed
as a percentage of a control response carried out simultaneously in
a parallel superfusion. Statistical comparisons were made using the
Mann-Whitney U test, using values for peak percentage stimulation of
release.
9.3 Results
The characteristics of basal and K+-stimulated release in both
ME and NI were described in Chapter 8. A submaximal (15mM K+)
stimulus was used throughout these experiments, and drugs were
introduced simultaneously with this.
IOOuM (±)baclofen inhibited the stimulation of release by
15mM K+ in ME but had no effect in NI. The peak stimulation was
reduced to 64 ± 6% of control in ME (Figure 9.1, P < 0.05, n = 5)
but remained at 101 ± 4% of control in NI. This concentration of
(±)baclofen had no effect on basal release of [^H]GABA from ME
(Figure 9.1).
The effect of (±)baclofen was concentration-dependent (Table
9.1), and stereospecific. (-) Baclofen was approximately equipotent
with the racemate, and (+)baclofen was without significant effect at
concentrations up to 100uM (Table 9.1).
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«AVA has been reported to have little GABA^ agonist action,
and to be a weak GABAg antagonist (Muhyaddin et al, 1982).
Attempts to use it here were complicated by a degree of
+ 3
heteroexchange, both basal and K -stimulated release of [ H]GABA
from ME being enhanced. Thus 10yM sAVA potentiated the response to
15mM K+ to 124 ± 5% of control (P < 0.05, n = 5), and was
therefore included in control perfusions as well as those testing
the effect of baclofen (Figure 9.2). lOOyM (±)baclofen, in the
presence of 10yM sAVA, slightly but still significantly inhibited
release (83 ± 3% of control, K+ + 5AVA). This effect was, though,
significantly less than that of lOOyM (±)baclofen alone (54 ± 6% of
+ .
control, K alone).
Experiments attempting to use GABA itself as a GABAg agonist
were also confounded by homoexchange, even at low concentrations
(lOOnM). Fluspirilene has been used as a GABA uptake blocker in
similar experiments, to allow the demonstration of GABA activity at
autoreceptors ('Mitchell and Martin, 1978a). However, in the present
study, at a concentration necessary to prevent uptake (lyM, as in
Mitchell and Martin, 1978a), fluspirilene was found to inhibit both
basal and K+-stimulated release of [^H]GABA.
9.4 Discussion
These results demonstrate a selective inhibition of evoked
release of [^H]GABA from ME but not NI by baclofen. The effect
was sterospecific, the (-) isomer being active and the (+) isomer
being inactive at lOOyM. This suggests that the effect is mediated
by a GABAg receptor (Hill and Bowery, 1981). It was not possible
to demonstrate an action of GABA itself, as considerable
homoexchange was found at concentrations above lOOnM, too low to
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have any marked receptormiedi ated effect without gross distortion of
the results. The presence of presynaptic GABA^ autoreceptors
(Chapter 8) would also complicate interpretation.
sAVA is a weak GABA^ receptor agonist in sympathetic ganglia
(Bowery and Brown, 1974) but appears to be a GABAg antagonist (or
very weak partial agonist) on noradrenergic terminals in rat
anococcygeus (Muhyeddin et al, 1982) and in the guinea-pig ileum
(Ong and Kerr, 1983). In that preparation, 500pM sAVA competitively
antagonised the effect of both GABA and (±)baclofen, with a pA^ of
4.1. Similar concentrations of sAVA in this preparation caused very
considerable stimulation of basal [ H]GABA release, probably by
heteroexchange as 6AVA shows considerable structural similarities to
GABA. When 10pM sAVA was tested, heteroexchange was still prominent
but as lower concentrations would not be expected to cause any
antagonism, this concentration was used. The results obtained show
that lOOviM (±)baclofen caused slight inhibition of release in the
presence of 10uM 6AVA, but the effect appeared to have been partly
antagonised. This result should be treated with great caution, as
the entry of sAVA into the terminals and subsequent stimulation of
release may have altered the receptor-mediated effect of baclofen,
independent of any competitive antagonism. While these results are
therefore consistent with 6AVA being a GABAg antagonist, they do
not provide any direct support as this is not a suitable model, and
the absence of a potent and specific GABAg antagonist precludes
further study.
Presynaptic GABAg receptors, which in all cases reported
inhibit neurotransmitter release, have been demonstrated to affect
the release of catecholamines, 5HT, acetylcholine and excitatory
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amino acids in the CNS (Nistri, 1975; Potashner, 1978b; Bowery et
al, 1980), and are found on both sympathetic and parasympathetic
terminals (Bowery et ai, 1981; Anwar and Mason, 1982; Muhyaddin et
ai, 1982; Kieinrok and Kilbinger, 1983). To this list should now be
added CNS GABAergic terminals of the ME, although such regulation
has not demonstrated elsewhere in the CNS. Previous experiments in
which an effect of baclofen on release of GABA has been reported
have not demonstrated the involvement of GABAg receptors. Kerwin
and Pycock (1978) found that (+)baclofen (but not the (-) isomer) at
200mM stimulated basal release of [ H]GABA from globus pal 1idus
slices, and Roberts, Gupta and Shargill (1978) reported a slight
enhancement of basal release of [ H]GABA from whole brain
synaptosomes by 50yM baclofen. These effects may represent an
effect on the GABA uptake carrier, as baclofen causes weak but
detectable inhibition of [^H]GABA uptake (Kerwin and Pycock, 1978)
although no uptake of [ Hjbaclofen itself is detectable (Bowery et
al, 1983). Curtis et al (1981) suggested that the inhibitory effect
of baclofen on primary afferent depolarisation might be a result of
a reduction in the release of GABA at axo-axonic synapses on la
terminals, but any definitive evidence is lacking and
autoradiographic study of GABAg receptors suggested that GABAg
receptors in substantia gelatinosa were predominantly located on
primary afferent terminals (Price, Wilkin, Turnbull and Bowery,
1984).
Electron-microscopic immunohistochemical studies have localised
presumed GABAergic terminals in the external layer of ME among
unlabelled axons and neurosecretory endings and in close vicinity to
fenestrated capillary perivascular space (Tappaz et al, 1983). If
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the GABAg receptors demonstrated here were present on GABAergic
terminals in all these locations, then their effect would either be
to inhibit GABA release into hypophysial portal blood or onto
peptidergic or aminergic terminals. This in turn could effect the
secretion of any of the anterior pituitary hormones. The effects of
GABA on releasing hormone secretion have not been extensively
investigated, but effects on somatostatin (Gamse et al, 1980) CRH
(Burden et al, 1974) and DA (Chapter 11) have been reported. An
effect on GHRH secretion has also been proposed (Fiok et al, 1984)
and the stimulatory effect of baclofen on GH secretion (Fiok et al,
1981b) may therefore be in part mediated by disinhibition of GHRH
secretion. The GABAg autoreceptors demonstrated here may
therefore have a variety of functions in neuroendocrine regulation.
The presence of GABA^ autoreceptors in ME was demonstrated in
Chapter 8, suggesting that GABAeregic terminals in ME are subject to
considerable autoregulation. The presence of both types of
autoreceptor on one neurone would represent a certain functional
redundancy and therefore seems perhaps unlikely, but the
considerable inhibitory influence of the GABAg autoreceptors here
(approximately 35% inhibition) suggests that they may well be
present on a significant proportion of terminals. The maximal level
of inhibition by GABA^ autoreceptors (Chapter 8) and GABAg sites
(here) are not possible to ascertain because of the exchange effects
of most of the agonists at higher concentrations. In other brain
areas, muscimol and other GABA^ receptor agonists have been
reported to cause up to 90% inhibition of evoked release of
[^H]GABA (Brennan et al, 1982) but such marked effects have never
been observed (without exchange-efflux) in this laboratory.
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Nevertheless, 6ABA and baclofen show similar potency at GABAg
receptors (Hill and Bowery, 1981) and as little as 0.3yM GABA acts
at GABA^ autoreceptors in similar experiments (Mitchell and
Martin, 1978a) to produce similar inhibition to that caused by lOOyM
baclofen here. It may be therefore, that GABAD autoreceptors are
D
somewhat less sensitive than GABA^ to accummulation of released
GABA, and therefore act as a reserve of inhibitory control. The
question of whether both types are present on one neurone remains to
be established, and further studies are also required to establish
the physiological significance of either of these sites.
TABLE 9.1
Inhibition of K+-stimulated release of [3h]GABA from ME by
baclofen and its stereoisomers.
Baclofen (Concentration) (±) (-) ( + )
10yM 85±6* 83±2* 106±6
lOOyM 64±6* 63±4* 90±2
lOOyM + 83±3*^
10yM fiAVA
Mean ± S.E.M, n = 5-6
* P<0.05 vs control (Mann-Whitney U Test).
4= P < 0.05 vs baclofen alone
Values represent stimulation of release as % of relevant control,
K+-evoked release. 15mMK+ in the absence of drugs evoked some
150% increase in release above basal efflux. lOOyM (±) baclofen had














Inhibition of stimulated [^HjGABA release from ME by baclofen.
K+/drugs were introduced at the arrow.
(•) 15mM K+
(O) 15mM K+ + 100yM (±)baclofen
(A) Effect of lOOyM (±)baclofen on basal release.









Antagonism of the effect of baclofen by s-aminovaleric acid.
K+ /drugs were introduced at the arrow.
(•) 15mM K+
(■) 15mM K+ + 10pM «AVA
(♦) 15mM K+ + 10pM 6AVA + lOOyM (±)baclofen
(A) Effect of lOviM 6AVA on basal release
Stimulated release: mean ± S.E.M., n = 5.
Basal release: mean of two experiments.
CHAPTER 10
3
Inhibition of [ H]GABA release from the neurointermediate
lobe by 1C opioid receptors.
-144-
10.1 Introduction
All three opioid peptide families have been described in the
pituitary: 8-endorphin derived from pro-opioimelanocortin in
corticotrophes and melanotrophes of PD and PI (Bloom, Battenberg,
Rossier, Ling, Leppaluoto, Vargo and Guillemin, 1977),
proenkephalin-derived leu- and met- enkephalin in nerve fibres in PN
(Rossier, Battenberg, Pittman, Bayon, Koda, Miller, Guillemin and
Bloom, 1979) and prodynorphin- (pro-neoendorphin-dynorphin-) derived
peptides in PN and a few cells in PD (Watson, Akil, Ghazarossian and
Goldstein, 1981) which may be gonadotrophes (Knepel and Schwanigner,
1985). These studies were all immunological and some details of
anatomical differentiation may no longer be tenable because of
cross-reactivity, particularly between leu-enkephalin and dynorphin,
as prodynorphin contains three copies of leu-enkephalin. Rossier et
al (1979) first suggested that leu- enkephalin, apparently found in
the supraoptic and paraventricular nuclei and in terminals in PN,
might be involved in the control of vasopressin secretion and Martin
and Voigt (1981) demonstrated coexistence of these two peptides.
Subsequent studies using purified anti-prodynorphin antisera
demonstrated that dynorphin but not leu-enkephalin coexisted with
vasopressin, and that leu-enkephalin was present in the
parvocel lul ar area of the paraventricular nucleus (Watson, Akil,
Fischli, Goldstein, Zimmerman and Nilaver, 1982). This has been
supported by lesion studies (Millan, Mill an and Herz, 1983).
Dynorphin was originally isolated from porcine pituitary, and
shown to be extremely potent as a 1C agonist in a number of assay
systems (Goldstein, Tachibana, Lowney, Hunkapiller and Hood, 1979).
The full 17 amino-acid sequence was subsequently determined
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(Goldstein, Fischli, Lowney, Hunkapiller and Hood, 1982) and found
to be widely distributed within the CNS (Watson et al, 1981). The
concentration of dynorphin-^_^y is particularly high in PN, which
also contains very large amounts of dynorphin^_g and
a-neoendorphin (Seizinger, Hoi It and Herz, 1981; Weber, Evans and
Barchas, 1982; Suda, Tozawa, Tachibana, Demura and Shizume, 1982).
Dynorphin-^_g and a-neoendorphin were found to be regionally
distributed in approximately equimolar concentrations, but this was
not true of dynorphin^^, suggesting possible physiological
differences in processing of the precursor (Weber et al, 1982).
Dynorphin^_g is much more readily degraded by peptidases than
dynorphin^y and is less potent, which has been suggested to be
more consistent with a transmitter than a hormonal role (Corbett,
Paterson, McKnight, Magnan and Kosterlitz, 1982).
Functionally, opioids in PN are associated with vasopressin
release. Morphine, s-endorphin and leu-enkephalin have been shown
to inhibit stimulated vasopressin release in vitro (Iversen, Iversen
and Bloom, 1980; AlZein, Lutz-Bucher and Koch, 1984) and in vivo,
naloxone potentiated the stimulation of vasopressin release by some
treatments such as angiotensin II infusion but not others (Knepel,
Nutto, Anhut and Hertting, 1982). The concentration of 3-endorphin
in plasma was also raised by the treatments which were potentiated
by naloxone (Knepel et al, 1982). Experiments with naloxone in
vitro have been equivocal: naloxone was found to increase release of
oxytocin but not vasopressin (Bicknell and Leng, 1982) but also to
prevent the inhibitory effect of sulpiride on stimulated vasopressin
release (Racke, Ritzel, Trapp and Muscholl, 1982). The enkephalins
are somewhat selective 6 agonists and 3 endorphin is equally active
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at u and 6 receptors, while naloxone is most potent at u receptors;
6 and 1C receptors requiring higher concentrations (Peterson, Robson
and Kosterlitz, 1983). This suggests that vasopressin nerve
terminals may have p or 5 receptors, but no 1C-mediated effects in NI
have been demonstrated.
GABAergic nerve terminals in NI are predominantly localised in
PI rather than PN (Oertel et al, 1982; Vincent et al, 1982). In PI,
GAD-IR terminals were observed in apposition to secretory cells and
in both areas to unlabel led axons (Oertel et al, 1982). GABA may be
involved in the control of aMSH and vasopressin secretion (Tomiko et
al, 1983; Knepel et al, 1984) but the experiments in Chapter 8
demonstrated that neither hormone affected the release of
3
[ H]GABA. In this Chapter, the interaction of opioids selective
3
for particular receptor types with the release of [ H]GABA from NI
was investigated, and subsequent experiments examined the ionic
mechanism of action of the probable K receptor thus demonstrated.
10.2 Materials and Methods
10.2.1 Materials
Dynorphin^_^, des-Tyr-dynorphin, Tyr-D-Al a-Gly-NMePhe-Gly-ol,
(DAGO), [D-Ser^] Leu-enkephalin-Thr, (DSLET) 4-aminopyridine (4AP)
and quinine were obtained from Sigma. Naloxone was the gift of Erdo
Laboratories.
Other materials were as described in Chapter 8.
10.2.2 Methods
o
The method for preparation of tissue, loading with [ H]GABA
and subsequent superfusion (and also treatment of data) was as
described in Chapter 8. The channel blockers 4AP, TEA, quinine and
DIDS were present in the medium from the start of superfusion when
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appropriate i.e. 30 min before fractions were collected. When
low-chloride medium was used, 114mM Na propionate was substituted
for NaCl (= 83% substitution) and was present from the start of
superfusion and during the K+ pulse. Propionic acid was used to
adjust the pH of the medium. In experiments to investigate the
effect of dynorphin^_^ on low-chloride-stimulated release, two
methodologies were used: in the first the normal protocol was
followed and normal medium was used to superfuse the tissue. At the
7th fraction, medium was changed to medium with 50% substitution of
Na propionate for NaCl, with or without luM dynorphin^_^- The
second series of experiments were carried out using a slightly
different protocol: the superfusion rate was increased to lml/min,
and 6 sec fractions were collected. In this series, Na propionate
was substituted for 33% of the NaCl in the test medium.
10.3 Results
3
10.3.1 Effect of opioid peptides on stimulated release of [ H]GABA
3
Dynorphin^^^ (lpM) reduced the stimulation of [ H]GABA
release evoked by 15mM K+ but had no effect on basal release
(Figure 10.1). The peak percentage stimulation of release was
reduced to 42±5% of control by this concentration (n=6). This
effect was concentration-dependent, with lOnM dynorphin^_^
causing a slight but significant inhibition of secretion (Figure
10.2). The inhibition of release by lOOnM dynorphin^_^ was
significantly antagonised by luM naloxone (introduced
simultaneously) and the non-opioid derivative des-Tyr-dynorphin was
without effect at luM (Figure 10.2), demonstrating that the effect
of dynorphin^ ^ was mediated by an opioid receptor.
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Dynorphin itself shows several fold greater affinity at K* rather
than n or 6 receptors but cannot be considered a specific K*
agonist. The pharmacological specificity of this effect was further
examined using more selective agonists. DAGO is highly
selective for y sites (Handa, Lane, Lord, Morgan, Ranee and Smith,
1981), DSLET shows several fold selectivity for 6 over y or sites
(Garcel, Fournie-Zaluski and Roques, 1980) and U50488H is a newly
developed compound apparently highly selective forlOsites (Lahti,
Von Voigtlander and Barsuhni, 1982). DAGO and DSLET at lyM were
without effect on 15mM K+-stimulated release, release being
104±11% of control in the presence of DAGO and 111±14£ of control in
the presence of DSLET (Figure 10.3). U50488H (lyM) caused a large
reduction in stimulated release, to 43±6% of control (Figure 10.3),
an effect similar in magnitude to that of dynorphin^_^' The
opioid receptor involved therefore shows every indication of TC-like
pharmacology, and GABA nerve terminals in NI appear devoid of y or 6
receptors.
10.3.2 Ionic basis of TC receptor effect
Three approaches to investigate the ionic dependence of the
effect of dynorphin-^_^2 were made:
I) Blockade of ion channel and ionic substitution, with
subsequent stimulation of release by 15mM K+.
II) Stimulation of release by Ba .
Ill) Stimulation of release by low-chloride medium.
10.3.2.1 K+-stimu1ation after ion channel blockade and ionic
substitution
4AP (ImM), TEA (lOmM) and quinine (0.3mM) selectively
block different subsets of K+ channels (see Section 5.4.1), but
were found to have no significant effect on the subsequent response
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to 15mM K+. None of these pretreatments affected the inhibitory
effect of lyM dynorphi(Figure 10.4). 100yM DIDS, which
selectively blocks anion channels (see Section 5.3.6), did not alter
the response to 15mM K+, but under these conditions the inhibitory
effect of lyM dynorphiwas significantly reduced (Figure
10.5). In low-chloride medium (=83% substitution) the effect of
15mM K+ was reduced to 75% of control, the inhibitory effect
of dynorphi n^_.^ was abolished (Figure 10.5). These data are
summarised in Table 10.1.
2+
10.3.2.2 Stimulation of release by Ba
?+
3mM Ba (MgC^ substituted for MgSO^ in the medium)
3
caused 96*8% stimulation of release of [ H]GABA (n=5). This was
not significantly affected by lpM dynorphin-^_^ (87*6%
stimulation).
10.3.2.3 Stimulation of release by low-chloride medium
When the tissue was superfused with medium containing only 50%
3
of normal chloride concentration release of [ H]GABA was
stimulated by 395*21%. Cointroduction of lpM dynorphin^_^ did
not significantly affect this, the response being 465*26%
stimulation, an increase of 18*6% over control (n=5). To enhance
the resolution of this possible stimulatory effect of
dynorphin^_^» technical modifications were made: the rate of
superfusion was increased to lml/min, and 6 sec fractions (compared
with 1 min normally) were collected. The induced chloride gradient
was also reduced, only 33% of chloride being substituted by
propionate. Under these conditions, the low-chloride medium caused
a peak of 159*13% stimulation of release, and this was increased to
287*21% by lpM dynorphi n^_^ (181*7% of control, p <0.05, n=5 )£f(y 10. 6^.
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10.4 Discussion
These results demonstrate that dynorphin^_^ causes an
3
inhibition of stimulated [ H]GABA release from NI. This effect
was concentration-dependent, antagonised by naloxone, and mimicked
by U50488H, suggesting that it is mediated by a ICopioid receptor.
Dynorphin^_^ may also have some non-opioid actions (Przewlocki,
Shearman and Herz, 1983), which are also caused by
3
des-Tyr-dynorphin^_^. This substance was tested on [ H]GABA
release, and found to be without effect at luM, providing further
support for the presence of specific 1C receptors. The lack of
effect of DAGO and DSLET suggest that GABAergic nerve terminals in
this area are free of u and 6 receptors, in contrast to dopaminergic
and vasopressinergic terminals (Iversen et al, 1980; Vizi and
Volbekas, 1980). TC receptors are also found on dopaminergic
terminals in the striatum (Mulder, Wardeh, Hogenboom and
Frankhuyzen, 1984), where, as found here, relatively high
concentrations of naloxone are required for antagonism compared with
6-mediated effects.
There are several possible endogenous ligands for this effect.
Dynorphin^_^ is found in high concentrations in PN (Goldstein et
al, 1982; Weber et al, 1982) but dynorphin^_g and dynorphin^_^g
have been suggested to be the predominant forms (Weber et al, 1982,
Suda et al, 1982) with the co-derived peptide a-neoendorphin (Weber
et al, 1982, Mill an et al, 1983). The smaller peptides have been
proposed to be neurotransmitters, as they have a short and rapid
action (Corbett et al, 1982).
Dynorphin has been shown to coexist with vasopressin in the
magnocel1ular projections to PN (Watson et al, 1982) and NI
concentrations of dynorphin are altered concommitantly with
vasopressin by endocrine manipulations and by lesions (Hollt,
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Haarmann, Seizinger and Herz, 1980; Mi 11 an et al, 1982). GABA
increased evoked vasopressin secretion in vitro (Knepel et al, 1984)
and it is therefore possible that dynorphin co-released with
vasopressin might indirectly regulate the secretion of vasopressin:
3
vasopressin itself was without effect on [ H]GABA release (Chapter
8). These results therefore may provide insight into the possible
function of multiple neurotransmitters/hormones coexisting within
one neurone, if one acts locally, perhaps in a negative feedback
manner, and the other at a distant site. The local transmitter
would therefore be an extra control, the magnitude of its effect
being dependent on the activity of the GABAergic neurones in this
case.
No evidence for the existence of n or 6 receptors was found.
This could be taken to suggest that GABAergic terminals in NI are
independent of regulation by 8-endorphin and the enkephalins
(Paterson et al, 1983), unlike dopaminergic terminals (Vizi and
Volbekas, 1980) and vasopressin terminals (Iversen et al, 1980;
AlZein et al, 1984) and therefore providing further evidence for
functional differences between the three families of opioids. Most
of the GABAergic terminals in NI are in PI (Vincent et al, 1982;
Oertel et al, 1982), which suggests that most of the [^H]GABA
release measured here is from PI. Dynorphin^_^ and U50488H
inhibited the stimulated release of [^H]GABA by =60%. The
apparent absence of dynorphin from PI (Watson et al, 1982) may
indicate that GABAergic terminals in PI have 1C receptors which are
not physiologically acted on by dynorphin. Alternatively,
dynorphin^_^y may act in PI at a distance from its site of
release, as it is both extremely potent and resistant to degradation
(Corbett et al, 1982).
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Inhibition of neurotransmitter release is a common effect of
opioids (Montel, Starke and Weber, 1974; Mudge, Leeman and
Fischbach, 1979). K receptor-mediated inhibition of
neurotransmitter release has been reported (Mulder et al, 1984;
Illes, Pfeiffer, von Kugelen and Starke, 1985), but stimulation may
also occur (Ueda, Muramatsu and Fujwara, 1985). The mechanism of
opioid receptor action has been studied electrophysiologically in
locus coeruleus neurones, dorsal root ganglia and myenteric plexus.
Mudge et al (1979) found that an enkephalin analogue decreased the
duration of the action potential, an effect which could be mediated
+
either by an increase in K conductance or by a direct reduction
2+ +
in Ca conductance. Enkephalin was found to open K channels
in locus coeruleus (Williams, Egan and North, 1982), which could be
9+ 9+
blocked by Ba , and subsequently the reduction in the Ca
component of the action potential observed in these cells was shown
to be a result of increased K+ conductance (North and Williams,
1983). This effect may be common to both y and 6 receptors (Werz
and Macdonald, 1982; 1983). While a direct increase in K+
conductance appears to be established both centrally and
peripherally (Morita and North, 1981) and can account for inhibition
2 +
of neurotransmitter release, a direct effect on Ca conductance
remains to be confirmed. None of these studies, however, relates to
receptors that are likely to be of the 1C type. One recent report
described the effect of dynorphin^_^ on cultured dorsal root
2 4"
ganglion cells and implicated a reduction in Ca -conductance
(Werz and Macdonald, 1984). This apparent lack of mechanistic
differentiation between quite different receptor subtypes is
surprising, and it should be considered (as with all these studies)
that dynorphin is not sufficiently K-selective for unequivocal
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identification of receptor type on the basis of that alone.
Interestingly, in earlier reports enkephalins have also been
considered to open chloride channels in cultured spinal cord
neurones (Barker, Gruol, Huang, Macdonald and Smith, 1980). The
receptor type was not then clearly identified, but may relate to the
apparently Cl-channel-operating TC receptor here.
In the present experiments 4AP, TEA and quinine were used to
block different subsets of K+ channel (Adams et al, 1980; LaTorre
and Miller, 1983; Cherubini, North and Suprenant, 1984). If
dynorphin was acting by increasing K+ conductance, one or more of
these blockers would be expected to attenuate the inhibitory effect
on release. This was not observed, suggesting that 14 receptors may
not influence K+ conductance. The use of high-molarity K+ as a
depolarising stimulus may not be ideal for the investigation of
K+-conductance-mediated effects, but n receptor activation was
successfully shown to inhibit K+ stimulated release of
noradrenaline from frontal cortex (Montel et al, 1974). Experiments
with K+ channel blockers in that model would prove a useful test
for the validity of this approach.
DIDS and low-chloride medium prevent the effect of substances
acting by opening of chloride channels. This is illustrated by the
antagonism of the effect of muscimol on prolactin secretion in
Chapter 5. Both of these reduced the effect of dynorphin on
K+-stimulated release, and in low-chloride medium the effect of
dynorphin was no longer significant. This contrasts with the lack
of effect of changing chloride concentration on the effect of
enkephalin in locus coeruleus (Williams et al, 1982), and suggests
that opening of chloride channels may be at least part of the
mechanism of action of 1C receptors.
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2+
Ba is a potent charge-carrier through voltage-dependent
2+
Ca channels (Hagiwara and Byerly, 1981) which may account for
its secretagogue action both on spontaneously active endocrine cells
(Douglas et al, 1982; Chapters 5 and 7) and on neurotransmitter
release (Douglas, Lywood and Straub, 1961; Boullin 1967). If
2+
dynorphin was acting by a direct effect on Ca -conductance, then
9 +
it might be expected to reduce the effect of Ba . In analagous
experiments, enkephalin and other transmitters reduced the duration
of action potentials elongated by being recorded in
9 +
Ba -containing medium (Mudge et al, 1979; Dunlap, 1985). The
lack of effect of dynorphin observed here suggests that a reduction
2+
in Ca conductance is not involved, and that its site of action
2+
is prior to voltage-dependent Ca channels.
2+ +
Ba also blocks some K channels (Fatt and Ginsborg, 1958;
Brown et al, 1982), a property which has been used in investigation
+
of p-mediated effects on K conductance in locus coeruleus
(Williams et al, 1982; North and Williams, 1983). This effect of
9-f
Ba is unlikely to be important here, as the secretagogue effect
2
of Ba on the synaptosomal preparation used is probably a result
2+ +
of penetration of Ca channels and the K channel blockers were
without effect on basal release.
Chloride-deficient medium elicited a marked release of
3
[ H]GABA from tissue previously superfused with normal medium,
presumably caused by chloride movement in response to its
artifically altered chemical gradient (Boakes, Turner and Virmani,
1984). As such chloride movement is likely to involve passage
through membrane anion channels, receptors which open such channels
should enhance ion movement, and thus may potentiate the effect on
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release. Using the normal superfusion protocol and 50% substitution
of chloride by the impermeant anion propionate, a slight but
non-significant potentiation of release by dynorphin^_^ was
observed. A more rapid superfusion rate and fraction collection
protocol revealed a prominent facilitation by lyM dynorphin^_^-
This supports the results obtained using K+-stimulated release in
the presence of DIDS or low-chloride medium, and suggests that this
TO receptor on GABAergic terminals in NI may act by enhancement of
membrane anion conductance. This may not be a ubiquitous mechanism
of action, as peripheral TC receptors appear to enhance acetylcholine
release from parasympathetic terminals (Ueda et al, 1985) and to
2+
inhibit Ca fluxes in erythrocytes (Yamasaki and Way, 1983),
2+
although such an effect on Ca flux may be secondary to changes
in anion conductance. Interestingly, in addition to reducing
release, an increased intracellular chloride concentration caused by
TC receptor activation may reduce GABAergic activity by inhibiting
GAD (Roberts and Kuriyama, 1968).
In conclusion, these results demonstrate the presence of
presynaptic K but not y or s opioid receptors on GABAergic nerve
terminals in NI, which may be acted on by an endogenous dynorphin to
inhibit GABA release. The mechanism of action of this receptor may
3
be to open chloride channels. [ H]GABA release from NI is also
controlled by GABA^ autoreceptors (Chapter 8). GABA^ receptors
also act by opening chloride channels, and this suggests that there
may be two populations of such receptor-controlled channels on








Inhibition of stimulated [3h]GABA release from NI by
dynorphini_X3. K+/dynorphin were introduced at the shaded bar.
( •) 15mM K+
(■) 15mM K+ + lpM dynorphini_i3
(4) Effect of lpM dynorphini_33 on basal release
Stimulated release: n = 5, mean ± S.E.M.
Basal release: mean of two experiments.
FIGURE 10.2
Concentration-dependence of the effect of dynorphini_i3 on
stimulated [^HjGABA release from NI. Results are expressed
percentage of a parallel control superfusion.
(•) Dynorphini.43
(■) lOOnM dynorphini_i3 + lyM naloxone
(O) lpM des-tyr-dynorphin
p<0.05 vs Control
























Receptor-specificity of the inhibition of [3H]GABA release by
opiate drugs. Results are expressed as a percentage of a control
(K+-only) stimulation of release carried out in parallel.
The peptides DAGO and DSLET had no significant effect on stimulated
release, while Dynorphin^_^3 and U50488H (all drugs at lyM) caused
significant inhibition of release. Mean ± S.E.M., n = 5 in each
case.
CON 4 AP TEA QUININE
FIGURE 10.4
The effect of K+-channel blockers on the inhibition of [3h]GABA
release by dynorphini_i3.
CON control responses. Open column: normal medium, hatched
column: normal medium + lyM dynorphini_i3.
Open columns: effect of 4AP (ImM), TEA (lOmM) and quinine
(0.3mM) on 15mM K+-stimulated release. None of these treatments
had any significant effect on release.
Hatched columns: effect of lyM dynorphin^_|3 on
K+-stimulated release in the presence of the various channel
blockers. Dynorphin^_^3 caused significant inhibition of release
in each case, of similar magnitude to that in normal medium.
Mean ± S.E.M., n = 5.
CON DIDS LOCL
FIGURE 10.5
The effect of anion-channel blockade and low-chloride medium on the
inhibition of [3H]GABA release by dynorphini_i3.
Open columns: effect of 15mM K+ alone
Hatched columns: effect of 15mM K+ + lpM dynorphini.43
CON: normal medium, control responses
DIDS: medium containing lOOuM DIDS
LOCL: medium containing Na propriate substituted for 83% of N5C1.
Mean ± .S.E.M., n = 5.




Effect of dynorphin on low-chloride stimulated release of [^HjGABA
from NI. Superfusion rate was increased to lml/min and 6 sec
fractions were collected. Low chloride medium (33% substitution of
Na propionate for NaCl) alone or with dynorphin;[_i3 introduced at
the hatched bar. The delay represents the dead-space of the
apparatus.
(•) Low-chloride medium
(■) Low-chloride medium + lpM dynorphini_]_3
Representative experiments. Results expressed as percentage of
pre-stimulus baseline release.
TABLE 10.1




drug concentration 15mM K+ 15mM K+ with
lyM dynorphini_i3
- - 100 42 ± 5*
4-aminopyridine 1 101 ± 7 33 ± 5*
tetraethylammoniurn 10 88 ± 10 48 ± 6*
quinine 0.3 92 8 50 ± 3*







75 ± 5* 65 ± 5**
Mean ± S.E.M., n = 5-7
* Significant inhibition compared to relevant controls
** Significant attenuation of inhibition
p<0.05, Mann-Whitney U test.
All ion channel drugs were present from the start of superfusion.
CHAPTER 11
3
The effects of 6ABA receptor agonists on [ H]dopamine release
from median eminence and pituitary neurointermediate lobe
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11.1 Introduction
It is well established that there is a dense dopaminergic
innervation of both ME and NI. The cell bodies of these
tuberoinfundibularand tuberohypophysial neurones are found mainly in
the arcuate nucleus with some in the periventricular nucleus
(Bjorklund, Flack, Hromek, Owman and West, 1970; Jonsson, Fuxe and
Hokfelt, 1972; Makara, Harris and Spyer, 1972) and there is also
some evidence for a projection to ME from substantia nigra (Kizer,
Palkovits and Brownstein, 1976). Dopaminergic terminals
(demonstrated by fluorescence histochemistry and [ H]DA uptake) in
ME are found in close proximity to capillaries of the
hypothalamo-pituitary portal vascular system and other nerve
terminals and axons (Hokfelt, 1967; Cuello and Iversen, 1973) while
those in NI are found in apposition to pituicyte processes,
neurosecretory endings and secretory cells (Baumgarten, Bjorklund,
Holstein and Nobin, 1972).
Dopaminergic terminals in both areas appear to show differences
from mesencephalic dopaminergic terminals. The DA uptake carrier is
of low affinity in both areas (Demarest and Moore, 1979a; Annunziato
and Weiner, 1980) and tyrosine hydroxylase activity in ME does not
appear to be subject to presynaptic control, although it is in NI
/
(Demarest and Moore, 1979b). Evidence for presynapatic
autoreceptors controlling DA release in ME is contradictory
(Annunziato et al, 1981; Sarkar et al, 1983). Instead, the activity
of tuberoinfundibular DA neurones may be subject to control by
prolactin (Hokfelt and Fuxe, 1972; Annunziato and Moore, 1978) and
tuberohypophysial DA turnover is increased by dehydration (Alper and
Moore, 1982).
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There are close parallels in both anatomy and function between
these dopaminergic systems and the GABAergic innervation of ME and
NI. For example, prolactin and dehydration also affect GABAergic
function in ME and NI respectively (Apud et al, 1984a; Hamberger et
al, 1979). GABA has been reported to stimulate DA release from
several brain areas (Starr, 1978; Stoof, Den Breejen and Mulder,
1979; Bowery et al, 1980) including MBH but not NI (Sharman, Holzer
and Holzbauer 1982). Negro-Vilar, Vijayan and McCann (1980) found
that i.c.v. injection of GABA increased DA concentration in both ME
and PD and decreased plasma prolactin concentrations, and inferred
the mechanism to be a GABA-induced release of DA into hypophysial
portal blood. Others, however, have reported that i.c.v. GABA
stimulates prolactin secretion (Ondo and Pass, 1978; Grandison and
Guidotti, 1979) and it has been proposed that GABA may act in that
case by inhibition of DA release into portal blood (Casanueva et al,
1981). This controversy has been tested directly in the present
experiments, by investigating the effect of GABA^ and GABAg
receptor agonists on the release of [ H]DA from ME.
GABA and muscimol affect the amplitude of the antidromic
compound action potential of hypothalamo-neurohypophysial axons
(Zingg et al, 1979), implying the presence of presynaptic GABA
receptors. Part of the effect may be on DA axons, in which case,
GABAergic agents might affect DA release in NI. Both GABA and DA
affect ctMSH secretion from NI (Bower et al, 1974; Tomiko et al,
1983) and the possibility of interactions in NI was therefore also
investigated.
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11.2. Materials and Methods.
11.2.1. Materials
[^HjDopamine ([^H]DA, 43.8 Ci/mmol) was obtained from
Amersham International, ascorbic acid and pargyline from Sigma.
(±)Baclofen, chlorimipramine and desimipramine were the generous
gifts of Ciba-Geigy. Other chemicals and drugs were as described in
Chapter 5.
11.2.2. Methods
The method and apparatus used was largely as described for
[ H]GABA release experiments described in Chapter 8. ME and NI
were dissected as described in Section 2.2, and tissue pooled from
10 rats was homogenised in 400yl of cold 0.32M sucrose. The tissue
homogenate was diluted into 3.2ml of oxygenated medium (composition
as in Chapter 8, with 10yM pargyline and 130yM ascorbic acid), and
3
incubated at 37°C for 15 min. [ H]DA was then added to give a
final concentration of 15nM, and sucrose concentration of 32mM.
After a further 15 min, aliquots corresponding to two dissected
areas were transferred to each superfusion chamber and superfused
with oxygenated medium at 37°C at a rate of 0.5ml/min. After 30 min
washout, basal release was approximately constant and 1 min
fractions were collected. At the beginning of the 7th fraction,
superfusion inlet lines were changed to medium containing 15mM KC1
(replacing NaCl) with drugs as appropriate. Radioactivity in each
fraction and that remaining in the tissue at the end of the
experiment was measured by LSC, as described in Chapter 8.
U.2.3. Uptake specificity experiments
Experiments were carried out to assess the specificity of
[^H]DA uptake using the selective 5-HT and NA uptake inhibitors
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chlorimipramine and desimipramine (Koe, 1976). lyM chlorimipramine
or O.luM desimipramine were present in the medium throughout an
uptake period identical to that used for release studies i.e. 15 min
preincubation and 15 min uptake in the presence of 15nM [ H]DA, at
37°C. Samples were then filtered through Whatman GF/B filters under
vacuum, washed with 3 x 5ml of medium at 37°C, and radioactivity in
filters/tissue was measured as described in Chapter 8. Tissue-free
(or detergent-lysed) blanks (~ 20% of total uptake for NI, 30% for
ME) were subtracted to give values for specific uptake, and the
percent inhibition of uptake by chlorimipramine and desimipramine
was calculated for both ME and NI.
11.2.4. Calculation of results
Radioactivity in each fraction was expressed as a percentage of
tissue radioactivity at the beginning of that fraction i.e. FRC.
From this, values of peak percentage stimulation of release were
calculated. In some cases these values were recalculated as a
percentage of a control response carried out at the same time. Data
are presented as mean ± S.E.M., and significance between two means
(values as percent stimulation of release) were determined by
Mann-Whitney U test.
11.3 Results
The possible contribution under these conditions of uptake of
3
[ H]DA into noradrenergic or serotonergic neurones was
investigated using desimipramine and chlorimipramine at
concentrations sufficient to cause prominent blockade of the NA and
5-HT, but not the DA uptake carrier (Koe, 1976). O.luM
desimipramine caused only 11 ± 5% inhibition of uptake in ME,
similar to that reported previously (Sarkar et al., 1983), and 15 ±
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5% in NI, whereas lyM chlorimipramine caused < 5% inhibition in ME
and 20 ± 2% in NI (n = 5 in each case). These results demonstrate
that under these conditions there is only a small contribution from
noradrenergic or serotonergic neurones in either area. (Cuello,
Horn, Mackay and Iversen, 1973; Bjorklund et al, 1970; Friedman et
al, 1983).
3
After 30 min of washout, spontaneous release of [ H]DA was
steady with an FRC of = 1% in both areas. Depolarisation with
medium containing 15mM K+ (replacing Na+) rapidly caused a
3
marked release of [ H]DA from both areas (Figures 11.1 and 11.2),
with a peak stimulation of 366 ± 10% from ME and 511 ± 54% from NI.
This stimulation was reduced to 65 ± 3% (18% of control) in ME
(Figure 11.1) and 79 ± 6% (15% of control) in NI (Figure 11.2)
2+ 2+
(n = 5, P < 0.05) by superfusion with Ca -free (Mg -
substituted) medium (in the absence of cation chelators).
The possible influence of presynaptic GABA receptors on
3
stimulus-evoked [ H]DA release was investigated using muscimol as
a selective GABA^ receptor agonist and baclofen as a selective
GABAg receptor agonist. lOpM muscimol reduced the response in ME
to 79 ± 2% of control stimulus-induced release (P < 0.05 Figure
11.1) but had no effect on stimulated release from NI (106 ± 10% of
control, Figure 11.2). IOOuM (±)baclofen had no effect in either
area (96 ± 3% in ME, 105 ± 14% in NI, n = 5 in all cases, Figures
11.1 and 11.2). The effect of muscimol was reversed (to 98±3% of
control) (P < 0.05) by BMI (10pM) but was unaffected by strychnine
(10yM, Table 11.1, antagonists introduced simultaneously with
K+/muscimol).
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The*pharmacology of this presynaptic GABA^ receptor in ME was
further investigated using homocarnosine. Homocarnosine was found
to cause a concentration-dependent inhibition of stimulated [ H]DA
release from ME, reducing the peak response to 58 ± 3% of control at
a concentration of ImM (P < 0.05, n = 5). This effect appeared to
be GABA^ receptor-mediated as it was antagonised by 10uM BMI
(Table 11.1). Neither muscimol nor homocarnosine had any effect on
3
basal release of [ H]DA at these concentrations.
11.4. Discussion
These results demonstrate that a crude synaptosomal preparation
3
can be used for the study of DA release by ME and NI, as [ HJDA is
rapidly accumulated by the tissue and can be released by a K+
2+
stimulus in a reproducible and Ca -dependent manner. This
preparation allows the demonstration of direct presynaptic effects
as interneuronal circuits will not be preserved, and in contrast to
the whole ME preparation (Sarkar et al., 1983), released [ H]DA is
rapidly removed, thus preventing reuptake. A similar preparation
3
has been used previously for the study of [ H]DA release by ME
(Annunziato et al, 1981) and for the study of [^H]DA uptake by NI
(Demarest and Moore, 1979a, Annunziato and Weiner, 1980) but this is
the first demonstration of its use for the release of [ H]DA by NI.
The effects of muscimol and homocarnosine on stimulated release
in ME and the antagonism of these effects by BMI suggest that DA
terminals in ME have presynaptic GABA^ receptors and that
activation of these results in reduced transmitter release. These
results therefore provide a basis for the suggestion of Casanueva et
al (1981) that the centrally-mediated stimulatory effect of GABA on
prolactin secretion is mediated by reduced release of DA into
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hypophysial portal blood and thus removal of a tonic inhibitory
effect. Negro-Vilar et al (1980) suggested the opposite, that
central administration of GABA increases DA release into portal
blood, and this was supported by the demonstration of a stimulatory
effect of GABA on DA release from MBH (Sharman et al., 1982). The
tissue preparation in that case is very different to the one studied
here, being > lOx larger, and containing several areas of cell
bodies. It is therefore possible that GABA may have several sites
of action on DA neurones in the hypothalamus.
The dense GABAergic innervation of ME (Vincent et al, 1982) with
terminals adjacent to non-GABAergic axons and terminals as well as
capillaries of the hypophysial portal system (Tappaz et al, 1983),
provides an anatomical basis for this effect. The GABAergic
innervation of ME appears to be most concentrated in the lateral
palisade zone (Everitt et al, 1984), the region of ME which also
receives the densest dopaminergic innervation (Ajika and Hokfelt,
1973). The functional significance of presynaptic regulation of
dopaminergic function in ME is not clear, but both anatomical and
physiological studies indicate some of the neuroendocrine systems
which may be so influenced. The distribution of DA within ME
parallels that of TRH and LHRH (Kizer, Palkovits, Tappaz, Kebabian
and Brownstein, 1976), and tyrosine hydroxylase immunoreactivity in
ME has been reported to show considerable overlap with that of LHRH
and somatostatin (Agnati, Fuxe, Hokfelt, Goldstein and Jeffcoate,
1977). Axo-axonic contacts between dopaminergic and LHRH neurones
in ME have also been demonstrated (Ajika, 1979). The dopaminergic
innervation of ME may therefore have several functions other than as
the source of DA for release into hypophysial portal blood. This is
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supported by the demonstration that DA stimulates LHRH release from
ME synaptosomes and MBH in vitro (Bennet, Edwardson, Holland,
Jeffcoate and White, 1975; Rotsztejn, Drouva, Patou and Kordon,
1978) and there is also evidence for a stimulatory effect on
somatostatin and TRH release (Negro-Vi1ar, Ojeda, Arimura and
McCann, 1978; Maeda and Frohman, 1980). Increased DA turnover in ME
is associated with the initiation of the proestrus LH surge (Ranee,
Wise, Selmanoff and Barraclough, 1981) but in vivo experiments on
the effect of DA on LH secretion have given rise to confusion, and a
steroid-dependent stimulatory effect of DA has been suggested
(Vijayan and McCann, 1978c; Weiner and Ganong, 1978).
The multiplicity of endocrine effects of GABA makes the
relevance of GABAergic regulation of ME DA release difficult to
interpret, but it may contribute to some GABA-elicited responses
e.g. inhibition of TSH secretion (Vijayan and McCann, 1979) by
indirect inhibition of TRH secretion (Negro-Vilar et al, 1978).
i.c.v. injection of muscimol has been shown to greatly reduce DA
turnover in MBH (Fuchs, Mansky, Stock, Vijayan and Wuttke, 1984),
and these experiments provide a possible site of action for this
effect.
High concentrations of homocarnosine are present in hypophysial
portal blood, although its origin is unknown as it does not appear
to be released on electrical stimulation of ME (Mitchell et al.,
1983). Homocarnosine appears to have weak partial agonist action at
GABA^ receptors as it can inhibit prolactin secretion in vitro
O
(Chapter 5) and displace [ Hjmuscimol binding at high
concentrations (Mitchell et al., 1983). The present results suggest
that homocarnosine may contribute to the GABAergic influence on DA
terminals in ME.
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The effect of muscimol in ME was antagonised by BMI but not by
strychnine, as is most commonly observed for GABA^ receptor
responses, and this is consistent with the demonstration that
recurrent inhibition in the tuberoinfundibular system is sensitive
to the other classical GABA^ antagonist, picrotoxin, but is
resistant to strychnine (Yaki and Sawaki, 1975). This GABA^
receptor also shows similarities with that causing inhibition of
prolactin secretion in vitro, which is responsive to homocarnosine
but is insensitive to antagonism by strychnine. Such a profile
contrasts with that of the GABA^ receptor complex mediating the
transient stimulation of prolactin secretion in vitro which is not
responsive to homocarnosine but is potently antagonised by
strychnine (Chapter 5).
The recent demonstration of apparent coexistence of GABA and DA
within ME (Everitt et al., 1984) raises the possibility that in
addition to DA autoreceptors (Sarkar et al, 1983) and GABA
heteroreceptors, GABA "co-transmitter autoreceptors" may be involved
in the regulation of DA release from ME terminals. The presence of
both GABA^ and GABAg autoreceptors in ME was demonstrated in
Chapters 8 and 9, and a schematic representation of the possible
complexity of regulation of release of GABA and DA from a terminal
in ME is shown in Figure 11.3. This hypothetical diagram shows all
the GABAergic feedback pathways demonstrated in this Thesis and the
presence of DA autoreceptors on one neurone, for which there is no
direct evidence.
Muscimol was found to have no effect on [ H]DA release from
NI, and baclofen was without effect in both ME and NI. The
dopaminergic projection to NI has been suggested to be the major
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inhibitory innervation of that gland (Passo, et al, 1981; Davis et
al, 1985) and may be involved in the control of peptide hormone
synthesis and secretion in both PI and PN (Bower et al, 1974; Vizi
and Volbekas, 1980; Lightman, Iversen and Forsling, 1982; Chen,
Dionne and Roberts 1983). Recently the DA projections to PI and PN
have been shown to have different properties (Lookingland, Farah,
Lovell and Moore, 1985). Although any effect of muscimol or
baclofen in only one of the lobes may therefore be less prominent
here, since a mixed preparation was used, the results provide no
evidence for any GABAergic influence on DA terminals in NI.
Tuberohypophysial DA neurones therefore appear unusual in this
respect, as DA release in a number of other areas can be affected by
either GABA^ or GABAg receptors (Starr, 1978; Stoof et al, 1979;
Bowery et al, 1980).
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The effect of muscimol and baclofen on K+-stimul ated [3h]DA
release from ME. K+/drugs were introduced at the arrow.
(•) Control response to 15mM K+
(O) 15mM K+ + 10pM muscimol
(A) 15mM K+ + 100uM (±) baclofen
(0) Response to 15mM K+ in Ca2+-free medium
(□) Effect of lOviM muscimol on basal release.
Mean ± S.E.M., n = 5 except muscimol on basal: n = 2.
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FIGURE 11.2
The effect of muscimol and baclofen on K+-stimulated [3h]DA
release from NI. K+/drugs were introduced at the arrow.
(#) Control response to 15miM K+
(O) 15mM K+ + 10yM muscimol
( A) 15mM K+ + 100yM (±1 baclofen
(0) Response to 15mM K in Ca2+-free medium
Mean ± .S.E.M., n = 5.
FIGURE 11.3
Schematic representation of inhibitory autofeedback mechanisms
modulating GABA and DA release in ME. The diagram represents GABA
and DA coexisting in a terminal in ME.
Large arrows: release of GABA and DA into perivascular space or
synapse.
Small arrows, filled arrow heads: released neurotransmitter also
binds to presynaptic DA, GABA/\ (G/\) or GABAg (Gg) receptors.
Small arrows, open arrowheads: intracellular inhibitory influence o1
receptor activation on release of neurotransmitter.
TABLE 11.1
Effects of GABA agonists on stimulus-induced release of
3
[ H]DA. Results are expressed as percentage of control response
to 15mM K+.
Drug ME NI
lOuM muscimol 79 ± 2* 106 ± 10
10yM muscimol + 10yM
bicuculline methiodide 98 ± 3**
10pM muscimol + lOuM
strychnine 84 ± 2*
lOOuM homocarnosine 73 ± 4*
ImM homocarnosine 58 ± 3*
ImM homocarnosine + 10yM
bicuculline methiodide 80 ± 4***
lOOyM (±)baclofen 96 ± 3 105 ± 14
Mean ± S.E.M., n = 5-6.
* P < 0.05 vs control
** P < 0.05 vs 10yM muscimol
*** P < 0.05 vs ImM homocarnosine
Mann-Whitney U test on values for peak percentage stimulation.
CHAPTER 12
Investigation into the presence of homocarnosinase in
the anterior pituitary gland.
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12.1 Introduction
Homocarnosine (Y-aminobutyryl-l_- histidine) was first identified
in bovine brain by Pisano, Wilson, Cohen, Abraham and Udenfriend
(1961). Subsequent studies demonstrated its presence in the brain
of several animals with especially high concentrations in man
(Abraham, Pisano and Udenfriend, 1967). It was not detectable in
any peripheral tissue. Homocarnosine synthesis was demonstrated in
frog brain in vivo and in vitro (Yockley and Marshall, 1969), and
the enzyme involved, homocarnosine-carnosine synthetase, is mainly
cytoplasmic and is regionally distributed in rat brain (Skaper, Das
and Marshall, 1973; Ng and Marshall, 1978). Homocarnosine is
degraded by a specific enzyme, homocarnosinase (Lenney, Kan, Sin and
Sugiyama, 1977). High homocarnosinase activity is detectable in
human brain (Kish, Perry and Hansen, 1979) but activity is low in
rat brain (Ng and Marshall, 1978).
The distribution of homocarnosine does not simply parallel that
of GABA (Young and Snyder, 1973) but the metabolism of the two
substances is linked: myenteric plexus can synthesise both GABA and
homocarnosine from glutamate (Jessen, Mirsky, Dennison and
Burnstock, 1979) and the concentrations of both substances in brain
and cerebrospinal fluid (CSF) are elevated by inhibitors of
GABA-transaminase (Perry and Hansen, 1973; Palfreyman, Bohlen, Huot
and Mellet, 1980). In Huntington's Chorea, the reduction in brain
GABA content is accompanied by a reduction in homocarnosine content
(Perry, Hansen and Kloster, 1973; Urquhart, Perry, Hansen and
Kennedy, 1975). Genetic deficiency of homocarnosinase has been
described, resulting in 'homocarnosinosis1, which may cause
paraplegia, mental deterioration and retinal pigmentation (Perry,
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Kish, Sjaastad, Gjessing, Nesbakken, Schrader and Loken, 1979).
The related dipeptide carnosine has been proposed to be a
neurotransmitter in the olfactory bulb (Margolis, 1974) but evidence
for a functional role of homocarnosine in GABAergic transmission has
been equivocal. In a number of models e.g. production of
hyperexcitability and shortened barbiturate sleeping time,
homocarnosine behaves like a GABA antagonist (Turnbull, Slater and
Briggs, 1972) and endogenous homocarnosine has been suggested to act
as a GABA antagonist, perhaps being responsible for dyskinetic
movements after GABA-transaminase inhibition (Robin and Palfreyman,
1982). Iontophoretic application of homocarnosine onto cerebral and
olfactory cortex neurones had little effect, although the neurones
were depressed by GABA (MacLeod and Straughan, 1979). Homocarnosine
has low but distinct affinity at GABA binding sites (Enna and
Snyder, 1976; Mitchell et al, 1983), and Schally et al (1977) showed
that concentrations as low as 6viM inhibited prolactin secretion
in vitro. Very high concentrations of homocarnosine may be present
in hypophysial portal blood (Mitchell et al, 1983) and further
studies on the effects of homocarnosine on prolactin secretion
in vitro were carried out in Chapter 5.
Human CSF contains homocarnosinase (Grove, Schechter, Tell,
Rumbach, Marescaux, Warter and Koch-Weser, 1982) but rat plasma and
CSF do not (Lenney et al, 1977; Grove et al, 1982). If the
pituitary gland were to contain significant homocarnosinase
activity, its action could elevate PD GABA concentrations above
those measured in hypophysial portal blood, thus increasing
GABAergic influences on PD function. The experiments described here
were carried out to investigate this possibility.
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12.2 Materials and Methods
The methodology used was based on that of Lenney et al, (1977)
for the enzyme assay, with determination of GABA formed by the
radioreceptor assay described by Mitchell et al, (1983).
12.2.1. Materials
N-ethylmorpholine, homocarnosine and GABA were obtained from
3
Sigma. Tris and CoSO^ were Analar grade, BOH, [ Hjmuscimol
3
(muscimol, [methylene - H (N)]-, specific activity 20.6 Ci/mmol)
was obtained from New England Nuclear. GABAase, NADP, and disodium
o-ketoglutarate were obtained from Boehringer-Mannheim (Lewes).
12.2.2. Enzyme assay
Kidney and PD tissue from male Wistar rats was stored frozen at
-20°C until use. Kidney tissue contains very high homocarnosinase
activity (Lenney et al, 1977) and was therefore used to develop the
assay. Tissue was thawed and homogenised at 20mg/ml for kidney or
50mg/ml for PD in cold 5mM N-ethyl morpholine buffer containing ImM
CoSO^ (pH7.2) in a teflon-glass homogeniser. 250ul aliquots of
homogenate were used in the assay, and were pipetted into 1.5ml
polypropylene tubes on ice. 550yl of homogenisation buffer were
then added, with 200^1 of 2.5mM homocarnosine in buffer, giving a
final concentration of 500uM. Tubes were then incubated at 30°C in
a waterbath for the required time (generally 40 min), before the
reaction was stopped by placing the assay tube in a boiling
waterbath for 3 min. The tube was then centrifuged at 16,000 rpm
for 10 min. The supernatant was assayed for GABA by radioreceptor
assay. Blanks consisted of samples that were boiled immediately the
homocarnosine was added.
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12.2.3. GABA radioreceptor assay
3
In this assay, the unknown competes with [ Hjmuscimol for
high-affinity GABA binding sites on rat cerebellar membranes.
12.2.3.1. Membrane preparation
Cerebella from male Wistar rats were stored at -20°C until use.
Tissue was homogenised in 50 vols of cold 50mM Tris HC1 buffer,
pH 7.1 using an Ystral high speed homogeniser and centrifuged at
48,000g at 4°C for 10 min. The supernatant was discarded and the
pellet resuspended in 50 vol Tris buffer containing 0.05% Triton
X-100 detergent and incubated for 30 min at 37°C. This results in a
preparation of near-uniform high-affinity binding sites for
[ H]muscimol, distinct from the mixed high- and low- affinity
binding seen using non-detergent treated tissue (Wong and Horng,
1977, Beaumont et al, 1978; Chapter 3). The membranes were
centrifuged as before, and washed a further seven times to remove
the detergent, endogenous GABA, and endogenous inhibitors of GABA
binding (Toffano et al, 1978, Gardner et al, 1981). After the final
centrifugation, the pellet was suspended in 10 vol of buffer and
stored frozen at -20°C. When required, membrane preparations were
made up to 50 vol, centrifuged and homogenised again in 50 vol
immediately before use.
12.2.3.2. Binding assay
Binding assays were carried out in 5ml polypropylene tubes and
contained 500pl membrane suspension, lOOyl [ Hjmuscimol (final
concentration 20nM), 10pl of a ^Idilution of enzyme assay
supernatant, lOOyl of GABA (for non-specific binding and standard
curve) and buffer to give a final volume of 1ml. 100pM GABA was
used to define non-specific binding, and concentrations from 3-100nM
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for standard curves. All determinations were made in duplicate.
Assays were incubated on ice for 60 min, then filtered through
Whatman GF/B filters under vacuum and washed three times with 5ml of
ice cold butter via the incubation tube. Radioactivity bound to the
filters was determined by LSC. Under these conditions, binding of
[ Hjmuscimol (approximately 18,000 dpm) was >95% specific.
Confirmation that the displacing activity of enzyme assays above
that found in blanks was due to authentic GABA was carried out using
the specific GABA-degrading enzyme mixture GABAase (Graham and
Aprison, 1966). 5ul of the following mixture was added to the
samples and buffer in the binding assay tubes: 20 units GABAase
(from Pseudomonas fluoresencens), 1.6mg NADP, 3mg disodium
a-ketoglutarate, 5ul 2-miercaptoethanol, 200vil Tris HC1 buffer.
O
Samples were then incubated at 37°C for 30 min before [ H]muscimol
binding was carried out.
Under these conditions, the final concentration of homocarnosine
in the binding assay was 300nM. This concentration caused 3±2%
displacement (n=4). The displacing activity of blanks (16±4% for
kidney) was therefore not attributable to homocarnosine. As used
GABAase was found to degrade >95% of authentic GABA (300nM), and the
displacement caused by high concentrations of homocarnosine (ICgg=
50uM) was unaffected by GABAase.
12.2.4. Calculation of results
The apparent concentration of GABA in samples was calculated
from the standard curve, derived at the same time from the same
membrane preparation. Blank values were subtracted from this, to
give the concentration of GABA formed. This was taken to be
equivalent to the amount of homocarnosine degraded, thus giving the
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activity of the sample after correction for the dilution involved.
Data is presented as mean ± S.E.M.
The limit of sensitivity of the method (ie activity that would
result in formation of GABA at a concentration double blank values)
was calculated to be 0.4 ymol/hr/g tissue for PD.
12.3 Results
Formation of GABA by kidney homogenate used to characterise the
method was found to be linear with time for 40 min (Figure 12.1) and
with tissue concentration up to at least lOmg/assay (Figure 12.2).
Activity in a preparation of supernatant (kidney homogenate
centrifuged at 12,000g for 20 min) was found to be the same as
homogenate. The amount of GABA formed by 250^1 of supernatant in 20
min was 3.1 ± 0.6nmol/g, and by homogenate was B.OiO.Sumol/g (n=4 in
each case).
Similar experiments using PD homogenates showed minimal
activity. After 40 min incubation, the apparent concentration of
GABA in samples was estimated as l.SiO.Snmol, giving an activity of
0.16vimol/hr/g, but this was well below the limit of sensitivity of
the assay and cannot be considered reliable. Furthermore, the total
'GABA' present was not altered by treatment with GABAase. The
apparent concentration of GABA in samples was 4.8±0.3pM before
GABAase, 4.9±0.4pM after (n=4 in each case). PD therefore shows no
detectable homocarnosinase activity. Immediate metabolism of any
GABA formed in very unlikely as GABA-transaminase activity, although
present in PD (Racagni et al, 1979), is dependent on the addition of
a-ketoglutarate (Hall and Kravitz, 1967).
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12.4 Discussion
These results do not provide any evidence for the hypothesis
that PD tissue can hydrolyse homocarnosine to GABA, thus increasing
the local concentration of GABA. Lenney et al (1977) also reported
that homocarnosinase was not detectable in rat brain, but Ng and
Marshall (1978) found some homocarnosine-degrading activity in rat
brain homogenates. The absence of activity in high-speed
supernatant suggests that activity measured in that study was not
true homocarnosinase, which is equally active in homogenate and
supernatant (Lenney et al, 1977; also present results). The rat
therefore shows considerable differences from the human in
homocarnosine metabolism. Human brain contains considerable amounts
of homocarnosinase, although homocarnosine-carnosine synthetase is
difficult to reliably measure because of post-mortem lability (Kish
et al, 1979).
The concentration of homocarnosine in hypophysial portal blood
is sufficient to cause considerable inhibition of prolactin
secretion (Chapter 5). Homocarnosine also appeared to be able to
antagonise the stimulatory effect of GABA on prolactin secretion,
but was without either agonist or antagonist action at somatotrophe
GABA receptors (Chapters 5 and 7). This variety of pharmacological
activity is also seen in the CNS, as described in the introduction
to this Chapter, and suggests that homocarnosine may be a
potentially useful GABAergic compound as a basis for new drug
development. The inhibitory GABA^ receptors on lactotrophes and
on DA terminals in ME (Chapter 10) appear to be the only models yet
described where homocarnosine has considerable efficacy, but the
affinity of homocarnosine for cerebellar GABA binding sites
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(Mitchell et al, 1983) may suggest that negative results obtained
elsewhere (eg MacLeod and Straughan, 1979) may be the result of too
low a concentration being reached at synaptic loci.
Although homocarnosine can be formed from GABA by rat brain
in vivo, this appears to be a slow process (Palfreyman et al,
1980). In contrast, the formation of GABA from homocarnosine is
rapid in, for example human CSF (Grove et al, 1982). Basal
GABAergic tone on PD in the human may therefore be more sensitive to
alterations in homocarnosine concentration in brain and plasma. The
concentration of homocarnosine in hypophysial portal blood was not
altered by electrical stimulation of ME, although the secretion of
GABA was greatly increased (Mitchell et al, 1983). The coexistence
of GAD-IR with histidine-decarboxylase-IR has recently been
demonstrated in magnocel1ular neurones in the rat hypothalamus
(Takeda, Inagaki, Shiosaka, Taguchi, Oertel, Tohyama, Watanabe and
Wada, 1984). The possibility therefore exists that these neurones
may metabolise homocarnosine in some way. One possibility is that
homocarnosine is a precursor and that histamine and GABA are
co-transmitters. The is supported by the cytoplasmic location of
carnosine-homocarnosine synthesis (Ng and Marshall, 1978). These
neurones project to the neocortex (Vincent et al, 1983), but any
projections within the hypothalamus are unknown. A
metabolic/storage role for homocarnosine as a 'buffer' for GABA
might explain why no increased secretion into hypophysial portal
blood was observed. The origin of the homocarnosine is therefore
unknown as sufficiently precise experiments to define the
distribution of carnosine-homocarnosine synthetase have yet to be
done. Considerable further study is needed to approach an
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understanding of the function of this dipeptide, either in relation
to GABA metabolism or GABAergic neurotransmission. Effects of
homocarnosine not related to GABA should not be ignored, as the
distribution of the two substances is not parallel (Young and
Snyder, 1973). More detailed localisation of the enzymes involved
in homocarnosine metabolism might shed considerable light on this
problem. Immunohistochemical studies using antiserum against
carnosinase have demonstrated the presence of that enzyme in
vomeronasal nerves (Margolis, Grillo, Grannot-Reisfelt and Farbman,
1983) supporting the suggestion of Margolis (1974) that carnosine
may be a neurotransmitter in the olfactory pathway. Carnosinase
immunoreactivity was also found in other sensory neurones and
analogous anatomical studies on homocarnosinase might provide






Time-dependence of formation of GABA from homocarnosine by kidney
tissue. Assays (5mg tissue) were incubated at 30°C for the time
stated.
SN: determination was carried out on high-speed supernatant




Tissue concentration-dependence of formation of GABA from
homocarnosine by kidney tissue. Assays were incubated at 30°C for
20min. Mean ± S.E.M., n = 4.
CHAPTER 13
GABA^ binding sites and Glutamic Acid Decarboxylase
activity in the Neurointermediate lobe of Brattleboro rats
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13.1 Introduction
Brattleboro rats suffer from hereditary diabetes insipidus,
caused by inability to synthesize vasopressin and its associated
neurophysin (Valtin, Sawyer and Sokol, 1965; Russel, Brownstein and
Gainer, 1980; Schmale and Richter, 1984). The supraoptic and
paraventricular nuclei show enlarged cells, and there is marked
hypertrophy of PN (Sokol and Valtin, 1965) suggesting excessive
activity, and homozygous Brattleboro rats are dehydrated even with
free access to water (Valtin et al, 1965). Oxytocin synthesis
appears to be unaffected (Sokol and Valtin, 1965; Russel et al,
1980) and the reduction in PN oxytocin content (Valtin et al, 1965)
and increased plasma oxytocin concentration may be a result of
dehydration (Dogterom, Van Wimermsma Greidanus and Swaab, 1977).
GABA may be involved in the control of vasopressin release.
Feldberg and Rocha e Silva (1978) reported that bicuculline and
picrotoxin, applied to the brain stem of cats, caused increased
release of vasopressin and i.e.v. administration of GABA or AOAA
reduced hypovolaemia-induced vasopressin release (Knepel et al,
1980). GABA also inhibited the firing of supraoptic neurones
(Bioulac, Gaffori, Harris and Vincent, 1978; Arnauld, Cirino, Layton
and Renaud, 1983), and the neurohypophysial antidromic compound
action potential (Zingg et al, 1979). A direct effect of GABA on
vasopressin release from PN in vitro has recently been demonstrated
(Knepel et al, 1984).
Brattleboro rats also appear to have a GABAergic deficit of some
description in PN. The concentration of GABA in the posterior
pituitary of Brattleboro rats was greatly reduced compared to
Sprague-Dawley rats, and showed little capacity for uptake of
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[ H]GABA (Hamberger et al, 1979). These results were interpreted
in terms of GABA uptake by glial cells. The demonstration of a
GABAergic innervation of NI from the CNS (Oertel et al, 1982;
Vincent et al, 1982) suggested that these neurones may be involved.
The present series of experiments were carried out to investigate
this GABAergic deficit further. Two markers of GABA neuronal
activity were measured: a postsynaptic marker, the number of GABA^
binding sites, and a presynaptic marker, the activity of the
GABA-synthesising enzyme glutamic acid decarboxylase. Brattleboro
rats were compared to their parent strain, Long-Evans.
13.2 Materials and methods
13.2.1 Animals
Homozygous male Brattleboro rats (200-280g) were bred in the
Department of Pharmacology. Urine excretion over a period of 24 hrs
was measured using individual metabolic cages and was greater than
50% (v/w) in all rats used in this study. Male Long-Evans rats were
obtained from Charles River (Margate) and all animals were housed as
described in Section 2.1.
3
13.2.2 r HlMuscimol binding assay
3
GABA^ binding sites were quantified using [ H]muscimol. The
method used was as described in Section 3.2 and will be only briefly
outlined here. Pooled NI were homogenised in Tris HC1 buffer,
centrifuged and the membranes frozen. At the time of assay,
membranes were thawed, and washed 4 times by repeated
centrifugation. Aliquots in duplicate were then incubated with
[ Hjmuscimol (2nM and 20nM) on ice for 1 hr, and the assays were
terminated by centrifugation, with superficial washing of the
pellet. Non-specific binding was defined by the presence of lOOpM
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GABA. Radioactivity in the pellet was counted by LSC after being
solubilised in Protosol. Protein content was determined as
described in Section 2.5.
13.2.3 L-Glutamic acid decarboxylase assay
The method used in this thesis was based on that of Alberts and
Brady (1959) and Tappaz, Brownstein and Kopin (1977) and depends on
measurement of the amount of [^C]C02 liberated from [^C] -L-
glutamate.
13.2.3.1 Materials
L-[1-^C] glutamic acid (59mCi/mmol) was obtained from
Amersham International. All other reagents were obtained from Sigma
(Poole) except KH2P04, K2HP04 and Triton X-100 (B.D.H.,
Poole).
13.2.3.3 Method
Fresh tissue (dissection as in section 2.3) was homogenised in
50yl of 0.1M K phosphate buffer containing 0.25% Triton X-100 and
O.lmM pyridoxal-5'-phosphate in an all-glass homogeniser. A 1M
stock of K phosphate buffer was prepared by mixing 1M K2HP04 and
1M KH2P04 to give pH 6.5. Duplicate 10p1 aliquots of homogenate
were pipetted into 1.5ml polypropylene tubes (Sarstedt) and 10pl of
incubation medium of the following composition was added (final
concentrations in brackets): K phosphate buffer pH 6.5 (lOOmM),
pyridoxal-51 phosphate (0.5mM), dithiothreitol (0.5mM),
[^C]glutamate (0.085mM), L-Na glutamate (lOmM), Triton X-100
(0.25%), Na arsenite (ImM). Tubes were then put into plastic
scintillation vials which contained lOOyl methylbenzethoniurn
hydroxide (hyamine, 1M in methanol). The vials were capped with a
rubber seal, and incubated in a shaking waterbath at 37°C for 20
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min. The reaction was stopped by injection of 200pl 6N H^SO^
into the tube using a 2ml syringe and needle, and the incubation was
continued for a further 60min to ensure complete absorption of
[^C]C02 by the hyamine. At the end of that period, the rubber
seals were removed and the outside of the reaction tubes washed with
2ml ethanol into the scintillation vials. 10ml NE265 scintillation
fluid was added, and the vials were chilled overnight before
radioactivity was counted. Blanks consisted of 10pl incubation
medium carried through the whole procedure, and were determined in
duplicate. Protein content of aliquots of homogenate were
determined according to Section 2.4.
13.2.3.3 Calculation of results.
Specific [^CjCOg evolution was found after subtraction of
blank dpm from mean of sample dpm. Blanks were less than double
background, and ME samples were approximately tenfold blank values.
0.202 pmoles [^C]glutamate were added, containing O.lpCi of
radioactivity (equivalent to 220,000dpm). From this the activity of
the sample was calculated as:
specific dpm x 0.202 x 3^ pmol/hr/pg protein
220,000 pg protein
Preliminary studies showed that the reaction was linear over the 20
min incubation used (Figure 13.1). Statistical comparisons were made
using Students t test.
13.3 Results
3
13.3.1 [ H]Muscimol binding assays
3
The experiments in Chapter 3 showed that [ H]muscimol at 2nM
and 20nM bound mainly (=60%) to high-affinity and low-affinity sites
respectively, and these concentrations were therefore used for the
3
experiments in this Chapter. Binding of [ H]muscimol was
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considerably greater to NI from both Brattleboro and Long-Evans than
from Wistar rats, but there was no difference between Brattleboro
and Long-Evans rats. At 2nM, [ H]muscimol binding comprised
23 ± 6 fmol/mg protein in Brattleboro NI, and 29 ± 4 fmol/mg protein
in Long-Evans NI. At 20nM, the values were 157 ± 21 fmol/mg protein
and 142 ± 18 fmol/mg protein respectively (n = 4 in each case).
(Values obtained for Wistar NI in Chapter 3 were 3.0 fmol/mg protein
at 2nM, and 5.8 fmol/mg protein at 20nM).
13.3.2 GAD assays
GAD activity in NI was much lower than in brain regions, but was
readily detectable at 5-6 times blank dpm values in Long-Evans
rats. The GAD activity of Long-Evans NI was 35.5 ± 1.9 pmol/hr/ug
protein, which was considerably greater than the activity in
Brattleboro rats: 20.1 ± 0.4 pmol/hr/yg protein (n = 5 in each case,
P < 0.001). The hypertrophy of the Brattleboro PN may have
accentuated this difference where expressed in terms of protein
content, so GAD activity was also calculated per gland. Long-Evans
NI had a GAD activity of 3358 ± 131 pmol/hr/NI and Brattleboro NI
had an activity of 2580 ± 71 pmol/hr/NI. Therefore Brattleboro NI
have 79% of the activity of Long-Evans NI, but the values were still
significantly different (P < 0.01). The protein content of
Long-Evans NI was 94.0 ± 5.5ug protein and of Brattleboro NI was
131.5 ± 5.5 ug protein.
Further experiments were carried out in an attempt to localise
the depletion of GAD activity to PI or PN. It was not possible to
directly determine GAD activity in PI due to the very small amounts
of tissue involved, but determinations could be made on PN after
removal of PI tissue. In these experiments, GAD activity in
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Long-Evans PN was 23.5 ± 3.3 pmol/hr/pg protein (1182 ± 149
pmol/hr/gland) and 9.44 ± 0.75 pmol/hr/pg protein in Brattleboro PN
(707 ± 46 pmol/hr/gland) (n = 5, P < 0.01 values per pg protein, P <
0.02, values per gland). This shows that Brattleboro GAD activity
in NI was 57% of the activity of Long-Evans NI, and that PN activity
is 40% of that in Long-Evans (values/pg protein). Recalculation of
these results to express activity per gland rather than per pg
protein, and subtraction of PN values from NI values to give an
estimated value for PI, gives values of 2176 pmol/hr/PI for Long
Evans (65% of total activity in NI) and 1973 pmol/hr/PI for
Brattleboro (74% of total activity in NI). These results are
summarised in Figure 13.2. Examination of the protein
determinations shows that on average, protein content of PN was 54%
of NI for Long Evans, and 57% for Brattleboro rats. No other
analysis of the completeness of dissection of PI from PN was made.
GAD activity in ME from Brattleboro and Long Evans rats was also
determined. Activity was 210 ± 43 pmol/hr/pg protein in Long Evans




[ H]Muscimol binding to NI membranes at both 2nM and 20nM was
very similar in Long-Evans and Brattleboro rats. If these values
can be taken to be indicative of GABA^ receptors, then these
results suggest that GABA receptor function in Brattleboro NI is
unaltered. This will be discussed further below, in the light of
the results on GAD activity.
The GAD assay used here is based on the stoichiometric
liberation of [ and formation of GABA from
-181-
[^Cjglutamic acid. This method is widely used and extensively
characterised, but several possible problems inherent in the method
should be considered. In certain tissues, non-equivalence of C02
and GABA formation is observed (Kanzawa, Iversen and Kelly, 1976;
Wu, Chude, Wein, Roberts, Saito and Wong, 1978), and the
[14C]C02 method gives over-estimates of GAD activity. Part of
this discrepancy has been attributed to metabolism of
[^4C]glutamic acid in the tricarboxylic acid cycle (Kanazawa et
al, 1976), which was inhibited by the presence of arsenite (included
in the incubation mixture here). GAD activity is detectable in many
non-neuronal tissues, but shows different immunological properties
(Wu et al, 1978). NI GAD activity, by the [^4C]C02 method
appears to be neuronal, as suggested by immunohistochemical studies,
because it is virtually abolished (giving lower values than PD or
liver) following section of the hypophysial stalk (Oertel et al,
1982). The value for GAD activity in NI found here is very similar
to that reported by Oertel et al (1982), as were values from trial
experiments using PD tissue (two values of 3.3 and 4.8 pmol/hr/yg
protein were obtained).
GAD activity in Brattleboro NI was significantly reduced
compared to Long-Evans rats. This difference was particularly
marked when expressed in terms of protein content, probably
reflecting the hypertrophy of PN (Sokol and Valtin, 1965; PN from
Brattleboro rats were found to contain = 50% more protein than
Long-Evans PN) but was still significant when expressed as activity
per gland. GAD activity in PN (per yg protein) of Brattleboro rats
was even more markedly reduced (to 40% of Long-Evans activity), but
calculated, and therefore only approximate, values for PI GAD were
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similar. The true neuronal GAD activity in Brattleboro PN may be
even lower, as this value was approaching the sensitivity of the
assay, and the value of non-neuronal GAD activity. These results
therefore suggest that the depletion of GAD activity is
predominantly localised to PN, and that the depletion is not merely
a consequence of the tissue hypertrophy with 'dilution' of GABAergic
terminals. GAD activity in PI may be normal in Brattleboro rats,
but this remains to be determined directly.
GAD has been suggested to be the limiting factor in GABA
synthesis (Tappaz et al, 1977), and therefore GABAergic transmission
might be functionally reduced in Brattleboro PN. GABA binding sites
have been reported to show denervation supersensitivity:
high-affinity [ H]GABA binding was increased by 81% (Bmax value)
in substantia nigra following kainic acid lesioning of striatum
(Waddington and Cross, 1978). In those experiments, nigral GABA
concentration was reduced by less than 50%. In contrast, Hamberger
et al (1979) found that GABA concentration in the posterior
pituitary of Brattleboro rats was 30% of controls, but the results
presented here show that there was no change in [ H]muscimol
binding. Taken together, these results suggest reduced GABAergic
activity in Brattleboro PN, rather than depletion of GABA through
increased activity (in which case GAD activity would be expected to
be elevated, not reduced), although partial degeneration of
GABAergic neurones is an alternative possibility, as GABA
concentration and GAD are presynaptic markers. Postsynaptic
supersensitivity (i.e. increased [ H]muscimol binding), might be
masked if the elements on which the binding sites occur have partly
degenerated. Alternatively, if the [ H]muscimol binding sites are
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predominantly localised in PI rather than PN, where there appears
to be no change in GAD activity, this would prevent observation of
any change in PN.
There is a brief report that high concentrations of GABA
inhibited oxytocin release in vitro (Dyball and Shaw, 1978) but this
has not been confirmed. Oxytocin turnover in Brattleboro rats
appears to be elevated (Valtin et al, 1965; Dogterom et al, 1977),
and the low GAD activity observed here may reflect reduced GABAergic
activity of oxytocin-associated GABAergic terminals. This
interpretation could be investigated by measuring GAD activity under
other conditions in which oxytocin secretion is altered and must
remain hypothetical at present.
An association of GABA with vasopressin release has been more
widely investigated, and recently GABA and other GABA^ agonists
have been reported to potentiate stimulus-induced vasopressin
release in vitro (Knepel et al, 1984). Cells of the supraoptic
nucleus of the Brattleboro rat are hypertrophied and show slightly
greater spontaneous activity than those in normal rats (Dyball,
1974), but respond normally to osmotic stimulation (Dyball and Leng,
1985) despite an altered noradrenergic innervation (Schloer and
Sladek, 1981). Dynorphin coexists with vasopressin in normal rats,
and is present in vasopressin-deficient neurones in Brattleboro rats
(Watson et al, 1982) although it may be in reduced concentration
(Martin and Voigt, 1981). The GABAergic deficit demonstrated here
may therefore be associated in some way with either the deficit of
vasopressin, or the increased electrical activity of the still
dynorphin-containing neurones. The experiments described in Chapter
10 demonstrated an inhibitory influence of dynorphin on GABA release
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from NI. Increased release of dynorphin may therefore reduce
GABAergic activity.
GAD activity in PI and ME appeared to be unaltered in
Brattleboro rats, demonstrating a tissue-specific alteration in
GABAergic activity. ME also receives a vasopressin innervation
(Zimmerman et al, 1978), but there is no evidence to support an
association with the GABAergic innervation of ME. The secretion of
many PD hormones is altered in Brattleboro rats (Sokol and
Zimmerman, 1982) and secretion of ACTH from NI in vitro is doubled
(Baertschi and Beny, 1982). The absence of changes in GAD activity
in either area suggests that GABA mechanisms are not of major
importance in these hormonal alterations.
In conclusion, these results demonstrate a marked depletion of
GAD activity in PN of Brattleboro rats, without concomitant
alteration of GAD activity in PI or ME, or GABA^ binding in NI.
The relationship between this deficit, which may reflect reduced
GABAergic transmission, and the neurohypophysial hormones (and
opioids) is at present purely speculative, but provides
circumstantial evidence for a physiological role in the regulation
of the neurohypophysis.
FIGURE 13.1
Linearity of [^^C]C02-evolution with time.
ME tissue (10ul of a lOOpl homogenate of two ME) was incubated for
the times indicated and the radioactivity evolved determined.
Values are means of duplicate determinations (which differed by
















The control of hormone secretion from PD is predominantly under
peptidergic control. The neurohormones GHRH, LHRH, CRH and TRH are
well-established stimulators of GH, LH, ACTH and TSH respectively,
and GH is also under the inhibitory control of somatostatin. The
control of prolactin secretion may be slightly different (see
Chapter 1): OA has long been recognised to be of considerable
inhibitory importance but more recently strong evidence has been
provided for the presence and importance of control by peptidergic
PRFs (e.g. VIP) and PIFs. The importance of these substances is no
longer in question, but their involvement in particular
physiological states, and interaction with other substances in the
control of PD hormone secretion, is largely unknown. It is in this
context that the experiments described in this Thesis were carried
out to examine whether the hypothesis of a role for GABA either as a
neurohormone or as a neuromodulator in neuroendocrine control could
be supported.
The evidence in the literature that GABA may be of importance
in the control of PD function can be summarised as follows:
I)There is a dense GABAergic innervation of the external layer of
ME, the site of secretion into hypophysial portal blood and
final control thereof.
II) GABA, derived from the CNS, is found in PD.
Ill) GABA is found in hypophysial portal blood, and the
concentration can be considerably elevated by stimulation of ME
or i.c.v. injection of prolactin.
Most of the experiments in the literature have provided in vivo
evidence suggesting that GABAergic systems may be of importance in
the control of all the pituitary hormones and these experiments were
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designed to investigate the mechanisms of such controls in a more
detailed, localised way, using in vitro methodologies.
Radioligand binding studies were carried out to examine GABA
3
binding sites in the pituitary (Chapter 3). [ H]GABA was used to
label GABAft and GABAg sites, and [^H]muscimol to label GABA^
sites. GABA^ sites were found in both PD and NI, predominantly in
the former. GABAg sites were found in PD, but were not detectable
in NI. Scatchard analysis of saturation data suggested the presence
of both high- and low-affinity GABA^ sites, with low-affinity
sites predominating, as found in the frontal cortex but not the
cerebellum.
Central-type benzodiazepine binding sites (Chapter 4) were
detectable in both PD and NI, but the distribution did not parallel
CSecC7«vv I).
that of GABA^ sites, being found predominantly in N^ A much
larger population of peripheral-type benzodiazepine binding sites
was also described, but, unlike the central-type sites, these were
not linked to GABA receptors. Further studies using a e-carboline
demonstrated that the pituitary central-type benzodiazepine sites
were apparently predominantly of the BZ^ sub-type, and showed
properties similar to those in cerebellum but distinct from the
mixed BZ-^/BZg population in hippocampus.
These two sets of experiments have demonstrated that the
pituitary contains binding sites of the GABA/benzodiazepine complex
which are indistinguishable from those in the CNS, but the inverse
distribution between PD and NI clearly shows that the two types of
site are not ubiquitously linked in a constant ratio. It appears
that PD contains a considerable population of
benzodiazepine-independent GABA sites.
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Preliminary experiments to investigate the interaction of
benzodiazepines with GABA-mediated inhibition of prolactin secretion
in vitro revealed a novel GABA^ receptor-mediated effect:
prolactin secretion was transiently stimulated, with subsequent
sustained inhibition (Chapter 5). Both effects were produced by a
number of GABA^ agonists in a concentration-dependent manner with
the exception of homocarnosine which at concentrations up to 2mM
caused no stimulation of secretion. The rigid GABA analogues P4S,
/
THIP, isoguavacine and APS were found to cause less stimulation than
that caused by GABA, but very similar inhibition. These experiments
provided evidence that the biphasic effect of GABA^ receptor
activation was more complex than originally thought, and that the
two components might be independent. The model proposed by
Taraskevich and Douglas (1982) was clearly not appropriate to a
selective agonist such as homocarnosine, but extrapolation from
melanotrophes to lactotrophes may be misleading and quite distinct
GABA-evoked events may occur in this cell type. Experiments with
antagonists provided further evidence that the two components of the
biphasic response to muscimol were mediated by separate populations
of GABA^ receptors: BMI was found to antagonise both effects
approximately equally, but PTX and strychnine selectively
antagonised the stimulatory effect, only antagonising the inhibitory
effect at very high concentrations. Conversely, glycine was found
to selectively potentiate the stimulatory effect of muscimol. It
therefore appears that homocarnosine and strychnine are selective
drugs for the inhibitory and stimulatory effects respectively. With
respect to the GABA^ site mediating stimulation of prolactin
secretion, the potency of strychnine as an antagonist and the
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ability of glycine to potentiate the effect of muscimol in the
absence of any direct effect, suggest that there may be a glycine
receptor interacting in a modulatory fashion in some molecular
complex with this GABA receptor and a chloride ion channel.
Analogies may be drawn with the way in which benzodiazepines and
barbiturates modulate GABA receptor function, though it is clear in
this case, that the modulator acts with considerable basal tone.
GABA and glycine receptors are generally independently linked to
chloride channels (Hamill, Bormann and Sakmann, 1983) and similar
modulatory effects have not been previously reported. The molecular
nature of these interacting GABA and glycine recognition sites here
is not apparent but is clearly of interest. If the two GABA^
responses described here are indeed independent, then they may have
separate physiological function. GABA, being active at both sties,
will cause both effects, but this may be modulated by homocarnosine
under certain conditions. If GABA was released into hypophysial
portal blood in short bursts of high concentration, then the effect
would be to stimulate prolactin secretion. More prolonged release
would tend to inhibit secretion, and the continued presence of GABA
(with consequent effects on membrane resistance) might also affect
lactotrophe responsiveness. Responses to GABA are often limited by
desensitisation, but the inhibitory effect measured here showed no
tendency to decline over the time-course examined.
Baclofen had no effect on basal secretion of prolactin, or on
+ 2
K or Ba -stimulated secretion. It did, however, inhibit
VIP-stimulated secretion in a stereospecific manner. Experiments to
investigate whether this was a result of inhibition of adenylate
cyclase proved inconclusive, as no effect of baclofen could be
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demonstrated on tissue treated with drugs which affect cAMP
concentrations. An interaction with K+ channels, as demonstrasted
in the hippocampus, was also investigated using 4AP and TEA. Both
these drugs caused a stimulation of prolactin secretion, and the
stimulation evoked by 4AP but not TEA was reduced by baclofen
(stereospecifically). Based on the selective properties of 4AP and
TEA, an interaction between GABAg receptors and transient K+
channels, with properties possibly similar to 1^ was proposed.
The considerable importance of 1^ in regulating membrane
excitability suggests that these GABAg receptors may be of
importance in the control of prolactin secretion particularly by
affecting responsiveness to other PIFs and PRFs. It was tentatively
suggested that this may be part of the mechanism of the interaction
observed between VIP and baclofen. Substance P has PRF activity and
affects K+ currents, as does TRH. It is therefore possible that
GABAg receptor effects on K currents may be an important
A I
postsynaptic mechapsjim of regulation of peptide responses and indeed
may not be necessarily confined to the pituitary.
The effects and mechanism of GABA-1inked benzodiazepine
receptors demonstrated in PD by radioligand binding studies were
investigated using prolactin secretion as a model in Chapter 6.
Clonazepam and Roll-6896, but not Ro5-4864, potentiated the
stimulatory effect of muscimol on prolactin secretion. No effect on
the inhibitory part of the response was observed, and the effect of
clonazepam was antagonised by Rol5-1788. Secobarbital also
selectively potentiated the stimulatory response. These results
demonstrate the presence of GABAft receptors linked to central-type
benzodiazepine- and barbiturate-recognising components at a
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non-synaptic location, not confined to the CNS. These results are
of interest with relation to the binding studies carried out in
Chapters 3 and 4, in which the existence of benzodiazepine-1inked
and -independent GABA receptors was suggested on the basis of their
differential distribution. The results on prolactin secretion
suggest that both types are present on 1actotrophes, but have
different effects, and provides further pharmacological
characteristics of the two sites/effects. A peptide termed
'diazepam-binding inhibitor' (DBI) has been isolated from rat brain
and characterised as having proconflict action, and
DBI-immunoreactivity was found to be especially dense in MBH (Costa,
Ferrero, Alko and Guidotti, 1985). If DBI, or a fragment, is an
endogenous ligand for benzodiazepine receptors, then this system may
be of particular value in the investigation of endogenous modulation
of GABAergic transmission as it is easily accessible in vivo and
in vivo, as well as being of physiological importance. Experiments
addressing the molecular mechanism of benzodiazepine modulation of
GABA^ receptors were also carried out using this model.
Clonazepam was found to reduce the potency of BMI as an antagonist
of the effect of muscimol on prolactin secretion, but had no effect
on the potency of PTX. This was interpreted as indicating an effect
of clonazepam on the GABA^ receptor itself, enhancing its affinity
or the number of available receptors but not affecting the molecular
linkage between receptor and ion channel.
GABAergic agonists were also found to effect the secretion of
GH, LH and ACTH but not TSH in vitro (Chapter 7). Muscimol
stimulated the secretion of GH, LH and ACTH: this effect was
transient in each case, and its magnitude varied greatly between the
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different hormones, being greatest for GH but only slight for LH.
The possibility exists that the slight effect on LH secretion was
indirect, perhaps mediated by elevated extracellular K+. This
would require cell purification for testing, and was not attempted.
If the effect was indirect, this would not obviate any physiological
importance but might reflect aspects of the organisation of PD i.e.
relative distribution of the cell types within the gland, and
electrical coupling between them. In no case was the secretion of
the hormones inhibited by muscimol, secretion rates rapidly returned
to pre-drug in the continued presence of muscimol, and the responses
therefore differed from the biphasic prolactin response. GABA may
contribute to the pulsatile nature of GH secretion, and the
existence of GH-releasing factors other than GHRH has been recently
proposed (Thomas, Groot and Arimura, 1985). In that study a
transient increase in GH secretion in response to antisomatostatin
antiserum was observed even after previous injection of antiGHRH
antiserum. Part of this may be caused by GABA. In the continued
presence of GABA, the responsiveness of the various cell types to
other releasing/inhibitory factors might be altered despite
secretion having returned to basal, but this was not investigated
although it may be of considerable physiological importance. The
effect of muscimol on GH secretion was demonstrated to be
concentration-dependent, and antagonised by BMI but not by
strychnine. GABA mimicked the effect of muscimol, but homocarnosine
had no effect alone and did not affect the response to GABA. The
effect of muscimol was potentiated by both Roll-6896 and
secobarbital.
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The stimulatory GABA^ receptor effects on prolactin and GH
therefore show both similarities and differences in their
pharmacology: both are linked to benzodiazepine/barbiturate sites,
and both are unaffected by homocarnosine (although experiments
described in Chapter 5 suggested some antagonistic action of
homocarnosine on the stimulation of prolactin secretion). The major
difference is that the prolactin response is antagonised by
strychnine (and potentiated by glycine) whilst the GH response is
not. The basic properties of the GABA^ receptors on the two cell
types are unlikely to be different, despite this, although the
various agonists investigated on prolactin secretion would need to
be tested on GH secretion for confirmation. The presence of
different modulatory components may conformationally modify them in
such a way as to alter the affinity for some agonists. If the
interpretation of the glycine/strychnine effects on prolactin
secretion discussed above is correct, then such modulatory sites
would appear to be absent from somatotrophes. The effect of glycine
on GH secretion was not investigated. Considerable numbers of PD
cells appear to secrete both prolactin and GH (Frawley et al, 1985)
and the selective inhibitory effect on prolactin secretion may
therefore involve a separate (non GH-secreting) cell type or
otherwise differential intracellular controls could operate.
Baclofen had no effect on basal secretion of any hormone, and
2+
did not affect Ba -stimulated secretion of GH or TSH. It did,
4* 9
however, reduce K and Ba -induced secretion of ACTH and both
GABA^ and GABAg effects could be demonstrated on LHRH-stimulated
LH secretion: GABA^ receptor activation enhanced secretion, and
GABAg receptor activation reduced secretion. GABA itself appeared
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to act on both types of receptor: the GABAg effect predominated at
higher LHRH concentrations, but at lower LHRH concentrations a
GABA^ response was observed, and these results suggest that GABA
may regulate gonadotrophe sensitivity in vivo. As discussed above,
the GABA^ effect may be indirect, or may be the result of a
paracrine interaction. Dynorphin appears to coexist in
gonadotrophes (Knepel and Schwaniger, 1985) but no effects in PD
have been described. Other, undiscovered, peptides may also exist
in PD cells, which may regulate the effects of the large number of
substances reported to affect PD hormone secretion. It therefore
appears that lactotrophes, gonadotrophes and corticotrophes have
both GABA^ and GABAg receptors, somatotrophes have only GABA^
receptors and thyrotrophes are devoid of GABA receptors.
The properties of GABA-releasing neurone terminals in ME and NI
were studied using a crude synaptosomal preparation (Chapter 8).
O
[ H]GABA was rapidly accumulated by tissue in a time-,
temperature- and Na+-dependent manner. In both areas, the uptake
carrier showed predominantly neuronal (rather than glial)
specificity. Kinetic analysis demonstrated that the carrier in both
areas had a value of =5pM, but the Vmax value in ME was 20x
greater than that in NI. Experiments in which muscimol reduced the
effect of 15mM K+, in a BMI-sensitive manner, suggested the
existence of GABA^ autoreceptors in both areas. A variety of
neurotransmitters and hormones (DA, 5HT, aMSH, prolactin,
vasopressin) had no effect on basal or stimulated release suggesting
a lack of direct feedback control. These terminals in ME and NI
therefore appear to have kinetic and autoregulatory characteristics
identical to those of other GABAergic terminals, despite their
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relatively specialised roles, in contrast to dopaminergic terminals
in ME which have a lower-affinity uptake system than dopaminergic
systems elsewhere and may not be subject to autoregulation. This
may suggest that perhaps the majority of the GABAergic terminals in
ME investigated here are involved in local, synaptically-mediated
control rather than secretion into hypophysial portal blood, but
this is not supported by the morphological evidence (Tappaz et al,
1983) It therefore appears that even neurosecretory GABAergic
terminals do not have specialised properties.
Stimulated release of [^H]GABA from ME but not NI was
inhibited by baclofen, in a concentration-dependent and
7o
sterospecific manner (Chapter 9). Release was reduced to =653 of
K
control by lOOuM (±) or (-) baclofen, and lOOuM ( + ) baclofen had no
effect. Attempts to use sAVA as a GABAg antagonist were equivocal
as this drug caused some heteroexchange, but it appeared to
antagonise the effect of baclofen. These results suggest that
GABAergic terminals in ME have inhibitory GABAg autoreceptors in
addition to GABAft autoreceptors. This is the first demonstration
of a GABAg autoreceptor, although presynaptic GABAg receptors
have been demonstrated on the terminals of a variety of other
neurotransmitters. The precise location and function of these
receptors is unknown. Their distribution within ME could be
determined by autoradiographic binding studies, perhaps in
conjuction with lesions of the acuate nucleus (the proposed origin
of the GABAergic innervation of ME) in an attempt to discriminate
presynaptic from postsynaptic locations. A comparison with the
distribution of GABA^ receptors (both autoreceptors and on
terminals releasing other transmitters) would also be of
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considerable interest, but it might be difficult to get unequivocal
data from such studies. One fundamental question is whether GABA^
and GABAg autoreceptors coexist on one terminal. GABA^
autoreceptors are likely to be of greater importance (as deduced
from the magnitude of inhibition caused by various agonists), but
this may merely reflect amore widespread distribution. The two
types of autoreceptors may be associated with different population
of GABAergic neurone, for example one type being associated with
GABAergic control of some transmitters/neurohormones and the other
with control of neurohaemal secretory GABAergic terminals. The
presence of GABAg autoreceptors may reflect specialisation of a
population of neurones, but their function is likely to remain
elusive without the discovery of a potent and specific antagonist.
3
The effect of opioids on release of [ H]GABA from NI was
investigated in Chapter 10, to examine the possible function of
dynorphins in that region. Dynorphin^g caused a marked
inhibition of stimulated release, an affect which was concentration-
dependent and antagonised by naloxone. This effect was mimicked by
the K-selective agonist U50488H, but 5- and y-selective peptides had
no effect: GABAergic terminals in NI therefore appear to have onlyTC
receptors, unlike dopaminergic and peptidergic terminals which have
been reported to be influenced by s/y opioids. The effect of
dynorphin^g was prevented by superfusion with low-chloride
medium, or medium containing OIDS but was unaffected by the K+
channel blockers 4AP, TEA and quinine. Dynorphin^g had no
2+
effect on Ba -induced release, but potentiated the secretagogue
effect of low-chloride medium. These results suggest that TC opioid
receptors act by opening anion channels, unlike 6 and y receptors
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which open K+ channels and provides a function for the very high
concentrations of dynorphin peptides in PN. The coexistence of
dynorphin with vasopressin in PN suggests that this effect may be of
importance in regulating the interaction between GABA and
vasopressin, as a local feedback control. There are two conclusions
suggested by the ionic dependence of the effect of dynorphin:K
receptors may be ubiquitously linked to chloride channels, but this
2+
seems unlikely as there is evidence for an interaction with Ca
channels (Werz and Macdonald, 1984), or alternatively this may be a
tissue-specific or sub-type-specific property. If this is the case,
it might be related to the fact that the location is GABAergic
terminals, and the increase in intracellular chloride concentration
might inhibit GAD activity as well as GABA release thus increasing
the effectiveness and duration of inhibition in vivo.
The interaction between GABAergic and dopaminergic
tuberoinfundibular and tuberohypophysiaI systems was further
3
investigated in experiments on the effects of GABA agonists [ H]DA
release from ME and NI (Chapter 11). Muscimol inhibited stimulated
release from ME but not NI, and this was antagonised by BMI but not
strychnine. Homocarnosine also inhibited release from ME, again in
a BMI-sensitive manner, but baclofen had no effect in either area.
The GABA receptor involved therefore appears to show similar
pharmacological characteristics to the receptor associated with
inhibition, but not stimulation, of prolactin secretion. Strychnine
and homocarnosine therefore appear to be of use in investigating
GABA^ receptor pharmacology and may provide the basis for a
putative subclassification of GABA^ receptors. As DA in ME is
involved in the control of the release of releasing factors into
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hypophysial portal blood, in addition to its own release into portal
blood, this may be the mechanism of action of some of the effects of
GABA on hormone secretion observed in vivo, particularly the
frequently reported stimulation of prolactin secretion following
i.c.v. injection of GABA.
In several Chapters in this Thesis, the pharmacological
properties of homocarnosine with respect to GABA receptor mediated
effects have been demonstrated. In addition to being a direct,
though weak GABA^ agonist, homocarnosine may also be a source of
GABA, if PD contains considerable amounts of the enzyme
homocarnosinase. Experiments were carried out to investigate the
presence of this enzyme in PD (Chapter 12), although previous
reports had been unable to detect any activity in rat brain. No
homocarnosinase was detectable, suggesting that any endocrine
function of this substance at the PD is directly attributable to it
and not to its conversion to GABA. The origin and fate of the high
concentration of homocarnosine reported in hypophysial portal blood
remain unknown, but the demonstration of GAD-IR and histidine-
decarboxylase-IR in magnocellular neurones in the hypothalamus
provides an intriguing possibility that these may be a major source
of the molecule.
There is evidence that GABA is involved in the control of
vasopressin secretion, and that Brattleboro rats, which are
genetically unable to synthesise vasopressin, have some deficit of
the GABAergic innervation of NI. This was investigated by measuring
GABA^ binding sites and GAD activity in NI (Chapter 13). No
change in GABA^ binding sites in Brattleboro rats compared to
Long-Evans controls was detectable, but GAD activity was
«
-198-
substantially reduced. This deficit appeared to be confined to PN,
with PI having normal GAD activity. GAD activity in ME was
unaltered from controls. As GAD is the rate limiting enzyme in the
synthesis of GABA, these results suggest that GABAergic transmission
in PN is compromised. The relationship between this deficit and the
absence of vasopressin in these animals is unknown but an
association between the two is possible. The GAD deficit may be a
consequence of atrophy through inactivity, excessive and prolonged
inhibition by dynorphin, and/or changes in the water balance and
hormonal alterations in the Brattleboro rats. These results also
suggest that the Brattleboro rat is not merely an animal model of
vasopressin deficiency but represents a more complex alteration of
PN function.
14.2 Conclusion
The present results provide further evidence that GABA may be a
neuroendocrine transmitter or neurohormone, acting directly on
pituitary cells, particularly in PD. The importance of GABA in the
CNS as the major inhibitory neurotransmitter may be reflected in the
pituitary but our knowledge is at present insufficient to identify
the precise nature of any tonic or phasic physiological roles. The
absence of detailed knowledge about the functional organisation of
PD is perhaps one of the more obvious stumbling blocks, as well as
the difficulty of investigation of the function of ME without resort
to traumatic manipulations of the physiological state of the
animal. The present experiments have also demonstrated the
widespread occurrence of the GABA/benzodiazepine/barbiturate
'receptor' association, here at non-synaptic sites, and provide
convenient in vitro models for the detailed study of their
interaction.
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The importance of GABA in neuroendocrine control is suggested
by the dense innervation of ME and NI, and the effect of GABA on the
secretion of virtually every pituitary hormone. These effects
should be seen in the context of peptidergic and aminergic control,
but on the basis of experiments carried out in this Thesis and by
other groups it is now clear that neuroendocrine control by GABA
itself can indeed be complex with not only multiple sites of action
but also multiple receptor types being involved. Thus for example
GABA may act both on dopaminergic terminals in ME and on
1actotrophes, both sites contributing to the control of prolactin
secretion. The widespread effects on PD hormone secretion imply
that GABA does not have just a specific function in controlling the
secretion of one hormone, but may be of broader importance in
regulating the sensitivity of PD as a whole to other releasing
factors. If this was the case, then elucidation of the role played
physiologically by such an action would be rather difficult,
requiring intervention with several transmitter/hormone systems at
once to establish their functional interaction.
Nevertheless, the following comments can be made:
i)The hypothalamo-hypophysial system may therefore be, at least in
PD, an example of GABAergic transmission that does not involve
point-to-point regulation in well-defined anatomical circuits but a
more generalised influence. The same does not necessarily apply to
NI (or indeed to effects within ME) where a 'classical' function
seems more 1ikely.
ii) GABA prevented the generation of action potentials in
melanotrophes for as long as exposure was maintained (Taraskevich
and Douglas, 1982). The same may well be true for somatotrophes and
-200-
corticotrophes, in which case the transient effect on secretion may
be of little physiological importance, but an ensuing low membrane
resistance would limit the secretagogue effects of substances which
acted by alterations of cellular electrical activity. This effect
of GABA on the electrical properties of the cell may be independent
of the actions of other substances that act by way of chemical
second messengers such as cyclic AMP, Ca2+ or inositol phosphates.
iii) The inhibitory effect of GABA on prolactin secretion suggests a
different physiological function to its effects on the electrical
properties of other cell types, although the same comments may apply
to the stimulatory effect. This inhibitory effect may itself be of
direct physiological importance, as an adjunct to dopaminergic
inhibition.
iv) The interaction of GABA with the response to LHRH demonstrates a
possible physiological role of GABA, having both stimulatory and
inhibitory effects, at different concentrations. The responsiveness
of the anterior pituitary gland to LHRH varies considerably (as much
as 150 fold) in different physiological states, and conceivably
these differences can be brough about, at least in part, by the
modulatory action of GABA. Indeed, steroid treatment has been
demonstrated to alter GABA binding sites in PD. GABA might
therefore contribute to the initiation yet limit the magnitude of
the prooestrous LH surge.
In conclusion, these results provide a systematic neurochemical
basis for hypotheses on the control or modulation of pituitary
function by GABA and establish how broad ranging and multifacetted
this action is. The new evidence provided should permit the design
of further experiments to establish under which conditions GABA is
of physiological importance in the control of the pituitary, and
what its precise functions are in those circumstances.
BIBLIOGRAPHY
MF, H.,NENGLER, D., MOLITCH, M.E., BOLLINGER-GRUBER, J. and
REICHLIN, S. (1985) Vasoactive intestinal peptide is a
physiological mediator of prolactin release in the rat.
Endocrinology 116, 1383-1390.
ABRAHAM, 0., PISANO, J.J. and UDENFRIEND, S. (1962) The
distribution of homocarnosine in mammals. Arch. Biochem.
Biophys. j)9, 210-213.
ACS, Z., MAKARA, G.B. and STARK, E. (1984) Growth hormone secretion
of the neonatal rat pituitaries is stimulated by gamma-
aminobutyric acid in vitro. Life Sci. _34, 1505-1511.
ACS, Z., PALKOVITS, M. and STARK, E. (1980) Changes in glutamic
acid decarboxylase activity after dexamethasone in selected areas
of the rat brain. Neurosci. Lett. 1_9, 97-101.
ACS, Z. and STARK, E. (1978) Possible role of gamma-aminobutyric
acid synthesis in the mechanism of dexamethasone feedback
action. J.Endocrinol. 77^, 137-141.
ADAMS, D.J., SMITH, S.J. and THOMPSON, S.H. (1980) Ionic currents
in molluscan soma. Ann. Rev. Neurosci. 3, 141-167.
ADAMS, P.R., BROWN, D.A. and CONSTANTI, A. (1982a) Pharmacological
inhibition of the M-current. J. Physiol. 332, 223-262.
ADAMS, P.R., CONSTANTI, A., BROWN, D.A. and CLARK, R.B. (1982b)
Intracellular Ca2+ activates a fast voltage-sensitive K+
current in vertebrate sympathetic neurones. Nature 296, 746-749.
AGNATI, L.F., FUXE, K., HOKFELT, T., GOLDSTEIN, M. and JEFFCOATE,
S.L. (1977) A method to measure the distribution pattern of
specific nerve terminals in sampled region. Studies on tyrosine
hydroxylase, LHRH, TRH and GIH immuno-f1uorescence. J.
Histochem. Cytochem. 25^, 1222-1236.
AJIKA, K. (1979) Simultaneous localization of LHRH and
catecholamines in rat hypothalamus. J. Anat. 128, 331-347.
AJIKA, K. and HOKFELT, T. (1973) Ultrastructural identification of
catecholamine neurones in the hypothalamus periventricular-
arcuate nucleus-median eminence complex with special reference to
quantitative aspects. Brain Res. 57_, 97-117.
ALDE, S. and CELIS, M.E. (1980) Influence of a-melanotropin on LH
release in the rat. Neuroendocrinology 3^, 116-120.
ALGER, B.E. and NICOLL, R.A. (1979) GABA-mediated biphasic
inhibitory responses in hippocampus. Nature 281, 315-317.
ALGER, B.E. and NICOLL, R.A. (1982) Pharmacological evidence for
two kinds of GABA receptor on rat hippocampal pyramidal cells
studied in vitro. J. Physiol. 328, 125-141.
ALPER, R.H. and MOORE, K.E. (1982) Injection of hypertonic saline
or mannitol accelerates the dehydration-induced activation of
dopamine synthesis in the neurointermediate lobe of the rat
neurohypophysis. Neuroendocrinology 3_5, 469-474.
ALZEIN, M., LUTZ-BUCHER, B. and KOCH, B. (1984) Modulation by
Leu-Enkephalin of peptide release from perifused
neurointermedi ate pituitary. Neuroendocrinology 39, 392-396.
ANNUNZIATO, L., CERRITO, F. and RAITERI, M. (1981) Characteristics
of dopamine release from isolated nerve endings of the
tuberoinfundibular neurones. Neuropharmacology, _20, 727-731.
ANNUNZIATO, L. and MOORE, K.E. (1978) Prolactin in CSF selectively
increases dopamine turnover in the median eminence. Life Sci.
22, 2037-2042.
ANNUNZIATO, L. and WEINER, R.I. (1980) Characteristics of dopamine
uptake and 3,4-dihydroxyphenylacetic acid (DOPAC) formation in
the dopaminergic terminals of the neurointermediate lobe of the
pituitary gland. Neuroendocrinology 3U 8-12.
ANWAR, N. and MASON, D.F.J. (1982) Two actions of y-aminobutyric
acid on the responses of the isolated basilar artery of the
rabbit. Brit. J. Pharmacol. _75, 177-181.
APUD, J.A., GUDELSKY, G., MASOTTO, C., LOCATELLI, V., COCCHI, D.,
RACAGNI, G. and MULLER, E.E. (1984a) Prolactin administration
enhances the synthesis and release of hypothalamic GABA.
Proceedings of Endocrine Society, Quebec, Abstract 119.
APUD, J.A., MASOTTO, C., COCCHI, D., LOCATELLI, V., MULLER, E.E. and
RACAGNI, G. (1984b) Prolactin control by the tubero¬
infundibular GABAergic system: role of anterior pituitary GABA
receptors. Psychoneuroendocrinology _9, 125-133.
APUD, J.A., RACAGNI, G., IULIANO, E., COCCHI, D., CASANUEVA, F. and
MULLER, E.E. (1981) Role of central nervous system-derived or
circulating y-aminobutyric acid on prolactin secretion in the
rat. Endocrinology 108, 1505-1510.
ARBILLA, S., KAMAL, L., LANGER, S.Z. (1979) Presynaptic GABA
autoreceptors on GABAergic nerve endings of the rat substantia
nigra. Europ. J. Pharmacol. 57_, 211-217.
ARNAULD, E., CIRINO, M., LAYTON, B.S. and RENAUD, L.P. (1983)
Contrasting actions of amino acids, acetylcholine, noradrenaline
and leucine enkephalin on the excitability of supraoptic
vasopressin-secreting neurons. Neuroendocrinology 3j>, 187-196.
ASANO, T., YAMADA, Y. and OGASAWARA, N. (1983) Characterisation of
the solubilised GABA and benzodiazepine receptors from various
regions of rat brain. J. Neurochem. 40, 209-214.
ASAWAROENGCHAI, H., RUSSELL, S.M. and NICOLL, C.S. (1978)
Electrophoretically separable forms of rat prolactin with
different bioassay and radioimmunoassay activities.
Endocrinology 102, 407-414.
AWAPARA, J., LANDAU, A.J., FUERST, R. and SEALE, B. (1950) Free
Y-aminobutyric acid in brain. J. Biol. Chem. 187, 35—39.
BAERTSCHI, A.J. and BENY, J.L. (1982) Central control of ACTH
secretion in diabetes insipidus Brattleboro rats. Ann. N.Y.
Acad. Sci. 394,. 591-602.
BALCAR, V.J. and JOHNSTON, G.A.R. (1975) High affinity uptake of
L-glutamine in rat brain slices. J. Neurochem. 24, 875-879.
BALDESSARINI, R.J. and VOGT, M. (1971) Uptake and release of
norepinephrine by rat brain tissue fractions prepared by
ultrafiltration. J. Neurochem. J3, 951-962.
BALDESSARINI, R.J. and YORKE, C. (1974) Uptake and release of
possible false transmitter amino acids by rat brain tissue. J.
Neurochem. Z3_, 839-848.
BARKER, J.L., DUFY, B., OWEN, D. and SEGAL, M. (1983) Excitable
membrane properties of cultural CNS neurons and clonal pituitary
cells. Cold Spring Harbor Symp. Quant. Biol. 43, 259-268.
BARKER, J.L., GRUOL, D.L., HUANG, L.M., MACDONALD, J.F. and SMITH,
T.G. (1980) Peptides: three forms of chemical excitability on
cultured mouse spinal neurones. Neuropeptides I, 63-82.
BARKER, J.L. and MATHERS, D.A. (1981) GABA analogues activate
channels of different duration on cultured mouse spinal neurons.
Science 212, 358-361.
BARKER, J.L. and McBURNEY, R.N. (1979a) GABA and glycine may share
the same conductance channel on cultured mammalian neurones.
Nature 277, 234-236.
BARKER, J.L. and McBURNEY, R.N. (1979b) Phenobarbitone modulation of
postsynaptic GABA receptor function on cultured mammalian
neurons. Proc. R. Soc. Lond. B. 206, 319-327.
BARKER, J.L. and NICOLL, R. (1972) Gamma-aminobutyric acid: role in
primary afferent depolarization. Science 176, 1043-1045.
BARKER, J.L. and RANSOM, B.R. (1978a) Amino acid pharmacology of
mammalian central neurones grown in tissue culture. J. Physiol.
280, 331-354.
BARKER, J.L. and RANSOM, B.R. (1978b) Phenobarbitone pharmacology
of mammalian central neurones grown in tissue culture. J.
Physiol. 280, 355-372.
BARNES, C.D. and MOOLENAR, G.M. (1971) Effects of diazepam and
picrotoxin on the visual system. Neuropharmacology H), 193-201.
BAUMGARTEN, H.G., BJORKLUND, A., HOLSTEIN, A.F. and NOBIN, A. (1972)
Organisation and ultrastructural identification of the
catecholamine nerve terminals in the neural lobe and pars
intermedia of the rat pituitary. Z. Zellforsch. 126, 483-517.
BAGEMORE, A.W., ELLIOT, K.A.C. and FLOREY, E. (1957) Isolation of
Factor 1. J. Neurochem. 1_, 334-339.
BARBER, R. and SAITO, K. (1976) Light microscopic visualization of
GAD and GABA-T in immunocytochemical preparation of rodent CNS.
In: "GABA in nervous system function", pp 113-132. Eds. E.
Roberts, Chase, T.N. and Tower, D.B. Raven Press, New York.
BEART, P.M., KELLY, J.S. and SCHON, F. (1974) y-aminobutyric acid
in the rat peripheral nervous system, pineal and posterior
pituitary. Biochem. Soc. Trans. 2, 266-268.
BEAUMONT, K., CHILTON, W.S., YAMAMURA, H.I. and ENNA, S.J. (1978)
Muscimol binding in rat brain: association with synaptic GABA
receptors. Brain Res. 148, 153-162.
BENAVIDES, J., BURGEVIN, M.C., DOBLE, A., LEFER, G. and UZAN, A.
(1985) A role for peripheral-type benzodiazepine binding sites
in regulating K+-evoked 45Qa2+ uptake in a rat pituitary
cell line. Brit. J. Pharmacol. Proc. Southampton meeting, C.68.
BENAVIDES, J., QUARTERONET, D., IMBAULT, F., MALGOURIS, C., UZAN,
A., RANAULT, C., DUBROEUEQ, M.C., GUEREMY, C. and LE FUR, G.
(1983) Labelling of "periperhal-type" benzodiazepine binding
sites in rat brain using [3h]PK11195, an isoquinoline
carboxamide derivative: kinetic studies and autoradiographic
locatisation. J. Neurochem. 41, 1744-1750.
BENJAMIN, A.M. and QUASTEL, J.H. (1972) Locations of amino acids in
brain slices from the rat. Biochem. J. 128, 631-646.
BEN-JONATHAN, N., OLIVER, C. , WEINER, H.J., MICAL, R.S. and
PORTER, J.C. (1977) Dopamine in hypophysial portal plasma of the
rat during oestrus cycle and throughout pregnancy. Endocrinology
100, 452-458.
BEN-JONATHAN, N. and PETERS, L.L. (1982) Posterior pituitary
lobectomy: differential elevation of plasmia prolactin and
luteinizing hormone in estrous and lactating rats. Endocrinology
110, 1861-1865
BENNET, J.P., LOGAN, W.J., and SNYDER, S.H. (1972) Anino acid
neurotransmitter candidates: sodium dependent high-affinity
uptake by unique synaptosomal fractions. Science 178, 997-999.
BENNETT, G.W., EDWARDSON, J.A., HOLLAND, D., JEFFCOATE, S.L. and
WHITE, N. (1975) Release of immunoreactive luteinising hormone-
releasing hormone and thyrotrophin-releasing hormone from
hypothalamic synaptosomes. Nature 257, 323-325.
BERGLAND, R.M. and PAGE, R.B. (1979) Pituitary-brain vascular
relations: a new paradigm. Science 204, 18-24.
BICKNELL, R.J. and LENG, G. (1982) Endogenous opiates regulate
oxytocin but not vasopressin secretion from the neurohypophysis.
Nature 298, 161-152
BIOULAC, B., GAFFORI, 0., HARRIS, M. and VINCENT, J.D. (1978)
Effects of acetylcholine, sodium glutamate and GABA on the
discharge of supraoptic neurones in the rat. Brain Res. 154,
159-162.
BIRGE, C.A., JACOBS, L.S., HAMMER, C.T. and DAUGHADAY, W.H. (1970)
Catecholamine inhibition of prolactin secretion by isolated rat
adenohypophyses. Endocrinology 86, 120-130.
BJORKLUND, A. (1968) Monoamine-containing fibres in the pituitary
neurointermediate lobe of the pig and rat. Z. Zellforsch 89,
573-589.
BJORKLUND, A., FLACK, B., HROMEK, F., OWMAN, C. and WERT, K.A.
(1970) Identification and terminal distribution of the
tubero-hypophysial monoamine fibre system in the rat by means of
stereotypic and microspectrofluorometric techniques. Brain Res.
17, 1-23.
BLOCK, B., BRAZEAU, P., LING, N., BOHLEN, P., ESCH, F.,
WEHRENBURG, W.B., BENOIT, R., BLOOM, F. and GUILLEMAN, R. (1983)
Immunohistochemical detection of growth hormone-releasing factor
in brain. Nature 301, 607-608.
BLOOM, F., BATTENBERG, E., ROSSIER, J., LING, N., LEPPALUOTO, J.,
VARGO, T.M. and GUILLEMAN, R. (1977) Endorphins are located in
the intermediate and anterior lobes of the pituitary gland, not
in the neurohypophysis. Life Sci. 20, 43-48.
BOAKES, R.J., TURNER, J.D. and VIRMANI, M.A. (1984) Quantitative
studies of transmitter release induced by impermeant anions from
rat brain slices. J. Physiol. 353, 95P.
BOGDANSKI, D.F., BLASZKOWSKI, T.P. and TISSARI, A.H. (1970)
Mechanism of biogenic amine transport and storage - IV.
Relationship between K+ and the Na+ requirement for transport
and storage of 5-hydroxytryptamine and norepinephrine in
synaptosomes. Biochim. Biophys. Acta 211, 521-532.
BOKOCH, G.M., KATADA, T., NORTHRUP, J.K. HEWLETT, E.L. and GILMAN,
A.G. (1983) Identification of the prominent substrate for
ADP-ribosylation by islet activating protein. J. Biol. Chem.
258, 2072-2075.
BOND, P.A. (1973) The uptake of y-[3H] aminobutyric acid by
slices from various regions of rat brain and the effect of
lithium. J. Neurochem. 20, 511-517.
BORMANN, H.B., PENNEY, D.P., CASE, K.R. and AVERILL, K. (1980)
Diazepam receptor: specific nuclear binding of [3H]
flunitrazepam. Proc. Natl. Acad. Sci. USA 77_, 1195-1198.
BORMANN, J. and SAKMANN, B. (1984) Properties of inhibitory
chloride channels and the action of diazepam. Proceedings of
IUPHAR Meeting, London. S13-4.
BOULLIN, D.J. (1967) The action of extracellular cations on the
release of the sympathetic transmitter from peripheral nerves.
J. Physiol. 189, 85-99.
BOWER, A., HADLEY, M.E. and HRUBY, V.J. (1974) Biogenic amines and
control of melanophore stimulating hormone release. Science 184,
70-72.
BOWERY, N.G. and BROWN, D.A. (1972) y-Aminobutyric acid uptake by
sympathetic ganglia. Nature New Biol. 238, 89-91.
BOWERY, N.G., DOBLE, A., HILL, D.R., HENDERSON, A.L., SHAW, J.S.,
TURNBULL, M.J. and WARRINGTON, R. (1981)
Bicuculline-insensitive GABA receptors on peripheral autonomic
nerve terminals. Europ. J. Pharmacol. 7_1, 53- 70.
BOWERY, N.G. and DRAY, A. (1976) Barbiturate reversal of amino
acid antagonism produced by convulsant agents. Nature 264,
276-278.
BOWERY, N.G., HILL, D.R. and HUDSON, A.L. (1983) Characteristics
of GABAg receptor binding sites on rat whole brain synaptic
membranes. Brit. J. Pharmacol. _78, 191-206.
BOWERY, N.G, HILL, D.R. and HUDSON, A.L. (1985) [3H](-)baclofen:
an improved ligand for GABAg sites. Neuropharmacology 24,
207-210.
BOWERY, N.G., HILL, D.R., HUDSON, A.L., DOBLE, A., MIDDLEMISS, D.N.,
SHAW, J. and TURNBULL, M. (1980) (-) Baclofen decreases
neurotransmitter release in the mammalian CNS by an action at a
novel GABA receptor. Nature 283, 92-94.
BOWERY, N.G. and HUDSON, A.L. (1979) GABA reduces the evoked
release of 3H-noradrenaline from sympathetic nerve terminals.
Brit. J. Pharmacol. 66, 108P.
BOWERY, N.G., JONES, G.R. and NEAL, M.J. (1976) Selective
inhibition of neuronal GABA uptake by cis-1, 3-aminocyclohexane
carboxylic acid. Nature 264, 281-284.
BRAESTRUP, C., ALBRECHTSEN, R. and SQUIRES, R.F. (1977) High
densities of benzodiazepine receptors in human cortical areas.
Nature 269, 702-704
BRAESTRUP, C. and NILSEN, M. (1980) Strychnine as a potent
inhibitor of the brain GABA/benzodiazepine receptor complex.
Brain Res. Bull. 5_, Suppl. 2. 681-684.
BRAESTRUP, C. and NIELSEN, M. (1981) [3H] Propyl
B-carboline-3-carboxyl ate as a selective radioligand for the
BZ^ benzodiazepine receptor subclass. J. Neurochem. 37,
333-341.
BRAESTRUP, C. NIELSEN, M. and H0N0RE, T. (1983) Benzodiazepine
receptor ligands with positive and negative efficacy. In "CNS
receptors - from molecular pharmacology to behaviour", pp
237-245. Eds. Mandel, P. and Defeudis, F.V. Raven Press, New
York.
BRAESTRUP, C., NIELSEN, M., KROGSGAARD-LARSEN, P. and FLACH, E.
(1979) Partial agonists for brain GABA/benzodiazepine receptor
complex. Nature 280, 331-333.
BRAESTRUP, C. and SQUIRES, R.F. (1977) Specific benzodiazepine
receptors in rat brain characterized by high-affinity [3H]
diazepam binding. Proc. Natl. Acad. Sci. USA 74, 3805-3809.
BRENNAN, M.J.W. and CANTRILL, R.C. (1979) s-Aminolaevulinic acid
is a potent agonist for GABA autoreceptors. Nature 280, 514-515.
BRENNAN, M.J.W., CANTRILL, J.C., OLDFIELD, M. and KROGSGAARD-LARSEN,
P. (1981) Inhibition of y-aminobutyric acid release by
y-aminobutyric acid agonist drugs. Molec. Pharmacol. 1_9, 27-30.
BRIAND, B., KOCH, B., LUTZ-BUCHER, B. and MIALHE, C. (1979)
In vitro regulation of ACTH release from neurointermediate lobe
of rat hypophysic II Effect of neurotransmitters.
Neuroendocrinology 20, 377-385.
BRINTON, R.E., GEE, K.W., WAMSLEY, J.K., DAVIS, T.P. and YAMAMURA,
H.I. (1984) Regional distribution of putative vasopressin
receptors in rat brain and pituitary by quantitative
autoradiography. Proc. Natl. Acad. Sci. USA 81_, 7248-7252.
BROWNER, M., FERKANY, J.W. and ENNA, S.J. (1981) Biochemical
identification of pharmacologically and functional distinct GABA
receptors in rat brain. J. Neuroscience 1_, 514-518.
BROWNSTEIN, M.J., ARIMURA, A., FERNANDEZ-DURANGO, R., SCHALLY, A.V.,
PALKOVITS, M. and KIZER, J.S. (1977) The effect of hypothalamic
deafferentation on somatostatin-1ike activity in the rat brain.
Endocrinology 100, 246-249.
BRUGGENCATE, G.T. and ENGBERG, I. (1971) Iontophoretic studies in
Deiters1 nucleus of the inhibitory effects of GABA and related
amino acids and the interactions of strychnine and picrotoxin.
Brain Res. 25, 431-448.
BRUNI, J.F., MIODUSZOWSKI, R.J., GRANDISON, L.J., SIMPINS, J.W. and
MEITES, J. (1977) Effects of cholinergic and GABAergic drugs on
serum growth hormone (GH) in male rats. Fed. Proc. ^36, 323.
BURDEN, J.L., HILLHOUSE, E.W. and JONES, M.T. (1974) The inhibitory
action of GABA and melatonin on the release of corticotrophin
releasing hormone from the rat hypophysiotropic area in vitro.
J.Physiol. 239, 116P-117P.
BURCH, T.P., THYAGARAJAN, R. and TICKU, M.K. (1983) Group-selective
reagent modification of the benzodiazepine-Y-aminobutyric acid
receptor-ionophore complex reveals that low-affinity
Y-aminobutyric acid receptors stimulate benzodiazepine binding.
Molec. Pharmacol. 22, 52-59.
CABANTCHICK, Z.I., KAUF, P.A. and ROTHSTEIN, A. (1978) The anion
transport system of the red blood cell: the role of membrane
protein evaluated by the use of probes. Biochim. Biophys. Acta.
515, 239-302.
CALIGARIS, L. and TALEISNIK, S. (1974) Involvement of neurones
containing 5-hydroxytryptamine in the mechanism of prolactin
release induced by oestrogen. J. Endocrinol. &2, 25-33.
CARMONA, E., GOMES, C. and TROLIN, G. (1981) Role of GABAergic
receptors for the synthesis of GABA in different compartments of
the rat cerebellum. Acta Physiol. Scand. 112, 109-110.
CASANNEUA, F., APUD, J., LOCATELLI, V., MARTINEZ-CAMPOS, A.,
CIVATI, C., RACAGNI, G., COCCHI, D. and MULLER, E.E. (1981)
Mechanisms subserving the stimulatory and inhibitory components
of Y-aniinobutyric acid-ergic control of prolactin secretion in
the rat. Endocrinology 109, 567-575.
CAVAGNINI, F., INVITTI, C., DILANDRO, A., TENCONI, L., MARASCHINI, C.
and GIROTTI, G. (1977) Effects of the GABA derivative baclofen
on growth hormone and prolactin secretion in man. J. Clin. Endo.
Metab. 45, 579-584.
CAVAGNINI, F., INVITTI, C., PINTO, M., MARASCHINI, C., DILANDRO, A.
DUBINI, A. and MARELLI, A. (1980) Effect of acute and repeated
administration of GABA on growth hormone and prolactin secretion
in man. Acta Endocrinologica 92, 149-154.
CHEN, G.L.C., DIONNE, F.T. and ROBERTS, J.L. (1983) Regulation
of the pro-opiomelanocortin mRNA levels in rat pituitary by
dopaminergic compounds. Proc. Natl. Acad. Sci. USA 80, 2211-2215,
CHERUBINI, E. and NORTH, R.A. (1984) Inhibition of calcium spikes
and transmitter release by Y-aminobutyric acid in the guinea-pig
myenteric plexus. Brit. J. Pharmacol. 82, 101-106.
CHERUBINI, E. and NORTH, R.A. (1985) Benzodiazepines both enhance
Y-aminobutyrate responses and decrease calcium action potentials
in guinea-pig myenteric neurones. Neuroscience 24, 309-315.
CHERUB INI, E., NORTH, R.A. and SUPRENANT, A. (1984) Quinine blocks
a calcium-activated potassium conductance in mammalian enteric
neurones. Brit. J. Pharmacol. 83, 3-5.
CHIU, T.H., DRYDEN, D.M. and ROSENBERG, H.C. (1982) Kinetics of
[^H] f1unitrazepam binding to membrane-bound benzodiazepine
receptors. Molec. Pharmacol., 21, 57-65.
CHOI, D.W., FARB, D.M. and FISHBACH, G.D. (1977) Chlordiazepoxide
selectively augments GABA action in spinal cord cell cultures.
Nature 269, 342-344.
CLEMENS, J.A. and SHAAR, C.J. (1981) An endogenous "benzodiazepine-
like" substance may regulate the sensitivity of the
adenohypophysis to gamma-aminobutyric acid. Program of 63rd
annual meeting of Endocrine Society, p.315.
COCCHI, D., CASANUEVA, F., LOCATELLI, V., APUD, J.,
MARTINEZ-CAMPOS, A., CIVATI, C., RACAGNI, G. and MULLER, E.E.
(1981) GABAergic mechanisms in the control of PRL and GH
release. In: GABA and Benzodiazepine receptors, pp 247-259.
Ed. E.Costa, Raven Press, New York.
COLLINS, C.G.S., ANSON, J. and KELLY, E.P. (1982) Baclofen: effects
on evoked field potentials and amino acid neurotransmitter
release in the rat olfactory cortex slice. Brain Res. 238,
371-383.
CONSTANTI, A. (1978) The "mixed" effect of picrotoxin on the GABA
dose/conductance relation recorded from lobster muscle.
Neuropharmacology 17, 159-167.
CORBETT, A.D., PATERSON, S.J. McKNIGHT, A.T., MAGNAN, J. and
KOSTERLITZ, H.W. (1982) Dynorphini_g and dynorphin^.g are
ligands for the K-subtype of opiate receptor. Nature 299, 79-81.
CORDA, M.G., BLAKER, W.D., MENDELSON, W.B., GUIDOTTI, A. and COSTA,
E. (1983) 8-Carbolines enhance shock-induced suppression of
drinking in rats. Proc. Natl. Acad. Sci (USA) 80, 2072-2076.
CORDA, M.G. and GUIDOTTI, A. (1983) Modulation of GABA receptor
binding by Ca2+. J. Neurochem. 41, 277-280.
CORDA, M.G., GUIDOTTI, A. and COSTA, E. (1982) Specific
proconvulsant action of an imidazobenzodiazepine (Rol5-1788) on
isoniazid convulsions. Neuropharmacology 2_1, 91-94.
COSTA, E., FERRERO, P., ALHO, H. and GUIDOTTI, A. (1985) GABA and
chloride channels: neuropeptide regulation. Int. Symposium on
Peptides and Ion Transport, Florence, P 19.
CRONIN, M.J., MYERS, G.A., MACLEOD, R.M. and HEWLETT, E.L. (1983)
Pertussis toxin actions on the pituitary-derived 235-1 clone:
effects of PGEi, cholera toxin and forskolin on cyclic AMP
metabolism and prolactin release. J. Cyc. Nuc. Research 9,
245-258.
CUELLO, A.C., HORN, A.S., MACKAY, A.V.P. and IVERSEN, L.L. (1973)
Catecholamines in the median eminence: new evidence for a major
noradrenergic input. Nature 243, 463-467.
CUELLO, A.C. and IVERSEN, L.L. (1973) Localization of tritiated
dopamine in the median eminence of the rat hypothalamus by
electron microscope autoradiography. Brain Res. 63, 474-478.
CUMMMINGS, S., ELDE, R., ELLS, J. and LINDALL, A. (1983)
Corticotrophin-releasing factor immunoreactivity is widely
distributed within the central nervous system of the rat: an
immunohistochemical study. J. Neurosci. 3^, 1355-1368.
CURTIS, D.R., DUGGAN, A.W., FELIX, D. and JOHNSTON, G.A.R. (1970)
GABA, bicuculline and central inhibition. Nature 226, 1222-1224.
CURTIS, D.R., DUGGAN, A.W., FELIX, D. and JOHNSTON, G.A.R. (1971a)
Bicuculline, an antagonist of GABA and synaptic inhibition in the
spinal cord of the cat. Brain Res. 32^, 69-96.
CURTIS, D.R., DUGGAN, A.W., FELIX, D., JOHNSTON, G.A.R. and
McLENNAN, H. (1971b) Antagonism between bicuculline and GABA in
the cat brain. Brain Res. 313, 57-73.
CURTIS, D.R. and FELIX, D. (1971) The effect of bicuculline upon
synaptic inhibition in the cerebral and cerebellar cortices of
the cat. Brain Res. 34, 301-321.
CURTIS, D.R., GAME, C.J.A., JOHNSTON, G.A.R. and McCULLOCH, R.M.
(1974) Central effects of &-(p-chlorophenyl)-y-aminobutyric
acid. Brain Res. 70, 493-499.
CURTIS, D.R., and JOHNSTON, G.A.R. (1974) Amino acid transmitters
in the mammalian central nervoys system. Rev. Physiol. Biochem.
Exp. Pharmacol. 69, 97-188.
CURTIS, D.R., LODGE, D., BORNSTEIN, J.C. and PEET, M.J. (1981)
Selective effects of (-)-baclofen on spinal synaptic transmission
in the cat. Exp. Brain Res. _42, 158-170.
CURTIS, D.R., LODGE, D., JOHNSTON, G.A.R. and BRAND, S.J. (1976)
Central action of benzodiazepines. Brain Res. 118, 344-347.
CURTIS, D.R., PHILLIS, J.W. and WATKINS, J.C. (1959) The
depression of spinal neurones by Y-amino-n-butyric acid and
S-alanine. J. Physiol. 146, 185-203.
DAVIDOFF, R.A. and SEARS, E.S. (1974) The effects of Lioresal on
synaptic activity in the isolated spinal cord. Neurology 24,
957-963.
DAVIES, J. and WATKINS, J.C. (1974) The action of e-phenyl-GABA
derivatives on neurones of the cat cerebral cortex. Brain Res.
70, 501-505.
DAVIS, M.D., HAAS, H.L. and LICHTENSTEIGER, W. (1985) The
hypothalamo-hypophysial system in vitro: electrophysiology of the
pars intermedia and evidence for both excitatory and inhibitory
inputs. Brain Res. 334, 97-104.
DEBELJUK, L., GOIJMAN, S., SEILICOVICH, A., DIAZ, M.C. and
RETTORI, V.B. (1980) Effect of aminooxyacetic acid and
bicuculline on prolactin release in castrated male rats. Life
Sci. 27, 2025-2029.
DEBELJUK, L., SEILICOVICH, A., and DIAZ, M.C. (1981) Effect of
3-aminopropanesulfonic acid and allylglycine on prolactin release
in male rats. Proc. Soc. Exp. Biol. Med. 168, 214-217.
DEBELJUK, L., TORRES-ALEMAN, I. and SCHALLY, A.V. (1985) Antiserum
to LHRH blocks haloperidol-induced hyperprolactinaemia in female
rats. Neuroendocrinology 40, 185-187.
DeFEUDIS, F.V. (1973) Sodium dependency of y-aminobutyric acid
binding to particulate fractions of mouse brain. Exp. Neurol.
41, 54-62.
DeFEUDIS, F.V. (1980) Binding studies with muscimol: relation to
synaptic y-aminobutyrate receptors. Neuroscience J5, 675-688.
deLORENZO, R.J., BURDETTE, S. and HOLDERNESS, J. (1981)
Benzodiazepine inhibition of the calcium-calmodulin protein
kinase system in brain membranes. Science 213, 546-549.
DEL ZOMPO, M., CHERILLARD, C., SAAVERDRA, J.M., PORT, R.M. and
TALLMAN, J.F. (1982) Benzodiazepine binding sites in kidney:
alterations by diabetes insipidus. Fed. Proc. 41_, 1328.
DEMAREST, K.T. and MOORE, K.E. (1979a) Lack of a high affinity
transport system for dopamine in the median eminence and
posterior pituitary. Brain Res. 171, 545-551.
DEMAREST, K.T. and MOORE, K.E. (1979b) Comparison of dopamine
synthesis regulation in the terminals of nigrostriatal,
mesolimbic, tuberoinfundibular and tuberohypophysial neurons. J.
Neurol. Transm. 46, 263-277.
DEMENEIX, B.A., DESAULLES, E., FELTZ, P. and LOEFFLER, J-P. (1984)
Dual population of GABA^ and GABAg receptors in rat pars
intermedia demonstrated by release of a-MSH caused by barium
ions. Brit. J. Pharmacol. 82, 183-190.
DENEF, C. and ANDRIES, M. (1983) Evidence for paracrine
interactions between gonadotropics and lactotrophes in pituitary
cell culture. Endocrinology 112, 813-822.
DESARMENIEN, M., FELTZ, P., OCCHIPINTI, G., SANTANGELO, F. and
SCHLICHTER, R. (1984) Coexistence of GABA/\ and GABAg
receptors on As and C primary afferents. Brit. J. Pharmacol. 81,
327-333.
DESARMENI EN, M., SANTANGELO, F., OCCHIPINTI, G., SCHLICHTER, R.,
LOEFFLER, J-P., DESAULLES, E., DEMENEIX, B.A. and FELTZ, P.
(1983) Electrophysiological study of GABA/\ versus GABAg
receptors on excitation secretion coupling. In: Mandel, P. and
DeFeudis, F.V (Eds), CNS Receptors, Adv. Biochem.
Psychopharmacol. 37, 93-105. Raven Press, New York.
DESCHENES, M. and FELTZ, P. (1976) GABA-induced rise of
extracellular potassium in rat dorsal root ganglia: an
electrophysological study in vivo. Brain Res. 118, 494-499.
DIERICKX, K. and VANDESANDE, F. (1979) Immunocytochemical
localization of somatostatin-containing neurones in the rat
hypothalamus. Cell. Tissue Res. 201, 349-359.
DOBLE, A., IVERSEN, L.L. and MARTIN, I.L. (1982) The
benzodiazepine binding site: one receptor or two? Brit. J
Pharmacol. 7J5, 42P.
DOGTEROM, J., VAN WIMERMSMA GREIDANUS, T.J.B. and SWAAB, D.F.
(1977) Evidence for the release of vasopressin and oxytoxin into
cerebrospinal fluid: measurements in plasma and CSF of intact and
hypophysectomized rats. Neuroendocrinology 24-, 108-118.
D0N0S0, A.O., and ZARATE, M.B. (1981) Changes in prolactin release
caused by GABA and endogenous GABA increase in rats. Brain Res.
Bull. 7, 359-364.
DORFLINGER, L.J. and SCHONBRUNN, A. (1983) Somatostatin inhibits
basal and vasoactive intestinal peptide-stimulated hormone
secretion release by different mechanisms in GH pituitary cells.
Endocrinology 113, 1551-1558.
DOUGLAS, W.W., LYWOOD, D.W. and STRAUB, R.W. (1961) The stimulant
effect of barium on the release of acetylcholine from the
superior cervical ganglion. J. Physiol. 156, 515-522.
DOUGLAS, W.W. and TARASKEVICH, P.S. (1980) Calcium component to
action potentials in rat pars intermedia cells. J. Physiol. 309,
623-630.
DOUGLAS, W.W. and TARASKEVICH, P.S. (1982) Slowing effects of
dopamine and calcium channel blockers on frequency of sodium
spikes in rat pars intermedia cells. J. Physiol. 326, 201-211.
DOUGLAS, W.W., TARASKEVICH, P.S. and TOMIKO, S.A. (1983)
Secretagogue effect of barium on output of melanocyte-
stimulating hormone from pars intermedia of the mouse pituitary.
J. Physiol. 338, 243-257.
DRAY, A. and STRAUGHAN, D.W. (1976) Benzodiazepines : GABA and
glycine receptors on single neurons in the rat medulla. J.
Pharm. Pharmacol. 28, 314-318.
DREIFUSS, J.J., KELLY, J.S. and KRNJEVIC, K. (1969) Cortical
inhibition and y-aminobutyric acid. Exp. Brain Res. £, 137-154.
DUFY, B., VINCENT, J-D., FLEURY, H., DU PASQUER, P., 60URDJI, D. and
TIXIER-VIDAL, A. (1978) Membrane effects of thyrotropin-
releasing hormone and oestrogen shown by intracellular recordings
from pituitary cells. Science 204, 509-511.
DUFY, B., VINCENT, J-D., FLEURY, H., DU PASQUER, P., GOURDJI, D. and
TIXIER-VIDAL, A. (1979) Dopamine inhibition of action
potentials in a prolactin-secreting cell line is modulated by
oestrogen. Nature 282, 855-857.
DUNLAP, K. (1981) Two types of y-aminobutyric acid receptor on
embryonic sensory neurones. Brit. J. Pharmacol. 74, 579-585.
DUNLAP, K. (1985) Forskolin prolongs action potential duration and
blocks potassium current in embryonic chick sensory neurones.
Pflugers Archiv. 403, 170-174.
DUNLAP, K. and FISCHBACH, G.D. (1981) Neurotransmitters decrease
the calcium conductance activated by depolarization of embryonic
chick sensory neurones. J. Physiol. 317, 519-535.
DYBALL, R.E.J. (1974) Single unit activity in the hypothalamo-
neurohypophysial system of Brattleboro rats. J. Endocrinol 60,
135-143. ~
DYBALL, R.E.J, and LENG, G. (1985) Supraoptic neurones in
Brattleboro rats repond normally to changes in plasma osmotic
pressure. J. Endocrinol. 105, 87-90.
DYBALL, R.E.J, and SHAW, F.D. (1979) Inhibition by GABA of hormone
release from the neurohypophysis of the rat. J. Physiol. 289,
78P-79P.
EHLERT, F.J., ROESKE, W.R. and YAMAMURA, H.I. (1981) Multiple
benzodiazepine receptors and their regulation by GABA. Life.
Sci. 29, 235-248.
ELDE, R.P. and PARSONS, J.A. (1975) Immunocytochemical
localization of somatostatin in cell bodies of the rat
hypothalamus. Am. J. Anat. 144, 541-548.
ELLIOTT, K.A.C. and VAN GELDER, N.M. (1958) Occlusion and
metabolism of y-aminobytyric acid by brain tissue. J. Neurochem.
3 , 28- 40.
ENJALBERT, A., ARANCIBIA, S., RUBERG, M., PRIAM, M., BLUET-PAJOT,
M.T., ROTSZTEJN, W.A. and KORDON, C. (1980) Stimulation of in
vitro prolactin release by vasoactive intestinal peptide.
Neuroendocrinology 31, 200-204.
ENJALBERT, A., RUBERG, M., ARANCIBIA, S., FIORE, L., PRIAM, M. and
KORDON, C. (1979a) Independent inhibition of prolactin
secretion by dopamine and y-aminobutyric acid in vitro.
Endocrinology 105, 823-826.
ENJALBERT, A., RUBERG, M., ARANCIBIA, S., PRIAM, M., BAUER, K. and
KORDON, C. (1979b) Inhibition of in vitro prolactin secretion
by histidyl-proline-diketopiperazine, a degradation product of
TRH. Europ. J. Pharmacol. 58, 97-98.
ENJALBERT, A., RUBERG, M., ARANCIBIA, S., PRIAM, M. and KORDON, C.
(1979c) Endogenous opiates block dopamine inhibition of
prolactin secretion in vitro. Nature 280, 595-597.
ENNA. S.J., BEAUMONT, K. and YAMAMURA, H.I. (1978) Comparison of
[3h] muscimol and [^H] GABA receptor binding in rat brain.
In 'Amino-acids as Chemical Transmitters' Ed Fonnum F. pp
787-792. Plenum Press, New York.
ENNA, S.J. and SNYDER, S.H. (1975) Properties of y-aminobutyric
acid (GABA) receptor binding in rat brain synaptic membrane
fractions. Brain Res. 100, 81-97.
ENNA, S.J. and SNYDER, S.H. (1976) A simple, sensitive and
specific radioreceptor assay for endogenous GABA in brain
tissue. J. Neurochem. 26_, 211-224.
ENNA, S.J. and SNYDER, S.H. (1977) Influences of ions, enzymes and
detergents on y-aminobutyric acid receptor binding in synaptic
membranes of rat brain. Molec. Pharmacol. 1_3, 442-453.
EVERETT, J.W. (1954) Luteotrophic function of autografts of the
rat hypophysis. Endocrinology 5j4, 685-690.
EVERITT, B.J., HOKFELT, T., WU, J-Y. and GOLDSTEIN, M. (1984)
Coexistence of tyrosine hydroxylase-1ike and gamma-aminobutyric
acid-like immunoreactivities in neurones of the arcuate nucleus.
Neuroendocrinology 39, 189-191.
FAGIN, K.D. and NEILL, J.D. (1981) The effect of dopamine on
thyrotropin-releasing hormone-induced prolactin secretion in
vitro. Endocrinology 109, 1835-1840.
FAGIN, K.D. and NEILL, J.D. (1982) Involvement of the
neurointermediate lobe of the pituitary gland in the secretion of
prolactin and luteinizing hormone in the rat. Life Sci. 30,
1135-1141. —
FARNEBO, L.O. and HAMBERGER, B. (1971) Drug-induced changes in the
release of ^H-monoamines from field-stimulated rat brain
slices. Acta Physiol. Scand. Suppl. 371, 35-44.
FATT, P. and GINSBORG, B.L. (1958) The ionic requirements for the
production of action potentials in crustacean muscle fibres. J.
Physiol. 142, 516-543.
FELDBERG, W. and ROCHA E SILVA, M. Jr. (1978) Vasopressin release
produced in anaesthetized cats by antagonists of y-aminobutyric
acid and glycine. Brit. J. Pharmacol. 62_, 99-106.
FILE, S.E and MABBUTT, P.S. (1983) Behavioural effects of
Ro5-4864, a ligand for the micromolar benzodiazepine receptor.
Brit. J. Pharmacol. 78_, 76P.
FIOK, A.J., ACS, Z.,. MAKARA, G.B. and ERDO, S.L. (1984) Site of
Y-aminobutyric acid (GABA)-mediated inhibition of growth hormone
secretion in the rat. Neuroendocrinology ^9, 510-516.
FIOK, J., ACS, Z. and STARK, E. (1981a) Possible inhibitory
influence of gamma-aminobutyric acid on growth hormone secretion
in the rat. J. Endocrinology 91^, 391-397.
FIOK, J., ACS, Z. and STARK, E. (1981b) Effect of changes in GABA
metabolism on the plasma growth hormone level. Acta. Physiol.
Acad. Sci. Hungaricae 5j>, 29.
FISCHLI, W., GOLDSTEIN, A., HUNKAPILLER, M.W. and HOOD., L.E.
(1982) Isolation and amino-acid sequence analysis of a
4,000-dalton dynorphin from porcine pituitary. Proc. Natl. Acad.
Sci. USA 79, 5435-5437.
FISZER DE PLAZAS, S., BECU, D., MITRIDATE DE NOVARA, A. and
LIBERTUN, C. (1982) Y-aminobutyric acid receptors in anterior
pituitary and brain areas after median eminence lesions.
Endocrinology 111, 1974-1978.
FISZER DE PLAZAS, S., SEILICOVICH, A., DUVALANSKI, B., GONZALEZ, N.N.
and RETTORI, V. (1983) Sex related differences in GABA binding
sites of rat anterior pituitary and hypothalamus. IRCS Med. Sci.
U, 976.
FLOREY, E. (1954) An inhibitory and an excitatory factor of
mammalian central nervous system, and their action on a single
sensory neurone. Arch. Int. Physiol. 62_, 33-53.
FOREMANN, M.M. and PORTER, J.C. (1981) Prolactin augmentation of
dopamine and norepinephrin release from superfused medial basal
hypothalamic fragments. Endocrinology 108, 800-804.
FOX, S., KRNJEVIC, K., MORRIS, M.E., PUIL, E., and WERMAN, R.
(1978) Action of baclofen on mammalian sympathetic
transmission. Neuroscience 3, 495-515.
FRAWLEY, L.S., BOCKFOR, F.R. and HOEFFLER, J.P. (1985)
Identification by plaque assays of a pituitary cell type that
secretes both growth hormone and prolactin. Endocrinology 116,
734-737.
FRIEDMAN, E., KRIEGER, D.T., MEZEY, E., LERANTH, C.S., BROWNSTEIN,
M.J. and PALKOVITS, M. (1983) Serotonergic innervation of the
rat pituitary neurointermediate lobe: decrease after stalk
section. Endocrinology 112, 1943-1947.
FROWAN, L. A., BERNARDIS, L.L. and KANT, K. (1968) Hypothalamic
stimulation of growth hormone secretion. Science 162, 580-582.
FUCHS, E., MANSKY, T., STOCK, K-W., VIJAYAN, E. and WUTTKE, W.
(1984) Involvement of catecholamines and glutamate in GABAergic
mechanism regulatory to luteinizing hormone and prolactin
secretion. Neuroendocrirology 38, 484-489.
GAHWILER, B.H. (1976) Diazepam and chlordiazepoxide: powerful GABA
antagonists in explants of rat cerebellum. Brain Res. 107,
176-183.
GALLAGHER, D.W., MALLORGA. P., OERTEL, W., HENNEBERRY, R. AND
TALLMAN, J. (1981) [^H] Diazepam binding in mammalian central
nervous system: a pharmacological characterisation. J. Neurosci.
1, 218-225.
GALLAGHER, J.P., STEVENS, D.R., AND SHINNICK-GALLAGHER, P. (1984)
Actions of GABA and baclofen on neurones of the dorsolateral
septal nucleus (DLSN) in vitro. Neuropharmacology 23^, 825-826.
GALLINDO, A. (1969) GABA-picrotoxin interaction in the mammalian
central nervous system. Brain Res. 14_, 763-767.
GAMSE, R., VACCARO, D.D., GAMSE, G., DIPACE, M., FOX, T.D. and
LEEMAN, S.E. (1980) Release of immunoreactive somatostatin from
hypothalamic cells in culture - inhibition by gamma-aminobutyric
acid. Proc. Natl. Acad. Sci. USA 77_, 5552-5556.
GARCEL, G., FOURNIE-ZALUSKI, M-C. and ROQUES, B.P. (1980)
D-Tyr-Ser-Gly-Phe-Leu-Thr, a highly preferential ligand for
5-opiate receptors. FEBS Lett. 118, 245-247.
GARDNER, C.R., KLEIN, J. and GROVE, J. (1981) Endogenous GABA
determines the characteristics of [3h]GABA binding. Europ. J.
Pharmacol. 7J5, 83-92.
GAUTVIK, K.M., IVERSEN, J-G. and SAND, 0. (1980) On the role of
extracellular Ca2+ for prolactin release and adenosine
3' :5'monophosphate formation induced by thyroliberin in cultured
rat pituitary cells. Life Sci. 2j5, 995-1005.
GEIGER, P.J. and BESSMANN, S.P. (1972) Protein determination by
Lowry's method in the presence of sulphydryl reagents. Analyt.
Biochem. 49_, 467-473.
GIACHETTI, A., BORGHI, C., NICOSIA, S. and SAID, S.I. (1979)
Vasoactive intestinal polypeptide (VIP) activates rat pituitary
adenylate cyclase. Fed. Proc. 38, 1129.
GIBBS, D.M. and NEILL, J.D. (1978) Dopamine levels in hypophysial
stalk blood are sufficient to inhibit prolactin secretion in
vivo. Endocrinology 102, 1895-1900.
GOLDSMITH, P.C., CRONIN, M.J. and WEINER, R.I. (1979) Dopamine
receptor sites in the anterior pituitary. J. Histochem.
Cytochem. 2L7, 1205-1207.
GOLDSTEIN, A., FISCHLI, W., LOWNEY, L.I., HUNKAPILLER, M. and
HOOD, L. (1981) Porcine pituitary dynorphin: complete amino
acid sequence of the biologically active heptadecapeptide, Proc.
Natl. Acad. Sci USA, 78, 7219-7223.
GOLDSTEIN, A., TACHIBANA, S., LOWNEY, L.I., HUNKAPILLER, M. and
HOOD, L. (1979) Dynorphin-(l-13), an extraordinary potent
opioid peptide. Proc. Natl. Acad. Sci. USA _76, 6655-6670.
GOTTSFELD, Z., KELLY, J.S. and RENAUD, L.P. (1972) The in vivo
neuropharmacology of amino-oxyacetic acid in the cerebral coretex
of the cat. Brain Res. 42, 319-335.
GRAHAM, L.T. and APRISON, M.H. (1966) Fluorimetric determination
of asparatate, glutamate and y-aminobutyrate in nerve tissue
using enzymic methods. Analyt. Biochem. 15_, 487-497.
GRANDISON, L. (1980) Effects of GABA agonists and modulators on
prolactin release. Brain Res. Bull., 5_, 701-704.
GRANDISON, L. (1981) Characterisation of benzodiazepine binding
and action on rat anterior pituitary cells. Neuroscience
Abstracts, 7_ , 503.
GRANDISON, L. (1982) Suppression of prolactin secretion by
benzodiazepines in vivo. Neuroendocrinology, 34, 369-373.
GRANDISON, L., CAVAGNINI, F., SCHMID, R., INVITTI, C. and
GUIDOTTI, A. (1982) y-aminobutyric acid- and benzodiazepine-
binding sites in human anterior pituitary tissue. J. Clin. Endo.
Metab. 54, 597-601.
GRANDISON, G. and GUIDOTTI, A. (1979) y-aminobutyric acid function
in rat anterior pituitary: evidence for control of prolactin
release. Endocrinology 105, 754-759.
GRAY, E.G. and WHITTAKER, V.P. (1962) The isolation of nerve
endings from brains: an electron microscope study of cell
fragments derived by homogenisation and centrifugation. J. Anat.
96, 79-88.
GREENLEE, D.V., VAN NESS, P.C. and OLSEN, R.W. (1978) Gamma-
aminobutyric acid binding in mammalian brain. Receptor-like
specificity of sodium-independent sites. J. Neurochem. 31,
933-938.
GROSSMAN, A., DELITALA, G., YEO, T. and BESSER, G.M. (1981) GABA
and muscimol inhibit the release of prolactin from dispersed rat
anterior pituitary cells. Neuroendocrinology, 32_, 145-149.
GROSVENOR, C.E., MENA, F. and WHITWORTH, N.S. (1980) Evidence that
the dopaminergic prolactin-inhibiting factor mechanism regulates
only the depletion-transformation phase and not the release phase
of prolactin secretion during suckling in the rat. Endocrinology
105, 481-485.
greenwood, f.c.. hunter, w.m. and GLOVER, J.S. (1963) The
preparation of "1i_]abel1ed human growth hormone of high
specific radioactivity. Biochem. J., 89_, 114-123.
GROVE, J., SCHECHTER, P.J., TELL, G., RUMBACH, L., MARESCAUX, C.
WARTER, J-M. and KOCH-WESER, J. (1982) Artefactual increases in
the concentration of free GABA in samples of human cerebrospinal
fluid are due to degradation of homocarnosine. J. Neurochem. 39,
1061-1065.
GUDELSKY, G.A., APUD, J.A., MASOTTO, C., LOCATELLI, V., COCCHI, 0.,
RACAGNI, G. and MULLER, E.E. (1983) Ethanolamine-O-sulfate
enhances y-aminobutyric acid secretion into hypophysial portal
blood and lowers serum prolactin concentrations.
Neuroendocrinology 2Z.> 397-399.
GUIDOTTI, A., GALE, K., SURIA, A. and TOFFANO, G. (1979)
Biochemical evidence for two classes of GABA receptors in rat
brain. Brain Res. 172, 566-571.
GUIDOTTI, A., TOFFANO, G. and COSTA, E. (1978) An endogenous
protein modulates the affinity of GABA and benzodiazepine
receptors in rat brain. Nature 275, 553-555.
GUIDOTTI, A., TOFFANO, G., GRANDISON, L. and COSTA, E. (1978)
Second messenger responses and the regulation of high affinity
receptor binding to study pharmacological modifications of
GABAergic transmission. In: "Amino acids as chemical
transmitters", Ed. Fonnum, F., Plennum Press. New York.
GUSTAFSSON, B., GAL VAN, M., GRAFE, P. and WIGSTROM, H. (1982) A
transient outward current in a mammalian central neurone blocked
by 4-aminopyridine. Nature 299, 252-254.
HABER, B., KURIYAMA, K. and ROBERTS, E. (1970) L-Glutamic acid
decarboxylase. A new type in glial cells and human brain
gliomas. Science 168, 598-599.
HADLEY, M.E., DAVIS, M.D. and MORGAN, C.M. (1977) Cellular control
of melanocyte stimulating hormone secretion. Front. Hormone Res.
4, 94-104.
HAEFELY, W., KULCSAR, A., MOHLER, H., PIERI, L., POLC, P. and
SCHAFFNER, R. (1975) Possible involvement of GABA in the
central action of benzodiazepines. Adv. Biochem.
Psychopharmacol. 14_, 131-151.
HAGIWARA, S. and BYERLY, L. (1981) Calcium channel. Ann. Rev.
Neurosci. £, 69-125.
HALL, Z.W. and KRAVITZ, E.A. (1967) The metabolism of y-amino-
butyric acid (GABA) in the lobster nervous system - 1. J.
Neurochem. 1£, 45-54.
HAMBERGER, A., NORSTROM, A., SANDBERG, M.and SVANBERG, U. (1979)
In vitro GABA transport in the neurohypophysis from rats with
hereditary diabetes insipidus and after osmotic stimulation.
Brain Res. 174, 341-334.
HAMILL, O.P., BORMANN, J. and SAKMANN, B. (1983) Activation of
multiple-conductance state chloride channels in spinal neurones
by glycine and GABA. Nature 305, 805-808.
HANDA, B.K., LANE, A,C,, LORD, J.A.M., MORGAN, B.A., RANCE, M.C. and
SMITH, C.F.C. (1981) Analogues of 8-LPH6i_64 possessing
selective agonist activity at u-opiate receptors. Europ. J.
Pharmacol. 70_, 531-540.
HARMAR, A.J. and ROSIE, R. (1983) Purification of radioiodinated
peptides by reverse-phase liquid chromatography. J. Physiol.
346, 22P.
HARRIS, D. and MITCHELL, R. (1984) Differential linkage of GABA
receptors to benzodiazepine receptor subtypes. Proceedings of
IUPHAR meeting, London, 742P.
HAYASHI, T. (1956) Chemical physiology of excitation in muscle and
nerve. Nakayama-Shoten, Tokyo.
HAYCOCK, J.W., LEVY, W.B.. DENNER, L.A. and COTMAN, C.W. (1978)
Effects of elevated [K ]0 on the release of neurotransmitters
from cortical synaptosomes: efflux or secretion? J. Neurochem.
30, 1113-1125.
HEISLER, S., REISINE, T.D., HOOK, V.Y.H. and AXELROD, J. (1982)
Somatostatin inhibits multireceptor stimulation of cyclic AMP
formation and c'orticotrophin secretion in mouse pituitary tumor
cells. Proc. Natl. Acad. Sci. USA 79_, 6502-6506.
HENN, F.A. and HAMBERGER, A. (1971) Glial cell functions: uptake
of transmitter substances. Proc. Natl. Acad. Sci. USA 68,
2686-2690.
HERSCHEL, M. and BALDESSARINI. R.J. (1979) Evidence for two types
of binding of GABA and ^H muscimol in rat cerebral cortex
and cerebellum. Life Sci. 24, 1849-1854.
HERTZ, L. (1979) Functional interactions between neurons and
astrocytes 1. Turnover and metabolism of putative aminoacid
neurotransmitters. Prog. Neurobiol. 13_, 277-323.
HILL, D.R. (1985) GABAg receptor modulation of adenylate cyclase
activity in rat brain slices. Brit. J. Pharmacol. 84, 249-257.
HILL, D.R. and BOWERY, N.G. (1981) [3H] baclofen and [3H] GABA
bind to bicuculline-insensitive GABAg sites in rat brain.
Nature 290, 149-152.
HILL, D.R., BOWERY, N.G. and HUDSON, A.L. (1984) Inhibition of
GABAg receptor binding by guanyl nucleotides. J. Neurochem.
42, 652-657.
HILL, R.G., SIMMONDS, M.A. and STRAUGHAN, D.W. (1972) Antagonism of
GABA by picrotoxin in the feline cerebral cortex. Brit. J.
Pharmacol. 44, 807-807.
HILLE, B. (1967) The selective inhibition of delayed potassium
currents in nerve by tetraethylammonium ion. J. Gen. Physiol.
50, 1287-1302.
HOKFELT, T. (1967) The possible ultrastructural identification of
tuberoinfundibular dopamine-containing nerve endings in the
median eminence of the rat. Brain Res. 5_, 121-123.
HOKFELT, T., EFENTIC, S., HELLERSTR0M, C. JOHNSSON, 0. LUFT, R. and
ARIMURA, A. (1975) Cellular localisation of somatostatin in
endocrine-like cells and neurons of the rat with special
references to the A^-eelIs of the pancreatic islets and to the
hypothalamus. Acta Endocrinol. Supp. 200, 5-41.
HOKFELT, T. and FUXE, K. (1972) Effects of prolactin and ergot
alkaloids on the tuberoinfundibular dopamine (DA) neurons.
Neuroendocrinology 9^, 100-122.
H0LLT, V., HAARMANN, I., SEIZINGER, B.R. and HERZ, A. (1981) Levels
of dynorphin-(l-13) immunoreactivity in rat neurointermediate
pituitaries are concomitantly altered with those of leucine
enkephalin and vasopressin in response to various endocrine
manipulations. Neuroendocrinology 33_, 333-339.
HORN, A.M. (1984) Interactions between peptides and monoamines
in the control of the release of hormones from the
adenohypophysis. Ph.D. Thesis, University of Edinburgh.
HORN, A.M., ROBINSON, I.C.A.F. and FINK, G. (1985) Oxytocin and
vasopressin in rat hypophysial portal blood: experimental studies
in normal and Brattleboro rats. J. Endocrinol. 104, 211-224.
HUNKELER, W., M0HLER, H., PIERI, L., P0LC, P., B0NETTI, E.P.,
CUMIN, R., SCHAFFNER, R. and HAEFELY, W. (1981) Selective
antagonists of benzodiazepines. Nature 290, 514-516.
ILLES, P., PFEIFFER, N., VON KUGELGEN, I. and STARKE, K. (1985)
Presynaptic opioid receptor subtypes in the rabbit ear artery.
J.Pharm. Exp. Ther. 232, 526-533.
INGRAM, C.D. and MASON, W.T. (1985) Intracellular recordings from
putative lactotrophes of bovine pituitary: modulation of
spontaneous action potentials by regulators of prolactin
secretion. J. Physiol. 364, 52P.
INOUE, M., MATSUO, T. and OKATA, N. (1985) Baclofen activates
voltage-dependent and 4-aminopyridine sensitive K+ conductance
in guinea-pig hippocampal pyramidal cells maintained in vitro.
Brit. J. Pharmacol. 84_, 833-841.
ISRAEL, J-M., DENEF, C. and VINCENT, J-D. (1983) Electrophysiological
properties of normal somatotrophes in culture. Neuroendocrine!.
37, 193-199.
ISRAEL, J.M., OUFY, B., GOURDJI, D. and VINCENT, J.D. (1981)
Effects of GABA on electrical properties of cultured rat
pituitary tumour cells: an intracellular recording study. Life
Sci. 29, 351-359.
IVERSEN, L.L., IVERSEN, S.D. and BLOOM, F.E. (1980) Opiate
receptors influence vasopressin release from nerve terminals in
rat neurohypophysis. Nature 284, 350-351.
IVERSEN, L.L. and JOHNSTON, G.A.R. (1971) GABA uptake in rat
central nervous system: comparison of uptake in slices and
homogenates and effects of some inhibitors. J. Neurochem. 18,
1939-1950.
IVERSEN, L.L. and KRAVITZ, E.A. (1968) The metabolism of
Y-aminobutyric acid (GABA) in the lobster nervous system - uptake
of GABA in nerve-muscle preparations. J. Neurochem. 15_, 609-620.
IVERSEN, L.L. and KELLY, J.S. (1975) Uptake and metabolism of
Y-aminobutyric acid by neurones and glial cells. Biochem.
Pharmacol. 24_, 933-938.
IVERSEN, L.L., MITCHELL, J.F. and SRINIVASAN, V. (1971) The release
of Y-arninobutyric acid during inhibition in the cat visual
cortex. J. Physiol. 212, 519-534.
IVERSEN, L.L. and NEAL, M.J. (1968) The uptake of [3h] GABA by
slices of rat cerebral cortex. J. Neurochem. 15_, 1141-1149.
IVERSEN, L.L., ROGAWSKI, M.A. and MILLER, R.J. (1976) Comparison
of the effect of neuroleptic drugs on pre- and postsynaptic
dopaminergic mechanisms in rat striatum. Molec. Pharmacol. .12,
251-262. —
JACOBSOHN, D. and WERTMAN, A. (1945) On the structure and function
of the mammary glands after hypophysectomy and transection of the
hypophysial stalk in rats. Acta Physiol. Scand. 9, 284-295.
JAFFE, E.H. and CUELLO, A.C. (1980) Release of y-aminobutyrate from
the external plexiform layer of the rat olfactory bulb: possible
dendritic involvement. Neuroscience 5^ 1859-1869.
JASPER, H.H., KHAN, R.T. and ELLIOTT, K.A.C. (1958) Amino acids
released from cerebral cortex in relation to its state of
activation. Science 147, 1448-1449.
JASPER, H.H. and KOYAMA, I. (1969) Rate of release of amino acids
from the cerebral cortex in the cat as affected by brainstem and
thalamic stimulation. Can. J. Physiol. Pharmacol. 47, 889-905.
JESSEN, K.R., MIRSKY, R., DENNISON, M.E. and BURNSTOCK, G. (1979)
GABA may be a neurotransmitter in the vertebrate peripheral
nervous system. Nature 281, 71-74.
JOHNSTON, G.A.R., HAILSTONE, M.H. and FREEMAN, C.G. (1980)
Baclofen: stereospecific inhibition of excitant aminoacid
release. J. Pharm. Pharmacol. 32, 230-231.
JONES, M.T., GILLHAM, B., ALTAHER, A.R.H., NICHOLSON, S.A.,
CAMPBELL, E.A., WATTS, S.M. and THODY, A. (1984) Clinical and
experimental studies in the role of GABA in the regulation of
ACTH secretion: a review. Psychoneuroendocrinology 9, 107-123.
JONSSON, G., FUXE, K. and HOKFELT, T. (1972) On the catecholamine
innervation of the hypothalamus, with special reference to the
median eminence. Brain Res. 40, 271-281.
JORDAN, C.C., MATUS, A.I., PIOTROWSKI, W. and WILKINSON, D. (1982)
Binding of [^H] y-aminobutyric acid and [^H] muscimol in
purified rat brain synaptic plasma membranes and the effects of
bicuculline. J. Neurochem. 39^, 52-58.
JORDAN, C., PONCET, C., VEISSEIRE, M. and MORNEX, R. (1983) Role of
GABA in the control of thyrotropin secretion in the rat. Brain
Res. 768, 105-110.
KACZOROWSKI, G.J., VANDLEN, R.C., KATZ, G.M. and REUBEN, J.P. (1983)
Regulation of excitation-secretion coupling by
thyrotrophin-releasing hormone (TRH): evidence for TRH
receptor-ion channel coupling in cultured pituitary cells. J.
Memb. Biol. 71_, 109-118.
KAMEYAMA, T., NABESHIMA, T., BANNO, S. and KAMATA, K. (1983) The
relationship between brain y-aminobutyric acid and plasma
corticosterone levels in mice exposed to high ambient temperature
or dexamethasone. Res. Commun. Psychol. Psychiat. Behav. 8,
11-21.
KANAZAWA, I., IVERSEN, L.L. and KELLY, J.S. (1976) Glutamate
decarboxylase activity in the rat posterior pituitary, pineal
gland, dorsal root ganglion and superior cervical ganglion. J.
Neurochem. 27, 1267-1269.
KARBON, E.W., DUMAN, R. and ENNA, S.J. (1983) Biochemical
identification of multiple GABAg binding sites: association
with noradrenergic terminals in rat forebrain. Brain Res. 274.
393-396.
KARBON, E.W. and ENNA, S.J. (1985) Characterization of the
relationship between y-aminobutyric acid B agonists and
transmitter-coupled cyclic nucleotide-generating systems in rat
brain. Molec. Pharmacol. 27_, 53-59.
KAROBATH, M. and LIPPITSCH, M. (1979) THIP and isoguvacine are
partial agonists of GABA-stimul ated benzodiazepine receptor
binding. Europ. J. Pharmacol. 58, 485-488.
KAROBATH, M., PLACHETA, P., LIPPITSCH, M. and KROGSGAARD-LARSEN, P.
(1979) Is stimulation of benzodiazepine binding mediated by a
novel GABA receptor? Nature 278, 748-749.
KARTESZI, M., FIOK, J. and MAKARA, G.B. (1982) Lack of episodic
growth hormone secretion in rats with anterolateral
deafferentation of the medial-basal hypothalamus. J. Endocrinol.
94. 77-81.
KATAKAMI, H., KATO, Y. , MATSUSHITA, N., SHIMATSU, A. and IMURA, H.
(1981) Possible involvement of y-aminobutyric acid in growth
hormone release induced by a met-enkephalin analog in conscious
rats. Endocrinology 109, 1033-1036.
KEHR, W., CARLSSON, A., LINQUIST, M., MAGNUSSON, T. and ATACK, C.
(1972) Evidence for a receptor-mediated feedback control of
striatal dopamine hydroxylase activity. J. Pharm. Pharmacol. 24,
744-747.
KELLY, J.S. and RENAUD, L.P. (1973) On the pharmacology of the
y-aminobutyric acid receptors on the cuneo-thalamic relay cells
of the cat. Brit. J. Pharmacol. 48, 369-386.
KERWIN, R. and PYCOCK, C. (1978) Baclofen (e-p-chlorophen^yl-y-
aminobutyric acid) enhances [^Hjy-aminobutyric acid
(^H-GABA) release from rat globus pallidus in vitro. J. Pharm.
Pharmacol. 20» 622-627.
KHORRAM, 0., DEPLATIS, L.R. and MCCANN, S.M. (1984) The effect and
possible mode of action of ct-melanocyte stimulating hormone on
gonadotrophin release in the ovariectomized rat: an in vivo and
in vitro analysis. Endocrinology 114, 227-233.
KHORRAM, 0., MIZUNUMA, H. and MCCANN, S.M. (1982) Effect of
ct-melanocyte stimulating hormone on basal and stimulated release
of prolactin: evidence for dopaminergic mediation.
Neuroendocrinology 34_, 433-437.
KID0K0R0 Y. (1975) Spontaneous calcium action potentials in a
clonal pituitary cell line and their relationship to prolactin
secretion. Nature 258, 741-742.
KIRKHAM, K.E. and HUNTER, W. (1971) Radioimmunoassay Methods
London: Churchill Livingstone.
KISH, S.J., PERRY, T.L. and HANSEN, S. (1979) Regional distribution
of homocarnosine, homocarnosine-carnosine synthetase and
homocarnosinase in human brain. J. Neurochem. 32, 1629-1636.
KIZER, J.S., PALKOVITS, M. and BROWNSTEIN, M.J. (1978) The
projections of the A8, A9 and A10 dopaminergic cell bodies:
evidence for a nigro-hypothalamic-median eminence dopaminergic
pathway. Brain Res. 108, 363-370.
KIZER, J.S., PALKOVITS, M., TAPPAZ, M., KEBABIAN, J. and
BROWNSTEIN, M.J. (1976) Distribution of releasing factors,
biogenic amines, and related enzymes in the bovine median
eminence. Endocrinology 98, 685-695.
KLEINROK, A. and KILBINGER, H. (1983) y-Aminobutyric acid and
cholinergic transmission in the guinea-pig ileum. Naunyn-
Schmiedeberg1s Arch. Pharmacol. 322. 216-220.
KLEPNER, C.A., LIPPA, A.S., BENSON, D.I., SANO, M.C. and BEER, B.
(1979) Resolution of two biochemically and pharmacologically
distinct benzodiazepine receptors. Pharmacol. Behav. 11, 457-462.
KNEPEL, W., NUTTO, D., ANHUT, H. and HERTTING, G. (1982)
Vasopressin and a-endorphin release after osmotic and non-osmotic
stimuli: effect of naloxone and dexamethasone. Europ. J.
Pharmacol. 77, 299-306.
KNEPEL, W., NUTTO, D. and HERRTING, G. (1980) Evidence for the
involvement of a GABA-mediated inhibition in the
hypervolaemia-induced vasopressin release. Pflugers Arch. 388,
177-183.
KNEPEL, W., NUTTO, D., LOEFFLER, J-P. and FELTZ, P. (1984) The
effect of GABA on vasopressin release from rat neurohypophysis in
vitro. Proceedings of IUPHAR meeting, London. 351.
KNEPEL, W. and SCHWANIGER, M. (1985) Release of dynorphin-1ike
immunoreactivity from rat anterior pituitary gland in vitro.
Naunyn-Schmiedeberg1s Arch. Pharmacol. 329, 94-96.
KOE, B.K. (1976) Molecular geometry of inhibitors of the uptake
of catecholamines and serotonin in synaptosomal preparations of
rat brain. J. Pharm. Exp. Ther. 199, 649-661.
KOULU, M., LAMMINTAUSTA, R. and DAHLSTROM, S. (1979) Stimulatory
effect of acute baclofen administration on human growth hormone
secretion. J. Clin. Endo. Metab. 413, 1038-1040.
KOULU, M., LAMMINTAUSTA, R., KANGAS, L. and DAHLSTROM, S. (1970)
The effect of methysergide, pimozide and sodium valproate on the
diazepam-stimulated growth hormone secretion in man. J. Clin.
Endo. Metab. 48, 119-122.
KOZHECHKIN, S.N. and OSTROVSKYA, R.V. (1977) Are benzodiazepines
GABA antagonists? Nature 269, 72-73.
KRNJEVIC, K. and PH ILL IS, J.W. (1963) Iontophoretic studies of
neurones in the mammalian cerebral cortex. J. Physiol. 165,
274-304.
KRNJEVIC, K. and SCHWARTZ, S. (1966) Is y-aminobutyric acid an
inhibitory neurotransmitter? Nature 211, 1372-1374.
KROGSGAARD-LARSEN, P. and FALCH, E. (1981) GABA agonists.
Development and interactions with the GABA receptor complex.
Mol. Cell. Biochem. 38, 129-146.
KROGSGAARD-LARSEN, P. and JOHNSTON, G.A.R. (1975) Inhibition of
GABA uptake in rat brain slices by nipecotic acid, various
isoxazoles and related compounds. J. Neurochem. 25_, 797-802.
KROGSGAARD-LARSEN, P., JOHNSTON, G.A.R., LODGE, D. and CURTIS, D.R.
(1977) A new class of GABA agonists. Nature 268, 53-55.
LAHTI, R.A., VON VOIGTLANDER, P.F. and BARSUHNI, C. (1982)
Properties of a selective kappa agonist, U50,488H. Life Sci. 31,
2257-2260.
LAMBERTS, R., VIJAYAN, E., GRAF, M., MANSKY, T. and WUTTKE, W.
(1983) Involvement of pre-optic-anterior hypothalamic GABA
neurons in the regulation of pituitary LH and prolactin release.
Exp. Brain Res. 52_, 356-362.
LAMBERTS, S.W.J, and MACLEOD, R.M. (1978) Studies on the mechanisms
of the GABA-mediated inhibition of prolactin secretion. Proc.
Soc. Exp. Biol. Med. 158, 10-13.
LANGER, S.Z. (1980) Presynaptic regulation of the release of
catecholamines. Pharm. Revs. _39, 337-362.
LARSEN, O.M., THORBEK, P., KROGSGAARD-LARSEN, P. and SCHOUSBOE, A.
(1981) Effect of homo-s-proline and other heterocyclic GABA
analogues on GABA uptake in neurones and astroglial cells and on
GABA receptor binding. J. Neurochem. 17, 1509-1516.
LATORRE, R. and MILLER, C. (1983) Conduction and selectivity in
potassium channels. J. Memb. Biol. _71, 11-30.
LAWSON, D.M., GALA, R.R., CHIN, M.L. and HAISENLEDER, D.H. (1980)
Size heterogeneity of plasma prolactin in the rat. TRH and
serotonin-induced changes. Life Sci. 27_, 1147-1151.
LERANTH, Cs., PALKOVITS, M. and KREIGER, D.T. (1983) Serotonin
immunoreactive nerve fibres and terminals in rat
pituitary-1 ight-and electronmicroscopic studies. Neuroscience 9_,
289-296.
LEEB-LUNDBERG, F., NAPIAS, C. and OLSEN, R.W. (1981)
Dihydropicrotoxinin binding sites in mammalian brain: interaction
with convulsant and depressant benzodiazepines. Brain Res. 216,
399-408.
LENNEY, J.F., KAN, S-C., SIU, K. and SUGIYAMA, G.H. (1977)
Homocarnosine: a hog kidney dipeptidase with a broader
specificity than carnosinase. Arch. Biochem. Biophys. 184,
257-266.
LEONG, D.A., FRAWLEY, S. and NEILL, J.D. (1983) Neuroendocrine
control of prolactin secretion. Ann. Rev. Physiol. 45, 109-127.
LERANTH, C., MACLUSKY, N.J., SAKAMOTO, H., SHANABROUGH, M. and
NAFTOLIN, F. (1985) Glutamic acid decarboxylase-containing
axons synapse on LHRH neurons in the rat medial preoptic area.
Neuroendocrinology 40, 536-539.
LEVI, G., BERTOLLINI, A., CHEN, J. and RAITERI, M. (1974) Regional
differences in the synaptosomal uptake of ^Hy-aminobutyric acid
and l^C-glutamate ancj possible role of exchange processes.
J.Pharm. Exp. Ther. 188, 429-438.
LEVI, G., COLETTI, A., POCE, U. and RAITERI, M. (1976) Decrease
of uptake and exchange of neurotransmitter amino acids after
depletion of their synaptosomal pools. Brain Res. 103, 103-116.
LEVI, G. and RAITERI, M. (1973) Detectabi1ity of high and low
affinity uptake systems for GABA and glutamate in rat brain
slices and synaptosomes. Life Sci. 12_, 81-88.
LEVI, G. and RAITERI, M. (1974) Exchange of neurotransmitter amino
acids at nerve endings can simulate high affinity uptake. Nature
250, 735-737.
LIBERTSUN, C., ARAKELIAN, M.C., LARREA, G.A. and FOGLIA, V.G. (1979)
Inhibition of prolactin secretion by GABA in female and male
rats. Proc. Soc. Exp. Biol. Med. 161, 28-31.
LIGHTMAN, S.C., IVERSEN, L.L. and FORSLING, M.L. (1982) Dopamine
and [D-Ala^, D-Leu^] enkephalin inhibit the electrically
stimulated neurohypophysial release of vasopressin in vitro:
evidence for calcium-dependent opiate action. J. Neurosci. 2,
78-81.
LINTON, E.A., WHITE, N., LIRA DE TINEO, 0. and JEFFCOATE, S.L.
(1981) 2-Hydroxyoestradiol inhibits prolactin release from the
superfused rat pituitary gland. J. Endocrinol. 9£, 315-322.
LOCATELLI, V., COCCHI, D., FRIGERIO, C., BETTI, R.,
KROGSGAARD-LARSEN, P., RACAGNI, G., and MULLER, E.E. (1979) Dual
y-aminobutyric acid control of prolactin secretion in the rat.
Endocrinology 105, 778-785.
LOCATELLI, V., COCCHI, D., RACAGNI, G., CATTABENI, F., MAGGI, A.,
KROGSGAARD-LARSEN, P. and MULLER, E.E. (1978)
Prolactin-inhibiting activity of gamma-aminobutyric acid-mimetic
drugs in the male rat. Brain Res. 145, 173-179.
LOEFFLER, J-P., DESAULLES, E., DEMENEIX, B.A. and FELTZ, P. (1982)
Electrophysiological study with K+-and Ca2+-sensitive
micropipettes of GABA receptors in the rat neurointermediate lobe
in vitro. Neurosci. Lett. M., 271-276.
LOOKINGLAND, K.J., FARAH, M.J., LOVELL, K.L. and MOORE, K.E. (1985)
Differential regulation of tuberohypophysial dopaminergic neurons
terminating in the intermediate lobe and in the neural lobe of
the rat pituitary gland. Neuroendocrinology 40, 145-151.
LOTZ, W. (1982) Benzodiazepine antagonist Rol5-1788 counteracts the
prolactin-lowering effects of other benzodiazepines in rats.
Neuroendocrinology ^3, 32-36.
LUMPKIN, M.D., SAMSON, W.K. and McCANN, S.M. (1983) Hypothalamic
and pituitary sites of action of oxytocin to alter prolactin
secretion in the rat. Endocrinology 112, 1711-1717.
MACDONALD, R.L. and BARKER, J.L. (1978) Benzodiazepines
specifically modulate GABA-mediated postsynaptic inhibition in
cultured mammalian neurones. Nature 271, 563-364.
MACDONALD, R.L. and BARKER, J.L. (1979) Enhancement of
GABA-mediated post-synaptic inhibition in cultured mammalian
spinal cord neurones: a common mode of anticonvulsant action.
Brain Res. 167, 323-336.
MACDONALD, R.L., SKERRITT, J.H. and MCLEAN, M.J. (1984)
Anticonvulsant drug actions on GABA responses and sustained
repetitive firing of neurones in cell culture. Neuropharmacology
23, 843-844.
MACDONALD, R.L. and YOUNG, A.B. (1981) Pharmacology of GABA-
mediated inhibition of spinal cord neurons in vivo and in primary
dissociated cell culture. MoT. cell Biochem. 38, 147-162.
MACLEOD, N.K. and STRAUGHAN, D.W. (1979) Responses of olfactory
bulb neurones to the dipeptide carnosine. Exp. Brain Res. 34,
183-188.
MACLEOD, R.M., FONTHAM, E.H. and LEHMEGER, J.E. (1970) Prolactin
and growth hormone production as influenced by catecholamines and
agents that affect brain catecholamines. Neuroendocrinology 6^,
283-294.
MADISON, D.V. and NICOLL, R.A. (1982) Noradrenaline blocks
accommodation of pyramidal cell discharge in the hippocampus.
Nature 299, 636-638.
MAEDA, K. and FROHMAN, L.A. (1980) Release of somatostatin and
thyrotropin-releasing hormone from rat hypothalamic fragments in
vitro. Endocrinology 106, 1837-1842.
MAJEWSKA, M.D. and CHUANG, D.M. (1985) Benzodiazepines enhance the
muscimol-dependent activation of phospholipase in glioma
Cg cells. J. Pharm. Exp. Ther. 232, 650-655.
MAKARA, G.B., HARRIS, M.C. and SPYER, M.K. (1982) Identification
and distribution of tuberoinfundibular neurones. Brain Res. 40,
283-290
MAKARA, G.B., PALKOVITS, M., ANTONI, F.A. and KISS, J.Z. (1983)
Topography of the somatostatin-immunoreactive fibres to the
stalk-mediam eminence of the rat. Neuroendocrinology 37_, 1-8.
MAKARA, G.B., RAPPAY, G. and STARK, E. (1975) Autoradiographic
localization of 3H_gamma-aminobutyric acid in the medial
hypothalamus. Exp. Brain Res. 22, 449-455.
MAKARA, G.B. and STARK, E. (1974) Effect of gamma-aminobutyric
acid (GABA) and GABA antagonist drugs on ACTH release.
Neuroendocrinology 16_. 178-190.
MANSKY, T., MESTRES-VENTURA, P. and WUTTKE, W. (1982) Involvement
of GABA in the feedback action of estradiol on gonadotropin and
prolactin release: hypothalamic GABA and catecholamine turnover
rates. Brain Res. 231, 353-364.
MAO, C.C., GUIDOTTI, A. and COSTA, E. (1974) Interactions between
gamma-aminobutyric acid and guanosine 3', 51-monophosphate in rat
cerebellum. Molec. Pharmacol. 10, 736-745.
MARANGOS, P.J., PATEL, J., BOULENGER, J-P and CLARK-ROSENBERG, R.
(1982) Characterisation of peripheral type benzodiazepine
binding sites in brain using [^H] Ro5-4864. Molec. Pharmacol.
22, 26-32.
MARGOLIS, F.L. (1974) Carnosine in the primary olfactory pathway.
Science 184, 909-911.
MARGOLIS, F.L., GRILLO, M., GRANNOT-REISFELD, N and FARBMAN, A.I.
(1983) Purification, characterization and immunocytochemical
localization of mouse kidney carnosine. Biochem. Biophys. Acta.
744, 237-248.
MARTIN, S.A. and SMITH, A.A. (1972) Ions and the transport of
gamma-aminobutyric acid by synaptosomes. J. Neurochem. 19,
841-855.
MARTIN, I.L., BROWN, C.L. and DOBLE, A. (1983) Multiple
benzodiazepine receptors: structures in the brain or structures
in the mind? A critical review. Life Sci., 32, 1925-1933.
MARTIN, I.L. and CANDY, J.M. (1978) Facilitation of benzodiazepine
binding by sodium chloride and GABA. Neuropharmacology, 17,
9 93- 998.
MARTIN, J.B. (1976) Brain regulation of GH secretion. In:
Frontiers in neuroendocrinology, vol. 4, pp.129-168. Eds.
L. Martini and W.F. Ganong, Raven Press, New York.
MARTIN, J.B., DURAND, D., GURD, W., FAILLE, G., AUDET, J. and
BRAZEAU, P. (1978) Neuropharmacologic regulation of episodic
growth hormone and prolactin secretion in the rat. Endocrinology
102, 106-113.
MARTIN, R. and VOIGT, K.H. (1981) Enkephalins coexist with
oxytocin and vasopressin in nerve terminals of rat neurohyophysis.
Nature 289, 299-303.
MARTINI, C., RIGACCI, T. and LUSACCHINI, A. (1983) [3H] muscimol
binding site on purified benzodiazepine receptor. J. Neurochem.
41, 1183-1185.
MASON, W.T. and WARING, D.W. (1984) Intracellular recording from
gonadotrophs of ovin hypophyseal pars tuberalis (PT).
J. Physiol. 350, 73P.
MATHERS, D.A. and BARKER, J.C. (1980) (-) Pentobarbital opens ion
channels of long duration in cultured mouse spinal neurons.
Science 209, 507-509.
MATHISON, R.D. and DREIFUSS, J.J. (1980) Structure-activity
relationships of a neurohypophysial GABA receptor. Brain Res.
187, 476-480.
MATSUSHITA, N., KATO, Y., SHIMATSU, A., KATAKAMI, H., YANAIHARA, N.
and IMURA, H. (1983) Effects of VIP, TRH, GABA and dopamine on
prolactin release from superfused rat anterior pituitary cells.
Life Sci. 32 (1983) 1263-1269.
MATTHEW, E., LASKIN, J.D., ZIMMERMAN, E.A., WEINSTEIN, I.B.,
HSU, K.C. and ENGELHARDT, D.L. (1981) Benzodiazepines have
high-affinity binding sites and induce melanogenesis in B16/C3
melanoma cells. Proc. Natl. Acad. Sci., USA., 78, 3935-3939.
MATTILA, J. and MANNISTO, P.t. (1980) Modification of GABAergic
activity and thyrotropin secretion in male rats. Acta Pharmacol,
et Toxicol. 47, 241-248.
McCANN, S.M., VIJAYAN, E., NEGRO-VILAR, A., MIZUNUMA, H. and
MANGAT, H. (1984) Gamma aminobutyriuc acid (GABA), a modulator
of anterior pituitary hormone secretion by hypothalamic and
pituitary action. Psychoneuroendocrinology 9^, 97-106.
Mclaughlin, b.j., wood, j.g., saito, k., barber, r., vaughn, j.e.,
ROBERTS, E. and wu, J-Y. (1974) The fine structural
localization of glutamate decarboxylase in synaptic terminals of
rodent cerebellum. Brain Res. 76, 377-391.
McLENNAN, H. (1959) The identification of one active component
from brain extracts containing Factor 1. J. Physiol. 146,
358-368.
MELIS, G.B., FUZETTI, F., PAOLETTI, A.M., MAIS, V., KEMENY, A.,
STRIGINI, F., BOLDRINI, A. and FIORETTI, P. (1984)
Pharmacological activation of y-aminobutyric acid-system blunts
prolactin response to mechanical breast stimulation in puerperal
women. J.Clin. Endo. Metab. ji8, 201-205.
deMELLO, F.G. (1984) GABA-mediated control of glutamate
decarboxylase (GAD) in cell aggregate culture of chick embryo
retina. Dev. Brain Res. 1£, 7—13.
MESTRE, M., CARRIOT, T., BELIN, C., UZAN, A., RENAULT, C.,
DUBROEUCQ, M.C., GUEREMY, C., DOBLE, A. and LEFUR, G. (1985)
Electrophysiological and pharmacological evidence that peripheral
type benzodiazepine receptors are coupled to calcium channels in
the heart. Life Sci. 36, 391-400.
MIDGLEY, A.R., NISWENDER, G.D. and REBAR, R.W. (1969) Principles
for the assessment of the reliability of radioimmunoassay methods
(precision, accuracy, sensitivity, specificity). Acta
Endocrinol. Suppl. 142, 163-180.
MILLAN, M.J., MILLAN, M.H. and HERZ, A. (1983) Contribution of the
supraoptic nucleus to brain and pituitary pools of immunoreactive
vasopressin and particular opioid peptides, and the
interrelationships between these in the rat. Neuroendocrinology
36, 310-319.
MINCHIN, M.C.W. and NORDMANN, J.J. (1975) The release of
[^Hjgamma-aminobutyric acid and neurophysin from the isolated
rat posterior pituitary. Brain Res. 90, 75-84.
MIODUSZEWSKI, R., GRANDISON, L. and MEITES, J. (1976) Stimulation
of prolactin release in rats by GABA. Proc. Soc. Exp. Biol. Med.
151, 44-46.
MITCHELL, P.R. (1979) Benzodiazepines and presynaptic mechanisms.
Ph.D. Thesis, University of Birmingham.
MITCHELL, R. (1982) Interactions of agonists and antagonists with
a novel GABA receptor. Biochem. Pharmacol. 31_, 2684-2686.
MITCHELL, R., GRIEVE, G., DOW, R. and FINK, G. (1983) Endogenous
GABA receptor ligands in hypophysial portal blood.
Neuroendocrinology 37^ 169-176.
MITCHELL, P.R. and MARTIN, I.L. (1978a) The effects of
benzodiazepines on K+-stimulated release of GABA.
Neuropharmacology 17, 317-320.
MITCHELL, R. and MARTIN, I.L. (1978b) Is GABA release modulated
by presynaptic receptors? Nature 274, 904-905.
MITCHELL, R. and OGIER, S-A. (1985) A novel stimulatory action of
somatostatin on prolactin secretion. Brit. J. Pharmacol.
Edinburgh meeting.
MITCHELL, R. and WILSON, L.E. (1984) Investigation of the effects
of muscimol on different components of [3h] propyl
B-carboline-3- carboxylate binding to rat hippocampal and
cerebellar membranes. Europ. J. Pharmacol. 97, 315-319.
MITTRA, I. (1980a) A novel 'cleaved prolactin' in the rat
pituitary: Part 1. Biosynthesis, characterization and regulatory
control. Biochem. Biophys. Res. Commun. 95, 1750-1759.
MITTRA, I. (1980b) A novel 'cleaved prolactin' in the rat
pituitary: Part II. In vivo mammary mitogenic activity of its
N-terminal 15K moiety^ Biochem. Biophys. Res. Commun. 95,
1760-1767.
MOHLER, H. and OKADA, T. (1977b) Properties of [^H] diazepam
binding to benzodiazepine receptors in rat cerebral cortex. Life
Sci., 20, 2101-2110.
MOHLER, H. and OKADA, T. (1977b) GABA receptor binding with
3h (+)bicuculline-methiodide in rat CNS. Nature 267, 65-67.
MOHLER, H., OKADA, T., HEITZ, P.H. and ULRICH, J. (1978)
Biochemical identification of the site of action of
benzodiazepines in human brain. Life Sci., 22_, 985-996.
MOHLER, H. and RICHARDS, J.G. (1983) Autoradiographical
visualisation and pharmacological characterization of
[^H] Ro5-4864 binding in the CNS. Brit. J. Pharmacol. _79. 280P.
MONTEL, H., STARKE, K. and WEBER, F. (1974) Influence of morphine
and naloxone on the release of noradrenaline from rat brain
cortex slices. Naunyn-Schmiedeberg's Arch. Pharmacol. 283,
357-369.
MOORE, K.E., DEMAREST, K.T., and JOHNSTON, C.A. (1980) Influence
of prolactin on dopaminergic neuronal systems in the
hypothalamus. Fed.Proc. _39, 2912-2916.
MORITA, K. and NORTH, R.A. (1980) Opiate activation of potassium
conductance in myenteric neurones: inhibition by calcium ion.
Brain Res. 242, 145-150.
MORONI, F., MULAS, A., MONETI, G. and PEPEU, G. (1982) In vivo
changes in y-aminobutyric acid output from the cerebral cortex
induced by inhibitors of y-aminobutyric acid uptake and
metabolism. J. Neurochem 39_, 582-584.
MUDGE, A.W., LEEMAN, S.E. and FISCHBACH, G.D. (1979) Enkephalin
inhibits release of substance P from sensory neurones in culture
and decreases action potential duration. Proc. Natl. Acad. Sci.
USA. 76, 526-530.
MUHYADDIN, M., ROBERTS, P.J. and WOODRUFF, G.N. (1982) Presynaptic
Y-aminobutyric acid receptors in the rat anococcygeus muscle and
their antagonism by 5-aminovaleric acid. Brit. J. Pharmacol. 77,
163-168.
MULCHALLEY, J.J. and NEILL, J.D. (1982) Gamma-aminobutyric acid
(GABA) in hypophyseal stalk plasma of rats. Life Sci. 31,
453-456.
MULDER, A.H. and SNYDER, S.H. (1974) Potassium-induced release of
amino acids from cerebral cortex and spinal cord slices of the
rat. Brain Res. 76_, 2 97- 308.
MULDER, A.H., WARDEH, G. H0GENB00M, F. and FRANKHUYZEN, A.L.
(1984) 1C- and s-opioid receptor agonists differentially inhibit
striatal dopamine and acetylcholine release. Nature 308, 278-280.
MULLER, W.E. and SNYDER, S.H. (1978) Glycine high affinity uptake
and strychnine binding associated with glycine receptors in the
frog central nervous system. Brain Res. 143, 487-498.
NADLER, J.V., WHITE, W.F., VACA, K.W., and COTMAN, C.W. (1977)
Calcium-dependent Y-aminobutyrate release by inter-neurones of
rat hippocampal regions: lesion-induced plasticity. Brain Res.
131, 241-258.
NEAL, M.J. and BOWERY, N.G. (1979) Differential effects of
veratridine and potassium depolarization on neuronal and glial
GABA release. Brain Res. 167, 337-343.
NEAL, M.J. and IVERSEN, L.L. (1969) Subcellular distribution of
endogenous and [^H] Y-aminobutyric acid in rat cerebral
cortex. J. Neurochem. L6, 1245-1252.
NEGRO-VILAR, A., OJEDA, S.R., ARIMURA, A. and McCANN, S.M. (1978)
Dopamine and norepinephrine stimulate somatostatin release by
median eminence fragments in vitro. Life Sci. ^3, 1493-1498.
NEGRO-VILAR, A., VIJAYAN, E. and McCANN, S.M. (1980) The effect of
intraventricular gamma-aminobutyric acid (GABA) on hypothalamic
catecholamines and LHRH on pituitary hormone release. Brain Res.
Bull. 5, 239-244.
NELSON, P.G., RANSOM, B.R., HENKART, M. and BULLOCK, P.N. (1977)
Mouse spinal cord in culture. IV. Modulation of inhibitory
synaptic function. J. Neurophysiol. 40, 1178-1187.
NESTOROS, J.N. and NISTRI, A. (1978) A presynaptic component of
the action of iontophoretically applied flurazepam on feline
cortical neurones. Can. J. Physiol. Pharmacol. 56_, 889-892.
NEWBERRY, N.R. and NICOLL, R.A. (1984a) Direct hyperpolarizing
action of baclofen on hippocampal pyramidal cells. Nature 308,
450-452.
NEWBERRY, N.R. and NICOLL, R.A. (1984b) A bicucul1ine-resistant
inhibitory postsynaptic potential in rat hippocampal pyramidal
cells in vitro. J. Physiol. 348, 239-254.
NG, R.H. and MARSHALL, F.D. (1978) Regional and subcellular
distribution of homocarnosine-carnosine synthetase in the central
nervous system of rats. J. Neurochem. 30, 187-190.
NICOLETTI, F., CLEMENTI, G., PRATO, A., CANONICO, P.L., RAMPELLO,
L., PATH, F., DIGI ORG 10, R.M. and SCAPAGNINI, U. (1983)
Effects of hyper- and hypoprolactinaemia on glutamate
decarboxylase activity in medial basal hypothalamus of male rat.
Neuroendocrinology 36, 13-16.
NICOLETTI, F., GRANDISON, L. and MEEK, J.L. (1985) Effects of
repeated administration of estradiol benzoate on
tubero-infundibular GABAergic activity in male rats. J.
Neurochem. 44, 1217-1220.
NICOLL, R.A. (1975) Pentobarbital: action on frog motorneurones.
Brain Res. 96_, 119-123.
NICOLL, R.A., ECCLES, J.C., OSHIMA, T.C. and RUBIA, F. (1975)
Prolongation of hippocampal inhibitory postsynaptic potentials by
barbiturates. Nature 258, 625-627.
NICOLL, R.A., PADJGEN, A. and BARKER, J.K. (1976) Analysis of
amino acid responses on frog motorneurones. Neuropharmacology
15_, 45-53.
NIELSEN, M., SCHOU, H. and BRAESTRUP, C. (1981) [3H] propyl
6-carboline-3-carboxylate binds specifically to brain
benzodiazepine receptors. J. Neurochem. 276-285.
NIKOLICS, K., MASON, A.J., SZONYI, E., RAMACHANDRAN, J. and SEEBURG,
P.H. (1985) A prolactin-inhibiting factor with the precursor
for human gondotrophin-releasing hormone. Nature 316, 511-517.
NISTRI, A. (1975) Further investigations into the effects of
baclofen (Lioresal) on the isolated spinal cord. Experimentia
31, 1066-1068.
NISTRI, A. and CONSTANTI, A. (1978) Effects of flurazepam on amino
acid-evoked responses recorded from the lobster muscle and frog
spinal cord. Neuropharmocology 17, 127-135.
NISWENDER, C.D., MIDGELEY, A.R.Jr., MONROE, S.E. and
REIHERT, L.G.Jr. (1968) Radioimmunoassay for rat luteinizing
hormone with antiovine LH serum and ovine LH—^-25j^ proc. Soc.
Exp. Biol. Med., 128, 807-811.
NORTH, R.A. and WILLIAMS, J.T. (1983) Opiate activation of
potassium conductance inhibits calcium action potentials in rat
locus coeruleus neurones. Brit. J. Pharmacol., 80, 225-228.
NOWAK, L.M. and MACDONALD, R.L. (1982) Substance P: ionic basis
for depolarizing responses of mouse spinal cord neurones in cell
culture. J. Neurosci. 2, 1119-1128.
O'DONOHUE, T.L., MILLER, R.L.and JACOBOWITZ, D.M. (1979)
Identification, characterization and stereotaxic mapping of
intraneuronal a-melanocyte stimulating hormone-like
immunoreactive peptides in discrete regions of the rat brain.
Brain Res. 176, 101-123.
OERTEL, W.H., MUGNAINI, E., TAPPAZ, M.L., WEISE, V.K., DAHL, A-L.,
SCHNECHEL, D.E. and KOPIN, I.J. (1982) Central GABAeregic
innervation of neurointermediate pituitary lobe: Biochemical and
immunocytochemical study in the rat. Proc. Natl. Acad. Sci. USA
79, 675-679.
OLIVER, C., MICAL, R.S. and PORTER, J.C. (1977) Hypothalamic
pituitary vasculature: evidence for retrograde blood flow in
pituitary stalk. Endocrinology 101, 598-604.
OLIVER, C. and PORTER, J.C. (1978) Distribution and
characterisation of ct-mel anocyte stimulating hormone in the rat
brain. Endocrinology 102, 697-705.
OLSEN, R.W. (1982) Drug interactions at the GABA receptor-
ionophore complex. Ann. Rev. Pharmacol. 22_, 245-277.
OLSEN, R.W., BAN, M., MILLER, T. and JOHNSTON, G.A.R. (1975)
Chemical instability of the GABA antagonist bicuculline under
physiological conditions. Brain Res. 98, 383-387.
OLSEN, R.W., BERGMAN, M.O., VAN NESS, P.C., LUMMIS, S.C.,
WATKINS, A.E., NAPIAS, C. and GREENLEE, D.V. (1981)
•y-aminobutyric acid receptor binding in mammalian brain.
Heterogeneity of binding sites. Molec. Pharmacol. 1^, 217-227.
OLSEN, R.W. TICKU, M.K., VAN NESS, P.C. and GREENLEE, D. (1978)
Effects of drugs on GABA receptors, uptake, release and synthesis
in vitro. Brain Res. 139, 277-294.
OLSEN, R.W. and WONG, E.H.F. (1984) Modulation of GABA and
benzodiazepine receptor antagonist binding by barbiturates in rat
cortical membranes. Brit. J. Pharmacol. 82, 237P.
ONDO, J.G. (1974) Gamma-aminobutyric acid, effects on pituitary
gonadotrophin secretion. Science 186, 738-739.
ONDO, J.G. and PASS, K.A. (1976) The effects of neurally active
amino acids on prolactin secretion. Endocrinology 98, 1248-1252.
ONG, J. and KERR, D.I.B. (1983) Interactions between GABA and
5-hydroxytryptamine in the guinea-pig ileum. Europ. J.
Pharmacol. 94, 305-312.
OZAWA, S. and KIMURA, N. (1979) Membrane potential changes caused
by thyrotropin-releasing hormone in the clonal GH3 cell and
their relation to secretion of pituitary hormone. Proc. Nat.,
Acad. Sci. USA. _76, 6017-6020.
OZAWA, S., and SAND, 0. (1978) Electrical activity of rat anterior
pituitary cells in vitro. Acta. Physiol. Scand. 102, 330-341.
PALFREYMAN, M.G., BOHLEN, P., HUOT, S. and MELLET, M. (1980) The
effect of y-vinyl GABA and y-acetylenic GABA on the concentration
of homocarnosine in brain and CSF of the rat. Brain Res. 190,
288-292.
PAGE, R.B. (1983) Directional pituitary blood flow: a micro-
cinephotographic study. Endocrinology 112. 157-165.
PALKOVITS, M., SAAVEDRA, M.J., JACOBOWITZ, D.M., KIZER, J.S.,
ZABORSZKY, L. and BROWNSTEIN, M.J. (1977) Serotonin innervation
of the forebrain: Effect of lesions on 5-HT and tryptophan
hydroxylase levels. Brain Res. 130, 121-134.
PASS, K.A. and ONDO, J.G. (1977) The effects of y-aminobutyric
acid on prolactin and gonadotropin secretion in the
unanaesthetized rat. Endocrinology 100, 1437-1442.
PASSO, S.S., THORNBOROUGH, J.R. and FERRIS, C.F. (1981) A
functional analysis of dopaminergic innervation of the
neurohypophysis. Am. J. Physiol. 241, E186-190.
PATERSON, S.J., ROBSON, L.E. and KOSTERLITZ, H.W. (1983)
Classification of opioid receptors. Brit. Med. Bull. 39 31-36.
PERKINS, N.A. and WESTFALL, T.C. (1978) The effect of prolactin on
dopamine release from rat striatum and medial basal
hypothalamus. Neuroscience 3, 59-63.
PERRY, T.L. and HANSEN, S. (1973) Sustained drug-induced elevation
of brain GABA in the rat. J. Neurochem. _21, 1167-1175.
PERRY, T.L., HANSEN, S. and KLOSTER, M. (1973) Huntington's
Chorea: deficiency of y-aminobutyric acid in brain. N. Eng. J.
Med. 288, 337-342.
PERRY, T.L., KISH, S.J., SJAASTAD, 0., GJESSING, L.V., NESBAKKEN, R.,
SCHRADER, H. and LOKEN, A.C. (1979) Homocarnosinosis: increased
content of homocarnosine and deficiency of homocarnosinase in
brain. J. Neurochem. 32_, 1637-1640.
PETERS, L.L., HOEFER, M.T. and BEN-JONATHAN, N. (1981) The
posterior pituitary: regulation of anterior pituitary prolactin
secretion. Science 213, 659-661.
PETERSEN, O.H. and MARUYAMA, Y. (1984) Calcium-activated potassium
channels and their role in secretion. Nature 307, 693-696.
PIERI, L., POLC, P., BONETTI, E.P., CUMIN, R., SCHERSCHLICHT, R. and
HAEFELY, W. (1983) Some neuropharmacological effects of
Ro5-4864, a specific ligand of the peripheral type of
benzodiazepine binding site. Naunyn-Schmiedebergs Arch.
Pharmacol. 322 R.95.
PICKERING, A.J.M.C. (1978) Aspects of the mechanism of action of
the gonadotrophin releasing hormone. D.Phil. Thesis: Oxford Univ.
PISANO, J.J., WILSON, J.D., COHEN, L., ABRAHAM, D. and UDENFRIEND, S.
Isolation of y-aminobutyryl histidine (homocarnosine) from
brain. J. Biol. Chem. 236, 499-502.
PITTMAN, Q.J., BLUME, H.W. and RENAUD, L.P. (1978) Electro¬
physiological indications that individual hypothalamic neurons
innervate both median eminence and neurohypophysis. Brain Res.
157, 364-368.
PLOTSKY, P.M. and NEILL, J.D. (1982) Interactions of dopamine and
thyrotropin releasing hormone (TRH) in the regulation of
prolactin release in lactating rats. Endocrinology 111, 168-173.
POLC, P., MOHLER, H. and HAEFELY, W. (1974) The effect of diazepam
on spinal cord activities: possible sites and mechanisms of
action. Naunyn-Schmiedebergs Arch. Pharmacol. 284, 319-337.
POTASHNER, S.J. (1978a) The effects of tetrodotoxin, calcium and
magnesium on the release of amino acids from slices of guinea-pig
cerebral cortex. J. Neurochem. 31.> 187-195.
POTASHNER, S.J. (1978b) Baclofen: effects on amino acid release
Can. J. Physiol. Pharmacol. 5_6, 150-154.
PRATO, A., CLEMENTI,G., NICOLETTI, F., CANONICO, P.L., PATTI, F.,
CONDORELLI, D.F., DIGIORGIO, R.M. and DRAZO, F. (1981) Possible
role of prolactin in the modification of medial basal
hypothalamic glutamic acid decarboxylase activity. Europ. J.
Pharmacol. Ti_, 169-172.
PRICE, G.W., WILKIN, G.P., TURNBULL, M.J. and BOWERY, N.G. (1984)
Are baclofen-sensitive GABAg receptors present on primary
afferent terminals of the spinal cord? Nature 307, 71-74.
PRZEWLOCKI, R., SHEARMAN, G.T. and HERZ, A. (1983) Mixed
opioid/nonopioid effects of dynorphin and dynorphin related
peptides after their intrathecal injection in rats.
Neuropeptides 3^, 233-240.
QUAST, U. and MAHLMANN, H. (1982) Interaction of
[^Hjflunitrazepam with the benzodiazepine receptor: evidence
for a 1 igand-induced confirmation change. Biochem. Pharmacol.
31, 2761-2768.
RACAGNI, G. and APUD, J.A. (1982) Y-aminobutyric acid (GABA) and
dopamine (DA) interactions in the hypothalamo-pituitary system;
physiological and functional role in prolactin secretion. Acta
Physiol, et Pharmacol. Bulgarica 8, 13-23.
RACAGNI, G., APUD, J.A., COCCHI, D., LOCATELLI, V. and MULLER, E.E.
(1982) GABAergic control of anterior hormone secretion. Life
Sci. 31, 823-838.
RACAGNI, G., APUD, J.A., IULIANO, E., COCCHI, D., LOCATELLI, V. and
MULLER, E.E. (1983) Anterior pituitary GABA receptors in
relation to prolactin secretion.In: CNS receptors - from
molecular pharmacology to behaviour. Ed. Mandel, P. and
DeFeudis, F.V. Raven Press, New York pp.123-135.
RACAGNI, G., APUD, J.A., LOCATELLI, V., COCCHI, D., NISTICO, G.
DIGIORGIO, R.M. and MULLER, E.E. (1979) GABA of CNS origin in
the rat anterior pituitary inhibits prolactin secretion. Nature
281, 575-578.
RACKE, K., RITZEL, H., TRAPP, B. and MUSCHOLL, E. (1982)
Dopaminergic modulation of evoked vasopressin release from the
isolated neurohypophysis of the rat. Possible involvement of
endogenous opioids. Naunyn-Schmiedebergs Arch. Pharmacol. 319,
56-65.
RANCE, N., WISE, P.M., SELMANOFF, M.K. and BARRACLOUGH, C.A. (1981)
Catecholamine turnover rates in discrete hypothalamic areas and
associated changes in median eminence luteinizing
hormone-releasing hormone and serum gonadotropins on proestrus
and diestrus day 1. Endocrinology 108, 1795-1802.
RANSOM, B.R. and BARKER, J.L. (1976) Pentobarbital selectively
enhances GABA-mediated post-synaptic inhibition in tissue
cultured mouse spinal neurones. Brain Res. 114, 530-535.
RAYMOND, V., BEAULIEU, M., LABRIE, F. and BOISSIER, J. (1978)
Potent antidopaminergic activity of estradiol at the pituitary
level on prolactin release. Science 200, 1173-1174.
REGAN, J.W., YAMAMURA, H.I., YAMADA, S. and ROESKI, W.R. (1981)
High affinity renal [^H]flunitrazepam binding:
Characterisation, localisation and alteration in hypertension.
Life Sci. 28, 991-998.
RIVIER, C. and VALE, W. (1983) Interaction of corticotrophin-
releasing factor and arginine vasopressin on adreno-
corticotrophin secretion in vivo. Endocrinology 113. 939-942.
ROBBERECHT, P., DESCHODT-LANCKMAN, M., CAMUS, J.C., DENEEF, P.,
LAMBERT. M. and CHRISTOPHE, J. (1979) VIP activation of rat
anterior pituitary adenylate cyclase. FEBS Lett. 103, 229-233.
ROBERTS, E. (1956) Function and utilization of y-aminobutyric
acid in brain. In: "Progress in Neurobiology: 1.
Neurochemistry", Ed. Korey, S.R. amd Numberger, J.I. Cassel,
London, pp.11—25.
ROBERTS, E. and BREGOFF, H.M. (1953) Transamination of
Y-aminobutyric acid and s alanine in brain and liver. J. Biol.
Chem. 201, 393-398.
ROBERTS, E. and FRANKEL, S. (1950) y-Aminobutyric acid in brain:
its formation from glutamic acid. J. Biol. Chem. 187, 55-63.
ROBERTS, E. and KURIYAMA, K. (1968) Biochemical-physiological
correlations in studies of the y-aminobutyric acid systems.
Brain Research 8, 1-35.
ROBERTS, P.J. (1976) Gamma aminobutyric acid homoexchange in
sensory ganglia. Brain Res. 113, 206-209.
ROBERTS, P.J., GUPTA, H.K. and SHARGILL, N.S. (1978) The
interaction of baclofen (e-(4-chlorophenyl) GABA) with GABA
systems in rat brain: evidence for a releasing action. Brain
Res. 155, 209-212.
ROBIN, M.M. and PALFREYMAN, M.G. (1982) Does homocarnosine mediate
the dyskinetic movements induced by GABA-transminase
inhibitors. Neuropharmacology 21, 479-482.
RODBARD, D. (1971) Statistical aspects of radioimmunoassays.
In "Principles of Competitive Protein-binding Assays",
pp.204-253. Eds. Odell, W.D. and Danghaday, W.H. Lippercot:
Phi 1adelphia.
RODBELL, M. (1980) The role of hormone receptors and GTP-regulatory
proteins in membrane transduction. Nature 284, 17-22.
ROSSIER, J., BATTENBERG, E., PITTMAN, A., BAYON, A., KODA, L.,
MILLER, R., GUILLEMAN, R. and BLOOM, F. (1979) Hypothalamic
enkephalin neurones may regulate the neurohypophysis. Nature
277, 653-655.
ROTSZTEJN, W.H., DROUVA, S.V., PATOU, E. and KORDON, C. (1978)
Met-enkephalin inhibits in vitro dopamine-induced LHRH release
from mediobasal hypothalamus of male rats. Nature 274, 281-282.
RUSSELL, J.T., BROWNSTEIN, M.J. and GAINER, H. (1980) Biosynthesis
of vasopressin, oxytocin, and neurophysins: isolation and
characterization of two common precursors (propressorphysin and
prooxyphysin). Endocrinology 107, 1880-1891.
RYAN, L.D. and ROSKOSKI, R. (1977) Net uptake of GABA by a high
affinity symptosomal system. J. Pharm. Exp. Ther. 200, 285-291.
SAID, S.I. and PORTER, J.C. (1979) Vasoactive intestinal
polypeptide; release into hypophysial portal blood. Life Sci.
24, 227-230.
SAITH, S., BICKNELL, R.J. and SCHOFIELD, J.G. (1982) Stimulation
by thyroliberin (TRH) of ®^Rb efflux from perifused bovine
anterior pituitary cells. FEBS Letts. 1_40, 121-123.
SALGANICOFF, L. and de ROBERTIS, E. (1963) Subcellular distribution
of glutamic decarboxylase and gamma-aminobutyric
alpha-ketoglutamic transaminase. Life Sci. 2, 85-91.
SAND, 0., HAUG, E. and GAUTVIK, K.M. (1980) Effects of thyroliberin
and 4-aminopyridine on action potentials and prolactin release
and synthesis in rat pituitary cells in culture. Acta. Physiol.
Scand. 108, 247-252.
SANO, K. and ROBERTS, E. (1963) Binding of y-aminobutyric acid by
mouse brain preparations. Biochem. Pharmacol. 1_2, 489-502.
SARKAR, D.K., GOTTSCHALL, P.E., MEITES, J., HORN, A., DOW, R.C.,
FINK, G. and CUELLO, A.C. (1983) Uptake and release of
[^Hjdopamine by the median eminence: evidence for presynaptic
dopamine receptors and for dopaminergic feedback inhibition.
Neuroscience 821-830.
SAWAYA, M.C.B., HORTON, R.W. and MELDRUM, B.S. (1975) Effects of
anticonvulsant drugs on the cerebral enzymes metabolising GABA.
Epilepsia 16^, 649-655.
SCATCHARD, G. (1949) The attractions of proteins for small
molecules and ions. Ann. N.Y. Acad. Sci. 51, 660-672.
SCHALLY, A.V., REDDING, T.W., ARIMURA, A., DUPONT, A. and
LINTHICUM, G.L. (1977) Isolation of gamma-amino butyric acid
from pig hypothalami and demonstration of its prolactin
release-inhibiting (PIF) activity in vitro and in vivo.
Endocrinology, 100, 681-691.
SCHETTINI, G., CRONIN, M.J., 0'DELL, S.B. and MACLEOD, R.M. (1984)
The benzodiazepine agonist diazepam inhibits basal and
secretogogue-stimulated prolactin release in vitro. Brain Res.
291, 343-350.
SCHLOSSER, W. and FRANCO, S. (1979) Modification of GABA-mediated
depolarization of the cat ganglion by pentobarbital and two
benzodiazepines. Neuropharmacology 18, 377-381.
SCHMALE, H. and RICHTER, D. (1984) Single base deletion in the
vasopressin gene is the cause of diabetes insipidus in
Brattleboro rats. Nature 308, 705-709.
SCHMIDT, R.F., VOGEL, M.E. and ZIMMERMANN, M. (1967) Die Wirkung
von diazepam auf die prasynaptische hemmung und andere
ruckenmarksreflexe. Naunyn-Schmiedebergs Arch. Pharmacol. 258,
69-82.
SCHOEMAKER, H., BOLES, R.G., HORST, W.D. and YAMAMURA, H.I. (1983)
Specific high-affinity binding sites for [3h]Ro5-4864 in rat
brain and kidney. J. Pharmacol. Exp. Ther., 225, 61-69.
SCHOFIELD, J.G. and SAITH, S. (1981) Potentiation of bovine growth
hormone release by an inhibitor of potassium channels. Europ.
J. Pharmacol. 75, 431-434.
SCHOLER, J. and SLADEK, J.R. (1981) Supraoptic nucleus of the
Brattleboro rat has an altered noradrenergic input. Science
214, 347-349.
SCHON, F. and KELLY, J.S. (1974) The characterisation of
[3h]GABA uptake into the satellite glial cells of rat sensory
ganglia. Brain Res. 66^, 289-300.
SEAMON, K.B. and DALY, J.W. (1981) Forskolin: an unique diterpene
activator of cyclic AMP-generating systems. J. Cyc. Nuc. Res.
7, 201-224.
SEIZINGER, B., HOLLT, V. and HERZ, A. (1981) Evidence for the
occurrence of the opioid octapeptide dynorphin- (1-8) in the
neurointermediate pituitary of rats. Biochem. Biophys. Res.
Commun. 102, 197-205.
SELLSTROM, A. and HAMBERGER, A. (1977) Potassium-stimulated
Y-aminobutyric acid release from neurons and glia. Brain Res.
119, 189-198.
SHARMAN, D.F., HOBZER, P. and HOLZBAUER, M. (1982) In vitro
release of endogenous catecholamines from the neural and
intermediate lobe of the neurohypophysis. Neuroendocrinology
34, 175-179.
SHIN, S.H. and CHI, H.J. (1979) Unsuppressed prolactin secretion
in the male rat is pulsatile. Neuroendocrinology 28, 73-81.
SHIN, S.H., OBONSAWIN, M.C. and BATES, L. (1984) Gamma-aminobutyric
acid is not likely a physiological prolactin-inhibiting factor.
Hormone Res. .19, 33-42.
SHIN, S.H. and REIFEL, C.W. (1981) Adenohypophysis has an inherent
property for pulsatile prolactin secretion. Neuroendocrinology
32, 139-144.
SIEGELBAUM, S.A., CAMARDO, J.S. and KANDEL, E.R. (1982) Serotonin
and cAMP close single K+ channels in sensory neurones. Nature
299, 413-417.
SIEGHART, W. and KAROBATH, M. (1980) Molecular heterogeneity of
benzodiazepine receptors. Nature 286, 285-287.
SIGEL, E., STEPHENSON, A., MAMALAKI, C. and BARNARD, E.A. (1983) A
Y-aminobutyric acid/benzodiazepine receptor complex of bovine
cerebral cortex. J. Biol. Chem. 258, 6965-6971.
SILVERMAN, A.J. (1976) Ultrastructural studies on the localization
of neurohypophysial hormones and their carried proteins. J.
Histochem. Cytochem. 24, 807-815.
SIMMONDS, M.A. (1980a) A site for the potentiation of GABA-mediated
responses by benzodiazepines. Nature 284, 558-560.
SIMMONDS, M.A. (1980b) Evidence that bicuculline and picrotoxin act
at separate sites to antagonise y-aminobutyric acid in rat
cuneate nucleus. Neuropharmacology lj), 39-45.
SIMMONDS, M.A. (1982) Classification of some GABA antagonists with
regard to site of action and potency in slices of rat cuneate
nucleus. Europ. J. Pharmacol. 80, 347-358.
SIMMONDS, M.A. (1983a) Depolarising responses to glycine,
e-alamine and muscimol in isolated optic nerve and cuneate
nucleus. Brit. J. Pharmacol. _79, 799-806.
SIMMONDS, M.A. (1983b) Variations in response of the GABA-
picrotoxin-benzodiazepine receptor complex to flurazepam.
Pharmacol. Biochem. & Behav. 18, 299-301.
SINHA, Y.N. and BAXTER, S.R. (1979) Identification of a non-
immunoreactive but highly bioactive form of prolactin in the
mouse pituitary by gel electrophoresis. Biochem. Biophys. Res.
Commun. 86, 325-330.
SKAPER, S.D., DAS, S. and MARSHALL, F.D. (1973) Some properties
of a homocarnosine-carnosine synthetase isolated from rat
brain. 0. Neurochem. 21, 1429-1445.
SKERRITT, J.H. and JOHNSTON, G.A.R. (1983) Enhancement of GABA
binding by benzodiazepines and related anxiolytics. Europ. J.
Pharmacol. 89, 193-198.
SKERRIT, J.H., WERZ, M.A., MCLEAN, M.J. and MACD0NALD, R.L. (1984)
Diazapam and its anomalous p-chloro-derivative Ro5-4864:
comparative effects on mouse neurones in cell culture. Brain
Res. 310, 99-105.
SKERRITT, J.H., WILLOW, m. and JOHNSTON, G.A.R. (1982) Diazepam
enchancement of low affinity GABA binding to rat brain
membrances. Neurosci. Letts. 29, 63-66.
SLADEK, J.R. and SLADEK, C.P. (1978) Localisation of 5-HT within
tanocytes of the rat median eminence. Cell Tissue Res. 186,
465-474.
SNODGRASS, S.R. (1978) Use of [^Hjmuscimol for GABA receptor
studies. Nature 273, 392-394.
SNODGRASS, S.R. and IVERSEN, L.L. (1973) Effects of
amino-oxyacetic acid on [3h]GABA uptake by rat brain slices.
J. Neurochem. 20, 431-439.
SNYDER, S.H. and ENNA, S.J. (1975) The role of central glycine
receptors in the pharmacological actions of benzodiazepines.
Adv. Biochem. Psychopharmacol. 14, 81-91.
SOKOL, H.W. and VALTIN, H. (1965) Morphology of the neurosecretory
system in rats homozygous and heterozygous for hypothalamic
diabetes insipidus. (Brattleboro strain) Endocrinology 77,
692-700.
SOKOL, H.W. and ZIMMERMAN, E.A. (1982) The hormonal status of the
Brattleboro rat. Ann. N.Y. Acad. Sci. 394, 535-548.
SQUIRES, R.F., BENSON, O.I., BRAESTRUP, C., COUPET, J., KLEPNER,
C.A., MYERS, V. and BEER, B. (1979) Some properties of
brain-specific benzodiazepine receptors: new evidence for
multiple receptors. Pharmacol. Biochem. Behav. 10, 825-830.
SQUIRES, R.F.. CASSIDA, J.E., RICHARDSON, M. and SAEDERUP, E.
(1983) [35s]t-Butylbicyclophosphorothionate binds with high
affinity to brain-specific sites coupled to Y-aminobutyric
acid-A and ion recognition sites. Molec. Pharmacol. 2!3, 326-336.
SQUIRES, R.F. and SAEDERUP, E. (1982) Y~aminobutyri c acid
receptors modulate cation binding sites coupled to independent
benzodiazepine, picrotoxin and anion binding sites. Molec.
Pharmacol. 22_, 327-334.
SRINIVASAN, V., NEAL, M.J. and MITCHELL, J.F. (1969) The effect of
electrical stimulation and high potassium concentrations on the
eflux of [^HjY-aminobutyric acid from brain slices. J.
Neurochem. 16^, 1235-1244.
STAPLETON, S.R., PRESTWICK, S.A. and HORTON, R.W. (1982) Regional
heterogeneity of benzodiazepine binding sites in rat brain.
Europ. J. Pharmacol. 84, 221-224.
STARKE, K. and MONTEL, H. (1973) A1pha-receptormiediated
modulation of transmitter release from central noradrenergic
neurones. Naunyn-Schmiedebergs Arch. Pharmacol. 279, 53-60.
STARKE, K., REIMANN, W., ZUMSTEIN, A. and HERTTING, G. (1978)
Effect of dopamine receptor agonists and antagonists on release
of dopamine in the rabbit caudate nucleus in vitro.
Nanunyn-Schmiedebergs Arch. Pharmacol. 305, 27-36.
STARR, M.S. (1978) GABA potentiaties potassium-stimulated
^H-dopamine release from slices of rat substantia nigra and
corpus striatum. Europ. J. Pharmacol. 48, 325-328.
STEPHENS, D.N., KEHR, W., SCHNEIDER, H.H. and BRAESTRUP, C. (1984)
Bidirectional effects on anxiety of e-carbolines acting as
benzodiazepine receptor ligands. Neuropharmacology 23_, 879-880.
STOOF, J.C., DEN BREEJEN, E.J.S. and MULDER, A.H. (1978) GABA
modulates the rease of dopamine and acetylcholine from rat
caudate nucleus slices. Europ. J. Pharmacol. 57, 35-42.
STORM-MATH ISON, J., LEKNES, A.K., BORE, A.T., VAALAND, J.L.,
EDMINSON, P., HAUG, F-M.S. and OTTERSEN, O.P. (1983) First
visualization of glutamate and GABA in neurones by
immunohistochemistry. Nature 301, 517-520.
STRATTON, W.P. and BARNES, C.D. (1971) Diazepam and presynaptic
inhibition. Neuropharmacology 10, 685-696.
STRAUGHAN, D.W., NEAL, M.J., SIMMONDS, M.A., COLLINS, C.G.S. and
HILL, R.G. (1971) Evaluation of bicuculline as a GABA
antagonist. Nature 233, 352-354.
STEINER, F.A. and FELIX, D. (1976) Antagonistic effects of GABA
and benzodiazepines on vestibular and cerebellar neurones.
Nature 260, 346-347.
STRITTAMATTER, W.J., HIRATA, F., AXELROD, J., MALLORGA, P., TALLMAN,
J.F. and HENNEBERRY, R.C. (1979) Benzodiazepine and
B-adrenergic receptor ligands independently stimulate
phospholipid methylation. Nature 282, 857-859.
STUDY, R.E. and BARKER, J.L. (1981) Diazepam and (-)pentobarbital:
fluctuation analysis reveals different mechanisms for
potentiation of y-aminobutyric acid responses in cultured
central neurones. Proc. Natl. Acad. Sci. USA 78, 7180-7184.
SUDA, T., TOZAWA, F., TACHIBANA, S., DEMURA, H. and SCHIZUME, K.
(1982) Multiple forms of immunoreactive dynorphin in rat
pituitary and brain. Life Sci. 31, 51-57.
SUH, H.K. and FRANTZ, A.G. (1974) Size heterogeneity of human
prolactin in plasma and pituitary extracts. J. Clin. Endo.
Metab. 39, 928-935.
SZERB, J.C. (1979) Relationship between Ca2+-dependent and
independent release of [3h]GABA evoked by high K+,
veratridine or electrical stimulation from rat cortical slices.
J. Neurochem. 32, 1565-1573.
SZERB, J.C. (1982) Effect of nipecotic acid, a y-aminobutyric acid
transport inhibitor, on the turnover and release of
y-aminobutyric acid in rat cortical slices. J. Neurochem. 39,
850-858.
SZERB, J.C. and SOMOGYI, G.T. (1973) Depression of acetyl-choline
release from cerebral cortical slices by cholinesterase
inhibition and by oxotremorine. Nature New Biol. 241, 121-122.
TAKAHARA, J., YUNOKI, S., HOSOGI, H., YAKUSHIJI, W., KAGEYANA, J.
and OFUJI, T. (1980) Concomitant increases in serum growth
hormone and hypothalamic somatostatin in rats after injection of
y-aminobutyric acid, amino-oxyacetic acid and y-hydroxybutyric
acid. Endocrinology 106, 343-347.
TAKEDA, N., INAGAKI, S., SHIOSAKA, S., TAGUCHI, Y., OERTEL, W.H.
TOHYAMA, M., WATANABE, T. and WADA, H. (1985)
Immunohistochemical evidence for the coexistence of histidine
decarboxylase-1ike and glutamate decarboxylase-1ike
immunoreactivities in nerve cells of the magnocellular nucleus
of the posterior hypothalamus of rats. Proc. Natl. Acad. Sci.
USA 81_, 7647-7550.
TALLMAN, J.F., THOMAS, J.W. and GALLAGHER, D.W. (1978) GABAergic
modulation of benzodiazepine binding site sensitivity. Nature
274, 383-385.
TAMMINGA, C.A., NEOPHYTIDES, A., CHASE, T.N. and FROHMAN, L.A.
(1978) Stimulation of prolactin and growth hormone secretion by
muscimol, a y-aminobutyric acid agonist. J. Clin. Endo. Metab.
4_7, 1348-1351.
TANIGUCHI, T., WANG, J.K.T. and SPECTOR, S. (1981) Changes in
platelet and renal benzodiazepine binding in spontaneously
hypertensive rats. Europ. J. Pharmacol. 70, 587-588.
TAPPAZ, M., AGUERA, M., BELIN, M.F. and PUJOL, J.F. (1980)
Autoradiography of GABA in the rat hypothalamic median
eminence. Brain Res. 186, 379-391.
TAPPAZ, M.L. and BROWNSTEIN, M.J. (1977) Origin of
glutamate-decarboxylase (GAD)-containing cells in discrete
hypothalamic nuclei. Brain Res. 132, 95—106.
TAPPAZ, M.L., BROWNSTEIN, M.J. and PALKOVITS, M. (1976)
Distribution of glutamate decarboxylase in discrete brain
nuclei. Brain Res. 108, 317-379.
TAPPAZ, M., WASSEF, M., OERTEL, W.H., PANT, L. and PUJOL, J.F.
(1983) Light- and electron-microscopic immunocytochemistry of
glutamic acid decarboxylase (GAD) in the basal hypothalamus:
morphological evidence for neuroendocrine y-aminobutyrate
(GABA). Neuroscience 9_, 271-287.
TARASKEVICH, P.S. and DOUGLAS, W.W. (1977) Action potentials occur
in cells of the normal anterior pituitary gland and are
stimulated by the hypophysiotropic peptide thyrotropin-releasing
hormone. Proc. Natl. Acad. Sci. USA _74, 4064-4067.
TARASKEVICH, P.S. and DOUGLAS, W.W. (1980) Electrical behaviour in
a line of anterior pituitary cells (GH cells) and the influence
of the hypothalamic peptide, thyrotropin releasing factor.
Neuroscience 5_, 421-431.
TARASKEVICH, P.S. and DOUGLAS, W.W. (1982) GABA directly affects
electrophysiological properties of pituitary pars intermedia
cells. Nature 299, 733-734.
TARASKEVICH, P.S. and DOUGLAS, W.W. (1985) Pharmacological and
ionic features of y-aminobutyric receptors influencing
electrical properties of melanotrophes isolated from the rat
pars intermedia. Neuroscience 1£, 301-308.
TASHJIAN, A.H., BAROWSKY, N.J. and JENSEN, O.K. (1971) Thyrotropin
releasing hormone: direct evidence for stimulation of prolactin
production by pituitary cells in culture. Biochem. Biophys.
Res. Commun. 43, 516-523.
THOMAS, C.R., GROOT, K. and ARIMURA, A. (1985) Antiserum to rat
growth hormone (GH)-releasing factor suppresses but does not
abolish antisomatostatin-induced GH release in the rat.
Endocrinology 116, 2174-2178.
THOMPSON, S.H. (1977) Three pharmacologically distinct potassium
currents in molluscan neurones. J.Physiol. 265, 465-488.
THORNER, M.O., HACKETT, J.T., MURAD, F. and MACLEOD, R.M. (1980)
Calcium rather than cyclic AMP as the physiological
intracellular regulator of prolactin release.
Neuroendocrinology 31_, 390-402.
TICKU, M.K., BAN, M. and OLSEN, R.W. (1978) Binding of
[^Hja-dihydropicrotoxinin, y- aminobutyric acid synaptic
antagonist, to rat brain membranes. Molec. Pharmacol. 14,
391-402. ~~
TICKU, M.K. and OLSEN, R.W. (1978) Interaction of barbiturates
with the dihydropicrotoxinin binding sites related to the GABA
receptor-ionophore system. Life Sci. 22, 1643-1652.
TOMIKO, S.A., TARASKEVICH, P.S. and DOUGLAS, W.W. (1981) Potassium-
induced secretion of melanocyte-stimulating hormone from
isolated pars intermedia cells signals participation of
voltage-dependent calcium channels in stimulus-secretion
coupling. Neuroscience 6_, 2259-2267.
TOMIKO, S.A., TARASKEVICH, P.S. and DOUGLAS, W.W. (1983) GABA acts
directly on cells of pituitary pars intermedia to alter hormone
output. Nature 301, 706-707.
TRIFILETTI, R.R., SNOWMAN, A.M. and SNYDER, S.H. (1984) Barbiturate
recognition site on the GABA benzodiazepine receptor complex is
distinct from the picrotoxinin/TBPS recognition site. Europ. J.
Pharmacol. 106, 441-447.
TURNBULL, M.J., SLATER, P. and BRIGGS, I. (1972) An investigation
of the pharmacological properties of homocarnosine. Arch. int.
Pharmacodyn. Ther. 196, 127-132.
TURNELL, D.C. and COOPER, J.D.H. (1982) Rapid assay for aminoacids
in serum or urine by pre-column derivitization and
reversed-phase liquid chromatography. Clin. Chem. 28, 527-531.
UDENFRIEND, S. (1950) Identification of y-aminobutyric acid in
brain by the isotope derivative method. J. Biol. Chem. 187,
65-69.
UEDA, N., MURAMATSU, I. and FUJWARA, M. (1985) Dual effects of
Dynorphin-(l-l3) on cholinergic and Substance P-ergic
transmission in the rabbit iris sphincter muscle. J. Pharm.
Exp. Ther. 232, 545-550.
URQUHART, N., PERRY, T.L., HANSEN, S. and KENNEDY, J. (1975) GABA
content and glutamic acid decarboxylase activity in brain of
Huntington's Chorea patients and control subjects. J.
Neurochem. 24, 1071-1075.
UTIGER, R.D., PARKER, M.L. and DAUGHADAY, W.H. (1962) Studies on
human growth hormone. I. A radioimmunoassay for human growth
hormone. J. Clin. Invest. 41, 254-261.
VALE, W., RIVIER, C., BRAZEAU, P. and GUILLEMAN, R. (1974) Effects
of somatostatin on the secretion of thyrotropin and prolactin.
Endocrinology, 95, 968-977.
VALTIN, H., SAWYER, W.H. and SOKOL, H.W. (1965) Neurohypophysial
principles in rats homozygous and heterozygous for hypothalamic
diabetes insipidus (Brattleboro strain). Endocrinology 77,
701-706.
VAN DER HAYDEN, J.A.M., DE KLOET, E.R., KORF, J. and VESTEEG, D.H.G.
(1979) GABA content of discrete brain nuclei and spinal cord of
the rat. J. Neurochem. ^3, 857-861.
VARON, S., WEINSTEIN, H., KAKEFUDA, T. and ROBERTS, E. (1965)
Sodium-dependent binding of y-aminobutyric acid by
morphologically characterized subcellular brain particles.
Biochem. Pharmacol. 14_, 1213-1224.
VIJAYAN, E. and MCCANN, S.M. (1978a) The effect of intraventricular
injection of gamma-aminobutyric acid (GABA) on prolactin and
gonadotropin release in conscious female rats. Brain Res. 155,
35-42.
VIJAYAN, E. and MCCANN, S.M. (1978b) Effects of intraventricular
injection of y-aminobutyric acid (GABA) on plasma growth hormone
and thyrotropin in conscious ovariectomised rats. Endocrinology
103, 1888-1893.
VIJAYAN, E. and MCCANN, S.M. (1978c) Re-evaluation of the role of
catecholamines in control of gonadotropin and prolactin
release. Neuroendocrinology Zb_, 150-165.
VIJAYAN, E. and MCCANN, S.M. (1979) Blockade of dopamine (DA)
receptors with pimozide and pituitary hormone release in
response to intraventricular injection of y-aminobutyric acid
(GABA) in conscious ovariectomized rats. Brain Res. 162, 69-76.
VINCENT, J.R., HOKFELT, T. and Wu, J-Y. (1982) GABA neuron systems
in hypothalamus and pituitary gland. Neuroendocrinology 34,
117-125.
VIZI, E.S. and VOLBEKAS, V. (1980) Inhibition by dopamine of
oxytocin release from isolated posterior pituitary lobe of the
hypophysis of the rat; disinhibitory effect of e-endorphin/
enkephalin. Neuroendocrinology 3^, 46-52.
VOIGT, M.M., DAVIS, L.G. and WYCHE, J.H. (1984) Benzodiazepine
binding to cultured human pituitary cells. J. Neurochem. 43,
1106-1113.
WADDINGTON, J.L. and CROSS, A.J. (1978) Denervation
supersensitivity in the striatonigral GABA pathway. Nature 276,
618-620.
WALAAS, I. and FONNUM, F. (1978) The effect of parenteral
glutamate treatment on the localization of neurotransmitters in
the mediobasal hypothalamus. Brain Res. 153, 549-562.
WATSON, S.J., AKIL, H., FISCHLI, W., GOLDSTEIN, A., ZIMMERMAN, E.
and NILAVER, G. (1982) Dynorphin and vasopressin: common
localization in magnocellular neurons. Science 216, 85-87.
WATSON, S.J., AKIL, H., GHAZAROSSIAN, V.E. and GOLDSTEIN, A. (1981)
Dynorphin immunocytochemical localization in brain and
peripheral nervous system: preliminary studies. Proc. Natl.
Acad. Sci. USA 78, 1260-1263.
WANG, J.R.T., MORGAN, J.I. and SPECTOR, S. (1982) Effect of
peripheral type benzodiazepines on the proliferation of thyoma
cells in culture. Fed. Proc. 41, 1328.
WEBER, E., EVANS, C.J. and BARCHEN, J.D. (1982) Predominance of
the amino-terminal octapeptide fragment of dynorphin in rat
brain regions. Nature 299, 77-79.
WEHRENBERG, W.B., MCNICOL, D., FRANTZ, A.G. and FERIN, M. (1980)
The effect of serotonin on prolactin and growth hormone
concentrations in normal and pituitary stalk-sectional monkeys.
Endocrinology 107, 1747-1750.
WEINER, R.O. and GANONG, W.F. (1978) Role of brain monoamines and
histamine in regulation of anterior pituitary secretion.
Physiol. Rev. 5£J, 905-976.
WE INSTEIN, H., VARON, S., MUHLEMAN, D.R. and ROBERTS, E. (1965) A
carrier-mediated transfer model for the accumulation of
C14-y-aminobutyric acid by subcellular brain particles.
Biochem. Pharmacol. 14_, 273-288.
WEISSMAN, B.A., COTT, J., PAUL, S.M. and SKOLNICK, P. (1983)
Ro5-4864: a potent benzodiazepine convulsant. Europ. J.
Pharmacol. 90, 149-150.
WERZ, M.A. and MACDONALD, R.L. (1982) Heterogeneous sensitivity of
cultured dorsal root ganglion neurones to opioid peptides
selective for u- and 6-opiate receptors. Nature 299, 730-733.
WERZ, M.A. amnd MACDONALD, R.L. (1983) Opioid peptides specific for
p- and 6-opiate receptors reduce calcium-dependent action
potential duration by increasing potassium conductance.
Neurosci. Letts. _42, 173-178.
WERZ, M.A. and MACDONALD, R.L. (1984) Dynorphin reduces calcium-
dependent action potential duration by decreasing
voltage-dependent calcium conductance. Neurosci. Letts. 46,
185-190.
WIEGLAND, S.J. and PRICE, J.L. (1980) Cells of origin of the
afferent fibres to the median eminence in the rat. J. Comp.
Neurol. 192, 1-19.
WILLIAMS, J.T., EGAN, T.M. and NORTH, R.A. (1982) Enkephalin opens
potassium channels on mammalian central neurones. Nature 299,
74-77.
WILLIAMS, M. and RISLEY, E.A. (1979) Characterisation of the
binding of [^Hlmuscimol, a potent y-aminobutyric acid agonist,
to rat brain synaptosomal membranes using a filtration assay.
J. Neurochem. Z2_, 713-718.
WILLOW, M. and JOHNSTON, G.A.R. (1981) Pentobarbitone slows the
dissociation of GABA from rat brain synaptosomal binding sites.
Neurosci. Letts. 23, 71-74.
WOJCIK, W.J., CAVALLA, D. and NEFF, N.H. (1985) Co-localized
adenosine A1 and y-aminobutyric acid B (GABAg)receptors of
cerebellum may share a common adenylate cyclase catalytic unit.
J. Pharm. Exp. Ther. 232, 62-66.
WOJCIK, W.J. amnd NEFF, N.H. (1984) y-Aminobutyric-B-receptors are
negatively coupled to adenylate cyclase in brain and cerebellum
- these receptors may be associated with granule cells. Molec.
Pharmacol. 23, 24-28.
WONG, D.T. and HORNY, J.S. (1977) Na+-independent binding of
GABA to the Triton X-100-treated synaptic membranes from
cerebellum of rat brain. Life Sci. 20, 445-452.
WONG, E.H.F. and IVERSEN, L.L. (1985) Modulation of [3H] diazepam
binding in rat cortical membranes by GABA/\ agonists. J.
Neurochem. 44_, 1162-1167.
WONG, B.S., LECAR, H. and ADLER, M. (1982) Single calcium-
dependent potassium channels in clonal anterior pituitary
cells. Biophys. J. 39, 313-317.
WU, J-Y., MATSUDA, T. and ROBERTS, E. (1973) Purification and
characterization of glutamate decarboxylase from mouse brain.
J. Biol. Chem. 248, 3029-3034.
WU, J-Y., CHUDE, 0., WEIN, J., ROBERTS, E., SAITO, K. and WONG, E.
(1978) Distribution and tissue specificity of glutamate
decarboxylase (EC4.1.1.15). J. Neurochem. 30, 849-857.
YAGI, K. and SAWAKI, Y. (1975) Recurrent inhibition and
facilitation: demonstration in the tuberoinfundibular system and
effects of strychnine and picrotoxin. Brain Res. 84, 155-159.
YALOW, R.S. (1980) Radioimmunoassay. Ann. Rev. Biophys. Bioeng.
9, 327-345.
YALOW, R.S. and BENSON, S.A. (1971) Introduction and general
considerations. In "Competitive Protein-binding Assays", pp.
1-21. Eds. Odel, W.D. and Daughaday, W.H. Philadelphia,
Lippincott.
YAMASAKI, Y. and WAY, E.L. (1983) Possible inhibition of Ca2+
pump of rat erythrocyte ghosts by opioid K agonists. Life Sci.
33, Supp. 1, 723-726.
YORKLEY, W.C. and MARSHALL, F.D. (1969) Incorporation of [14C]
histidine into homocarnosine and carnosine of frog brain in vivo
and in vitro. Biochem. J. 114, 585-588.
YOUNG, A.B. and SNYDER, S.H. (1973) A sensitive specific
enzymatic-fluorometric assay for homocarnosine. J. Neurochem.
21, 387-396.
ZBINDEN, G., and RANDALL, L.O. (1967) Pharmacology of
benzodiazepine: Laboratory and clinical correlations. Adv.
Pharmacol. Chemother. 5_, 213-291.
ZIMMERMAN, E.A., STILLMAN, M.A., RECHT, L.D., ANTUNES, J.L. and
CARMEL, P.W. (1977) Vasopressin and corticotrophin-releasing
factor: an axonal pathway to portal capillaries in the zona
externa of the median eminence containing vasopressin and its
interaction with adrenal corticoids. Ann. N.Y. Acad. Sci. 197,
405-419.
ZINGG, H.H., BAERTSCHI, A.J. and DREIFUSS, J.J. (1979) Action of
Y-aminobutyric acid on hypothalamo-neurohypophysial axons.
Brain Res. 171, 453-459.
ZUKIN, S.R., YOUNG, A.B. and SNYDER, S.H. (1974) Gamma-
aminobutyric acid binding to receptor sites in the rat central
nervous system. Proc. Natl. Acad. Sci. USA 71, 4802-4807.
Appendix I Radioimmunoassays for prolactin GH, LH and TSH.
1.1 Stock solutions





per litre distilled water, pH 7.6
Antiserum buffer
500ml 0.01M PBS
9.306g ethylenediamine tetra-acetic acid disodium salt
I.7ml normal serum: rabbit for prolactin, LH and TSH
human for GH
pH 7.0
Assay buffer (0.01M PBS/ffBSA)
11 0.01M PBS
lOg bovine serum albumin








per litre distilled water, pH 7.6
Rinse for prolactin iodination
0.18g KI
0.8g sucrose
10ml disti1 led water
1.2 Iodination
Columns: Prolactin. 25 x 1cm Sephadex G50 coated with 200yl
human albumin (4.5% in PBS). Eluted with 0.01M
borate buffer.
GH. 20 x 1cm Sephadex G50 coated with 200yl human
albumin (4.5% in PBS). Eluted with 0.05M Na
barbitone buffer (pH 8.6).
LH. 12 x 1cm column Biogel G60 coated with 1.5ml
egg white (5% in PBS). Eluted with 0.01M PBS.
TSH. 30 x 1cm column Sephadex G-75 coated with 4m1
PBS/2% BSA. Eluted with PBS.
Hormones: Prolactin. Rat-PRL-I-S, 20yl aliquots of 250yg/ml
in 0.01M NaHC03.
GH. Rat-GH-I-4, 50yl aliquots of lOOyg/ml in O.OlM
NaHC03
LH. LER-1056-C2, 10yl aliquots of 500yg/ml in O.OlM
PBS.
TSH. Rat-TSH-I-6 20yl aliquots of 250yg/ml in 0.25M
phosphate buffer.
Nal25i; lmCi in 10yl for each iodination
Chloramine T:Prolactin: lmg/ml in 0.05M phosphate buffer. 15u1
used.
GH: 0.5mg/ml in H2O. 10yl used.
LH: 5mg/ml in O.OlM PBS. 10yl used.
TSH: 1.5mg/ml in 0.05M phosphate buffer. 20yl used.
Sodium metabisulphate: Prolactin: 2.4mg/ml in 0.05M phosphate
buffer. 50yl used.
GH: 1.2mg/ml in H2O. 10yl used.
LH: 5mg/ml in O.OlM PBS. 25yl used.
TSH: 2.4mg/ml in 0.05M phosphate buffer
50y1 used.
Protocol I) Add 25yl 0.5M phosphate (pH 7.5) to hormone
II) Add lmCi Na125I
III) Add Chloramine T, mix gently.




V) Add Na2S205, mix gently
VI) Transfer to column
Prolactin: rinse vial with 2 x lOOyl Kl/sucrose
solution.
VII) Elute with buffer.
Prolactin: borate buffer
GH, LH and TSH: O.OlM PBS
VIII) Collect fractions: 0.5ml into 0.5ml PBS/1% BSA for
prolactin, GH and TSH. 0.5ml into 0.5ml O.OlM
PBS/5% egg white for LH.
Estimate radioactivity per fraction. Retain peaks.
In all cases, iodinated hormone eluted before free iodine.
Prolactin and TSH were only used on the day of iodination, GH and LH
could be used up to 20 days later following rechromatography.
1.3 Standards
Prolactin: rat-PRL-RP-1. 0.5, 1, 2, 4, 8, 16, 32, 64ng/ml in
0.01M PBS/1% BSA. Stored as 200ul aliquots.
GH: rat-GH-RP-L 0.5, 1, 2, 4, 8, 16 32ng/ml in 0.01M PBS/1%
BSA.
LH: NIH-LH-S18. 0.25, 0.5, 0.75, 1.2, 2, 5, 8, 16ng/ml in
0.01M PBS/1% BSA.
TSH: rat-TSH-RP-2. 0.3, 0.8, 1.2, 2, 5, 10, 20, 50ng/ml in
0.01M PBS/1%BSA.
1.4 Assay timetable
All incubations were carried out at 4°C
Day 1. All assays: 200^1 samples/standards.
200ul 0.01M PBS/1% BSA
200yl antiserum in buffer
Day 2. All assays: 200ul ^25j—hormone in PBS/1% BSA
= 10,000 cpm for prolactin, LH and TSH
= 5,000 cpm for GH
Day 3. GH only: 200pl AHGG in 0.01M PBS
Day 4 GH only: Centrifuge tubes (30 min at 2000g, 4°C)
aspirate supernatant and count pellet.
Prolactin and LH: 200yl ARGG in 0.01M PBS
Day 5. Prolactin and LH: Centrifuge, aspirate, count.
Day 6. TSH: 200til ARGG in 0.01M PBS
Day 7 TSH: Centrifuge, aspirate, count







3.5% silicic-acid-cleaned BSA: lOOmg SIL-A-200, 60-200mesh
screen (Sigma) per ml, mixed for 30 min at 20°C,




The method used was based on Harmar and Rosie (1983).
A HPLC apparatus consisting of a two channel pump in
series with a three way valve, a sample injection valve
and a disposable cartridge of bonded phase cyanopropyl
(CN) silica was used.
Solvent A: 0.2% Trifluoric acid (TFA) in H20
Solvent B: 0.2% TFA in methanol
A solvent gradient from 100% solvent A to 100% solvent B
was generated by changing the proportions of the two
solvents delivered to the column
Hormone: Human-ACTH (NIADDK), 10yl of 200pg/ml in 0.01M HCI
Chloramine T: lmg/ml 0.05M phosphate buffer.
Sodium metabisulphite: 25mg/ml 0.05M phosphate buffer.
Protocol: I) Add lOyl 0.25M phosphate buffer to hormone
II) Add lmCi Na125i„
III) Add 10yl Chloramine T. Mix.
IV) Reaction time: 20 sec
V) Add 10vi 1 sodium metabisulphite
VI) Add 180yl 0.25M phosphate buffer
VII) Add 620yl lOmg/ml KI/0.2% TFA
VIII) Inject into HPLC
IX) Elute at lml/min.
X) Label could be stored at -80°C for 3 weeks.
Collect 6 lmin fractions for each gradient step:
0%, 50%, 60%, 100% methanol. 125i_aCTH was found
to elute with 60% methanol.
11.3 Standards
Human-ACTH (NIADDK). 3.1, 6.25, 12.5, 25.0, 50, 100 and
200pg/ml in assay buffer. Stored at -40°C in lOOul
al iquots.
11.4 Primary antibody
lgG-ACTH-1 (lgG Corporation, Nashville, TN) diluted
1:10,000 in assay buffer + ]% normal rabbit serum.
11.5 Assay timetable
Day 1. lOOul samples/standards
lOOul antiserum in buffer
Incubate at room temperature
Day 2. lOOyl 125I-ACTH in buffer
= 10,000 cpm
Incubate at room temperature for 8 hr.
100vi 1 ARGG ino0.0lM PBS
Incubate at 4°C
Day 3. Add 1.6ml of PBS/3^ BSA
Centrifuge, aspirate and count
Appendix III Protein assay
Ail protein assays in this Thesis were carried out according to




made up to 20ml, distilled water
4g NaOH
20g NaHC03
made up to 200ml, distilled water
Alkaline copper reagent is prepared by mixing the above two
solutions together.
Protocol: Standards (0-20yg) of bovine serum albumin and samples
(5-20ul) are made up to 200yl with distilled water in LP3
tubes.
500yl alkaline copper reagent is added and mixed well.
Tubes are left for 20 min
lml of diluted Folin-Ciocalteau reagent is added (1:10 in
distilled water) and tubes are rapidly mixed.
After a further 20 min, absorbance is read at 725nm in a
spectrophotometer and a standard curve is constructed.
Samples are read off the standard curve.
[From the Proceedings of the Physiological Society, 23-24 September 1983
Journal of Physiology, 346, 126P]
Multiple receptors for y-aminobutyric acid (GABA) in rat pituitary
By R. A. Anderson and R. Mitchell (introduced by G. Fink). M.R.C. Brain
Metabolism Unit, 1 George Square, Edinburgh
Gamma-aminobutyric acid (GABA) may be involved in the regulation of hormone
release from the pituitary gland (Raeagni, Apud, Cocchi, Locatelli & Muller, 1982;
Vincent, Hokfelt & Wu, 1982). Specific binding sites for GABA have been described
in anterior pituitary (Grandison & Guidotti, 1979) but the contribution of different
subtypes and their distribution within the gland has not been described.
Pituitary glands were removed from freshly killed adult male Wistar rats, dissected
into anterior (AP) and neurointermediate (NI) lobes and stored at — 20 °C. Tissue
was homogenized and centrifuged in 100 vol. of cold buffer at 48000 g for 10 min,
resuspended in fresh buffer and frozen. Before assay the membranes were washed a
further four times. [3H]GABA was used as a radioligand for both GABAa and GABAb
receptors in Tris HC1 buffer (50 mM, pH 7T) containing 2-5 mM-CaCl2 (Bowery, Hill
& Hudson, 1983). [3H]muscimol was used to label selectively GABAa sites in Ca2+-free
Tris buffer. Assays were terminated by centrifugation and pellets washed superficially
before measurement of bound ligand. Specific binding of 10 nM [3H]GABA to
pituitary membranes showed a differential distribution of both A and B type sites,
discriminated in the presence of 100 jim ( + ) baclofen (GABAa: AP, 20-9+ P7; NI,
5-5 + 07; and GABAb: AP, 16-5+1*8; NI, 0-6+14 fmol/mg protein; n = 5).
Experiments using [3H]muscimol at concentrations of 2 and 20 nM to label
predominantly high- and low-affinity components of GABAa sites confirmed a
relative concentration of GABAa sites in AP, with 9-5 + 0-8 and 21-3+1-2 fmol/mg
protein (n = 5), respectively, but only 3-0 + 0-2 and 6-3 + 0-4 fmol/mg protein (n = 4)
in NI. Scatchard analysis of [3H]muscimol binding to pituitary membranes revea'ed
two components of similar affinity to c.n.s. regions; Km, 1-1+0-1 nM, Bml
9-4 + 0-4 fmol/mg protein and KD2 34-7 + 3-0 nM, Bm2 46-8 + 6-7 fmol/ml protein
(n = 3). This relatively large contribution of low affinity sites was found to be similar
to that in frontal cortex but not cerebellum.
These results show the presence of moderate concentrations of both GABAa and
GABAb receptors in AP but only a minor population of GABAa and no detectable
GABAb receptors in NI.
R.A.A. is a Houldsworth scholar.
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[From the Proceedings of the Physiological Society, 26-27 March 1984
Journal of Physiology, 353, 100PJ
GABAa receptors have a biphasic effect on prolactin release in vitro from
anterior pituitary of the rat
By R. A. Anderson and R. Mitchell. MRC Brain Metabolism Unit, 1 George Square,
Edinburgh
Gamma-aminobutyric acid (GABA) has been reported to inhibit the release of
prolactin by a direct action on the pituitary both in vitro and in vivo (Schally,
Redding, Arimura, Dupont & Linthicum, 1977). We have re-examined control
by GABA of prolactin release from the anterior pituitary using a sensitive rapid
superfusion technique which allows the measurement of transient effects.
Anterior pituitary (AP) glands from male Wistar rats (200—300 g) were chopped
into 500 //.m prisms and incubated for 1 h at 37 °C in oxygenated Krebs bicarbonate
medium, pH 7-4, containing 0-1 % BSA, 2 g/1 glucose and 30 /tg/1 bacitracin. Tissue
from two pituitary glands was then superfused with medium at 05 ml/min. Fractions
(2 min) were collected serially and prolactin was measured by radioimmunoassay.
After 90 min the potent GABAa receptor agonist muscimol was added to the medium,
and produced two effects which were both concentration-dependent from 10 nM to
100 /am ; a rapid prominent stimulation of release, with a peak at 6-8 min, followed
by a decline to a steady reduced rate of release within 30 min. The inhibitory effect
was maximal (— 51 + 3 % ; n = 5 ; mean + s.e. of the mean) at 10 /iM. The stimulatory
component increased further with a peak increment of 117 + 13 % at 100 /am (n = 5),
and was inhibited by (+ )bicuculline methiodide (BMI) and picrotoxinin in a
concentration-dependent manner throughout the range 1—100 /im. The stimulatory
effect of 10 /am muscimol was reduced from +65+10% to +24 + 5% and the
inhibitory effect from —51+3% to —34 + 2% by 10/im-BMI (n = 5, P < 005 in
each case). The antagonists alone had no effect on prolactin release. By contrast the
established prolactin release inhibitory factor dopamine produced only inhibition of
secretion ( — 71+5% at 0T /im, n = 3).
These results demonstrate a biphasic influence of GABAa receptors on prolactin
release similar to the effects described on aMSH release (Tomiko, Taraskevitch &
Douglas, 1983). The electrophysiological events accompanying these phenomena in
melanotrophes (Taraskevitch & Douglas, 1982), which are likely to underly the
changes in hormone release, may well be paralleled in lactotrophes. It is possible that
a transient elevation of t he output of several hormones may be a physiologically
important aspect of pituitary response to GABA.
R.A.A. is a Houldsworth Scholar of the University of Edinburgh.
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[From the Proceedings of the Physiological Society, 9-10 November 1984
Journal of Physiology, 360, 39P]
Homocarnosine may selectively activate one of two GABAa receptor sub¬
types on lactotrophes in the rat
By R. A. Anderson and R. Mitchell. M.R.C. Prain Metabolism Unit, 1 George
Square, Edinburgh
The GABA-containing dipeptide homocarnosine (HC) is found in high concentra¬
tions in hypophysial portal blood and has been shown to have moderate affinity for
GABAa receptors (Mitchell, Grieve, Dow & Fink, 1983). We have investigated the
effects of HC on prolactin secretion from an adenohypophysial slice preparation,
which has previously been used to demonstrate a biphasic influence of GABAa
receptors on lactotrophes (Anderson & Mitchell, 1984).
Anterior pituitary glands from male Wistar rats were prepared and superfused as
previously described (Anderson & Mitchell, 1984). GABA produced a transient
stimulation followed by prolonged inhibition of prolactin secretion both of which
occurred throughout a similar concentration range. The GABAb receptor agonist (+ )
baclofen (100 /<m) (Hill & Bowery, 1981) had no effect on basal secretion or on that
induced by K+ or Ba2+. Muscimol was approximately tenfold more potent than GABA
in both effects, but other GABAa receptor agonists which were equipotent with
GABA at inhibiting prolactin secretion were markedly less potent at stimulation. The
most selective amongst these was HC, which appeared to be totally specific for the
site mediating inhibition, up to the highest concentration tested (2 mM-HC, 31 + 2 %
inhibition, no significant stimulation).
This effect of HC was mediated by a GABAa receptor since, like both effects of
GABA, it was sensitive to bicuculline methiodide (1 niM-HC, 28 + 4% inhibition;
I mivi-HC with 10/im bicuculline methiodide, 17 + 2% inhibition; P < 005, n = 5).
It seems unlikely that the effect of HC may be partly due to its degradation to GABA
by the anterior pituitary, since we were unable to detect any homocarnosinase
activity (Lenney, Kan, Sin & Sugiyama, 1977) in the gland, in contrast to the kidney
which showed a high activity of 9 //mol g-1 h-1.
Although HC is approximately 100-fold less potent than GABA, its presence in high
concentrations and its selectivity for one of two GABAa receptor-mediated effects
suggest that it may be an important factor in the GABA-mediated control of anterior
pituitary function.
R. A. A. is a Houldsworth Scholar of the University of Edinburgh.
references
Anderson, R. A. & Mitchell. R. (1984). ./, Physiol. 353. 100/f
Hill, 1). R. & Bowery, N. (J. (1981). Nature, Bond. 290, 149—152.
Lenney, J. K.. Kan, N.-C., Sin, K. & Suoiyama, G. H. (1977). Archs. Biochem. Biophys. 184,
257-266.
Mitchell, R., Grieve, G., Dow, It. & Fink, G. (1983). Neuroendocrinology 37. 109-176.
[From the Proceedings of the Physiological Society, 4-5 January 1985
Journal of Physiology, 362, 24P]
Presynaptic autoreceptors inhibit [3H]GABA release from neurone terminals
in the median eminence of the rat
By R. A. Anderson and R. Mitchell. MRC Brain Metabolism Unit, 1 George Square,
Edinburgh EH8 9JZ
A role for y-aminobutyric acid (GABA) in the control ofanterior pituitary hormone
secretion is supported by both autoradiographic and immunohistochemical studies,
indicating a plexus ofGABA neurone terminals in the hypothalamic median eminence
(ME) (Tappaz, Aguera, Belin & Pujol, 1980; Vincent, Hokfelt & Wu, 1982). The
present studies describe the characteristics of the uptake and release of [3H]GABA
by ME in vitro.
Tissue from male Wistar rats was homogenized in 032 M-sucrose before dilution
into physiological medium (pH 7-4) (Mitchell & Martin, 1978). Uptake experiments
were performed at 25 °C. For release experiments (at 37 °C), tissue was incubated
with 50 /im-[3H]GABA (including 10 /tm-amino-oxyacetic acid) for 15 min and then
superfused at 0-5 ml/min while collecting 1 min fractions.
[3H]GABA was accumulated with an affinity (A"m) of 5-0/<m. /^-alanine (1 mm)
inhibited uptake into ME by only 18%, while l-2,4-diaminobutyric acid (500/im)
inhibited uptake by 56%, indicating that uptake in ME is mainly neuronal. Basal
sfflux of [3H]GABA was around 0-5% of tissue content/min and was stimulated by
slevated K+ concentrations in a Ca2+-dependent manner. The peak response to
15 mM-K+ (154+10% increase), was inhibited by 100 nM-muscimol (114 + 8%,
P < 0'025) and this was antagonized by 10 /^M-bicuculline methiodide (135 + 3%,
P < 0-02 compared to muscimol), (mean + s.E.M., n = 4 or 5, in each case).
These results indicate that neurosecretory GABA neurone terminals in ME have
iharacteristics like those elsewhere in the CNS, including the presence of GABA
■eceptors (Mitchell & Martin, 1978). These sites may regulate the secretion of GABA
nto hypophysial portal blood (which can be elicited in vivo by electrical stimulation
)fME; Mitchell, Grieve, Dow & Fink, 1983), and thereby contribute to physiological
;ontrol of anterior pituitary function.
R. A. A. is a Houldsworth Scholar of the University of Edinburgh.
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GABA-related anion channels, labelled by [35S]t-butylbicyclophosphoro-
thionate ([35S]TBPS), in rat pituitary
By R. A. Anderson, R. H. McAllister-Williams and R. Mitchell. MRC Brain
Metabolism Unit, 1 George Square, Edinburgh EH8 9JZ
Multiple receptors for y-aminobutyric acid (GABA) are present in both anterior
and neurointermediate pituitary gland (Anderson & Mitchell, 1983a), where they may
be involved in controlling the secretion of hormones such as prolactin (Anderson &
Mitchell, 1984) and a-MSH (Tomiko, Tareskevich & Douglas, 1983). Recognition sites
for benzodiazepines that represent a component of some GABAA-type receptor
complexes are also present (Anderson & Mitchell, 19836). The experiments described
here use a specific ligand ([35S]TBPS) to label the picrotoxinin/barbiturate-sensitive
site of the anion channel component in GABAa receptor complexes (Squires, Casida,
Richardson & Saederup, 1983).
Pituitary glands were removed from adult male Wistar rats and dissected into
anterior (AP) and neurointermediate (NI) lobes. Tissue was homogenized and
centrifuged in 100 volumes of 5 mM-Tris HC1 buffer, containing 1 mM-EDTA, pH 7-5
and washed three further times in fresh buffer. Binding of [35S]TBPS was studied by
the method of Squires et al. (1983), as described by McAllister-Williams & Mitchell
(1984).
Specific binding of 2 nM-[35S]TBPS (defined by 100 /iM-picrotoxinin) was detected
in both AP and NI at 278±26 and 133+ 13 fmol/g tissue respectively (n = 5). This
relative concentration of sites in AP matches that of GABAa receptors (Anderson
& Mitchell, 1983a) but contrasts with the distribution of benzodiazepine recognition
sites (Anderson & Mitchell, 19836). Displacement of [35S]TBPS binding to AP
membranes by muscimol (2-2000 nM) revealed two components, similar to observa¬
tions in certain CNS areas such as cerebellum, where only some of the complexes are
regulated by benzodiazepines (McAllister-Williams & Mitchell, 1984). These results
demonstrate the presence of an anion channel component linked to GABAa receptors
in the pituitary gland, as in the CNS, and are consistent with the existence of both
benzodiazepine-regulated and benzodiazepine-independent GABAa receptor
complexes in AP.
R. A. A. is a Houldsworth Scholar of Edinburgh University. R. H.McA-W. was supported in part
by the S.H.H.D.
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Evidence for GABA receptors on rat somatotrophes and gonadotrophes
By R. A. Anderson and R. Mitchell. M.R.C. Brain Metabolism Unit, 1 George
Square, Edinburgh
Gamma aminobutyric acid (GABA) may be involved in the control of secretion of
many anterior pituitary (AP) hormones, although prolactin is the only hormone
"eported to be influenced directly at the pituitary (Racagni, Apud, Cocchi, Locatelli
& Muller, 1982). We have here investigated GABAergic control ofother AP hormones.
Anterior pituitary glands from male Wistar rats were chopped into 500 /im prisms
tnd superfused as previously described (Anderson & Mitchell, 1984). Growth hormone
GH) and luteinizing hormone (LH) were measured by radioimmunoassay. The
4ABAa receptor agonist muscimol (10 /lvi) caused a stimulation of secretion of both
lormones: 186 + 21 % for GH and 17 + 1 % for LH (n = 5). This effect on GH was
3oncentration-dependent and the response to 10 /iM muscimol was reduced to 20 ± 2 %
iy 10 /iM-bicuculline methiodide (BMI) which abolished the effect on LH. In both
;ases the response was transient; secretion returned to near pre-drug concentrations
vithin 30 min. The GABAb receptor agonist baclofen (100 jlim) was not found to have
my effect on basal secretion of either hormone. We have also investigated the effects
>f muscimol and baclofen on LH release stimulated by LH-releasing hormone
LHRH). When introduced simultaneously, 10 /tM-muscimol potentiated the effect
af 300nM-LHRH, increasing the peak stimulation from 117 + 4% to 164 + 6%
[P < 0-05). This was prevented by BMI (91+9% stimulation, P < 0-05 vs.
LHRH +muscimol, n = 5 in each case). By contrast, baclofen reduced the effect of
LHRH (300 nM-LHRH+ 100 /im baclofen : 82 + 8% stimulation, P < 0-05).
These results demonstrate direct effects of GABA agonists on secretion of AP
hormones other than prolactin. The effect of muscimol on both GH and LH is in
marked contrast to its effects on prolactin (Anderson & Mitchell, 1984), in that no
inhibitory effect subsequent to the stimulation was seen here. Furthermore, these
results demonstrate the presence of a GABAb receptor in AP, supporting the results
3f radioligand binding studies (Anderson & Mitchell, 1983).
We thank NIADDK for RIA materials. R.A.A. is a Houldsworth Scholar of the University of
Edinburgh.
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PRELIMINARY NOTES
CENTRAL-TYPE BENZODIAZEPINE BINDING SITES IN RAT PITUITARY GLAND
ARE OF THE BZi SUBTYPE
R.A. Anderson and R. Mitchell
MRC Brain Metabolism Unit, Department of Pharmacology, 1 George Square, Edinburgh
(Accepted 24 S&p£e.mbeA 1984)
SUMMARY Experiments were performed to investigate the subtype of
central-type benzodiazepine binding site present in rat pituitary
gland. Bmax values for [3H] n-propyl B-carboline-3-carboxylate
and [3H] flunitrazepam (for central-type binding only) were similar.
Displacement of [3H] flunitrazepam by n-propyl s-carboline-3-
carboxylate gave a linear Hofstee plot and a Hill coefficient close to
unity. These results suggest that the central benzodiazepine binding
sites in the pituitary are predominantly of the BZ^ subtype, as found
in the cerebellum.
Benzodiazepines have been reported to affect the secretion of various hormones from the
pituitary gland. Secretion of growth hormone is stimulated (Koulu, Lammintausta, Kangas and
Dahlstrom, 1979) while prolactin secretion is reduced (Lotz, 1982). The possibility that
some of these effects might be the result of a direct action on the pituitary was supported
by the demonstration of both central- and peripheral- type benzodiazepine binding sites in
pituitary of the rat (Anderson and Mitchell, 1983). As in the CNS, the central type sites
are allosterically influenced by y-aminobutyric acid (GABA), indicating their association
with GABA-mediated control of the gland. Indeed, secretion of prolactin is modified by GABA
(Schally, Redding, Arimura, Dupont and Linthicum, 1977) and we have recently demonstrated
that clonazepam can potentiate the effect of muscimol on secretion of prolactin in vitro
(Anderson and Mitchell, 1984).
Further to the division of benzodiazepine binding sites into 'central' and 'peripheral'
types, it has recently been suggested that the central type sites may not be homogeneous, on
the basis of their interactions with some non-benzodiazepine compounds. These compounds,
including triazolopyridazines (Squires, Benson, Braestrup, Coupet, Klepner, Myers and Beer,
1979) and esters of b carboline-3-carboxylic acid (Braestrup and Nielsen, 1981), show
regional variations in affinity consistent with populations of two distinct subtypes of
receptor, BZi and BZ2, being differentially distributed within the CNS.
Benzodiazepines, however, appear to have very similar affinities for the two putative
subtypes. Kinetic analyses of the ligand interactions with these sites have led to
suggestions that they represent different functional states with co-operative interactions
rather than distinct molecular entities (see Martin, Brown and Doble, (1983) for review).
Nevertheless it is clear that benzodiazepine binding sites exhibit regionally different
properties and the possibility that subtypes may exert different roles in vivo points to the
importance of characterising the receptor present in the pituitary.
METHODS
Male Wistar rats (150-250g) were stunned and decapitated, the pituitary gland and brain
regions removed and stored at -20°C. Membranes were prepared by homogenisation of tissue
in 100 volumes of ice-cold 25mM KH2PO4 buffer (pH 7.1) using an Ystral high frequency
homogeniser ^setting 3 for 5 seconds). Homogenates were centrifuged at 48,000g for 10
minutes at 4 C. After discarding the supernatant, the membrane pellet was resuspended in
fresh buffer before centrifugation. The washing procedure was repeated a further 3
times. The final resuspension of membrane preparations gave concentrations of 250-500ug
protein/ml for pituitary tissue and 400-600ug protein/ml for CNS tissues. Aliquots of
500y1 were used for radioligand binding assays, in a final assay volume of 2ml.
[3H] Flunitrazepam, ([3H] FNM, [methyl- 3H] flunitrazepam, 70—80Ci/mmol, NEN) was
used at concentrations between O.lnM and lOnM for Scatchard analyses and at 0.5nM for
displacement studies. [3H] Propyl-s-carboline-3-carboxylate ([3H]PCC, [propyl-2, 3—3H]
B-carboline-3-carboxylate, 95Ci/mmol, NEN) was used at concentrations between 0.05nM and 5nM
for Scatchard analyses. Non-specific binding was defined by 200nM clonazepam. Adsorption
phenomena were corrected for as previously described (Mitchell and Wilson, 1984). Assays
NP 23/ll-G 1331
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in duplicate (or triplicate for [3H] PCC Scatchard analyses) were incubated on ice for 120
minutes in the dark, then filtered through GF/B filters under vacuum and washed with 3 x
5mls of ice-cold buffer via the incubation tube.
FIGURE 1.
Bound fmol / mg protein
Scatchard analysis of [3H] FNM (•) and [3H] PCC (O) binding to
pituitary membranes. In [3H] PCC experiments the proportion of
specific binding was less than for [3H] FNM (i.e. ~ 250dpm
representing approximately one third of total binding at O.lnM) and
assays were therefore carried out in triplicate. Typical of 7-8
experiments.
RESULTS
Both ligands bound to pituitary membranes in a specific, saturable manner. When 200nM
clonazepam is used to define non-specific binding, the binding of [3H] FNM to the
population of peripheral type sites present in the pituitary is discounted (Anderson and
Mitchell, 1983). [3H] PCC was found not to bind to peripheral type sites at
concentrations up to 20nM. Scatchard analyses of the binding of both ligands were linear
(Fig. 1), and the B^x values were similar: 32.8 ± 2.6fmol/mg protein (mean ± S.E.M.,
n = 8) for [3H] FNM and 36.7 ± 4.8fmol/mg protein (n = 7) for [3H] PCC. As in CNS
regions, the affinity of [3H] PCC was rather higher than that of [3H] FNM: 0.33 ±
0.05nM vs 1.9 ± 0.3nM (see Table). The results from control experiments on hippocampal and
cerebellar membranes are also included in the table. As reported by Braestrup and Nielsen
(1981), [3H] PCC binds to a similar number of sites to [3H] FNM in the cerebellum, but
significantly fewer (= 50% of [3H] FNM Bmax) in the hippocampus.
The displacement of bound [3H] FNM (0.5nM) by unlabelled PCC also differed between
cerebellum and hippocampus in accordance with the results of Braestrup and Nielsen (1981).
In the cerebellum, PCC gave an IC50 of 1.3nM and clearly linear Hofstee plots but in the
hippocampus, the apparent affinity of PCC was less with an IC50 of 8.7nM and distinct
curvature (consistent with two components) in Hofstee plots (Fig. 2a, b). Hill
coefficients of this displacement data were 0.96 and 0.71 in cerebellum and hippocampus
respectively. When similar experiments were carried out using pituitary membranes, PCC
showed a similarly high affinity to that in cerebellum (Fig. 2a, IC50 of 1.1 ± 0.2nM, n =
4), giving linear Hofstee plots with no indication of curvature (Fig. 2b) and Hill




Pituitary Kp (nM) 1.9 ± 0.3 0.33 ± 0.05
Bmax (fmol/mg
protein) 32.8 ± 2.6 36.7 ± 4.8
Cerebellum Kp 2.59 0.02 0.28 0.01
Bmax 855 18 737 34
Hippocampus Kp 1.57 ± 0.01 0.42 ± 0.01
Bmax 1659 ± 47 836 ± 24
Results of Scatchard analysis of [3H] FNM and [3H] PCC binding to
pituitary, cerebellar and hippocampal membranes. Mean ± S.E.M. n = 7-8
for pituitary, and n = 4 for cerebellum and hippocampus.
DISCUSSION
PCC binds with high affinity to virtually all benzodiazepine binding sites in cerebellum
but in hippocampus shows a similar high affinity at only some sites with approximately
10-fold lower affinity at the remainder. The high affinity sites in cerebellum and
hippocampus (that can be selectively labelled by low concentrations of [3H] PCC) have been
denoted &l\ and the lower affinity, BZg (Braestrup and Nielsen, 1981). By comparison
of the relative Bmax values of [3h] FNM and [3h] PCC binding it is possible to
estimate the proportion of the two sites in an area. The results presented in the table
confirm that under the present conditions, the cerebellum appears to contain almost
exclusively {- 92%) BZ]_ sites with similar Bmax values for either ligand, whereas the
Bmax f°r [ PCC in the hippocampus is only 50% of that for [3H] FNM (p < 0.001),
suggesting that BZj and BZ^ sites are present there in approximately equal numbers.
This heterogeneity in the properties of the sites is further demonstrated by Hofstee plots
of the displacement of bound [3H] FNM by unlabelled PCC (Fig. 2), showing curvilinearity
(and a low Hill coefficient) in hippocampus but not cerebellum.
FIGURE 2.
a) Displacement curves of 0.5nM [3H] FNM by PCC from (•) cerebellum,
(■) hippocampus and (a) pituitary membranes.
b) Hofstee plots of the results in (a). Results are representative
of 4 experiments performed in duplicate.
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Application of the same approach to the pituitary gland revealed that [3h] PCC binds
there to a similar number of central sites to [3h] FNM (Fig. 1), suggesting that the sites
present are predominantly of the BZ^ type. This conclusion is fully supported by the
results on displacement of [^H] FNM by PCC showing a single component of similar affinity
to that in cerebellum.
It therefore appears that BZ^ receptors must mediate any facilitation of GABA events
in the pituitary gland elicited by benzodiazepines. The effectiveness of benzodiazepines in
such systems will thus be characteristic of action at a specified, BZ^ type site. The
presence of these sites in both anterior and neurointermediate lobes of the gland (Anderson
and Mitchell, 1983) and reports of BZ-potentiated GABA responses in both areas (Anderson and
Mitchell, 1984; Taraskevitch and Douglas, 1983) suggests that drugs active at BZ
receptors may have marked effects on a number of endocrine systems.
R.A.A. is a Houldsworth Scholar of the University of Edinburgh.
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